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Abstract 
Co-nanoprecipitation: Preparation of Sterically Stabilised Nanoparticles for Drug 
Delivery Applications 
 
The co-nanoprecipitation of linear amphiphilic A-B block copolymers and branched 
hydrophobic co/terpolymers has been used for the first time to generate uniform, salt 
stable dispersions of aqueous polymer nanoparticles. The nanoprecipitation of the 
branched polymers was studied in the absence of A-B block copolymers and the 
conditions chosen for further co-nanoprecipitation studies were chosen on the ability to 
ensure the mixed solvent system immediately after good solvent addition would guarantee 
nanoparticle formation. Variation of the ratio of the two polymer architectures using this 
simple technique has led to varying z-average diameters, narrow polydispersity particle 
distributions and tuneable stability to salt addition and storage within aqueous salt 
conditions. Polarity studies provided further evidence that during addition of increasing 
amounts of A-B block copolymer, the hydrophobicity of the internal core was maintained 
and only slight deviations were observed suggesting the PEG chains were located on the 
nanoparticle surface. Multiple nanoprecipitations were also shown to be possible through 
direct addition of polymer solutions to aqueous nanoparticle dispersions after solvent 
removal, leading to particle concentration increase without modification of the initial 
nanoprecipitate size.  
 
The dye molecule fluoresceinamine was selected as a model guest molecule for 
encapsulation during co-nanoprecipitation (10 wt %). Nanoparticles which were stable 
under physiologically relevant conditions were generated and studied for their cytotoxicity 
and transcellular permeability using Caco-2 cells. These materials showed low toxicity at 
the concentrations studied and enhanced permeation though the Caco-2 cell monolayer, 
which is a model of the intestinal epithelial cells. A nanomaterial was taken forward for 
accumulation studies and transcellular permeability in the presence of endocytic 
inhibitors, suggesting uptake proceeded via an active mechanism. Excellent drug loading 
potentials were observed during co-nanoprecipitation experiments with HIV anti-
retrovirals, and up to 25 wt % of efavirenz and ritonavir and 20 wt % lopinavir were 
encapsulated. As well as anti-retrovirals, encapsulation of an anti-cancer drug molecule 
SN-38 was studied and colloidally stable nanoparticles with narrow polydispersity particle 
distributions were obtained. In vitro cytotoxicity testing of the materials showed a 
comparable toxicity to that of SN-38. Multiple nanoprecipitations including SN-38 were 
successful and an increased concentration of SN-38 was achieved, whilst maintaining the 
same volume of anti-solvent. 
Overall, the co-nanoprecipitation approach has provided a fast and efficient route to 
sterically stabilised nanoparticles without the need for additional surfactants or filtration. 
Particles can be loaded with various drug molecules and pharmacological benefits were 
observed for some materials, suggesting future use for drug delivery applications. 
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1.1 Introduction to Nanomedicine 
 
Nanotechnology is an area of scientific research devoted to the development and design 
of functional materials existing within the nanometre range (1–1000 nm).1 Nanomedicine 
is one of the fastest growing sub-disciplines of nanotechnology and is defined by the 
National Institute of Health as the advancement of treatment, diagnosis, monitoring and 
control of biological systems via nanomaterials. Materials within the nanometre size range 
have physicochemical properties that are distinct from those of bulk materials or single 
molecules or atoms. The development of a new nanomedicine is a slow process (Figure 
1.1) and usually requires three different stages. The initial development ranges from 7 – 
20 years, followed by a further 1 – 7 years of clinical studies through to the production of 
a commercial product. 
 
 
Figure 1.1 The three general stages of nanomedicine development.*Adapted from ref 2 
 
During the past two decades, nanomedicine has played a major role towards the 
development of new treatments for a range of diseases and conditions such as cancer, 
diabetes, asthma, allergies and kidney disease. To date there are 77 approved 
nanomedicine products and ~70 in various stages of preclinical and clinical development.3  
Nanomedicines are beneficial as they can provide alternative routes of drug 
administration, lower therapeutic toxicity and provide a reduction in healthcare costs.4 For 
many reasons, the majority of research within the nanomedicine field has focused upon 
cancer and several new formulations have successfully entered routine clinical use.5, 6 
Current drug delivery systems (DDS) are effective at releasing drug molecules at 
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relatively high concentrations in vivo, yet the scope is limited to targeting tissues rather 
than individual cells.7 Over the coming years, nanomedicine will continue to provide 
benefits for an increasing number of patients, therefore having a positive impact on global 
health. 
 
1.2 Nanocarriers for drug delivery 
 
A nanocarrier can be defined as a material within the nanometre size range, which 
transports therapeutic molecules to target sites for improved drug delivery. The potential 
advantages of therapeutic nanocarriers include; (1) ability to improve the pharmaceutical 
and pharmacological properties of drugs (e.g. solubility) whilst not altering the drug 
molecules themselves; (2) preparation of targeted DDSs to enhance therapeutic effects; 
(3) delivery of drugs across biological barriers (e.g. gut, skin); (4) delivery of drugs to 
intracellular sites; and (5) ability to deliver drug molecules via combination therapies.8 
Selected nanocarriers include micelles, vesicles, polymer-drug conjugates, dendrimers 
and polymer nanoparticles (Figure 1.2). Current drug molecules which are cytotoxic or 
unstable active compounds (e.g. anti-tumour medication) can be encapsulated, dispersed, 
adsorbed or conjugated9 to improve their pharmacokinetic properties and reduce adverse 
effects.10 The particle shape and morphology strongly influence carrier performance and 
the various types of carrier will be discussed below.  
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic representation of types of polymer nanocarriers commonly used in drug 
delivery research. 
Polymer Micelle
Polymer Nanoparticle
Polymer-drug ConjugatePolymer Vesicle
Dendrimer
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1.2.1 Brief introduction to block copolymers  
 
The first report of block copolymers was during the 1950s using anionic polymerisation,11 
however, their renaissance didn’t occur until the 1990s when controlled polymerisation 
developed rapidly. Controlled polymerisation techniques such as atom transfer radical 
polymerisation (ATRP),12 reversible addition-fragmentation chain transfer (RAFT)13 and 
nitroxide mediated polymerisation (NMP)14 can yield block copolymers with both 
hydrophilic and hydrophobic moieties present within the same molecule. The advantage 
of these methods is the excellent control that can be achieved over composition and 
molecular weight distribution of the synthesised polymers.15 For these reasons, the 
amphiphilic nature of these polymers has led to many actual and potential applications 
within many fields including nanomedicine,16 biomedicine,17 emulsion polymerisations18 
and cosmetics.19 The hydrophobic block is often composed of styrene, acrylates, olefins 
and polyethers. Hydrophilic blocks are typically made up of positively or negatively 
charged monomers, such as acrylic or vinylic bearing amino group, carboxylic, 
sulfonated, or neutral blocks such as poly(ethylene) glycol (PEG) or water soluble 
methacrylates such as hydroxyl ethyl methacrylate (HEMA).15 Combinations of these 
monomers in the formation of various amphiphilic block copolymers have been studied 
for their self-assembling properties. In aqueous solutions, A-B amphiphilic copolymers 
form a range of various morphologies and are virtually all stabilised by hydrophobic 
forces. Particulate structures formed via self assembly, such as micelles, are prepared in 
solvents which selectively dissolve one of the block segments. A-B copolymers form well 
defined micelles with the core consisting of the insoluble block and will be discussed in 
detail below.20  
 
1.2.2 Polymeric micelles 
 
Polymeric micelles are colloidal particles generally formed via the self-assembly of 
amphiphilic block copolymers in an aqueous environment.21-23 The micelle adopts a core-
shell structure; the inner core is composed of the hydrophobic block and the outer 
hydrophilic shell provides sufficient hydrophilicity to stabilise the core and maintain the 
micelle dispersion. The formation of micelles is an entropy-driven process and their 
formation depends on the critical micelle concentration (CMC). The CMC is the minimum 
concentration of amphiphilic block copolymer required to form micelles in aqueous 
solution; below the CMC the co-polymer will solubilise and exist as unimers (Figure 1.3). 
The average size of reported micelles ranges from ~5-100 nm,24-26 which is dependent on 
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the materials’ properties such as block segment chemistry, segment chain length and 
experimental preparation conditions, including concentration and temperature.15  
 
Block copolymer micelles have become particularly interesting for the formation of DDSs 
for many reasons.  Firstly, the solubility of hydrophobic drugs can be enhanced by 
encapsulation inside the hydrophobic core; therefore, they can be transported at much 
higher concentrations than would ever be possible if administered alone. Secondly, the 
chemical composition, block lengths, and molecular weights can all be varied to control 
the size and architecture of the micelles.27, 28 Examples of such DDSs utilising polymer 
micelles for clinical applications will be discussed in section 2.1. 
 
Figure 1.3 Schematic representation of the equilibrium between unimers (left) and polymeric 
micelles (right). 
 
1.2.3 Polymer vesicles (a.k.a. polymersomes, liposomes) 
 
Vesicles can be prepared from many different compounds including surfactants,29 
phospholipids30 and block copolymers.31-34 The preparation of vesicles from block 
copolymers has been a growing area of interest due to the potential versatility of 
engineered polymers to match desired design criteria i.e. varying block length and block 
composition to optimise towards various applications. A major difference between 
vesicles and other nanocarriers is their hollow and lamellar bilayer structure which has the 
potential to solubilise both hydrophobic and hydrophilic drug molecules and dimensions 
can vary within the range of nanometres to micrometres depending on the chemical 
composition and application required. The main research and development focus has been 
for vesicles within the nanometre range.35 Vesicle formation can be thought of as a two 
step self-assembly process in which the amphiphilic polymer forms a bilayer which then 
closes to form the vesicle structure.36 Vesicles allow encapsulation of both hydrophilic 
and hydrophobic drug molecules, due to their unique bilayer structure, and have been used 
in the clinical drug delivery of anti-cancer drugs for tumour treatment in humans.37 
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1.2.4 Polymer-drug conjugates  
 
A polymer-drug conjugate, also known as a prodrug, can be defined as an inactive 
precursor of a drug molecule that usually requires an enzymatic or chemical 
transformation to release the active drug. The development of polymer-drug conjugates 
was first reported during the 1950s when Jatzkewitz prepared a polyvinylpyrrolidone–
mescaline conjugate that contained a short peptide spacer between the drug and the 
polymer.38 However, the main research focus was a study of the chemical interactions 
between different polymers and drug molecules without the consideration of the biological 
applications.39, 40 The first model which explored both chemical and biological aspects 
necessary for the design of prodrugs was during 1975.41 Ringsdorf recognised the full 
potential of prodrugs and all that was needed was polymer chemists, biologists and 
pharmacologists to collaborate within this field. The Ringsdorf prodrug model includes a 
polymeric backbone, spacer molecule, solubilising group (if required), targeting group 
and the drug molecule (Figure 1.4 A). Polymer-drug conjugates are not limited to a linear 
architecture and include monofunctional linear, polyfunctional linear, branched, micellar 
and dendritic architectures (Figure 1.4 B).  
 
Figure 1.4 A) The Ringsdorf  Model (Adapted from ref 40) B) Various polymer-drug conjugate 
architectures.
42 
 
The attachment of a pharmaceutical agent to a polymer including; synthetic polymers, 
polysaccharides & proteins, can significantly increase water solubility, protect the active 
drug molecule during transportation, improve the pharmacokinetics and, depending on 
size, can avoid first pass metabolism.43 First pass metabolism occurs when an 
administered drug enters the body and is transported to the liver via the hepatic portal 
vein. This process greatly reduces the drug molecule concentration, due to breakdown in 
Drug molecule
Polymer
Linear Conjugate Amphiphilic Diblock Conjugate
Branched Conjugate Micellar Conjugate Dendritic Conjugate
Targeting 
Moiety
Solubilising 
Group Drug
Cleavable 
Spacer
Polymer Backbone
A) B)
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the liver before entry into the systemic circulation, therefore a higher circulating dose may 
be achieved if small drug molecules are conjugated to polymers.44 
 
1.2.5 Dendrimers 
 
From a polymer chemistry point of view, dendrimers are nearly perfect monodisperse 
macromolecules with a regular and highly branched three-dimensional architecture 
consisting of a core, branching points and surface groups. This class of polymeric material 
were first synthesised during the late 1970s into early 1980s by Vӧgtle and co-workers,45 
Tomalia et al46 and Newkome et al.47 The technique used during the first reports of 
dendrimer synthesis was referred to as divergent growth. The divergent method is often a 
repetitive two-step process, whereby the reaction starts at a multifunctional core to which 
layers of repeat units are attached consecutively. The unreactive terminal groups are 
activated to create bonding sites for the next generation of growth. The divergent approach 
is very effective for the preparation of large dendrimers but, unfortunately, incomplete 
reaction steps and unwanted side reactions may lead to a low yield and polydisperse 
products. As a response to the weaknesses of the divergent approach, Hawker and 
Fréchet48 first reported a convergent growth approach, during which, the dendrimer 
growth begins at the periphery and proceeds to the core. This method provided a greater 
control over the preparation of dendrimers and reduced the need for excess reagents; 
however, product yields were still a problem. During recent years, click reactions have 
been developed providing simplified and faster routes to dendritic materials, employing 
diels alder reactions,49 thiol-ene reactions50 and azide-alkyne reactions.51  
Since their discovery, dendrimers have been studied for many different applications, in 
particular towards biomedical applications.52 The first successful encapsulation 
experiments utilising dendrimers was reported by Meijer et al.53 A water soluble 
poly(propylene imine) dendrimer (64 functional groups at the periphery) with a diameter 
of ~5 nm was used to encapsulate a host molecule named Bengal rose dye and prolonged 
heating was required to promote release of the dye. To date, there are numerous examples 
of dendrimers being evaluated as potential drug delivery vehicles in the literature54 and an 
example of a current tumour targeting dendrimer is the generation 3 PEGx-
poly(amidoamine) which is conjugated to folic acid, PEG, and doxorubicin as an anti-
cancer therapy.55 
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Despite continued efforts to improve dendritic materials, the synthesis remains very 
challenging, time consuming and expensive. As an alternative to dendrimers, 
‘hyperbranched polydendrons’ have been developed by Hatton et al, describing the 
synthesis of new dendritic branched polymer hybrids for drug delivery applications 
(Figure 1.5). The preparation of hyperbranched polydendrons combines controlled radical 
polymerisation, hyperbranched vinyl polymerisation and linear dendritic hybrids to form 
this new polymer architecture. These materials present a new approach to maintain surface 
functionality within a relatively rapid time scale, yet bypass the extensive dendrimer 
synthesis.56 
 
 
Figure 1.5 Schematic representation of the formation of a hyperbranched polydendron. Adapted from 
ref56 
 
1.3 Polymer nanoparticles 
The research interest in polymer nanoparticles has increased dramatically, as can be seen 
by the number of publications each year when searching for “polymer nanoparticle” using 
the scientific database, SciFinder (April 2015) (Figure 1.6).  
Nanoparticles are generally defined as solid, colloidal particles within the range 10 –1000 
nm.27 The term nanoparticle encompasses both nanospheres and nanocapsules to which 
the drug of interest can be dissolved, entrapped, absorbed, attached, and encapsulated into 
the nanoparticle. Nanospheres have a ‘matrix like’ structure whereby active compounds 
can be firmly adsorbed at their surface or dissolved/entrapped in the core, whilst 
nanocapsules have a core-shell morphology with the drug molecule dissolved within the 
core by a unique polymer membrane or, in some cases, adsorbed at the surface.57  
ATRP
+=
Dendron 
Functionalised 
Initiator
Monomer
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Figure 1.6 Graphical representation of the number of publications cited in SciFinder® based on the 
search term ‘Polymer nanoparticle’ (1980 - April 2015). 
1.3.1 Preparation of polymer nanoparticles 
 
Polymer nanoparticles can be prepared by both polymerisation of monomers and by use 
of preformed polymers during the following processes; emulsion diffusion, emulsion 
evaporation, double emulsification, emulsion-coacervation, layer by layer, polymer 
coating and nanoprecipitation.57 The general fabrication processes for the formation of 
nanoparticles are outlined below (Figure 1.7). Collectively, these methods offer control 
over key parameters such as particle diameter, polydispersity, encapsulation efficiency, 
porosity and drug compartmentalisation for preparation of spherical nanoparticles.58  
 
The emulsion–evaporation method (Figure 1.8) has also been employed for the 
preparation of nanoparticles and in terms of experimental technique, is closely related to 
the nanoprecipitation process.59 Emulsion-evaporation is often preferable over other 
emulsification methods as the experimental conditions are often milder than for the other 
techniques. During a typical emulsion-evaporation experiment, the organic solvent, 
organic compound, water and stabiliser are emulsified in an aqueous solution, which is 
then exposed to a high-energy source, such as a homogeniser.  
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Figure 1.7 Most frequently used processes for formation of nanoparticles. Adapted from ref57 
 
The subsequent removal of the organic solvent by vacuum, heat, or both results in the 
formation of an aqueous dispersion of particles. Although there have been many reports 
of this technique being used for nano-encapsulation,65 the majority of research has been 
focused upon micro-encapsulation and, unlike nanoprecipitation,57 this still requires a high 
energy source. Due to this, no further discussion will be presented. 
 
 
 
Figure 1.8 Schematic representation of the emulsion-evaporation technique. Adapted from ref59 
 
1.3.2 Preparation of non-spherical polymeric nanoparticles 
 
The majority of research into the properties and applications of polymer nanoparticles has 
been focused upon the formation of spherical morphologies as discussed above, and there 
is limited knowledge of shape effects. Non-spherical nanoparticles of varying shape and 
architectures have been prepared, named polymer nano-objects (PNOs) which are not 
Organic compound 
+
Organic solvent
Water
+
Stabiliser
Emulsification
Separation of 
Solvent
Ref Nanoparticle 
concentration, purification 
& stabilisation 
 
1) Nanoprecipitation
Organic Phase Aqueous Phase
Dropwise/Stirring
2) Emulsion-Diffusion / emulsion-evaporation
Organic Phase
Aqueous Phase
Emulsification
(High shear mixer)
Diffusion
(Moderate stirring)
Dilution Phase
3) Double emulsification
Organic Phase
Aqueous Phase 1
Emulsification 
w/o
(Sonication)
Emulsification 
o/w
(Sonication/high shear 
mixer)
4) Layer by Layer
Aqueous Phase 2
Template
Coat charged 
polymer 1 
Coat charged 
polymer 2 
Anionic or 
cationic 
polymer
n times
Anionic or 
cationic 
polymer
Solvent Elimination
Solvent Elimination
Recovery
(Ultracentrifugation)
Stabilisation
(Spray dry, lyophilisation)
Emulsification
(High shear mixer)
Nanocarrier Formation 
  
10 
 
limited to but include, worms, branched worms, disks and ribbons.66, 67 Preparation 
strategies often include grafting chemistry and block copolymer self-assembly which both 
result in a narrow size distributions. An example includes the preparation of hairy 
spherical PNO’s which are composed of a cross-linked block copolymer which has been 
modified with fluorescent dye molecules68 and super-paramagnetic Fe2O3
69
 for early 
biomedicine applications. The lack of research into this area is due to the extensive 
difficulties in preparation and synthesis of these polymer structures. However, scientists 
have demonstrated that the shape of nanoparticles does have a large effect in vivo and in 
vitro so there is clearly a need for investigation into this area further.70  
 
In contrast to the bottom-up approaches, previously discussed for formation of spherical 
nanoparticles, is the particle replication in non-wetting templates (PRINT) strategy; a top-
down fabrication method which has been more recently developed (Figure 1.9). PRINT 
enables independent control over nanoparticle size, shape, surface chemistry and 
composition. There are a wide range of biocompatible and biodegradable polymers which 
are compatible with the PRINT technology.71 Although the PRINT process has been 
successful, due to the top-down fabrication process of the nanomaterials they are not 
within the scope of this work and polymeric nanoparticles via nanoprecipitation will be 
the focus of later discussion.      
 
 
 
Figure 1.9 Particle Replication in Non-wetting Templates (PRINT) technologies A) Schematic 
representation of the PRINT process B) Examples of various PRINT particles. *Taken from ref72 
 
 
 
 
 
 
A) B)
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1.3.3 Nanoprecipitation 
 
The formation of spherical nanoparticles via nanoprecipitation has most relevance to the 
research presented within this thesis, and will be discussed in detail below. 
Nanoprecipitation is the most commonly used of the nanoparticle preparation methods 
and accounts for ~50% of the nanoparticles reported (Figure 1.10). This technique, also 
known as solvent displacement or solvent shifting, was first developed by Fessi et al in 
1989.60 The technique employs a solution of hydrophobic polymer within a good, water-
miscible organic solvent, followed by addition to water as a miscible anti-solvent; the 
order of addition can also be reversed so that the anti-solvent can be added to the polymer 
dissolved in the good solvent. The organic solvent is usually water miscible and volatile 
(e.g. acetone) and can be quickly removed to leave the nanoparticles as an aqueous 
dispersion.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Method selection for nanoparticle preparation.*Adapted from ref57 
 
There are two main preparation techniques which can be applied to the manufacturing of 
polymeric nanoparticles via nanoprecipitation, namely dialysis and the dropping 
technique73 (Figure 1.11 A). The dropping technique is often preferred because any 
miscible solvents can be used, which reduces the cost of consumables such as dialysis 
tubing, and is overall less time consuming. However, dialysis is a milder process and 
enables the complete removal of any monomers or initiator molecules, which may still be 
present from previous polymerisation steps. Both methods differ from each other in the 
rate of nanoparticle formation; the dropping technique instantly shocks the system 
whereas dialysis takes a long time to equilibrate and polymers are slowly introduced to 
the poor solution environment. Generally, both methods enable a controlled and complete 
Nanoprecipitation
Emulsion-diffusion
Double emulsification
Emulsification-coacervation
Layer by layer
Polymer Coating
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exchange of solvents, including solvents with high boiling points (i.e. DMF, DMSO) and 
depend highly upon the choice of solvent/non-solvent, temperature, agitation speed (if 
necessary) and the polymer concentration.73  In addition to dialysis and the dropping 
technique, nanoparticles can also be prepared by microfluidics, a technique that is still in 
the early stages of development but has shown a great potential for the preparation of 
nanoparticles on a large scale (Figure 1.11 B).74-76  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Schematic representation of nanoprecipitation techniques, A) i) Drop nanoprecipitation, 
ii) dialysis. Adapted from ref77 B) Microfluidics. Taken from ref75 
The nanoprecipitation technique does not require an external energy source (e.g. high-
energy mixing or sonication) and can be regarded as a low input procedure with low cost 
in comparison to the previously discussed emulsion techniques. In contrast to the 
preparation of nanoparticles via emulsion methods, surfactants are not necessarily 
required for nanoprecipitation, which can have an effect on the surface characteristics and 
increase toxicity of the nanoparticles. Additionally, a broad variety of solvents, such as 
acetone or DMSO, can be utilised. The size and shape of nanoparticles can be influenced 
by changing concentration, solvent/non-solvent selection, and preparation technique.73  
 
 
i) ii)
A)
B)
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1.3.4 Theoretical background to nanoprecipitation 
 
The proposed mechanism for nanoprecipitation can be divided into three stages; 
nucleation, growth and aggregation.  Firstly, polymeric materials are dissolved in a ‘good’ 
solvent (Figure 1.12 i), followed by addition to the anti-solvent. At this stage, the polymer 
progressively collapses to form nuclei and the solvent and anti-solvent exchange (Figure 
1.12 ii&iii). The small nuclei increase in size, aggregate to form swollen assemblies and 
grow until they reach a colloidally stable size (Figure 1.12 iv-vi). Finally, the assemblies 
desolvate and decrease slightly in hydrodynamic diameter (Figure 1.12 vii).  
 
Figure 1.12 Schematic representation of the nanoprecipitation approach, i) solubilisation of polymer 
molecules in a ‘good’ solvent, ii) addition of polymer in good solvent to anti-solvent, iii) exchange of 
‘good’ and anti-solvent, iv) association of polymer molecules in an increasing concentration of anti-
solvent, v) progressive collapse of solvated polymers to form nuclei, vi) association of nuclei to form 
swollen assemblies vii) desolvation of assemblies, resulting in a slight decrease in hydrodynamic 
diameter. 
The rate of these stages, especially aggregation, strongly correlates with the polymer 
concentration and consequently the viscosity of the solution.56, 78 A low viscosity is 
favoured due to the reduced possibility of entanglements between polymer chains, which 
can reduce the potential of nanoparticle formation or, in some cases, result in polymer 
precipitation. The amount of polymer added to the anti-solvent is also an important factor 
in order to obtain colloidally stable nanoparticles. 
Solvent Rich
Water Rich
i)
ii)
iii)
iv)
v)
vi) vii)
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1.3.5 Examples of nanoprecipitation 
 
Examples of the most often used polymers for nanoprecipitation include; poly(lactic acid) 
(PLA), poly(lactic-co-glycolic acid) PLGA and poly(caprolactone) (PCL) (Figure 1.13 A, 
B, C respectively) due to their evident biocompatibility and bioavailability, which are 
necessary when considering a new candidate for drug delivery (Figure 1.13). Other 
alternative polymeric materials such as poly(styrene), poly(methacrylates) (Figure 1.13 
D), poly(cyanoacrylates), poly(methyl vinyl ether-co-maleic anhydride) and cellulose 
derivatives have also been investigated. Recent research has reported nanoprecipitation of 
block copolymers, which form core-shell structures due to their amphiphilic nature. This 
approach has been very successful for the large-scale generation of polymer nanoparticles 
under clinically relevant conditions as highlighted in different reports of positive Phase II 
human clinical trial results from nanoprecipitates. The formulations were derived from 
linear A-B block copolymers from poly(ethylene glycol) and PLGA or Accurin 
technology (will be discussed in Section 1.4.1).79-81 The small range of polymers which 
have been investigated using the nanoprecipitation technique are shown in Table 1.1, and 
to date the influence of polymer architecture and further mechanistic studies of 
nanoprecipitation have not been widely studied.82  
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Examples of polymers used for nanoprecipitation A) Poly(lactic acid) (PLA); B) 
Poly(lactic-co-glycolic acid) (PLGA) C) Poly(caprolactone) (PCL) D) Poly(methyl methacrylate) 
(PMMA). 
 
Closely related to the research within this thesis, Slater et al reported the first controlled 
nanoprecipitation of branched poly(2-hydroxyl propyl methacrylate) in the absence of 
stabilisers.82 The branched polymer nanoparticles were within a controllable size range of 
60-800 nm, which was governed by the primary chain length and nanoparticle conditions. 
They were also stable to other external conditions such as temperature.  When compared 
with linear p(HPMA), the formation of nanoparticles using branched p(HPMA) demonstrated 
A) B)
C) D)
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enhanced stability for extended periods of time, suggesting the formation of nanoparticles can 
be architecture dependant and the use of branched polymers for the preparation of 
nanoparticles via nanoprecipitation is yet to be further investigated. 
1.4 Clinical application and design of polymer nanocarriers  
During the last two decades, there has been significant progress in the field of 
nanomedicine, including the control of physical, chemical and biological properties of 
nanocarriers, their stability in physiological environments (i.e. blood) and distribution to 
target sites. Polymeric nanoparticles offer a versatile approach for a range of both 
therapeutic and biomedical applications and continue to enter clinical trials (Table 1.2). 
To date, many clinically administered drug molecules have a short half-life in the blood 
stream and a high clearance rate due to their relatively low molecular weight (> 500 g/mol) 
and when administrated, diffuse rapidly into healthy tissue and are distributed evenly 
throughout the body. Consequently, minimal amounts of the drug reach the target site and 
unwanted side effects are experienced. These disadvantages are mainly associated with 
drugs which have a narrow therapeutic index, such as anti-cancer agents, which limit the 
higher doses due to toxic side effects and therefore less effective treatments.42 Polymeric 
based nanocarriers have demonstrated great potential towards the enhancement of 
transport of drug molecules for a wide range of diseases, mainly cancer but also conditions 
including but not limited to diabetes,83 renal failure,84 asthma.85  
 
1.4.1 Approved and preclinical drug delivery nanocarriers  
 
Early examples of nanocarrier drug delivery systems were based on liposomes and 
polymer-drug conjugates. One of the first non-targeted, liposome-encapsulated 
nanotherapy, containing doxorubicin (Doxil®), was approved for use in 1995 (Table 1.2) 
by the US Food and Drug Administration (FDA). Doxil® is an intravenously (IV) 
administered therapy which was originally developed for HIV-related Kaposi’s sarcoma 
and later approved for ovarian and metastatic breast cancer (Table 1.2). 
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Table 1.1 Examples of polymer nanoparticles prepared via nanoprecipitation. 
Polymer Good Solvent Anti-solvent 
Encapsulated 
molecule 
Surfactant Size (d. nm) Ref 
PMMA DMF H2O - 
 
Poly(N,N-dimethylacrylamide) 
Poly(poly(ethylene glycol)methacrylate) 
Poly(2-methoxyacrylate-co-poly(ethylene glycol)acrylate) 
130-225 86 
PMMA Acetone H2O - - 95-150 78 
PLGA ACN H2O Procaine HCl - 160-210 87 
PLGA Acetone H2O Curcumin Poly(vinyl alcohol) 95-560 88 
PLGA Acetone/Ethanol H2O DiI Tween 20 65-90 89 
PCL Acetone H2O Griseofulvin Polysorbate 80 250-400 90 
PCL Acetone H2O Primidone PE/F68 310-350 91 
PCL Acetone H2O Spironolactone Span 20 740-925 92 
PLA THF H20 - - 100-300 93 
PLA Acetone H2O MTP-Chol Synperonic PE/F68 200-300 94 
PHPMA Acetone H2O - - 60-800 82 
PLGA Acetone, ACN H2O Ubiquinone - 165-170 95 
PS THF 
H2O or 
H2O/NaCl 
- - 50-300 96 
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The Doxil® liposomal formulation is composed of hydrogenated soya 
phosphatidylcholine, cholesterol and PEG modified phosphatidylcholine.97 This 
formulation has been proven to significantly reduce cardiotoxicity, enhance its deposition 
in tumours and increase drug circulation half-life when compared with freely administered 
doxorubicin.98, 99 Further examples of liposome encapsulated doxorubicin therapies that 
have been approved include; Myocet® and Daunoxome® (Table 1.2). 
 
Another nanocarrier system which has been extensively investigated and approved for 
clinical applications are polymer-drug conjugates.4,1 PEG, has been one of the most widely 
studied polymers for polymer-drug conjugate systems due to its biocompatibility and 
versatility. Polymer-drug conjugates have a prolonged circulation in vivo and have 
demonstrated the ability to reduce cellular uptake via the endocytic route which in turn 
enhances the delivery of drugs to target sites with leaky blood vessels e.g. tumours.100 
During 1994, Oncaspar® (PEG-L-asparaginase) became one of the first polymer-drug 
conjugates to receive approval by the FDA for the treatment of acute lymphocytic 
leukaemia via IV administration. Other approved PEGylated therapeutics include 
Adagen® (PEG–adenosine deaminase), for treatment of severe combined 
immunodeficiency disease, and Genoxal-PM® for breast cancer therapy. Many other 
examples have been approved and others are in phase I-III clinical trials, as shown in 
Table 1.2. In addition to PEG, another hydrophilic polymer used for polymer-drug 
conjugates is N-2-hydroxypropyl methacrylamide. This polymer provides functional side 
chains for drug attachment or addition of targeting ligands. It is also non-toxic, 
biodegradable and can improve aqueous drug solubility. Examples include ProLindac 
currently in Phase II clinical trials for the transport of the active form of the approved drug 
oxaliplatin to tumors.101 
 
Besides liposomes and polymer-drug conjugates, other common nanocarrier systems that 
have also demonstrated therapeutic potential include polymeric micelles and polymer 
nanoparticles. Polymeric micelles within the 10-200 nm size range provide an ideal 
structure for a drug delivery nanocarrier, due to their core-shell micellar structure and 
loading capability. The hydrophilic shell often includes PEG which can provide a steric 
‘stealth’ outer surface, which enhances the stability in a physiological environment, and 
functional groups can be incorporated for targeting.4 The addition of stealth qualities 
increases the ability of a nanocarrier to avoid immune recognition, therefore, their time in 
vivo is enhanced and the chance of reaching the target is increased. PLA, PLGA, PCL and 
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their copolymers are all biodegradable and often synthesised to incorporate PEG, for the 
preparation of polymeric micelle formulations.102, 103 
 
In terms of nanoparticle systems, Transdrug® is a novel formulation of 
poly(isohexylcyanoacrylate) loaded with doxorubicin via the emulsion evaporation 
technique and has been approved for the treatment of multidrug-resistant protein-over-
expressing hepatocellular carcinoma.104 Additionally, BIND Therapeutics, Inc. have 
utilised the nanoprecipitation and emulsification evaporation processes to prepare 
polymer nanoparticles on a large-scale under clinically relevant conditions. The polymer 
nanoparticles are commercially known as Accurins™ and are currently undergoing Phase 
II clinical trials. They are designed to have a stealth outer layer for prolonged circulation 
within the bloodstream, target specific sites within the body and have a controlled and 
timely release of encapsulated therapeutic molecules.79, 80 (Table 1.2). 
 
1.4.2 Design of polymeric nanocarriers towards nanomedicine 
 
Significant research efforts continue towards the design and development of polymeric 
nanocarriers for drug delivery applications.4, 39, 105 A safe and effective drug delivery 
system could potentially improve the performance of medicines currently on the market 
and assist development of new therapeutic strategies.106 One of the current obstacles of 
drug delivery is poor aqueous drug solubility and there are approximately 30-40% of new 
drug candidates which have not been further investigated, due to problems encountered 
during formulation.107 Nanocarriers show great potential for improved delivery of 
hydrophobic drugs and through careful design can be further modified to enhance the 
biodistribution of the encapsulated drug.7 Drug encapsulation within polymer micelles and 
polymer vesicles is typically less than 10%.108-110 Formulations which have demonstrated 
potential increased drug loading are those prepared via the nanoprecipitation technique.107 
An increase in drug loading levels offers the potential for an increased amount of drug at 
desired sites and therefore a lower dosage to achieve the same therapeutic effect of both 
hydrophilic and hydrophobic drug molecules. Nanomaterials continue to enter clinical 
trials and achieve approval, however, there are still barriers to overcome and further 
research is required, which forms the basis of this research project, to design polymeric 
nanoparticles for biomedical applications. 
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Table 1.2 Nanocarriers currently used for clinical practice and applications.4, 104, 111 
 
Nanocarrier Name Compound Administration Disease/Condition Status Ref 
Liposome 
Doxil Doxorubicin Intravenous Ovarian, metastatic breast cancer, Kaposi sarcoma Approved - 
Myocet Doxorubicin Intravenous Breast cancer Approved - 
Daunoxome Daunorubicin Intravenous Kaposi Sarcoma Approved 112 
Markibo Vincristine Intravenous Various leukemia, melanoma II - 
Amphotec 
Colloidal 
suspension of 
lipid based 
amphotericin B 
Subcutaneous 
 
Invasive aspergillosis patients who are refractory to or 
intolerant of conventional amphotericin B 
 
Approved - 
Polymer Drug 
Conjugate 
Cyclosert  Camptothecin Intravenous 
Various cancers, Metastatic colon or rectal cancer 
 
II 113, 114 
Oncaspar L-asparaginase Intravenous Acute lymphocytic leukaemia Approved  
Xyotax Paclitaxel Intravenous Breast, ovarian II 115 
PK1 Doxorubicin Intravenous Breast, lung, colon II 116 
PK2 Doxorubicin Intravenous Various cancers, particularly lung and breast II 117 
DE-310 Camptothecin Intravenous Various cancers I 118 
CT-2106 Camptothecin Intravenous Various cancers I 119 
EZN-2208 SN38 Intravenous Breast, colorectal, pancreatic I 120 
NKTR-102 Irinotecan Intravenous 
Various cancer 
Breast cancer 
II 
III 
121 
Adagen 
Adenosine 
deaminase ADA 
Intramuscular Severe combined immunodeficiency disease (SCID) Approved - 
Cimzia TNF-a inhibitor Subcutaneous Crohn’s disease, rheumatoid arthritis Approved - 
Macugen Pegaptanib Intravitreal Age-related macular degeneration Approved - 
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Table 1.2 continued Nanocarriers currently used for clinical practice and applications. 
 
Nanocarrier Name Compound Administration Disease/Condition Status Ref 
Polymeric  
  Micelle 
Genoxel-PM Paclitaxel Intravenous Breast cancer Approved 122, 123 
ProLindac Oxaliplatin  Intravenous  Ovarian cancer II 101 
FCE28068 Doxorubicin Intravenous Liver I/II 124 
NK911 Doxorubicin Intravenous Various cancers, particularly lung and breast I 125 
NK105 Paclitaxel Intravenous Ovarian, breast and non-small cell lung cancer II 126 
Estrasorb 
Estradiol 
hemihydrate 
 
Transdermal 
Reduction in vasomotor symptoms in 
menopausal women  
 
Approved - 
Nanoxel Paclitaxel 
 
Intravenous Advanced breast cancer  
 
I 
127 
SP1049C Doxorubicin  
 
Intravenous Oesophageal carcinoma  
 
II 128 
Taxotere Docetal Intravenous 
Breast, prostate, non-small cell lung 
cancer,stomach and head and neck cancer 
Approved - 
Abraxane Paclitaxel  
 
Intravenous Breast cancer, non-small cell lung cancer, 
pancreatic 
Approved 129 
Nanoparticle 
Transdrug Doxorubicin Intravenous Hepatocarcinoma Approved 130 
Accurin Docetaxel Intravenous 
Non-small cell lung cancer 
metastatic castrate-resistant prostate cancer, 
various cancers 
II 
- 
Rondel CALAA-01 Intravenous Tumour reduction, various cancers  I 131 
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1.4.3 Factors affecting the biodistribution of nanoparticles 
 
There are many factors to consider when designing a new drug delivery nanocarrier, 
including size, charge, stealth and various routes of administration (Figure 1.15), which 
will be discussed in detail below. The surface functionalisation and addition of targeting 
moieties will be discussed in Section 2.2.2 under active targeting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15 Design properties for polymeric nanoparticles. Information from ref132 
 
1.4.3.1 Size and surface charge 
 
The size, surface characteristics and shape of nanocarriers all play a key role within in 
vivo biodistribution. There are many reports within the literature which state that 
nanocarriers for therapeutics are often within the size range of 10-100 nm,98 but further 
research shows this is not essential and larger particles can be just as effective in vivo. 
After IV administration, small particles < 20-30 nm are rapidly eliminated by renal 
clearance,133 whereas larger particles are usually taken up by the mononuclear phagocytic 
system (MPS). The MPS is a vital part of the immune system, consisting of phagocytic 
cells, which engulf foreign particles if they have been tagged by a specific marker known 
as a opsonin.134 Opsonins are blood serum proteins, which are responsible for selectivity 
and enable phagocytes to recognise and attack only foreign substances and not their own 
macromolecules. Nanoparticles between 150–300 nm are often found in the liver and 
Design of Polymeric 
Nanoparticles 
Stealth
Surface chemistry
Smart Ingredients 
Size/aspect ratio
Route of 
administration
Stability
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spleen and the slightly smaller range (30–150 nm) are generally located in bone marrow, 
the heart, the kidney and the stomach.135 It has been reported that nanoparticles should be 
less than 150 nm to cross endothelial barriers, but cancerous tumour growth results in a 
discontinuous endothelium, therefore larger particles can penetrate due to fenestrations, 
which allow the passage of nanoparticles up to 780 nm.136 The optimum size of 
nanoparticles for cancer treatment has been reported within the 70 – 200 nm range.132 
 
The surface chemistry of nanocarriers can be modified to modulate hydrophilicity, in vivo 
circulation, bioavailability and biodistribution.132 The interaction of nanocarriers with 
their local environment e.g. shape, surface charge, determines the fate of nanoparticles 
within the body. For example, the introduction of steric stabilisation using PEG, which 
has a minimal positive or negative charge, is likely to have minimal interactions. 
Additionally, the negative charges which dominate the surface of cells and inside blood 
vessels would repel any negative charge, hence a neutral polymer would have a negligible 
effect on uptake by the MPS. An increase in surface charge (either positive or negative) 
can lead to a greater clearance rate by the MPS system. Therefore, controlling the surface 
charge of nanoparticles is important to minimise particle loss to undesired locations.98 The 
addition of targeting ligands onto nanocarriers has been extensively researched to enhance 
cellular uptake and maintain a high concentration of drug at desired sites for a prolonged 
period of time in order for their therapeutic action to take effect.137  
 
1.4.3.2 Stealth nanocarriers  
 
As briefly discussed in Section 1.4.1, nanocarriers are often coated with a hydrophilic 
polymer to prevent adsorption of proteins and to avoid recognition by the MPS, which can 
cause clearance of materials from circulation.138 PEG is a linear or branched polyether 
diol, synthesised by linking repeated units of ethylene oxide to obtain a wide range of 
molecular weights. PEG can be modified to form a monomethoxy PEG (MeO-PEG), 
which can be useful in PEGylation and preparation of amphiphilic A-B and A-B-A block 
copolymers.139, 140 MeO-PEG is also chemically inert and the terminal hydroxyl group 
enables selective reactions with many different functional groups.141 PEG is most 
commonly used to coat particles, and it has been shown that the length and number of 
chains can have an effect on blood circulation times vs. elimination in clearance organs.142-
144 Additionally, PEG chains can provide steric stabilisation of particles and prevent 
aggregation, which is observed experimentally for charge stabilised nanocarriers.82 There 
have been reports that low molecular weight PEG chains (shorter than 400 g/mol) are 
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transformed to toxic metabolites in vivo and longer PEG chains ( <20 kg/mol) are likely 
to be excreted in urine. Although research has suggested very high molecular weight PEG 
( >20 kg/mol) is also excreted through kidney filtration, other pathways such as liver 
uptake via the immune system may dominate.145 Webster and co-workers have suggested 
PEG chains of varying molecular weights are excreted unchanged in the urine and higher 
molecular weight PEG molecules generally give rise to an increase in the residence time 
in the body rather than a fundamental change in excretory route.146, 147 Although the 
research of stealth nanocarriers has been focused upon PEG, other examples of 
hydrophilic polymers which have been used to coat nanoparticles include poly(acrylic 
acid),148 poly(acrylamides), poly(vinyl alcohol) (PVA) and polysaccharides.134, 149 
 
1.4.4 Permeation through biological barriers 
In order to successfully deliver therapeutic molecules there are various biological barriers 
to overcome and they can be classified as external (skin and mucosa), en route (blood and 
extracellular matrix) and cellular (cellular uptake, endosomal, translocation to subcellular 
organelles) (Figure 1.12).132   
 
 
Figure 1.12 Barriers towards the delivery of nanocarriers; external, en route and cellular. Adapted 
from ref132 
 
External Barriers. The initial external barrier will vary depending on the route of 
administration. The skin is made up of thick tissues; stratum corneum (10 – 20 µm), 
epidermis (50 – 100 µm), dermis and subcutaneous tissues (1 -2 mm).150 The dermis and 
subcutaneous tissues have a rich blood supply, which can be used for trandermal delivery; 
however, the lipid bilayers of the stratum corneum must be penetrated for permeation 
through the skin. 
External Barriers En-route Barriers Cellular Barriers
•Skin – Several layers, the outer 
layer is hydrophobic consisting of 
several layers.
•Mucus – Include the 
gastrointestinal tract, eyes, lungs 
airways, nasal, rectal and vaginal 
cavities.
•Blood – Capillary diameter ~5-
40µM
•Renal clearance – Renal molecular 
weight cut off ~ 10 nm.
•Hepatic and splenic clearance –
Liver and spleen fenestration 
(<500nm)
•BBB – Pore upper size limit ~12nm
•Extracellular matrix
•Cellular uptake – Passive diffusion 
(<1 kDa)
•Endocytosis – Internailised vesicles 
(60-120 nm or larger)
•Cytoplasm – Degradation
•Translocation to subcellular
organelles – Nuclear pore complexes    ( 
~ 10nm)
•Exocytosis – Cellular clearance of 
nanoparticles
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Mucus is a viscoelastic gel, which is secreted by mucosal glands to protect the lung 
airways, gastrointestinal (GI) tract, eye and other mucosal surfaces. Mucus is a viscous 
and sticky layer which lines tissues to trap and remove foreign particles and other 
hydrophobic molecules.151 Oral drug delivery via the GI tract can be challenging due to 
the presence of digestive enzymes and an extreme pH switch from 1 to 3.5 in the stomach 
to and pH 5 to 7 in the small intestine.  
 
En-route Barriers. The injection of polymer nanocarriers into the systemic circulation 
bypasses the skin and mucosal barriers. Although IV is the most common method of 
nanocarrier administration, the procedure often lowers patient adherence as it is 
considered invasive and unfavourable. Adherence is defined as the extent to which 
patients take medication as prescribed by their healthcare providers, however, the full 
benefits are not often realised because approximately 50% of patients do not take their 
medications as advised.152 Nanocarriers in the blood become subject to many barriers such 
as renal and hepatic clearance, aggregation, opsonisation and clearance by the MPS. In 
order to reach their intended destination, nanocarriers must avoid multiple organ clearance 
mechanisms such as those operating in the spleen and liver. The spleen has fenestrations 
which are within the range of  200–500 nm,133 therefore particles exceeding ~200 nm must 
be modified in order to remain within circulation. Opsonisation, the process of elimination 
by phagocytes, is a major challenge in vivo. There are many opsonins, which adsorb onto 
the surface of nanocarriers and make them more susceptible for attack by the MPS.  
 
The BBB is a highly selective, semi-permeable membrane that regulates movement of 
molecules from the circulatory system into the central nervous system. There are a range 
of methods of molecular transport for entry of compounds into the brain including 
paracellular diffusion, passive diffusion, active transport (via membrane transporters) and 
endocytosis. The passage across the BBB is more feasible for smaller molecules than for 
larger ones,153 and there are still many transport problems since 98% of drug molecules 
are not able to pass from the blood to the brain.154 Passive anti-cancer targeting of micelles, 
liposomes, polymer nanoparticles and dendrimers are still lacking the selectivity needed 
to target the brain, thus, preventing drug delivery to the central nervous system.155 
 
Cellular Barriers. Cellular uptake is highly challenging and there are several biological 
barriers at the cellular level which nanocarriers must overcome, starting with penetration 
of the phospholipid cell membrane which has a cut off of ~1 kDa. Endocytosis is an energy 
dependent process by which materials move into a cell by engulfing extracellular fluid 
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(including any materials dissolved or suspended in it) without passing through the cell 
membrane.132 The endocytic pathway depends on various properties of the nanoparticles 
including size, morphology, surface chemistry and varies from one cell line to another.156 
To date, there are three main mechanisms for the cellular uptake of nanoparticles; 
phagocytosis, pinocytosis and receptor-mediated endocytosis and the preferred process 
depends on the assisting proteins during the process.157 Phagocytosis plays a crucial role 
in the defence against organisms such as bacteria, viruses and drug delivery vehicles.158 
The phagocytic process occurs in macrophages, monocytes, neutrophils and dendtritic 
cells.159 Other cells which express a lower phagocytic activity include epithelial and 
endothelial cells.160 Opsonisation, as mentioned briefly above, is one of the most important 
biological barriers to control drug delivery. Opsonin proteins are present in the blood, and 
bind to non-stealth nanoparticles, allowing macrophages of the MPS to easily recognise 
and remove them before achieving their therapeutic effect. A macrophage is a large 
specialised white blood cell which can remove ‘unprotected’ particles from the blood 
within seconds after IV administration.161 As discussed previously, the introduction of 
PEG onto the surface of nanoparticles minimises opsonisation, which allows them to 
bypass recognition by the MPS and increase their circulation half-life.  
Following endocytosis, entry of the nanocarrier into the endosome can trigger degradation 
due to the decrease in pH and the presence of enzymes. The nanoparticles or drug 
molecules if intact, can exit the endosomes into the cytoplasm, which is essential for them 
to reach the targeted subcellular organelles, if these are the target. The movement to 
subcellular organelles i.e. nucleus, mitochondria also can be challenging due to their 
membrane bound nature. Nanocarriers can also be excreted from cells via a process known 
as exocytosis.  
 
1.5 Passive and active drug delivery 
 
Drug targeting strategies for the preparation of nanomaterials may be classified as either 
‘passive’ or ‘active’. The properties of passively targeted nanocarriers depend upon the 
nanocarrier size and surface properties (no affinity ligands) which directs them towards 
particular organs and across biological barriers. To date, most clinically validated 
therapeutic and imaging nanoparticles are considered passively targeted.162 This is due to 
their straightforward methods of preparation, prolonged circulation times in vivo and their 
accumulation at particular sites due to diffusive mechanisms. The PEGylated micelle 
formulations SP1049C and NK911 (Table 1.2) are examples of passive nanocarriers, 
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which are now in early phase clinical trials for treating a variety of cancers. Passive 
targeting was widely researched for oncology applications since tumours facilitate the 
accumulation of nanocarriers via enhanced permeation retention (EPR), which will be 
discussed below. 
1.5.1 Passive targeting of tumours via the enhanced permeation retention (EPR) 
effect 
When designing a new drug delivery vehicle, passive targeting to solid tumour sites can 
be achieved through the EPR, which was first reported during the 1980s by Matsumura 
and Maeda.163 Since then, there have been many in vivo studies which have demonstrated 
the EPR effect using polymer-drug conjugates,164 liposomes,165 micelles166 and 
nanoparticles.167 Solid tumour tissue is highly heterogenous and blood vessels in tumours 
possess different characteristics to normal blood vessels. These characteristics include 
defective vascular architecture, large gaps in endothelial cell-cell junctions (varying from 
one tumour type to another), lack of smooth muscle layer cells and impaired lymphatic 
clearance of macromolecules and lipids from interstitial tissue.168 After IV administration, 
the therapeutic drug molecules encapsulated within nanocarriers can passively target 
tumours and accumulate at much higher concentrations in tumour tissues as opposed to 
normal tissues/organs. When they reach normal tissue, the endothelial cells are tightly 
compacted and only very small molecules can penetrate them, contrasting to tumour tissue 
which have an unorganised arrangement of endothelial cells (Figure 1.14). Smaller 
molecules accumulate faster within tumour tissues, whilst larger molecules remain for a 
prolonged time periods. EPR is most effective with macromolecules of >40 kDa or a 
hydrodynamic radius from 1 - 1000 nm, and can occur in the absence of targeting ligands 
on nanoparticles.169 There are a number of PEGylated polymeric nanoparticles in early 
phase clinical trials for treating a range of cancers via the EPR effect.8, 170 
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Figure 1.14 Schematic representation for passive or active targeting of drug delivery nanocarriers 
using the EPR effect. Redrawn from ref42 
 
1.5.2 Active targeting  
 
Active targeting is used to describe specific interactions between the nanocarrier and the 
target cells, usually ligand-receptor interactions. Targeted nanocarriers have attached 
ligands, which can vary from antibodies to nucleic acid aptamers, peptides or small 
molecules (e.g. folic acid and sugar molecules). To ensure a maximum therapeutic effect, 
the actively targeted nanocarriers include ‘stealth’ properties for prolonged circulation. 
Stealth nanocarriers, both actively and passively targeted, usually arrive at the tumour via 
EPR. However, there is an improvement in therapeutic effect when a drug molecule is 
encapsulated into targeted particles due to ligand-receptor interactions.171, 172 The 
development of active therapies has been mainly focused upon cancer, as tumour cells 
express different molecules on their surface in comparison to normal cells. During the last 
30 years, there have been no actively targeted particle formulations approved by 
regulatory authorities but there are a number being explored in clinical trials. Some of the 
targeted polymeric nanoparticle formulations undergoing clinical trials are BIND-014,81 
CALAA-01131 and SEL-068.8 As previously discussed, there are a number of ways to 
prepare polymeric nanocarriers. Most techniques make use of the self-assembly of block 
copolymers, with varying block solubilities. The choice of preparation technique can be 
dependent upon the properties of the encapsulated drug molecule and particle size 
requirement.  
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Figure 1.14 A) Schematic representation of an actively targeted nanocarrier, B) BIND therapeutic 
nanoparticles and properties to achieve selective targeting of diseased cells and tissues.173 
 
The use of hydrophobic-hydrophilic PEG based A-B block copolymers during 
nanoparticle preparation, results in a hydrophobic core, entrapped hydrophobic drugs and 
a PEG shell providing steric stabilisation. BIND-014 is a prostate membrane specific 
antigen targeted docetaxel encapsulated polymeric nanoparticle formulation and is 
prepared via nanoprecipitation on a large-scale. This formulation has demonstrated 
promising preliminary results in an open label Phase II clinical study in 40 patients.173 It 
is evident that actively targeted particles require a much more complex formulation 
process, expensive ligands, complex scale up and difficulty to make large quantities for 
in vivo studies. 
 
1.6 Aims of the project 
 
1.6.1 Previous research  
 
Previous literature has compared the architectural effect of linear and branched 
hydrophobic polymers and their formation of aqueous nanoparticles via nanoprecipitation, 
however, only the branched polymer derived nanoparticles were stable for extended 
periods of time. Unfortunately, their stability was compromised during small additions of 
an electrolyte such as NaCl, as they are charge stabilised, as shown by their highly 
negative zeta potential (ζ).82 This limited the application of the nanoparticles as potential 
drug delivery vehicles, because after introduction of buffers/salts to the system to mimic 
the electrolyte concentration in the blood, the nanoparticles became unstable and 
aggregated. 
Antibodies
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More recently, Hatton et al introduced the concept of hyperbranched polydendrons and 
the preparation of aqueous nanoparticles from these materials. The synthesis of 
hyperbranched polydendrons, and subsequent polymerisation of dendron functionalised 
initiators, presents a fast and efficient one step synthesis to combine dendrons and 
maintain surface functionality, without the need for complex dendrimer synthesis. 
Polymer nanoparticles were then prepared via nanoprecipitation and due to the 
hydrophobic nature of dendron and monomer, a highly negative ζ was obtained, which is 
representative of charge stabilisation.56 Similar to the branched nanoparticles discussed 
above, pharmacology testing was limited, as the addition of an electrolyte to the 
hyperbranched polydendron nanoparticles resulted in aggregation.   
As a continuation of the hyperbranched polydendron research, Hatton et al described the 
preparation of hydrophilic PEG modified polydendron nanoparticles and their permeation 
through a model gut epithelium. As previously discussed, many successful drug delivery 
systems include a PEG coating on the outer surface to improve their bioavailabilty and 
biocompatabilty. In order to achieve this, PEG functional groups were incorporated by the 
use of a mixed initiator system of PEG:dendron at various ratios during the synthesis of 
the branched polymers. Again, the nanoparticles were prepared via nanoprecipitation 
(Figure 1.15). The nanoparticles demonstrated potential in a gut epithelium model, but the 
drug loading capability is yet to be fully investigated.174  
 
Figure 1.15 Schematic representation of idealised hyp-polydendron synthesis. Atom transfer radical 
copolymerization (ATRP) of 2-hydroxypropyl methacrylate and ethylene glycol dimethacrylate 
initiated by the functional G2 dendron to form, A) hyp-polydendrons; and B) inclusion of a PEGx-
initiator to form hyp-polydendrons with controlled and mixed surface functionality. 
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1.6.2 Project aims 
 
The research presented here aims to investigate the potential for forming biologically-
relevant polymer nanoparticles using highly branched, high molecular weight copolymers 
which builds upon previous reports. The lack of colloidal stability during electrolyte 
addition has hampered the use of these systems and direct synthetic strategies have sought 
to overcome this problem. Within this project, the potential to utilise combinations of 
amphiphilic block copolymers with branched hydrophobic copolymers will be studied, as 
this would provide a highly flexible platform for nanoparticle production under controlled 
conditions. The chemical compositions of both branched and A-B block copolymers will 
be varied to investigate the encapsulation of hydrophobic drug molecules and assessment 
of their suitability towards drug delivery applications. 
 
1.6.2.1 Synthetic aims  
 
The project aims to generate a series of branched high molecular weight statistical 
copolymers and a complementary series of linear block copolymers to investigate the 
effects of copolymer composition and molecular weight, within a mixed polymer 
nanoprecipitation process. The target synthetic aims of this project are summarised in 
Figure 1.16 and polymers will be prepared via ATRP.  
 
 
Figure 1.16 Schematic representation of the target synthetic aims of this project. 
The copolymerisation of mono- and bi-functional monomers to produce high molecular 
weight branched polymers will not be limited to 2-hydroxypropyl methacrylate (HPMA), 
and will include the synthesis of polymers utilising other hydrophobic monomers such as, 
n-butyl methacrylate (n-BMA) and t-butyl methacrylate (t-BMA) (Figure 1.16 A). The 
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amphiphilic A-B block copolymers (Figure 1.16 B) will be synthesised from a PEG 
macroinitator and HPMA with a varying degree of polymerisation (DPn). The ATRP 
polymerisation experiments appear feasible and, if successful, will provide a range of 
polymeric materials for subsequent nano and co-nanoprecipitation studies. 
1.6.2.2 Nanoparticle formulations 
 
After synthesis of the component materials, the formation of nanoparticles via the 
nanoprecipitation approach will be studied (Figure 1.17).  
 
 
Figure 1.17 Schematic representation of the nanoparticle aims of the project for both nanoprecipitated 
and co-nanoprecipitated aqueous nanoparticles, A) i) Previously reported collapse of the branched 
polymer core to form charge stabilised nanoparticles; ii) Addition of an A-B block copolymer to 
potentially form sterically stabilised nanoparticles; B) Nanoprecipitation of a branched polymer core, 
A-B block copolymer and potential encapsulation of a guest molecule i.e. dye or drug. 
 
The inclusion of an A-B block copolymer during the nanoprecipitation of a branched 
hydrophobic copolymer will be investigated to assess if the formation of sterically 
stabilised nanoparticles would be possible. It is of interest to study if non-covalently bound 
A-B block copolymers could become involved in the nanoprecipitation of a branched 
copolymer and sufficiently improve the stabilisation during the nanoprecipitation 
procedure. The nanoparticle compositions of branched polymer:A-B block copolymer 
will be varied to determine the optimum ratio in order to achieve steric stabilisation. The 
stability of the polymeric nanoparticles is a crucial factor if the materials are to be 
i)
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considered for in vitro experiments; therefore, stable nanodispersions will be tested using 
electrolyte and buffer solutions to mimic physiological conditions. The proposed 
nanoparticles (Figure 1.17 B) would be expected to be composed of a hydrophobic core 
with PEG from the A-B block copolymer remaining on the surface providing steric 
stabilisation. Such nanoparticles could potentially increase loading capabilities within the 
high molecular weight branched core. If successful, the ultimate aim of the nanoparticles 
would be to encapsulate drug molecules and evaluate loading capacities.  
 
1.6.2.3 Pharmacology studies 
 
Polymer nanoparticles have been widely reported widely for cancer therapies but other 
diseases such as HIV, may receive considerable benefits if tailored materials were 
available. In order to determine the suitability of nanomaterials as potential drug delivery 
vehicles, their in vitro behaviour must firstly be ascertained. Cytotoxicity assays were 
deemed appropriate to ensure the nanomaterials were non-toxic to cells and act only as 
nanocarriers of the drug molecules. The route of administration of a drug delivery vehicle 
will determine which type of pharmacological assay is to be carried out. For example, for 
orally administered therapeutics, a well-known transwell plate assay using the Caco-2 cell 
line is typically used to predict the permeability of molecules across a model intestinal 
tract into the systemic circulation. This assay will be considered if nanoprecipitated 
nanodispersions are stable to electrolyte/buffer solutions used during these assays and if 
so, the dispersion will be taken forward for further studies such as apparent permeability 
ratios and the cellular accumulation ratio (CAR).  
Alternatively, for IV administered anti-cancer therapies, it would be desirable to carry out 
cell viability studies and dose response experiments using a human cancer cell line, to 
determine if the encapsulated drug molecules are toxic to cancerous cells when 
encapsulated within nanoparticles and assess how this compares with the toxicity of the 
free drug molecules.  
Overall, the research presented within this thesis aims to provide a detailed study into a 
modified nanoprecipitation approach, which could provide a facile route to a variety of 
sterically stabilised nanoparticles. Varying polymers will be studied to evaluate the 
versatility of the process and the nanoparticle behaviour will be thoroughly investigated 
with respect to ratio, chemical composition and mechanism. If stable nanoparticles are 
formed, the encapsulation of a range of hydrophobic guest molecules will be carried out 
to determine their potential within a pharmacological setting.  
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Chapter 2 
 
Synthesis and Characterisation of p(HPMA) for 
Investigation and Optimisation of Nanoprecipitation 
Conditions and Introduction to 
Co-nanoprecipitation 
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2.1 Introduction  
 
The first nanoprecipitation of hydrophobic branched copolymers comprised 
predominantly of poly(2-hydroxypropyl methacrylate) (HPMA) and a low molar 
concentration of ethylene glycol dimethacrylate (EGDMA) (p(HPMAx-co-EGDMAy)) 
were reported by Rannard and co-workers. These high molecular weight soluble 
architectures1-3 produced stable nanoparticles without the need for stabilisers. These 
reports utilised atom transfer radical polymerisation (ATRP) to synthesise both linear and 
branched statistical copolymers containing either ethyl functionality at the chain ends or 
ideally branched dendrons of varying generation. When linear-dendritic hybrid polymers 
are branched, the resulting materials have been termed hyperbranched polydendrons (hyp-
polydendrons). In most cases, uniform polymer nanoparticles were generated via 
nanoprecipitation into water, from rapidly assembling collapsed branched copolymers, 
which yielded diameters ranging from 60 to 800 nm.   
 
When designing polymer nanoparticles for drug delivery applications, it is important that 
they can endure various biological environments, including salts and buffers, which are 
present in the human body. Unfortunately, nanoparticles previously prepared from 
p(HPMAx-co-EGDMAy) were charge stabilised and therefore precipitated during NaCl 
addition. Charge stabilised colloids can be easily de-stabilised by addition of electrolytes, 
due to the screening of repulsive charges by the ions present, which ultimately leads to 
polymer precipitation.4 The lack of colloidal stability in electrolyte solutions has delayed 
the use of these systems and relatively complex synthetic strategies have sought to 
overcome this problem. Steric stabilisation can be achieved through the incorporation of 
a hydrophilic moiety to the nanoparticle, usually a hydrophilic polymer.5 Typical 
hydrophilic polymers which have been used as such to stabilise hydrophobic aqueous 
nanoparticles include; polyethylene glycol (PEG), polycyclodextrin, polyglutamate, PLA 
PLGA.6 
 
Nanoprecipitation of hydrophobic polymers into aqueous media is still a relatively poorly 
understood concept, therefore the initial studies presented in this research chapter will 
seek to investigate the optimum conditions for the preparation of p(HPMAx-co-EGDMAy) 
nanoparticles. To date, there have been no reports of nanoprecipitation of a branched 
hydrophobic polymer and A-B block copolymer to produce sterically stabilised 
nanoparticles. Therefore, this research aims to investigate the nanoprecipitation of the 
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hydrophobic copolymer p(HPMAx-co-EGDMAy) and a range of PEG A-B block 
copolymers to assess if steric stabilisation can be achieved via this method.  
 
2.2 Controlled polymer synthesis 
 
Conventional free radical polymerisation (FRP) has many advantages over other 
polymerisation methods, including less stringent conditions, wide range of solvents 
(including water) and polymerisation of an extensive range of vinyl monomers. Hence, 
nearly ~50% of all commercial synthetic polymers are synthesised by FRP, providing a 
wide range of polymers for varying applications.7 However, the major limitations of FRP 
include; the poor control of the molecular weight, broad molecular weight distribution, 
and the difficulty (or even impossibility) of preparing well-defined copolymers or 
polymers with a predetermined functionality. During the last two decades, various 
controlled radical polymerisation (CRP) techniques have been developed that enables FRP 
to offer some of the benefits of ‘living’ polymerisations. 
2.2.1 Atom transfer radical polymerisation 
ATRP is among the most effective and most widely used CRP methods. This technique 
was first reported independently by Wang and Matyjaszewski8 and Sawamoto9 and co-
workers during 1995. Since then, there has been a vast amount of research within this area 
and ATRP has become a very useful technique towards the preparation of functional 
polymers10, 11 and, contrasting to FRP, ATRP enables the control of polymer molecular 
weight and architecture. 
The general mechanism for ATRP is shown in Scheme 2.1 and a typical reaction includes 
a halogen initiating species (R-X), monomer and a transition metal complex (Mtn/L). The 
initiating species (R-X) is abstracted by the transition metal catalyst to form both X-
Mtn+1/L and the initiating radical species R●, which occur with a rate of activation (kact).  
During this process, the halogen undergoes a one electron redox reaction with the 
transition metal catalyst. The transition metal catalyst is added to the reaction in a lower 
oxidation state and forms the reactive species and catalyst complex in the higher oxidation 
state, which can then deactivate the propagating radical. The initiating radical species, R● 
reacts with the vinyl group of the monomer via a radical mechanism resulting in R-M● 
which subsequently propagates with the rate constant kp, by further reaction with 
monomer units. This process reduces the concentration of active chain ends by 
establishing a dynamic equilibrium between the radical and the dormant species. The 
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equilibrium lies heavily towards the dormant species (the rate of this step is denoted as 
kdeact), therefore reducing the number of reactive chain ends present at any one time and 
so reducing the possibility of unwanted side reactions, which would result in higher 
molecular weights and broader molecular weight distributions. The mechanism of ATRP 
allows for the preparation of more precisely controlled polymer molecular weights with a 
low dispersity (Đ <1.3). Termination reactions may also occur, usually as coupling or 
disproportionation, and the rate is denoted as kt, however they are minimal during the 
reaction. Due to the presence of radicals and a transition metal catalyst, care must be taken 
to ensure no oxygen is present, which would scavenge radicals, terminate the 
polymerisation and oxidise the copper catalyst.  
 
Scheme 2.1 General mechanism for ATRP. 
ATRP has attracted both research and commercial interests for the following reasons; (1) 
relatively straight forward experimental setup, (2) compatibility with a wide range of 
different solvents and solvent mixtures, including water which is attractive for biomedical 
applications, (3) polymers can be prepared over a range of temperatures without the 
formation of side products, (4) use of readily available and inexpensive catalyst 
components and (5) commercially available or easily prepared initiators or 
macroinitiators, depending on the desired composition and application.12 
2.2.2 Preparation of amphiphilic block copolymers via ATRP 
As briefly discussed in Chapter 1 (Section 1.2.1), the self assembly of block copolymers 
has been extensively researched for the development of drug delivery vehicles. Block 
copolymers can consist of two or more distinct monomers and can have various 
architectures such as linear block copolymer (A-B), triblock (A-B-A), multiblock or 
segmented polymers (A x-B y) and can be prepared via ATRP.
13-15 Due to its radical nature, 
the topology of the polymer (linear, branched etc.) and the composition of the polymeric 
chains (statistical, grafts, block copolymers etc.) can be varied depending on the intended 
application. ATRP allows for the incorporation of the initiator functionality at every 
primary polymer chain end, which can enable functionalities such as vinyl, cyano, 
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hydroxyl and other groups at one end of the polymer chain, whilst the other chain end 
remains an alkyl halide, under ideal conditions.16   
 
A wide range of well defined, near monodisperse amphiphilic block copolymers have 
been prepared for many applications, including drug delivery nanocarriers,17 (Chapter 1, 
Section 1.2), which are the main focus of this research project. Many examples of 
amphiphilic block copolymers incorporate PEG as the hydrophilic component, due to its 
previously discussed biocompatibility and versatility with hydrophobic monomers.18 The 
synthesis of polymers from a PEG isobutyryl bromide macroinitiator has been a successful 
route for the preparation of A-B block copolymer.19 Some examples of monomers used 
for A-B and A-B-A block copolymer include (but not limited to); 2-hydroxyl ethyl 
methacrylate,20 styrene,19 N-isopropylacrylamide,21 tert-butyl methacrylate and 2-
(dimethylamino)ethyl methacrylate.22  
 
2.2.3 Branched polymers via ATRP 
Branched vinyl polymerisation has been utilised to produce various branched copolymers 
with varying compositions. Examples of structures achieved include; branched 
homopolymers, branched block copolymers, branched statistical copolymers, branched 
graft-copolymers and more complex structures such as shaped branched amphiphilic 
copolymers.23 Various polymerisation techniques have been employed to produce 
branched copolymers and include; chain transfer agent mediated free radical 
polymerisation (Strathclyde approach),24 atom transfer radical polymerisation (ATRP),25 
and reversible addition-fragmentation chain-transfer (RAFT) polymerisation.26 
The use of ATRP to produce branched copolymers is most relevant to the research project 
and the copolymerisation of a vinyl and a divinyl monomer using ATRP was first reported 
during 2001.27 Branched architectures can be prepared by incorporation of a vinyl and 
divinyl monomer during the polymerisation. The intention of this research was to form 
soluble branched copolymers as opposed to insoluble gels. During 2004, Isaure et al. 
reported the preparation of branched soluble polymers via ATRP,25 utilising methyl 
methacrylate (MMA) and the divinyl monomer, EGDMA, to form branched p(MMAx-co-
EGDMAy). Further examples of branched copolymers reported include p(HPMAx-co-
EGDMAy)
28 and polystyrene, p(styrene-co-divinylbenzene).29 This useful one-pot 
reaction has provided a route to synthesise new material architectures, including 
amphiphilic blocks and graft copolymers.30 Utilising ATRP for the formation of branched 
copolymers produces architectures similar to those expected via the Strathclyde 
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approach,24 however, ATRP allows for the incorporation of the initiator functionality at 
every primary polymer chain end. 
During the early stages of a branched copolymerisation via ATRP, the divinyl monomer 
and monomer behave almost identically and the divinyl monomer incorporates into the 
polymer chain leaving pendant unreacted double bonds (Figure 2.1). At low monomer 
conversion, the ratio is so highly biased towards unreacted monomer, therefore it is not 
until high conversions, when the number of unreacted monomers and pendant vinyl 
groups becomes comparable, which results in the onset of intermolecular coupling of 
polymer chains. At this point, the probability of the growing chains incorporating a 
pendant vinyl group of another polymer chain increases, hence a large increase in 
molecular weight and broad molecular weight distribution. For effective initiation, 
experimentally the ratio of divinyl monomer/initiator should be ≤ 1, if not, then the 
polymer formed will be an insoluble crosslinked material or microgel. 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic representation of a branched copolymerisation via ATRP. Adapted from ref28 
The aims of this research chapter is to synthesise HPMA polymers based upon previous 
reports1 and assess their nanoprecipitation behaviour in detail. Nanoparticles composed of 
HPMA alone are charge stabilised, therefore, it was of interest for the research project to 
investigate if steric stabilisation could be introduced via addition of a PEG A-B block 
copolymer. The synthesis of the branched copolymer, p(HPMAx-co-EGDMAy) and a 
range of varying PEG A-B block copolymers will be conducted via ATRP, and the 
properties of the resulting nanoparticles formed via nanoprecipitation will be investigated. 
 
Initiation Propagation Branching
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2.3 Synthesis of linear p(HPMAx) and the branched copolymer 
p(HPMAx-co-EGDMAy) 
Both linear and branched HPMA polymers (Scheme 2.2) were synthesised for the 
following study via previously reported copper catalysed methanolic ATRP chemistry.28 
HPMA was the selected monomer for further studies as previous research within the 
Rannard group had determined the optimum polymerisation conditions via ATRP, the 
subsequent preparation of nanoparticles from varying polymeric architectures, resulting 
in nanoparticle stability for extended periods of time. The polymerisations and 
copolymerisations of HPMA with a targeted number average degree of polymerisation 
(DPn) of 50, and for the branched copolymer, the DPn targeted is based upon the primary 
chain length only. The polymerisations were carried out at 30°C in methanol with 
CuCl:bipyridyl (bpy) (1:2), as the catalytic system. The initiator, ethyl bromo isobutyrate 
(EBiB) (1), presented in Scheme 2.2 was utilised for both polymerisations due to previous 
success during ATRP reactions and commercial availability. The formation of branched 
HPMA was achieved by addition of EGDMA (2) to yield, p(HPMA50-co-EGDMA0.9) (3). 
The molar ratio of initiator:divinyl monomer (EBiB:EGDMA) is crucial to ensure the 
formation of a soluble high molecular weight polymer, therefore in order to avoid gelation 
a ratio of 1:0.9 was employed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.2 Polymer synthesis. A) linear p(HPMA50), B) branched p(HPMA50-co-EGDMA0.9). 
 
(1)
50
0.9
(3)
(2)
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Triple detection gel permeation chromatography (GPC) was used to determine molecular 
weights and dispersities of the synthesised polymers; the targeted number average 
molecular weight (Mn) for the linear p(HPMA50) homopolymer was 7200 g/mol. A higher 
than expected Mn of 9900 g/mol was obtained by GPC, which may be due to the initiating 
efficiency of EBiB. The weight-average molecular weight (Mw) was 12400 g/mol with a 
dispersity (Đ) of 1.25. The branched copolymer, p(HPMA50-co-EGDMA0.9) exhibited a 
much higher molecular weight; Mn = 24200 g/mol, Mw = 251400 g/mol and Đ = 10.4, as 
a result of the presence of the EGDMA during the polymerisation. The HPMA monomer 
conversion for both polymers was determined using 1H NMR analysis, by integration of 
the vinyl protons to an internal reference (anisole) (Appendix, Fig. A1) and both polymers 
reached high monomer conversion (>98%). The GPC overlays for p(HPMA50) highlight 
the differences between both linear and branched architectures via the refractive index 
(RI) (Figure 2.2A) and right angle light scattering (RALS) (Figure 2.2B) chromatograms. 
The RI detector response is dependent upon the concentration of the polymer, whilst the 
RALS detector response is dependent upon the size of the polymeric material present in 
solution. The RI overlay, illustrates a narrow monomodal and broad, multi-modal 
molecular weight distribution for the linear p(HPMA50) polymer and branched 
p(HPMA50-co-EGDMA0.9) copolymer respectively. Due to the statistical nature of 
EGDMA incorporation, a broad and multi-modal molecular weight distribution suggests 
polymer species that range across linear, lightly branched and highly branched 
architectures, which is typical of branched copolymers formed via this mechanism.1 It is 
useful to compare both RI and RALS chromatograms because although a small RI 
response for branched p(HPMA50-co-EGDMA0.9) is detected between a retention volume 
of 14 - 15.5 mL, the RALS detector response (Figure 2.2B) is much larger between these 
retention volumes as the highly branched copolymer scatters significantly more light than 
the small polymer molecules. 1H nuclear magnetic resonance (NMR) analysis of the final 
polymer can also be used to determine the DPn of the primary chains but unfortunately for 
the linear p(HPMA50), the proton environments of the initiating chain end overlap with 
the polymer peaks so this value cannot be calculated. However, the main proton 
environments can be depicted by 1H NMR for both linear p(HPMA50) and branched 
p(HPMA50-co-EGDMA0.9), Appendix, Fig. A2 & A3.  
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Figure 2.2 GPC chromatogram overlays of linear p(HPMA50) and branched p(HPMA50-co-
EGDMA0.9). A) refractive index, B) right angle light scattering detectors. 
 
2.4 Aqueous nanoprecipitation studies 
 
2.4.1 Aqueous nanoprecipitation studies of linear p(HPMA50) and branched 
copolymer p(HPMA50-co-EGDMA0.9) 
 
Although the nanoprecipitation of polymers has been studied for several decades, some 
aspects of the mechanism are not fully understood or studied in detail. As previously 
discussed, there are different approaches towards nanoprecipitation but prior studies 
within the Rannard research group have employed rapid addition of polymer solutions to 
volumes of stirring water,1-3 therefore continuation of this method will allow a direct 
comparison and broaden our understanding of the process. A series of experiments were 
conducted, whereby a consistent mass of polymer was nanoprecipitated into a set volume 
of water with increasing amounts of good solvent. Maintaining a constant mass of polymer 
during the different nanoprecipitations was important to evaluate the quality of the mixed 
solvent environments. 
 
A schematic representation of nanoprecipitation is represented in Figure 2.3 and for the 
following studies, previously synthesised p(HPMA50) and p(HPMA50-co-EGDMA0.9) 
were dissolved in either tetrahydrofuran (THF) or acetone, as recent literature has shown 
that the nature of the good solvent can affect nanoprecipitation outcomes, therefore testing 
within two different solvents was considered important for the study.31 From this point 
onwards, the organic solvent will be described as the good solvent, as this readily 
solubilises the polymers. The term anti-solvent will be used to describe the solvent in 
A) B)
Mn = 9900 g/mol
Mw = 12400 g/mol
Ð = 1.25
Mn = 24200 g/mol
Mw = 251400 g/mol
Ð = 10.4
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which the polymers are nanoprecipitated into and for the purpose of this research and often 
used within the literature, this anti-solvent is water (the bad solvent for the polymers). The 
polymers were dissolved at specific concentrations from 25 to 1.5625 mg/mL and varying 
volumes of each solution ranging from 0.5 mL of the 25 mg/mL solution to 8 mL of the 
1.5625 mg/mL solution were added to 5 mL of water. This system ensured that a consistent 
fixed mass (12.5 mg) of each polymer was precipitated into a set volume of water under 
varying solvent conditions (Table 2.1). A constant mass of polymer during each 
nanoprecipitation experiment was important to determine if increasing volumes of good 
solvent can prevent the formation of stabilised nanoparticles. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Schematic representation of the nanoprecipitation process. 
 
Table 2.1 The conditions for nanoprecipitation experiments of both linear p(HPMA50) and p(HPMA50-
co-EGDMA0.9). Mass of polymers dissolved in good solvent (kept constant at 12.5 mg), during each 
nanoprecipitation. 
 
 
Fast addition 
into stirring 
water
Evaporation 
of acetone
or
Association 
of polymers and 
formation of 
nanoparticles
Linear or branched 
polymer 
nanoparticles in 
water
Linear or 
branched poly 
HPMA dissolved 
in a volatile, 
‘good’ solvent
Volume of good solvent 
(acetone or THF + polymer (mL)
Concentration of polymer
in good solvent (mg/mL)
Volume of
water (mL)
Volume fraction
of good solvent
0.5 25 5 0.0909
1 12.5 5 0.1667
2 6.25 5 0.2857
3 4.167 5 0.3750
4 3.125 5 0.4444
5 2.5 5 0.5000
8 1.5625 5 0.6154
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The following nanoprecipitation experiments aim to investigate if there is an advantage 
of using branched p(HPMA50-co-EGDMA0.9) copolymers rather than linear p(HPMA50), 
when seeking to achieve narrow, monomodal polymer nanoparticle distributions. 
Nanoparticles prepared during this study were analysed using dynamic light scattering 
(DLS). DLS analysis of nanoparticles can be used to determine parameters such as the z-
average diameter (Dz) (d. nm) and polydispersity index (PdI), which is a measure of the 
width of the size distribution. The derived count rate, measured in kilo counts per second 
(kcps) is also a calculated parameter, which is the number of photons detected and is and 
takes into account the attenuation factor used. Light scattered is directly proportional to 
the size and number of particles present in a sample, therefore the derived count rate can 
be used to indicate the presence of nanoscale objects. Unless otherwise stated, an average 
of 3 repeat measurements were taken for each nanoparticle sample. During the 
nanoprecipitation of linear p(HPMA50) (Figure 2.4A), no clear trends were observed using 
DLS, when measuring the samples immediately after addition or after complete 
evaporation of the good solvent phase.   
 
 
Figure 2.4 DLS analysis of linear p(HPMA50). A) nanoprecipitation from acetone, B) nanoprecipitation 
from THF, A, B) i) derived count rate from samples immediately after addition of the acetone or THF 
solution into water, using a constant mass (12.5 mg) of polymer and A, B) ii) z-average diameter (nm) 
(closed symbols) and PdI (open symbols) of the samples in the acetone/water mixture (blue symbols) 
and in water (red symbols) after acetone or THF evaporation. 
A very high intensity of light scattering was only observed when <1 mL of either acetone 
or THF was present within the anti-solvent (Figure 2.4 Ai & Bi). When >1 mL of good 
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solvent was introduced, the derived count rate rapidly decreased, suggesting a very low 
concentration of nanoscale objects present upon increasing volumes of good solvent. The 
DLS results show that for linear p(HPMA50), there is a large increase in size (>500 nm) 
during removal of acetone and THF and PdI values exceed 0.3, suggesting the formation 
of large unstable aggregates.  
 
The nanoprecipitation of branched p(HPMA50-co-EGDMA0.9) demonstrated considerably 
different behaviour (Figure 2.5). Highly significant light scattering intensities were 
obtained when the branched copolymer solutions were added to water when dissolved in 
up to 3 mL of good solvent (Figure 2.5 Ai & Bi), and similarly, nanoparticles with a Dz 
less than 250 nm were readily observed (Figure 2.5 Aii & Bii). After evaporation of the 
good solvent, the measured Dz values of the nanodispersion were lower than Dz values 
obtained in the presence of the good solvent. This is due to the desolvation of assemblies 
resulting in a slight decrease in hydrodynamic diameter. The nanoprecipitated particles 
also exhibited a uniform size distribution (PdI values <0.1) which was maintained after 
evaporation of the good solvent (Appendix, Table A1). As may be expected, when 
volumes >3 mL of each acetone solution were used in the nanoprecipitation, a sudden 
decrease in the light scattering intensity was seen, with a concomitant loss of quality 
within the correlation functions, within the samples measured immediately after acetone 
solution addition (Figure 2.5 Ai). A corresponding decrease was observed in the measured 
Dz values; however, after solvent evaporation, particles with Dz values >1 μm were 
observed (Figure 2.5 Aii) with broad PdIs (>0.3); the slow formation of particles during 
evaporation of acetone is clearly not controlled. An identical trend was seen when using 
THF as the good solvent phase, but up to 4 mL volumes of polymer solution were able to 
generate nanoprecipitates immediately after addition and the sudden decrease in light 
scattering of samples containing good solvent and anti-solvent was observed at volumes 
> 4 mL (Figure 2.5 Bi & ii). The solvent swollen nanoprecipitates formed immediately 
after THF addition were significantly larger than those derived from acetone solutions, 
and this increased size was also seen within the nanoparticles after solvent evaporation. 
The nanoparticle sizes were generally larger during mixing of the solvents, which could 
be due to swelling of the nanoprecipitates in the solvent mixture during the evaporation 
stages and THF appears to be a better solvent for p(HPMA50-co-EGDMA0.9). Therefore, 
after complete solvent removal there is an overall decrease in size. From this study, it is 
unclear whether these differences indicate considerable or slight differences in the 
solubility of branched p(HPMA50-co-EGDMA0.9) in these aqueous solvent environments. 
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The larger swollen nanoprecipitates, and resulting solvent-free aqueous dispersions, do 
suggest different factors controlling the nucleation and growth mechanism when using 
these two different solvents. It appears that branched chains can effectively collapse to 
form relatively large nuclei that assemble to form the larger, colloidally stable 
nanoparticles.  
 
The investigation of a good solvent/anti-solvent phase ratio, suggests that during the 
addition of large volumes of good solvent to the anti-solvent phase, the nanoprecipitation 
process is prevented due to the saturated environment. It is apparent from the obtained 
derived count rate values, that nanoparticles are formed very quickly on mixing and will 
be present within the mixed solvent/anti-solvent environment during solvent evaporation 
stages, rather than being formed slowly from a dissolved state as the good solvent is 
removed.  
 
 
Figure 2.5 DLS analysis of branched p(HPMA50-co-EGDMA0.9) (A) nanoprecipitation from acetone, 
B) nanoprecipitation from THF, i) derived count rate from samples immediately after addition of the 
acetone or THF solution  into water, using a constant mass (12.5 mg) of polymer and ii) z-average (d. 
nm) (closed symbols) and PdI (open symbols) of the samples in the acetone/water mixture (blue 
symbols) and in water (red symbols) after acetone or THF evaporation. 
 
2.4.2 Multiple nanoprecipitation studies 
 
The formation of colloidally stable nanoparticles via nanoprecipitation has the potential 
to allow additional subsequent nanoprecipitations into the same anti-solvent mixture, after 
removal of good solvent, assuming the mixed good/anti-solvent environment does not 
pass the nanoprecipitation boundary. It was hypothesised, that during a multiple 
nanoprecipitation experiment i.e. addition of polymer in good solvent (i5-f1) to already 
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formed nanoparticles, one of the two following outcomes could occur; (i) the growth of 
existing nanoparticles will continue and an increase in Dz would be observed or, (ii) the 
formation of new nanoparticles of identical Dz. A schematic representation of a the 
proposed multiple nanoprecipitation process is outlined in Figure 2.6, and the details of 
each step are as follows; (i) addition of polymer dissolved in a good solvent to the aqueous 
anti-solvent, (ii) removal of good solvent to generate stable nanoparticles in water, and 
(iii) a second and identical addition of polymer solution in a good solvent to the aqueous 
nanoparticle dispersion, with (iv) removal of the second volume of good solvent to create 
a greater number of nanoparticles whose size increases or matches the original 
distribution. 
 
 
 
Figure 2.6 Schematic representation of multiple nanoprecipitations of branched copolymers: (i) 
addition of polymer in good solvent to water, (ii) formation of particles in mixed solvent/water, (iii) 
evaporation of good solvent and desolvation to generate aqueous nanoparticle dispersion and second 
addition of polymer solution, (iv) formation of new particles of identical size, (v) growth of existing 
particle diameters.  
 
Acetone and THF solutions of p(HPMA50-co-EGDMA0.9) were prepared at a 
concentration of 5 mg/mL, and varying volumes of the solutions from 0.5 to 4 mL were 
rapidly added to 5 mL of water with vigorous stirring; samples were studied by DLS after 
solvent evaporation. As can be seen from Table 2.2 and Figure 2.7, for repeated additions 
of the branched copolymer solution up to 2 mL of acetone addition, the recorded Dz values 
of the nanoprecipitated particles are almost identical and only slight changes in PdI are 
observed, as would be expected if no perturbation of the initial nanodispersion occurred 
and the existing nanoparticles do not act as nuclei for further growth. When repeating 
additions of volumes >3 mL, the nanoparticles formed from p(HPMA50-co-EGDMA0.9) 
i) ii) iii)
iv)
v)
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varied considerably after the second addition and subsequent evaporation of good solvent; 
repeated addition of 3 and 4 mL of the polymer solution in acetone and THF led to 
considerable phase separation, for DLS analysis see Appendix, Table A2.  
 
When using THF as the good solvent phase, similar behaviour was observed but repeated 
nanoprecipitations only tolerated volumes of <2 mL; higher volumes generated 
appreciable variation in Dz or observable precipitates on second addition. This suggests 
that the mixed THF/water environments formed during the second sample addition were 
more capable of perturbing the initial nanoparticles, potentially solvating them to a point 
where they were able to aggregate or able to act as nuclei for additional growth. 
 
Table 2.2 DLS results for multiple nanoprecipitations from both acetone and THF polymer solutions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Volume of Polymer 
Solution Added (mL)
Addition no. Dz (nm) PdI Derived
count rate (kcps)
Acetone
0.5 1 72 0.119 66551
2 75 0.193 176697
1 1 79 0.075 254902
2 83 0.099 442959
2 1 105 0.113 1049237
2 112 0.081 1451725
3 1 162 0.054 1443879
2 293 0.156 1369080
THF
0.5 1 83 0.107 106516
2 81 0.118 276651
1 1 91 0.08 356127
2 92 0.103 629711
2 1 107 0.083 1318163
2 130 0.080 1531601
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Figure 2.7 DLS overlays for the multiple nanoprecipitations of branched p(HPMA50-co-EGDMA0.9) 
A) Overlay of DLS data for multiple nanoprecipitations of p(HPMA50-co-EGDMA0.9) from acetone B) 
Overlay of DLS data for multiple nanoprecipitations of p(HPMA50-co-EGDMA0.9) from THF. For (A) 
and (B), first nanoprecipitation (black trace) followed by the second nanoprecipitation (red dashed 
trace). 
 
The derived count rates obtained by DLS after each nanoprecipitation varied in a very 
consistent manner across the two solvent systems studied. When using either acetone or 
THF as the good solvent phase, an approximate 2.6-fold increase was seen during the 
second addition of 0.5 mL of polymer solution, which, in conjunction with the similarity 
of Dz, would suggest an approximate doubling of the number of nanoparticles within the 
aqueous phase after good solvent evaporation (Figure 2.6 iv). The comparisons of derived 
count rates after the first and second nanoprecipitations when using 1 mL addition were 
also similar across the two good solvents. Generally, an increase in scattering was 
observed during each subsequent addition of polymer dissolved in good solvent and 
similar Dz values were obtained. This suggests that after the second addition of polymer 
in good solvent, additional nanoparticles of the same size are present as well as the existing 
nanoparticles in the aqueous dispersion. An exception to the general trend was for the 
multiple addition of 3 mL of polymer dissolved in acetone, where the Dz almost doubled 
and a slight decrease in scattering was observed. This may suggest that for the increasing 
addition of polymer in good solvent, the growth of existing nanoparticles can result, as 
opposed to the formation of a new particle distribution. In terms of drug delivery 
nanocarriers, the ability to instantly increase the concentration of polymer nanoparticles 
via low volume additions is very appealing for increasing the concentration of therapeutic 
drug molecules whilst maintaining a constant volume.  
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2.4.3 Variation of concentration and temperature  
 
So far, the mass of polymer has been kept constant during the nanoprecipitation 
experiments, in order to evaluate the effects of increasing volume additions from both 
acetone and THF. The following experiments aimed to determine if the concentration of 
polymer within the good solvent would affect the Dz values if varied. In order to 
investigate this, nanoprecipitation experiments of p(HPMA50-co-EGDMA0.9) were 
conducted using fixed volumes of solutions with polymer concentrations varying from 25, 
10, and 5 mg/mL. Irrespective of good solvent choice, solutions containing the branched 
copolymer at 5 mg/mL consistently produced smaller nanoparticles. Nanoprecipitations 
using >1mL of these solutions (acetone or THF) conducted at the higher concentrations 
of 10 mg/mL and 25 mg/mL, resulted in the formation of large unstable aggregates (Figure 
2.8). During an increase in polymer concentration, the DLS results suggest that the growth 
of the nanoparticles becomes limited by the poor diffusion of the polymer molecules to 
the nuclei surface. An increased number of nuclei will limit the diffusion into the anti-
solvent and the growth of nanoparticles will occur through random collisions of existing 
particles and most likely result in aggregation.32 
 
 
Figure 2.8 DLS analysis of nanoprecipitation of p(HPMA50-co-EGDMA0.9) dissolved within either 
acetone (left) or THF (right) using varying volumes of three different solution concentrations (25 
mg/mL – red circle, 10mg/mL – blue triangle and 5 mg/mL – black square. (Each volume was added 
to 5 mL of water and the solvent was evaporated prior to measurement). 
 
In summary, the nanoprecipitation experiments of p(HPMA50-co-EGDMA0.9) from 
acetone generally gave lower PdI and smaller Dz values prior to, and after, good solvent 
removal; therefore, THF was not selected for further study. Acetone also has the practical 
advantage of a lower boiling point to aid removal. Therefore, based on these experimental 
results, all nanoparticles from this point onwards (unless otherwise stated) will be 
prepared from 1 mL of a 5 mg/mL polymer solution nanoprecipitated from acetone into 5 
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mL of water. The initial and final concentration of samples prepared by aqueous 
nanoprecipitation will be described as ix-fy, where x represents the initial concentration 
and y the final concentration in mg/mL, therefore unless otherwise stated; the conditions 
will be i5-f1. 
 
In order to study the effect of the water temperature during the nanoprecipitation of 
p(HPMA50-co-EGDMA0.9), experiments were conducted at both ambient and elevated 
temperatures of 50°C (Figure 2.9). From previous experiments, it is evident that up to a 3 
mL addition of acetone, there is a very small effect on the nanoparticle dispersion, which 
suggests any sudden increase in temperature will have negligible effects on the formation 
of the nanoparticles’ size and dispersity. 
 
Figure 2.9 The formation of p(HPMA50-co-EGDMA0.9) polymer nanoparticles into both ambient and 
50°C water, red square = volume of acetone (mL) vs ambient temp z-average (nm), red cross = volume 
of acetone (mL) vs ambient temperature PdI, blue square = volume of acetone (mL) vs 50°C z-average 
(nm), blue cross = volume of acetone (mL) vs 50°C PdI. 
 
The nanoprecipitation conditions which have been carried out support the previous 
research that there are clear advantages to using p(HPMA50-co-EGDMA0.9) copolymers 
rather than linear homopolymers for formation of nanoparticles which have narrow, 
monomodal size distributions. The direct observations that (a) nanoparticles are formed 
immediately after addition of the polymer within a good solvent to the anti-solvent, (b) 
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the addition of large volumes of good solvent can prevent nanoprecipitation, and (c) 
repeated nanoprecipitations into the same anti-solvent sample led to increased numbers of 
particles that match previous nanoprecipitations and also support the nucleation and 
growth mechanism that has been proposed.2, 32 Unfortunately, nanoparticles formed from 
branched p(HPMA50-co-EGDMA0.9) are charge stabilised as they exhibit high negative 
zeta potentials (~ -40 mV), and are, therefore, unstable during addition of small amounts 
of buffer/NaCl. As set out in the initial aims of the project, it would be desirable to 
introduce steric stabilisation into the system for nanoparticles to be considered for 
potential drug delivery applications. In order to do this, the next part of the research will 
describe the synthesis of A-B amphiphilic block copolymers and subsequent 
nanoprecipitation and co-nanoprecipitation studies. 
 
2.5 Synthesis and characterisation of A-B block copolymers 
 
2.5.1 A-B block copolymer compositions 
 
As discussed, the charge stabilisation of branched p(HPMA50-co-EGDMA0.9) 
nanoparticles limits their development for use as drug delivery nanocarriers. To improve 
the properties of these hydrophobic nanoparticles, it has been hypothesised that the 
synthesis of PEG containing A-B block copolymers and their inclusion within the 
nanoprecipitation process, could introduce steric stabilisation. After the nanoprecipitation 
of both p(HPMA50-co-EGDMA0.9) and p(PEGy-b-HPMAx) A-B block copolymers, it has 
been hypothesised that there are several potential outcomes which could occur and this is 
presented schematically in Figure 2.10 suggesting either; i) the HPMA chain from the A-
B block copolymer could become adsorbed onto the p(HPMA50-co-EGDMA0.9) 
nanoparticle surface resulting in a pendant PEG chain, ii) the incorporation of 
hydrophobic HPMA of the A-B block copolymer within the nanoparticle core and PEG 
chains existing at the surface, iii) entrapment of the A-B block copolymer within the 
branched nanoparticle core,  iv) formation of two or more different nanoscale objects of 
p(HPMA50-co-EGDMA0.9) nanoparticles and micellar structures from p(PEGy-b-HPMAx) 
A-B block copolymers.  
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Figure 2.10 Schematic representation of potential outcomes of the formation of nanoparticles during 
addition of p(HPMA50-co-EGDMA0.9) and an A-B block copolymer; i) adsorption of the A-B block 
copolymer on the surface of p(HPMA50-co-EGDMA0.9) nanoparticles resulting in a pendant PEG chain, 
ii) incorporation of hydrophobic HPMA into the nanoparticle core and PEG chains at the surface, iii) 
entrapment of the A-B block copolymer within the branched nanoparticle core, iv) formation of two or 
more different nanoscale objects of p(HPMA50-co-EGDMA0.9) nanoparticles and micellar structures 
from p(PEGy-b-HPMAx) A-B block copolymers. 
 
 
The choice of macroinitiator, monomer and subsequent A-B block copolymers is 
demonstrated in Figure 2.11. The molecular weight of the macroinitiators (PEG45-Br or 
PEG114-Br) and targeted DPn of HPMA were varied in order to investigate the effects of 
different PEGy vs HPMAx block lengths. The synthesis and characterisation of the 
macroinitiators and copolymers will be discussed below.  
 
 
i)
ii)
iv)
iii)
Varying PEG 
chain length
Varying HPMA
chain length
p(HPMA50-co-EGDMA0.9) 
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Figure 2.11 Schematic representation of targeted PEGy-HPMAx A-B block copolymers via ATRP. 
 
2.5.2 PEG45-Br and PEG114-Br macroinitiator synthesis  
 
The PEG45-Br macroinitiator (4), was synthesised as previously reported
19 via an 
esterification reaction from poly(ethylene glycol) monomethyl ether (average molecular 
weight ~2000 g/mol)  and α-bromoisobutyryl bromide as shown below in Scheme 2.3A. 
 
The monomethoxy PEG, MeO-PEG45-OH (Mn ~2000 g/mol) was dissolved in toluene 
with the addition of triethylamine, 4-dimethyl-aminopyridine (DMAP) and degassed with 
N2 for 20-30 minutes. The α-bromoisobutyryl bromide was added drop wise over 30 
minutes to the reaction vessel which was cooled to 0°C. The rapid formation of a white 
precipitate (triethylamine salt Et3NH
+Br-) indicated progress of the reaction. The reaction 
medium was left to stir for 24 hours at room temperature under N2. The precipitate was 
filtered and the solvent was concentrated in vacuo.  The resulting product was diluted in 
acetone and purified by precipitation into cold petroleum ether (40-60°C). This last step 
was repeated and the product was finally dried under vacuum at 40°C for 24 hours. 
The formation of 4 was confirmed by 1H NMR spectroscopy, as shown in Figure 2.12. 
The integration ratios for proton environments h:a are 6:3 respectively, which corresponds 
to the proposed structure and environments b, c, d, e, & f integrate to give a value of 180 
which is representative of a PEG repeat unit with an Mn  ~2000 g/mol. Proton environment 
g, results from the formation of the ester bond, as this peak does not appear in the original 
mono methoxy alcohol 1H NMR. For further confirmation, the mass spectrometric 
analysis MALDI-TOF is shown in the Appendix (Fig. A4). 
Polyethylene glycol (PEG) PEG45-Br
HPMA DPn = 40
HPMA DPn = 80
HPMA DPn = 120
2-hydroxy propyl methacrylate
(HPMA)
Polyethylene glycol (PEG) PEG114-Br
HPMA DPn = 40
HPMA DPn = 80
HPMA DPn = 120
or
PEG45-Br 
initiated
PEG114-Br 
initiated
Initiator Monomer Polymer
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Scheme 2.3 Synthesis of MeO-PEGy-Br macroinitiators, A) MeO-PEG45-Br, B) MeO-PEG114-Br. 
 
 
 
 
Figure 2.12 1H NMR (D2O, 400MHz) of the mono-functional ATRP macroinitiator, MeO-PEG45-Br. 
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The MeO-PEG114-Br macroinitiator (5) (Scheme 2.3B) was synthesised using a 
monomethoxy PEG Mn ~5000 g/mol under the same conditions as the esterification 
reaction discussed above for the MeO-PEG45-Br macroinitiator. The formation of 5 was 
confirmed by 1H NMR spectroscopy (Appendix, Fig. A5). The integration value obtained 
for the MeO-PEG114-Br repeat unit was 455, which is expected for a ~5000 g/mol MeO-
PEG114-Br macroinitiator.  
 
2.5.3 Synthesis of linear A-B block copolymers  
 
The ATRP polymerisations of HPMA initiated by the PEG macroinitiators (PEG45-Br or 
PEG114-Br) with a targeted DPn of 40, 80 and 120 were carried out at 30°C in methanol 
utilising the same catalytic system of CuCl:bpy (1:2) discussed in Section 2.3. A 
generalised reaction scheme for the polymerisations is illustrated in Scheme 2.4 below.  
 
Scheme 2.4 Generic reaction scheme for the ATRP synthesis of p(PEGy-b-HPMAx) A-B block 
copolymers. 
Confirmation of the DPn using 
1H NMR was possible due to the presence of the methyl 
end group on the PEG chain and high molecular weight of the macroinitiator. The targeted 
DPn for this polymerisation was 40 monomer units. The 
1H NMR spectrum presented in 
Figure 2.13 shows that environment d has been calibrated to 3 protons and the 
corresponding b, b’, e and e’ integrate to ~242, which when divided by 6 equals ~40 which 
would be expected for this polymerisation.  The 1H NMR spectra for all other amphiphilic 
copolymers are assigned and located in the Appendix (Fig. A6-A10) and the DPn values 
by 1H NMR for all A-B block copolymers are reported in Table 2.3. Kinetic experiments 
were carried out for p(PEG45-b-HPMA40) and p(PEG114-b-HPMA40) to confirm that each 
polymerisation followed first order kinetics with respect to monomer concentration 
(Appendix, Fig. A11 & A12). 
x = DPn 40, 80 or 120
y = 45, 114
y y
x
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Figure 2.13 1H NMR spectrum of p(PEG45-b-HPMA40) (DMSO-d6, 400 MHz). 
 
The GPC and 1H NMR analysis for the linear A-B block copolymers synthesised from 
both macroinitiators is presented below (Table 2.3). The DPn values calculated by 
1H 
NMR spectroscopy were lower than the values obtained by GPC for all A-B block 
copolymers. These differences are most likely due to the initiator efficiency of the PEG 
macroinitiators being less than 100%. It is also worth taking into consideration that the 1H 
NMR evaluation may include unreacted initiator, resulting in calculations of polymer 
chains that are shorter than reported than GPC analysis and is discussed in the literature.33, 
34 The GPC RI overlays for the macroinitiators and linear A-B block copolymers 
demonstrate monomodal distributions for all polymers (Figure 2.14 A&B). The height of 
each peak has been normalised, so does not reflect the true differences in detector 
response. 
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Table 2.3 GPC and 1H NMR data for MeO-PEG45-Br and MeO-PEG114-Br initiated A-B block 
copolymers. 
 
 
Figure 2.14 GPC analysis of p(PEGy-b-HPMAx) A-B block polymers. A) GPC RI chromatogram 
overlays of PEG45-Br initiated A-B block copolymers B) GPC RI chromatogram overlays of PEG114-
Br initiated A-B block copolymers.  
2.6 Introduction to co-nanoprecipitation 
2.6.1 Aqueous nanoprecipitation studies of linear A-B block copolymers 
In order to assess whether the p(PEGy-b-HPMAx) A-B block copolymers could provide 
stability during addition to the nanoprecipitation process of branched p(HPMA50-co-
EGDMA0.9) nanoparticles, it was firstly important to nanoprecipitate both the A-B block 
copolymers and branched p(HPMA50-co-EGDMA0.9) individually to study their 
behaviour. The nanoprecipitation of the A-B block copolymers is an essential control 
Target Polymer 
Composition
GPC (DMF) 1H NMRa
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Mn
(g/mol)
Mw 
(g/mol)
Ð DP
n
DPn Conversion
(%)
MeO-PEG45-Br ~2000 2100 2200 1.05 - - -
MeO-PEG114-Br ~5000 5800 5840 1.01 - - -
p(PEG45-b-HPMA40) 7800 9250 11200 1.21 58 40 98
p(PEG45-b-HPMA80) 13500 18800 24400 1.29 110 82 98
p(PEG45-b-HPMA120) 19300 20300 25000 1.23 130 91 98
p(PEG114-b-HPMA40) 10800 16500 21000 1.27 79 39 98
p(PEG114-b-HPMA80) 16500 20000 25200 1.26 104 78 98
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experiment before carrying out the co-nanoprecipitation experiments, to see if nanoscale 
objects (if any) are formed. The A-B block copolymers were individually dissolved in 
acetone at 5 mg/mL and nanoprecipitated into 5 mL of water to give a final concentration 
of polymer in water of 1 mg/mL. The DLS size by intensity traces for the 
nanoprecipitation of solutions solely containing the A-B block copolymers are presented 
in Figure 2.15. A multi-modal peak was observed for p(PEG45-b-HPMA40) suggesting the 
sample consisted of two different size distributions after nanoprecipitation of this A-B 
block copolymer in water. In addition to this, a very low derived count rate (Table 2.4) 
and high attenuation value of 9 was observed, which suggests a low concentration of 
nanoscale objects present and an appreciable solubility of the A-B copolymer solubility 
in water. The nanoprecipitation of the higher molecular weight A-B copolymer, p(PEG45-
b-HPMA80) gave a monomodal peak when analysed by DLS and although the PdI 
obtained was reasonably broad, there was an increase in derived count rate when 
compared with p(PEG45-b-HPMA40). As p(PEG45-b-HPMA80) is insoluble in water, it 
would be expected that the amphiphilic nature of the polymer would result in formation 
of micellar objects within this environment. It is worth noting that the DLS results for two 
of three block copolymers, p(PEG45-b-HPMA40) and p(PEG45-b-HPMA80), did not 
provide reliable scattering data. The most hydrophobic A-B block copolymer of the PEG45 
series, p(PEG45-b-HPMA120), as expected, was also insoluble in water and a monomodal 
peak was observed during nanoparticle analysis by DLS. The nanoscale objects formed 
gave a large Dz of 372 nm, with a moderately low PdI, and the scattering of large objects 
was confirmed by the increased derived count rate. 
The p(PEG114-b-HPMAx) A-B block copolymer series were all water soluble due to the 
increased length of the hydrophilic PEG block (5000 g/mol); this increase in 
hydrophilicity becomes apparent when attempts are made to nanoprecipitate the polymers 
into water from acetone. Again, the DLS results obtained for p(PEG114-b-HPMA40) and 
p(PEG114-b-HPMA80) gave low quality data and the low derived count rates also 
confirmed their solubility in water. The highest molecular weight A-B block copolymer 
of the p(PEG114-b-HPMAx) series appeared to form small nanoscale objects, however 
multi-modal peaks were observed for the z-average size distribution and the large PdI 
value would not be ideal if we were to use these nanodispersions for further applications.  
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Figure 2.15 DLS Dz overlays of the nanoprecipitation of A-B block copolymers from acetone into 
water. (i5-f1) A) p(PEG45-b-HPMAx), B) p(PEG114-b-HPMAx). 
 
Table 2.4 DLS results for the nanoprecipitation of linear p(PEGy-b-HPMAx) A-B block 
copolymers (1 mg/mL). 
 
 
Overall, this control experiment has shown that when the A-B block copolymers are 
nanoprecipitated individually, nanoscale objects were formed for two of the polymeric 
materials. Interestingly, the polymers which gave reliable results when measured by DLS, 
were water insoluble p(PEG45-b-HPMA120) and soluble p(PEG114-b-HPMA120) polymers, 
which are both the most hydrophobic polymers, due to the highest compositions of HPMA 
within each respective p(PEGy-b-HPMAx) series. The scattering data obtained for 
p(PEG45-b-HPMA80) also demonstrated the formation of nanoscale objects, however, 
Polymer Dz (nm) PdI Dn(nm) Derived
Count Rate (kcps)
p(PEG45-b-HPMA40)* 268
(153 79%, 25 21%)
0.338 21 1850
p(PEG45-b-HPMA80)* 131 0.227 75 71500
p(PEG45-b-HPMA120) 372 0.145 340 50300
p(PEG114-b-HPMA40)* 317 0.373 109 2280
p(PEG114-b-HPMA80)* 88
(320 49%, 45 39%, 4000 12%)
0.738 23 3720
p(PEG114-b-HPMA120) 49 
(49 90%, 921 5%, 4657 4%)
0.265 30 10020
* Inadequate scattering data
p(PEG45-b-HPMA40)
p(PEG45-b-HPMA80)
p(PEG45-b-HPMA120)
p(PEG114-b-HPMA40)
p(PEG114-b-HPMA80)
p(PEG114-b-HPMA120)
A) B)
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inconsistent data from DLS analysis limited the reliability of the results. These control 
experiments will be important when studying the co-nanoprecipitation system, which will 
be discussed further in section 2.6.3. 
2.6.2 Aqueous nanoprecipitation studies of branched p(HPMA50-co-EGDMA0.9)  
 
Although the nanoprecipitation of branched p(HPMAx-co-EGDMAy) has been previously 
discussed and recently reported,1 it is important to nanoprecipitate the branched 
copolymer as a control, before carrying out the subsequent co-nanoprecipitation 
experiments. Due to complete consumption of the previous sample, a new batch of 
p(HPMA50-co-EGDMA0.9) was synthesised as previously described in section 2.3. The 
GPC analysis of the original sample exhibited an Mn = 24200 g/mol, Mw = 251400 g/mol 
and a Đ of 10.4. The GPC data below (Figure 2.16A) shows the RI chromatogram for the 
new sample of p(HPMA50-co-EGDMA0.9) and the molecular weight values were 
comparable with the original sample as a broad molecular weight distribution was 
obtained as observed previously (Mn = 39100 g/mol, Mw = 293100 g/mol and a Đ of 7.49). 
To ensure all nanoparticle dispersions were comparable, the nanoparticles were prepared 
under the same conditions as previously described, i5-f1 from acetone into water. The DLS 
analysis for aqueous p(HPMA50-co-EGDMA0.9) nanoparticles via nanoprecipitation of the 
newly synthesised sample (Figure 2.16B) gave a monomodal peak with a Dz of 148 nm 
(PdI 0.080). This correlates accordingly with the nanoparticles prepared in Section 2.4.1 
from the original sample (Dz = 111, PdI = 0.081) and p(HPMA50-co-EGDMA0.9) 
nanoparticles prepared by Slater et al with a Dz of 146 nm (PdI 0.034), so although there 
are differences in polymer molecular weights, similar nanoparticle sizes were obtained. 
Generally, nanoparticles prepared from p(HPMA50-co-EGDMA0.9) under these 
conditions, range within the size range of 110-150 nm and from this point onwards all 
nanoprecipitation experiments will be conducted using the new sample of p(HPMA50-co-
EGDMA0.9). The presence of spherical nanoparticles consisting of p(HPMA50-co-
EGDMA0.9) were further confirmed by scanning electron microscopy (SEM) (Figure 
2.16C) and the number average diameter (Dn) size value from DLS correlates closely with 
the Dn calculated from SEM (DSEM). The DSEM value obtained, was averaged over a sample 
of 220 nanoparticles. During the project, various batches of aqueous p(HPMA50-co-
EGDMA0.9) nanoparticles were prepared and the DLS analysis for the various batches are 
presented in the Appendix (Table. A3).  
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Figure 2.16 Branched p(HPMA50-co-EGDMA0.9) analysis and subsequent nanoparticle preparation A) 
GPC RI chromatogram of p(HPMA50-co-EGDMA0.9), B) DLS analysis of p(HPMA50-co-EGDMA0.9) 
aqueous nanoparticles (i5-f1), C) SEM image of p(HPMA50-co-EGDMA0.9) nanoparticles (diluted to 0.1 
mg/mL for imaging). 
2.6.3 Co-nanoprecipitation studies of branched p(HPMA50-co-EGDMA0.9) and A-
B block copolymers 
Before conducting the following co-nanoprecipitation experiments, it was hypothesised 
that the nanoprecipitation of these two architecturally different polymers could result in 
different outcomes, as shown in Figure 2.10, Section 2.5.1. Ideally, the hydrophobic 
branched copolymer, p(HPMA50-co-EGDMA0.9) and A-B block copolymer, p(PEGy-b-
HPMAx) would associate when nanoprecipitated simultaneously. It may be expected that 
the hydrophobic p(HPMA) segment from the A-B block copolymer would become 
incorporated within the core and the hydrophilic PEG chain would reside on the 
nanoparticle surface (Figure 2.10ii). It is also likely that either; the A-B block copolymer 
would adsorb onto the surface of p(HPMA50-co-EGDMA0.9) nanoparticles resulting in a 
pendant PEG chains (Figure 2.10i), entrapment of the A-B block copolymer within the 
hydrophobic p(HPMA50-co-EGDMA0.9) nanoparticles could occur; (Figure 2.10iii) or 
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individual objects would form from both the p(HPMA50-co-EGDMA0.9) and p(PEGy-b-
HPMAx) resulting in two distinct size populations (Figure 2.10iv). This latter result could 
occur due to both polymers being able to stabilise themselves independently. 
 
During a typical co-nanoprecipitation experiment, the branched p(HPMA50-co-
EGDMA0.9) and A-B block copolymer were both dissolved in the good solvent at various 
ratios for 12-24 hours to ensure complete solubilisation of both polymers. Conditions for 
the nanoprecipitation experiments were as described in Section 2.4.3, therefore, acetone 
was employed as the good solvent, water as the anti-solvent and concentrations of i5-f1 
were maintained, in order to ensure consistency and allow comparison between different 
polymers and nanoprecipitations in the absence of an A-B block copolymer. The amount 
of branched copolymer and A-B block copolymer were varied between the ratios of 100:0 
to 0:100 wt % respectively. Experimentally, this is a relatively straightforward method 
and is presented schematically in Figure 2.17.  
 
 
Figure 2.17 Schematic representation of a typical co-nanoprecipitation experiment. 
During the nanoprecipitation of solutions containing only A-B block copolymer, four of 
the six nanodispersions did not provide adequate scattering data. As expected, the 
nanoprecipitation of branched p(HPMA50-co-EGDMA0.9) gave stable spherical 
nanoparticles but as discussed previously, they were charge stabilised which is supported 
by a highly negative zeta potential (ζ) of -41 mV. Charge stabilised nanoparticles can 
easily be de-stabilised by addition of electrolytes, such as NaCl, due to the screening of 
the repulsive forces by the Na+ and Cl- ions.4 Therefore, a co-nanoprecipitation study was 
conducted to establish whether the inclusion of an A-B block copolymer could introduce 
steric stabilisation and provide benefits. It was also important to determine how the 
Fast addition 
into stirring 
water
Branched 
copolymer and 
A-B block 
copolymer 
dissolved in 
acetone
Formation of 
nanoparticles
Evaporation of 
acetone
+
 
 
72 
 
varying chemical compositions of the A-B block copolymer (i.e. ratio of PEGy:HPMAx) 
could affect the resulting nanoparticles in terms of size (Dz), PdI and morphology. 
 
2.6.3.1 Co-nanoprecipitation of p(HPMA50-co-EGDMA0.9) and p(PEG45-b-
HPMAx)  
 
The DLS analysis including Dz, PdI, ζ and Dn for the p(PEG45-b-HPMAx) A-B block 
copolymer series is shown in Table 2.5. In almost all cases, the co-nanoprecipitation 
experiments successfully generated uniform, monomodal particle distributions without 
sample filtration. It is worth noting that the ratios discussed below correspond to branched 
copolymer:A-B block copolymer respectively. The sample which did not follow this trend 
was p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA80) 10:90 wt %, which may be due to 
the very low wt % of p(HPMA50-co-EGDMA0.9), therefore poor association occurs 
between the polymers during the early stages of the nanoprecipitation. The Dz values of 
the nanoprecipitated particles for p(PEG45-b-HPMAx) block copolymers between the 
ratios of 90:10 to 50:50 wt %, varied between 94–127 nm. As the p(PEG45-b-HPMAx) 
content was increased beyond 50 wt %, nanoparticles containing p(PEG45-b-HPMA40) and 
p(PEG45-b-HPMA80) decreased in size (56-78 nm) and interestingly the PdI values for the 
samples increased after 50:50 wt %. Therefore, to maintain a size ~ 100 nm and a narrow 
PdI, the optimum wt % during inclusion of both A-B block copolymers was 10–50 wt %. 
On the other hand, the nanoparticles containing >50 wt % for p(PEG45-b-HPMA120), 
witnessed an increase in Dz. The p(PEG45-b-HPMA120) is the most hydrophobic across the 
A-B block copolymer series (<0.13 mg/mL solubility) and the co-nanoprecipitation 
experiments suggest an optimum wt % range in which the which the p(PEG45-b-HPMA120) 
associates with the branched copolymer. Although during addition of 20 wt % of p(PEG45-
b-HPMA120), nanoparticles were slighter larger, they were consistent with sizes obtained 
for the varying ratios throughout the series and narrow PdI values were maintained 
(<0.068). The presence of only 10 wt % p(HPMA50-co-EGDMA0.9) i.e. inclusion of > 90 
wt % of this A-B block copolymer, resulted in an increase for both Dz and PdI, therefore 
suggesting the optimum amount of p(PEG45-b-HPMA120) for a successful co-
nanoprecipitation was 10–80 wt %. 
 
As previously discussed, a strongly negative zeta potential was obtained for charge 
stabilised p(HPMA50-co-EGDMA0.9) polymer nanoparticles (-41 mV), however during 
addition of the varying ratios of p(PEGy-b-HPMAx), a decrease in ζ across all co-
nanoprecipitates was observed. For example, the addition of only 10 wt % stabilising 
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p(PEG45-b-HPMA120) block copolymer into the acetone solution with p(HPMA50-co-
EGDMA0.9), led to a considerable decrease in ζ from -41 mV to -19 mV, suggesting the 
presence of PEGy chains on the nanoparticle surface, which is consistent with PEG 
stabilised nanoparticles or micelles.35, 36 
 
The sizes of the co-nanoprecipitated particles, obtained from SEM, were measured and 
used to calculate a number average, which could be compared to the number average 
measured by DLS. The SEM images for p(HPMA50-co-EGDMA0.9):p(PEG45-b-
HPMA120) (100:0 – 50:50 wt%) are presented in Figure 2.18A-H and provide evidence of 
spherical nanoparticle formation. The Dn values determined for the co-nanoprecipitated 
particles by DLS were consistent with the same assessment by SEM (Table 2.5 & Figure 
2.19) (220 particles per reported DSEM value, for histogram analysis see Appendix Fig. 
A13). Although evidence of nanoparticle formation was observed, determination of DSEM 
by SEM analysis became increasingly difficult with increasing amounts of A−B block 
copolymer, due to possible film formation and the presence of objects resembling 
flattened vesicles at higher ratios (Figure 2.18I-K). The DLS analysis overlays for all co-
nanoprecipitates including p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMAx) are presented 
in the Appendix (Fig. A14). 
 
Table 2.5 DLS and SEM characterisation of nanoparticles comprising of either p(HPMA50-co-
EGDMA0.9), p(PEG45-b-HPMAx) or varying ratios of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMAx) 
both via co-nanoprecipitation from acetone (5 mg/mL) into water (Final concentration = 1 mg/mL). 
 
* Inadequate scattering data
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p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMAx)
Weight ratio (%)
100:0 90:10 80:20 70:30 60:40 50:50 40:60 30:70 20:80 10:90 0:100
p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA40)
Dz (nm) 148 113 94 106 115 109 75 75 78 77 268*
PdI 0.080 0.067 0.123 0.029 0.047 0.048 0.152 0.166 0.111 0.163 0.338*
ζ (mV) -41 -30 -31 -19 -25 -32 -23 -25 -20 -24 -15
Dn (nm) 112 87 67 87 94 85 57 54 58 54 21
p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA80)
Dz (nm) 148 114 127 115 111 115 76 69 56 76 131*
PdI 0.080 0.045 0.061 0.053 0.037 0.055 0.113 0.122 0.126 0.717 0.227*
ζ (mV) -41 -28 -28 -26 -23 -27 -26 -19 -18 -20 -23
Dn (nm) 112 91 101 91 91 85 55 49 38 40 75
p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120)
Dz (nm) 148 120 111 108 103 109 95 114 159 217 372
PdI 0.080 0.066 0.033 0.037 0.069 0.032 0.051 0.061 0.068 0.167 0.145
ζ (mV) -41 -19 -24 -21 -22 -20 -17 -14 -12 -17 -11
Dn (nm) 112 92 89 88 80 88 74 89 135 157 340
DSEM (nm) 117 81 105 117 88 110 - - - - -
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Figure 2.19 SEM images of nanoprecipitates and co-nanoprecipitates produced using varying p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120) ratios: (A) 100:0, (B) 90:10, 
(C) 80:20, (D) 70:30, (E) 60:40, (F) 50:50, (G) 40:60, (H) 30:70, (I) 20:80, (J) 10:90, (K) 0:100 wt %. 
 
 
 
200 nm
A)
200 nm
B)
200 nm
C)
300 nm
D)
200 nm
E)
200 nm
F)
250 nm
G)
200 nm
H)
200 nm
I)
200 nm
J)
300 nm
K)
 
 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18 Histogram analysis of nanoparticles via SEM imaging (average of 220 particles) (grey bar 
chart) overlaid with the DLS size distribution by intensity (black solid line) and number traces (black 
dashed line) for p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120) 60:40 wt %. 
 
2.6.3.2 Co-nanoprecipitation of p(HPMA50-co-EGDMA0.9) and p(PEG114-b-
HPMAx)  
 
To enhance the steric stabilisation, the following nanoprecipitation experiments were 
conducted including the A-B block copolymers previously synthesised with an increased 
PEG chain length (5000 g/mol). As observed with the p(PEG45-b-HPMAx) block 
copolymer series, the majority of these newly formed co-nanoprecipitates from 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA40), generated monomodal particle 
distributions without sample filtration. The DLS analysis including; Dz, PdI, ζ and Dn is 
presented in Table 2.6. It is worth noting that the ratios discussed below correspond to 
branched copolymer:A-B block copolymer respectively.  
 
The inclusion of p(PEG114-b-HPMA40) and p(PEG114-b-HPMA80) with p(HPMA50-co-
EGDMA0.9), between the ratios of 90:10 to 50:50 wt % produced nanoparticles within the 
range of 103-117 nm. When 50-90 wt % of A-B block copolymer was present, the 
nanoparticle Dz values decreased (~56-84 nm) and the PdI values for the nanoparticles 
increased up to a value of 0.332. This decrease in size along with broader PdI values 
suggests loss of control and the formation of smaller nanoscale objects, possibly micelles 
or flattened vesicles from the self assembly of the A-B block copolymers. The inclusion 
of p(PEG114-b-HPMA120), resulted in the narrowest distribution of the six A-B block 
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copolymers selected for the study. The co-nanoprecipitates obtained upon inclusion of this 
A-B block copolymer from 40:60 to 10:90 wt % were generally less affected by an 
increase in A-B block copolymer as narrow PdI values were obtained throughout. The 
overall decrease in size with increasing amount of A-B block copolymer observed for all 
p(PEG114-b-HPMAx) A-B block copolymers suggests that a lower ratio of p(HPMA50-co-
EGDMA0.9) encourages colloidal stability and the ratio of branched copolymer:A-B block 
copolymer does have an effect on the co-nanoprecipitation process. The DLS size value 
overlays for p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMAx) are presented in the 
Appendix, Fig. A15.  
 
Introduction of a p(PEG114-b-HPMAx) block copolymer, again, as witnessed with 
p(PEG45-b-HPMAx) association, produces a decrease in ζ across all co-nanoprecipitates, 
suggesting presence of PEGy chains on the surface. 
 
To determine the morphology of the p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 
nanoparticles, nanodispersions containing p(PEG114-b-HPMA120) block copolymer were 
analysed by SEM, which confirmed the presence of spherical nanoparticles (Figure 
2.20A-G). Dn values determined by DLS were consistent with the same assessment by 
SEM, Table 2.6 & Appendix A16. As reported for p(HPMA50-co-EGDMA0.9):p(PEG114-
b-HPMA120) nanoparticles, the DSEM values were obtained from a sample of 220 particles. 
Although SEM has provided evidence of nanoparticle formation, the analysis became 
increasingly difficult with increasing amounts of A−B block copolymer, possibly due to 
PEG film formation and hence the detailed analysis of 100:0 to 50:50 wt % ratios only. 
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Table 2.6 DLS and SEM characterisation of nanoparticles comprising of either p(HPMA50-co-EGDMA0.9), p(PEG114-b-HPMAx) or varying ratios of p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMAx) both via co-nanoprecipitation from acetone (5 mg/mL) into water (Final concentration = 1 mg/mL). 
 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMAx)
Weight ratio (%)
100:0 90:10 80:20 70:30 60:40 50:50 40:60 30:70 20:80 10:90 0:100
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA40)
Dz (nm) 148 111 103 121 107 117 76 75 75 73 317*
PdI 0.080 0.055 0.152 0.061 0.028 0.088 0.178 0.224 0.212 0.254 0.373*
ζ (mV) -41 -30 -27 -28 -28 -32 -30 -26 -26 -25 -15
Dn (nm) 112 88 72 96 87 129 53 49 49 48 105
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80)
Dz (nm) 148 112 106 106 103 111 84 71 67 56 88*
PdI 0.080 0.045 0.118 0.124 0.045 0.081 0.332 0.096 0.140 0.184 0.738*
ζ (mV) -41 -27 -29 -29 -28 -21 -24 -22 -16 -14 -20
Dn (nm) 112 90 74 74 79 112 54 54 46 33 23
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120)
Dz (nm) 148 132 127 113 117 103 70 62 56 46 49
PdI 0.080 0.059 0.043 0.069 0.059 0.051 0.085 0.085 0.075 0.152 0.265
ζ (mV) -41 -13 -21 -23 -17 -15 -15 -10 -15 -13 -15
Dn (nm) 112 90 74 74 79 82 54 54 46 33 30
DSEM (nm) 117 101 85 88 82 95 - - - - -
* Inadequate scattering data
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Figure 2.20 SEM images of nanoprecipitates and co-nanoprecipitates produced using varying 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) weight ratios: (A) 100:0, (B) 90:10, (C) 80:20, (D) 
70:30, (E) 60:40, (F) 50:50, (G) 0:100 wt %. 
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Overall, the nanoparticles obtained via co-nanoprecipitation from the association of 
p(PEG45-b-HPMAx)/p(PEG114-b-HPMAx) A-B block copolymers with p(HPMA50-co-
EGDMA0.9) were within the ideal size range to be considered as drug delivery 
nanocarriers. It should be highlighted that none of the nanoparticle dispersions required 
filtration in order to obtain a narrow monomodal distribution. Generally, the Dz values 
remained around ~100 nm between the ratios of 90:10 to 50:50 wt % p(HPMA50-co-
EGDMA0.9):p(PEGy-b-HPMAx) respectively. This was followed by a noticeable decrease 
from 40:60 wt % onwards, which could be due to nanoparticles reaching colloidal stability 
at a smaller size and competition of the A-B block copolymer. Interestingly, the increasing 
wt % of the two most hydrophobic A-B block copolymers of each series, p(PEG45-b-
HPMA120) and p(PEG114-b-HPMA120), resulted in nanoparticles which maintained narrow 
PdI values throughout the variations of ratios. These trends observed are presented 
schematically in Figure 2.21. An exception of the general trend was recognised for 
p(PEG45-b-HPMA120), where minor deviations in size were observed at high wt % A-B 
block copolymer, contrasting to all the other A-B block copolymers. The Dz and narrow 
PdI values obtained for up to 80 wt % of this particular A-B block copolymer, suggest the 
mechanism of nanoparticle formation is less affected when an insoluble A-B block 
copolymer is utilised and may imply that there is less competition between the A-B block 
copolymer and p(HPMA50-co-EGDMA0.9) branched copolymer.  
  
 
Figure 2.21 Schematic representation of the nanoparticles formed via nanoprecipitation and co-
nanoprecipitation of branched p(HPMA50-co-EGDMA0.9) and an A-B block copolymer. 
 
2.6.3.3 Aqueous nanoprecipitation of branched p(HPMA50-co-EGDMA0.9) into 
an aqueous solution of water soluble A-B block copolymers 
 
Previous research studies of the preparation of polymer nanoparticles via 
nanoprecipitation often include commercial surfactants such as Tween 20 and polyvinyl 
alcohol to stabilise the polymer within the aqueous phase (see Chapter 1, Table 1.1). The 
50:50100:0 0:100
Branched p(HPMA50-co-EGDMA0.9):A-B block copolymer (wt%)
Solubilised block 
copolymer
or
90:10 80:20 70:30 60:40 40:60 30:70 10:9020:80
Micelle
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aim of the following experiments was to investigate if it was possible to form stable 
nanoparticles after addition of branched p(HPMA50-co-EGDMA0.9) into aqueous 
solutions of the four soluble A-B block copolymers; p(PEG45-b-HPMA40), p(PEG114-b-
HPMA40), p(PEG114-b-HPMA80) and p(PEG114-b-HPMA120). If so, it was of interest to see 
if a difference in size was observed when using this method compared with the co-
nanoprecipitation, and the process is represented graphically in Figure 2.21. The 
nanoprecipitation was conducted by preparing a stock solution of p(HPMA50-co-
EGDMA0.9) (2.5 mg/mL) in acetone and 1 mL of this solution was added to one of the 
four A-B block copolymers solubilised in H2O (0.1 mg/mL in 5 mL H2O). The same final 
concentration of both polymers (1 mg/mL) was maintained in order to draw direct 
comparisons with the simultaneous addition experiments and the ratio of branched 
copolymer:A-B block copolymer studied was 50:50 wt %. 
 
It was hypothesised that the addition of p(HPMA50-co-EGDMA0.9) into a solution of 
solubilised A-B block copolymer may have resulted in two or more different nanoparticle 
size distributions, due to the association of both the branched copolymer with the A-B 
block copolymer and formation of nanoscale objects composed of A-B block copolymer 
only (DLS results for the solubilisation of the A-B block copolymers in water, Appendix, 
Fig. A17 & Table A4), however this was not the case. The data presented in Table 2.7, 
shows that for all nanoprecipitation experiments involving the addition of p(HPMA50-co-
EGDMA0.9) into aqueous solutions of water soluble A-B block copolymer, single size 
distributions were obtained, as well as a noticeable decrease in size when compared with 
simultaneous addition. This decrease in size could be due to the large differences in 
concentration of polymers during the nanoprecipitation experiment. The dropwise 
addition of p(HPMA50-co-EGDMA0.9) into an excess aqueous solution of p(PEGy-b-
HPMAx) A-B block copolymer could result in the A-B block copolymers concentrating at 
the particle surface to stabilise p(HPMA50-co-EGDMA0.9) nanoparticles. This suggests 
adsorption of the A-B block copolymers onto the surface and as seen previously with 
simultaneous addition, the PdI values obtained were <0.101, which is evident of a 
controlled nanoprecipitation. The monomodal distributions observed (Figure 2.22) 
suggest that the A-B block copolymers are becoming incorporated during the 
nanoprecipitation of p(HPMA50-co-EGDMA0.9), and if this was not the case, two different 
size populations would have been observed for both p(HPMA50-co-EGDMA0.9) and the 
A-B block copolymer present in the water. These experiments provide further evidence 
that the HPMA chain from the A-B block copolymer becomes either associated/adsorbed 
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onto p(HPMA50-co-EGDMA0.9) (Figure 2.10i) or incorporated into the p(HPMA50-co-
EGDMA0.9) nanoparticle during the nanoprecipitation (Figure 2.10ii). If successful, the 
electrolyte stability of these nanoparticles will be explored in section 2.7.1 to further 
evaluate the nanoparticle behaviour and how this compares to nanoparticles prepared 
during simultaneous addition. It is worth noting that the addition of all branched 
p(HPMA50-co-EGDMA0.9) polymer solutions into A-B block copolymer aqueous 
dispersions, were conducted under the same conditions and during the same day to ensure 
consistency. 
 
Figure 2.21 Graphical representation of the formation of co-nanoprecipitated nanoparticles by addition 
of branched p(HPMA50-co-EGDMA0.9) to a solution of a water soluble A-B block copolymer. (Final 
concentration of total polymer 1 mg/mL in H2O). 
 
Table 2.7 Comparison of DLS results for branched p(HPMA50-b-EGDMA0.9) and A-B block 
copolymer added co-nanoprecipitated vs nanoprecipitation of p(HPMA50-co-EGDMA0.9) into aqueous 
solutions of water soluble A-B block copolymer. All ratios were fixed at 50 wt % of each polymer. 
 
Fast addition into  A-B 
block copolymer dissolved 
in stirring water
Branched 
polymer  
dissolved in 
acetone
Formation of 
sterically
stabilised 
nanoparticles
Evaporation of 
acetone
Sample (50:50 wt %)
Dz
(nm)
PdI
Dn
(nm)
Nanoprecipitation
Addition of p(HPMA50-co-EGDMA0.9) into an aqueous solution of p(PEG45-b-HPMA40) 80 0.073 64
Addition of p(HPMA50-co-EGDMA0.9) into an aqueous solution of p(PEG114-b-HPMA40) 83 0.069 63
Addition of p(HPMA50-co-EGDMA0.9) into an aqueous solution of p(PEG114-b-HPMA80) 89 0.101 67
Addition of p(HPMA50-co-EGDMA0.9) into an aqueous solution of p(PEG114-b-HPMA120) 90 0.055 70
Co-nanoprecipitation
Simultaneous addition of p(HPMA50-co-EGDMA0.9) and p(PEG45-b-HPMA40) 109 0.048 85
Simultaneous addition of p(HPMA50-co-EGDMA0.9) and p(PEG114-b-HPMA40)
117 0.088 129
Simultaneous addition of p(HPMA50-co-EGDMA0.9) and p(PEG114-b-HPMA80)
111 0.081 84
Simultaneous addition of p(HPMA50-co-EGDMA0.9) and p(PEG114-b-HPMA120) 103 0.045 82
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Figure 2.22 DLS trace overlays A) i) Z-average sizes for branched p(HPMA50-co-EGDMA0.9) added 
simultaneously (black trace), p(HPMA50-co-EGDMA0.9) added to p(PEG45-b-HPMA40) dissolved in 
H2O (red trace), ii) Number average sizes for p(HPMA50-EGDMA0.9) and p(PEG45-b-HPMA40) added 
simultaneously (black trace), p(HPMA50-co-EGDMA0.9) added to p(PEG45-b-HPMA40) dissolved in 
H2O (red trace) and B), C) & D) have the same labelling system. B) p(HPMA50-EGDMA0.9):p(PEG114-
b-HPMA40) C) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80) D) p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120), all 50:50 wt % ratios. 
Core into diblock
10 100 1000
Core into diblock 2KHPMA40 50:50 z-ave vs Col 2 
Both into water 2KHPMA40 50:50 z ave vs Col 4 
Number average 2KHPMA40
10 100 1000
Num average Core into diblock 2KHPMA40 50:50 vs Col 6 
Core and diblock together 2K number average vs Col 8 
R
el
at
iv
e 
in
te
n
si
ty
R
el
at
iv
e 
in
te
n
si
ty
Dz (nm) Dn (nm)
10 100 1000
number avergae vs Col 7 
5KHPMA40 number agerage core and diblock together vs Col 9 
10 100 1000
core added to diblock 5KHPMA40 vs Col 2 
PEG5KHPMA40 50:50 core and diblock together 50:50 vs Col 4 
10 100 1000
PEG5KHPMA80 core into diblock  vs Col 2 
PEG5KHPMA80 core into diblock  vs core and diblock together 
10 100 1000
PEG5KHPMA80 core into diblock  vs Col 4 
PEG5KHPMA80 core into diblock  vs Col 5 
R
el
at
iv
e 
in
te
n
si
ty
R
el
at
iv
e 
in
te
n
si
ty
R
el
at
iv
e 
in
te
n
si
ty
R
el
at
iv
e 
in
te
n
si
ty
10 100 1000
peg5khpma120 core into diblock vs Col 2 
peg5khpma120 core into diblock vs Col 3 
10 100 1000
peg5khpma120 core into diblock vs number averages 
peg5khpma120 core into diblock vs Col 5 
R
el
at
iv
e 
in
te
n
si
ty
R
el
at
iv
e 
in
te
n
si
ty
Dz (nm) Dn (nm)
Dz (nm) Dn (nm)
Dz (nm) Dn (nm)
A)
B)
i) ii)
i)
i)
i)
ii)
ii)
ii)
C)
D)
Z-ave (d.nm) Number average (nm)
Branched 
p(HPMA) 
into 
solution of 
H2O 
solubleA-B 
block 
copolymer
Branched 
p(HPMA) and A-B 
block copolymer 
added 
simultaneously
  
83 
 
The shape of the aqueous nanoparticles prepared by addition of p(HPMA50-co-
EGDMA0.9) into aqueous solutions of the A-B block copolymers; p(PEG45-b-HPMA40), 
p(PEG114-b-HPMA40), p(PEG114-b-HPMA80) and p(PEG114-b-HPMA120) via 
nanoprecipitation, were also analysed by SEM and spherical nanoparticles were observed 
for each sample (Figure 2.23 A-D). The nanoparticle dispersions did not exhibit any sign 
of polymer precipitation (Figure 2.23 E) and did not require further filtration. The NaCl 
stability of these nanodispersions will be investigated in Section 2.7.4, in order to gain a 
further insight into this nanoprecipitation process. 
 
 
Figure 2.23 SEM images for branched p(HPMA50-co-EGDMA0.9) nanoprecipitated into water soluble 
A-B block copolymers 50:50 wt% (Nanoparticle dispersions diluted to 0.1 mg/mL for imaging) A) 
p(PEG45-b-HPMA40), B) p(PEG114-b-HPMA40), C) p(PEG114-b-HPMA80), D) p(PEG114-b-HPMA120), 
E) Photograph to show nanoparticle dispersions after nanoprecipitation of p(HPMA50-co-EGDMA0.9) 
into A-B block copolymers. For all co-nanoprecipitation experiments, the ratio for all experiments was 
50:50 wt %. 
2.7 Stability studies of aqueous co-nanoprecipitated particle 
dispersions 
 
2.7.1 Stability of co-nanoprecipitated nanoparticles in the presence of NaCl   
 
To be considered as a potential drug delivery vehicle, it is important for the nanoparticles 
to remain stable under physiologically relevant conditions. During a typical NaCl addition 
experiment, aliquots (20 μL) of an aqueous 0.5 M NaCl solution were added to 1 mL 
samples of the aqueous nanoparticle dispersions, and Dz and PdI values were measured 
during a 21 day period at ambient temperature. It is worth noting that an aliquot of NaCl 
was added to ensure any dilution effects were minimised and a final concentration of NaCl 
was kept constant at 0.01M for all samples. After evaporation of the good solvent, DLS 
300 nm 200 nm
200 nm 200 nm
A) B)
C) D)
E) p(HPMA50-co-EGDMA0.9) into solution of H2O 
soluble A-B block copolymer
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measurements were conducted and the solution was agitated before addition to a 
disposable sizing cuvette (Dz, Dn and ζ values were taken as the average of 3 repeated 
measurements per sample). The nanodispersion was returned to the original sample vial 
and stored at ambient temperature for the 1, 7 and 21 day measurements, and studies were 
carried out as described above.   
 
As previously discussed, it is desirable to produce nanoparticles which would be sterically 
stabilised, rather than charge stabilised, to afford stability in physiological conditions. 
Nanoparticles composed solely of branched p(HPMA50-co-EGDMA0.9), can be easily de-
stabilised by addition of electrolytes, due to the screening of repulsive charges by the ions 
present. The screening of charges reduces the repulsive forces between the nanoparticles 
and as a result attractive forces dominate, bringing the particles closer together causing 
aggregation and ultimately precipitation. Branched p(HPMA50-co-EGDMA0.9) 
nanoparticles are stable for long periods of time and have shown no increase in Dz after 1 
month under ambient storage conditions (Figure Bi&ii). However, during NaCl addition 
the polymer nanoparticles become destabilised and precipitation was observed. This was 
expected for the charge stabilised particles and the precipitation of the polymer is 
illustrated in Figure 2.24C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.24 Stability of aqueous branched p(HPMA50-co-EGDMA0.9) nanoparticles. A) DLS analysis 
of branched p(HPMA50-co-EGDMA0.9) nanoparticles, B) i) DLS analysis of branched p(HPMA50-co-
EGDMA0.9) nanoparticles after 1 month, ii) Photograph of a stable p(HPMA50-co-EGDMA0.9) 
nanodispersion, C) Photograph of NaCl addition to a p(HPMA50-co-EGDMA0.9) nanodispersion (20 µL 
of 0.5M NaCl to 1 mL of 1 mg/mL dispersion). 
After
1 month
Z-ave:147nm
PdI: 0.052
NaCl
Addition
Z-ave: 148nm
PdI: 0.080
A)
B) ii)i)
C)
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The DLS measurements for the nanoprecipitation of solutions composed solely of 
p(PEG45-b-HPMA120) and p(PEG114-b-HPMA120) generated accurate, meaningful data 
and interestingly both A-B block copolymers were composed of the longest hydrophobic 
HPMA chains. The DLS results obtained for the nanoprecipitation of 100 wt % of the 
remaining four A-B block copolymers were inconclusive due to inadequate light 
scattering. Therefore, the NaCl stability experiments were only conducted for p(PEG45-b-
HPMA120) and p(PEG114-b-HPMA120). For p(PEG45-b-HPMA120), after 1 day exposure to 
NaCl, the nanoparticle Dz values showed a decrease of 148 from 404 nm (instant addition 
measurement), as introduction of the electrolyte had greatly affected the nanoscale objects 
(Figure 2.25A). To rationalise this effect, it has been reported that the introduction of 
electrolyte solution disturbs the water structure around PEG and can cause shrinking of 
PEGy chains at the nanoparticle surface.
37 The decrease in size was further confirmed by 
comparing the average Dn values for this sample as an additional smaller size population 
was observed (Figure 2.26 A). An increase in size was observed between the 1 and 21 day 
NaCl addition measurements; up to a final Dz of 466 nm and the number average traces 
also highlight this (Figure 2.26 B&C). These results suggest that after 1 day, the nanoscale 
objects associated together to form larger objects and although the PEG chains on the 
surface have decreased in size due to NaCl addition, they are still sufficient to provide 
steric stabilisation and therefore prevent aggregation.  
 
 
Figure 2.25 Stability of nanodispersion of A-B block copolymer in the presence of NaCl during a 0-21 
day period. A) p(PEG45-b-HPMA120), B) p(PEG114-b-HPMA120). 
 
A small decrease in Dz (~10 nm) was observed for p(PEG114-b-HPMA120) A-B block 
copolymer after 21 days when compared to the original nanodispersion (Figure 2.25 B). 
During the first 24 hours the nanoscale objects increased ~15 nm, suggesting the 
association of nanoscale objects in order to minimise the effects of the addition of NaCl. 
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The decrease observed between 7-21 day, again as seen previously with p(PEG45-b-
HPMA120), the presence of NaCl can result in a shrinking of PEG chains at the surface 
and therefore a smaller size, but not enough to cause precipitation of the polymer. The Dn 
trace overlays (Appendix, Fig. A18), also show the small changes in size observed 
throughout the study. Although both nanodispersions of the A-B block copolymers 
remained stable to NaCl throughout the 21 day test period, there were large variations in 
sizes within this study and PdI values which often exceeded > 0.2.  
 
Figure 2.26 Dn analysis by DLS after NaCl addition. A) p(PEG45-b-HPMA120) in the absence of NaCl 
(black line), p(PEG45-b-HPMA120) 1 day NaCl addition (red line), B) p(PEG45-b-HPMA120) in the 
absence of NaCl (black line), p(PEG45-b-HPMA120) 21 day NaCl addition (red line), C) p(PEG45-b-
HPMA120) 7 day NaCl addition (black line), p(PEG45-b-HPMA120) 21 day NaCl addition (red line). 
 
2.7.2 Stability of p(PEG45-b-HPMAx) A-B block copolymer aqueous co-
nanoprecipitated particles 
 
Up to now, it is evident that NaCl addition to nanoparticles composed solely of 
p(HPMA50-co-EGDMA0.9), results in de-stabilisation and precipitation of the polymer. 
Although stable to NaCl, the nanoscale objects of p(PEGy-b-HPMA120) A-B block 
copolymers demonstrated large size deviations throughout the 21 day study period and 
final sizes of nanoparticles obtained were not ideal. To further investigate the co-
nanoprecipitation process, it was of interest to conduct NaCl stability studies across the 
varying ratios of p(HPMA50-co-EGDMA0.9):p(PEGy-b-HPMAx), to provide a greater 
understanding of how the A-B block copolymer becomes involved during the 
nanoprecipitation. As previously discussed and schematically presented in Figure 2.10, 
there are four potential outcomes, which could occur during a co-nanoprecipitation 
experiment. Up to now, the hypothesis which suggested the formation of various sized 
nanoscale objects (Figure 2.10iv) is unlikely due to the results obtained from previous co-
nanoprecipitation studies (monomodal size distributions and narrow PdI values). It is more 
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likely that the A-B block copolymer is either; adsorbing loosely onto the p(HPMA50-co-
EGDMA0.9) nanoparticle with pendant PEG chains on the surface (Figure 2.10i), the 
HPMA segment from the A-B block copolymer becomes incorporated into p(HPMA50-
co-EGDMA0.9), with PEG chains on the surface (Figure 2.10ii) or entrapment of the A-B 
block copolymer within the p(HPMA50-co-EGDMA0.9) core (Figure 2.10iii). If the co-
nanoprecipitates were behaving as suggested in Figure 2.10iii, then it would be expected 
that the resulting nanoparticles would behave identically to nanoparticles composed only 
of p(HPMA50-co-EGDMA0.9) i.e. charge stabilised and precipitate upon NaCl addition. 
The varying chemical compositions of the A-B block copolymers are expected to have a 
large effect on the stability of co-nanoprecipitates (i.e. PEGy to HPMAx content), therefore 
it may be observed that different mechanisms are adopted during incorporation of the 
varying A-B block copolymers. It would be anticipated that the p(PEG114-b-HPMAx) A-
B block copolymer series should offer an increased resistance to NaCl, due the increased 
PEGy chain length (~ 5000 g/mol). 
 
So far, the low ζ values obtained from the co-nanoprecipitation experiments of an A-B 
block copolymer and p(HPMA50-co-EGDMA0.9) have demonstrated an overall decrease 
in surface charge when compared with branched p(HPMA50-co-EGDMA0.9). The reduced 
ζ values obtained during the inclusion of the A-B block copolymer suggests that the PEG 
chains from the A-B block copolymer are situated on the outer surface of the 
nanoparticles, and should therefore offer a level of resistance to salt addition due to steric 
stabilisation. In order to investigate the effect of A-B block copolymer concentration 
required to stabilise p(HPMA50-co-EGDMA0.9) during exposure to NaCl, the experiments 
were carried out for the ratios between 90:10-10:90 wt %, p(HPMA50-co-
EGDMA0.9):p(PEGy-b-HPMAx) respectively.  
 
The addition of 10 and 20 wt % of p(PEG45-b-HPMA40) A-B block copolymer had no 
meaningful effect on the salt stability of the co-nanoprecipitates, as demonstrated by a 
large increase in Dz values and precipitation after 1 day for both samples (Figure 2.26A). 
However, 30 wt % addition led to an increase in stability during the 7 day test period, yet 
a large Dz increase (>300 nm) was observed. The 21 day test measurement was not 
conducted on this sample due to polymer precipitation (Figure 2.26B). Further increase in 
A−B block copolymer content within the co-nanoprecipitates (60:40-20:80 wt %), led to 
increasing stability and no visible precipitate after the 21 day study period was observed. 
The size and PdI values of nanodispersions 40:60, 30:70 and 20:80 wt % were least 
affected by NaCl addition during the 21 day period. For samples >40:60 wt % there was 
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an observed decrease ~75 nm from previous values >100 nm. After instantaneous NaCl 
addition, the co-nanoprecipitates including p(HPMA50-co-EGDMA0.9):p(PEG45-b-
HPMA40) 10:90 wt %, did not provide reliable DLS data. This behaviour suggests that 
although there is a huge excess of stabilising PEG chains from the A-B block copolymer, 
the ratio of both polymers is not favourable and results in an unstable dispersion.  
 
Figure 2.26 Stability of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA40) to NaCl during a 21 day 
period. A) Dashed line open squares, 100:0 = red, 90:10 = blue, 80:20 = dark green, B) Dashed line 
open circles, 70:30 = pink 60:40 = dark red, 50:50 = dark blue, 40:60 = dark purple, 30:70 = light green 
= 30:70, orange = 20:80, yellow = 10:90, grey = 0:100 wt %*. (*Inadequate light scattering data 
obtained) 
 
There are notable differences in stability when the DPn of HPMA of p(PEG45-b-HPMAx) 
A-B block copolymer is increased from 40 to 80 monomer units. The co-nanoprecipitates 
between 90:10-50:50 wt % ratios remained stable during the 21 day test period and 
contrasting to p(PEG45-b-HPMA40), the lower ratios of 10 and 20 wt % A-B block 
copolymer were stabilised (Figure 2.27). The effects on Dz were minimal during addition 
of NaCl to the 80:20 wt % ratio, as there is almost no difference between the blank vs 21 
day sample. The 40:60 and 30:70 wt % ratios became unstable between instant and 1 day 
measurement, whilst 20:80 and 10:90 wt % remained stable, yet, large changes in Dz were 
observed throughout the 21 day test period. Apart from 40:60 and 30:70 wt % and some 
observed increases in Dz, all co-nanoprecipitated dispersions including p(PEG45-b-
HPMA40) were stable to NaCl during the 21 day period. 
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Figure 2.27 Stability of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA80) to NaCl during a 21 day 
period, 90:10-0:100 wt %. Dashed line open circles, 90:10 = blue, 80:20 = dark green, 70:30 = pink 
60:40 = dark red, 50:50 = dark blue, 40:60 = dark purple, 30:70 = light green = 30:70, orange = 20:80, 
yellow = 10:90, grey = 0:100 wt %*. (*Inadequate light scattering data obtained). 
 
The results for NaCl addition to the co-nanoprecipitates including p(PEG45-b-HPMA120) 
A-B block copolymer are presented in Figure 2.28. The incorporation of 10 wt % of the 
A−B block copolymer had no meaningful effect on the salt stability of the co-
nanoprecipitates (Figure 2.28A), however, 20 wt % incorporation led to stability over the 
21 day test period. An immediate approximate doubling in Dz was seen on addition of salt 
(110 to 190 nm), and a small variation was observed from this point (Figure 2.28B). 
Further increases in A−B block copolymer led to increasing stability as demonstrated by 
a decreasing impact on Dz immediately after salt addition, low Dz values on storage, and 
maintenance of low PdI values (<0.085) throughout 7 days, after which precipitation was 
observed for 70:30 and 50:50 wt %. Interestingly, this benefit was seen to decrease after 
the 50:50 ratio of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120), and nanoparticles 
comprising more than 60 wt % A−B block copolymer were progressively less stable and 
unable to avoid aggregation after 1 day. The only exception was the co-nanoprecipitates 
formed from a 10:90 wt % ratio. This behaviour may be due to the lack of an efficient co-
nanoprecipitation at high levels of the stabilising block copolymer leading to a non-
uniform A−B incorporation within the nanoparticle distribution; the optimum composition 
appeared to be a 60:40 wt % ratio of p(HPMA50-co-EGDMA0.9) and p(PEG45-b-
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HPMA120). The ability of the co-nanoprecipitates to tolerate salt was in marked contrast 
to the behaviour of the branched copolymer p(HPMA50-co-EGDMA0.9) nanoprecipitated 
in the absence of the A−B block copolymer. The size and PdI values obtained for the 
PEG45 series are located in the Appendix (Table A5).  
 
Figure 2.28 Stability of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120) to NaCl during a 21 day 
period. A) Dashed line open squares, 100:0 = red, 90:10 = blue, B) Dashed line open circles, 80:20 = 
dark green, 70:30 = pink 60:40 = dark red, 50:50 = dark blue, 40:60 = dark purple, 30:70 = light green 
= 30:70, orange = 20:80, yellow = 10:90, grey = 0:100 wt %.  
 
During the variation of the A-B block copolymer composition, different results were 
obtained during NaCl addition. Overall, the addition of p(PEG45-b-HPMA40) with 
p(HPMA50-co-EGDMA0.9) led to stability when >70 wt % A-B block copolymer was 
added, yet, large deviations in size during the 21 day study period were observed. An 
increase in DPn of HPMA from 40 to 80 monomer units i.e. p(PEG45-b-HPMA80), 
improved the stability, as only 10 wt % was required to stabilise p(HPMA50-co-
EGDMA0.9). Generally, the dispersions remained relatively stable during 21 days but for 
increasing amounts of A-B block copolymer, large fluctuations in size were observed. A 
further increase in the HPMA chain length for the A-B block copolymer p(PEG45-b-
HPMA120), did not appear to increase the stability, as addition of 10 wt % resulted in 
precipitation upon instant NaCl addition and the majority of samples started to precipitate 
<7 days. 
 
Although stability to a set concentration of NaCl is of interest, it was also important to 
establish the impact of varying salt concentrations over a relatively short period of time, 
for example after injection or during formulation with other ingredients. As such, an 
evaluation of the behaviour of fresh samples of the varying co-nanoprecipitates consisting 
of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120) was studied, as successive aliquots 
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of the 0.5 M NaCl solution were added to 1 mL samples (Figure 2.30); again, DLS 
measurement was used to study the Dz and PdI of the nanoparticles. As seen previously, 
the nanoparticle samples comprising 100:0 and 90:10 wt % ratios of the p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA120) polymers showed significant aggregation after low 
concentrations (0.01M) of added aqueous NaCl. Interestingly, all other p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA120) co-nanoprecipitates were stable up to 2 mL addition; 
however, only the co-nanoprecipitates containing 30, 40, 80, and 90 wt % A−B block 
copolymer were able to maintain PdI values <0.090, with the 60:40 wt % material showing 
only a 13 % variance from its initial Dz value and a PdI = 0.039 after the addition of 2 mL 
of salt solution. The PdI value obtained for 50:50 wt % increased up to 0.161 after 2 mL 
addition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.30 Analysis of co-nanoprecipitated particles with varying p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA120) wt % ratios after sequential addition of aliquots of aqueous 0.5 M 
NaCl to a 1 mL sample of nanoparticles at 1 mg/mL. Dz variation of samples is shown. Open squares: 
red = 100:0, blue = 90:10, green = 0:100. Open circles: red = 80:20, blue = 70:30, green = 60:40, gray 
= 50:50, purple = 40:60, black = 30:70, orange = 20:80, dark pink = 10:90. 
 
2.7.3 Stability of p(PEG114-b-HPMAx) A-B block copolymer aqueous co-
nanoprecipitated particles 
 
To assess if an increase of the hydrophilic PEG chain length (5000 g/mol) enhances the 
stability, NaCl addition experiments were also conducted for p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMAx) co-nanoprecipitated particles. It would be expected that 
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an increase in PEG length from PEG45 to PEG114 for the A-B block copolymers would 
provide additional steric stabilisation to the nanoparticles and as a result, be less affected 
when exposed to NaCl.  
 
The NaCl stability plots are shown in Figure 2.31 for the p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMAx). The addition of 10 wt % of the A-B block copolymer 
had no meaningful effect on the NaCl stability of the co-nanoprecipitates and precipitation 
was observed instantly. Whilst there was some stability, the addition of NaCl to the 80:20 
wt % nanodispersion resulted in broad PdI values (>0.3) and Dz which were triple their 
original value. This suggests that for both 90:10 and 80:20 wt % ratios, there is an 
insufficient amount of PEG chains present to stabilise p(HPMA50-co-EGDMA0.9). 
However, the varying ratios between 70:30-50:50 wt % demonstrated an increased 
stability after NaCl addition. After 21 days, all PdI values remained <0.037, although a 
127 % and 120 % increase in size was observed for 70:30 and 60:40 wt % respectively, 
the polymers did not precipitate. Within the 21 day period, the 50:50 wt % nanoparticles 
increased by a negligible amount of 17 nm and resulting PdI of 0.018. Above 50 wt % A-
B block copolymer, a general decrease in size was observed. For 40:60, 20:80 and 10:90 
wt %, the nanoparticles were generally stable for 7 days, after which, DLS data became 
unreliable for both 20:80 and 10:90 wt %. The nanoparticles formed from a 30:70 wt % 
ratio, increase slightly but up to 21 days period gave a final size of 104 nm and PdI <0.082. 
 
Figure 2.31 Stability of branched p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA40) A-B block 
copolymer to NaCl during a 21 day period. A) Dashed line open squares, 100:0 = red, 90:10 = blue, B) 
Dashed line open circles, 80:20 = dark green, 70:30 = pink 60:40 = dark red, 50:50 = dark blue, 40:60 
= dark purple, 30:70 = light green = 30:70, orange = 20:80, yellow = 10:90, grey = 0:100 wt %*. 
(*Inadequate light scattering data obtained). 
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In comparison with p(PEG114-b-HPMA40), the increase in DPn of HPMA to 80 monomer 
units did appear to result in an overall increase in stability of the nanoparticles in the NaCl 
environment, in particular for the 80:20 wt % ratio (Figure 2.32). The ratios between 
90:10-50:50 wt % were stable during 21 days and although for 90:10, 80:20 and 60:40 wt 
% the PdI values remained below 0.057, a slight increase was observed to ~0.19 for 80:20 
and 50:50 wt %. The nanoparticle dispersions which were least effected after NaCl 
addition were 70:30, 60:40 and 50:50 wt %. From 40:60 wt % there is a general decrease 
in size of the nanoparticles and instability after 7 days is observed for 40:60, 30:70, 20:80 
and 10:90 wt % as all 21 day measurements were considered unreliable by DLS analysis. 
There was no visible precipitate after 7 days but an increase in PdI for 40:60 20:80 and 
10:90 wt % and PdI values remained below 0.2. 
 
Figure 2.32 Stability of p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80) to NaCl during a 21 day 
period, 90:10-0:100 wt %. Dashed line open circles, 90:10 = blue, 80:20 = dark green, 70:30 = pink 
60:40 = dark red, 50:50 = dark blue, 40:60 = dark purple, 30:70 = light green = 30:70, orange = 20:80, 
yellow = 10:90, grey = 0:100 wt %*. (*Inadequate light scattering data obtained). 
 
The p(PEG114-b-HPMAx) A-B block copolymer with the highest HPMA content (DPn = 
120), showed a higher stability when compared with the other p(PEG114-b-HPMAx) 
polymers. The Dz values for the varying ratios of p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMAx) during the 21 day test period are presented in Figure 2.33 and interestingly, as 
the mass of A-B block copolymer is increased the starting size decreases almost 
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systematically. The nanoparticles experienced negligible changes between the ratios of 
90:10-50:50 wt % during the 21 day NaCl addition test period. The addition of 80 wt % 
A-B block copolymer resulted in a nanodispersion which was stable for 21 days, however 
the PdI increased to 0.249. The co-nanoprecipitate ratios of 40:60, 30:70 and 10:90 wt % 
were stable up until 7 days, and although there was no visible precipitate, the DLS data 
was not reliable and therefore not included as part of the stability plot. It is evident that an 
increase in the DPn of HPMA for the A-B block copolymer does in fact increase the 
stability of the PEG114 nanoparticles and the optimum weight % ratios for stability are 
between 90:10 and 50:50 wt %. The size and PdI values obtained for the PEG114 series are 
located in the Appendix (Table A6). 
 
Figure 2.33 Stability of branched p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) A-B block 
copolymer to NaCl during a 21 day period, 90:10-0:100 wt %. Dashed line open circles, 90:10 = blue, 
80:20 = dark green, 70:30 = pink 60:40 = dark red, 50:50 = dark blue, 40:60 = dark purple, 30:70 = 
light green = 30:70, orange = 20:80, yellow = 10:90, grey = 0:100 wt %. 
 
Overall, the NaCl stability studies have shown that the length of both the PEGy and 
HPMAx chain of the A-B block copolymer when nanoprecipitated with p(HPMA50-co-
EGDMA0.9), greatly affects the stability. There are clear trends during the inclusion of 
p(PEG114-b-HPMAx) A-B block copolymers when compared to the  p(PEG45-b-HPMAx) 
series. The A-B block copolymer which maintained the greatest level of stability was 
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p(PEG114-b-HPMA120), due to the very minor changes in size between 10-50 wt % 
addition of A-B block copolymer to p(HPMA50-co-EGDMA0.9). 
 
When considering the original hypothesis, if the A-B block copolymer was loosely 
absorbed onto the surface (Figure 2.10i), it would be expected that destabilisation would 
occur during NaCl addition. Although some nanodispersions did precipitate upon NaCl 
addition, many remained stable, particularly those including p(PEG45-b-HPMA80) and 
p(PEG114-b-HPMAx) A-B block copolymers. These results suggest the HPMA chain from 
the A-B block copolymer is most likely incorporated into the p(HPMA50-co-EGDMA0.9) 
branched core, hence, steric stabilisation is provided by the residing PEG chains on the 
surface (Figure 2.34). 
 
 
 
 
 
 
 
 
 
Figure 2.34 Schematic representation of the proposed co-nanoprecipitation approach. 
 
As discussed, the p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) co-nanoprecipitated 
system demonstrated the highest tolerance during exposure to NaCl, therefore, it was of 
interest to establish the minimum amount of A-B block copolymer required to stabilise 
p(HPMA50-co-EGDMA0.9). As illustrated in Figure 2.34, the nanodispersion containing 
<10 wt % p(PEG114-b-HPMA120) was not stable and polymer precipitation was observed, 
suggesting insufficient PEG chains for steric stabilisation. 
 
 
Varying PEG 
chain length
Varying HPMA
chain length
p(HPMA50-co-EGDMA0.9) 
Co-nanoprecipitation
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Figure 2.34 Photograph of co-nanoprecipitated nanodispersions p(HPMA50-co-EGDMA0.9):p(PEG114-
b-HPMA120), left control nanodispersion, right NaCl addition. i) 99:1 wt %, ii) 97:3 wt %, iii) 95:5 wt 
%, iv) 97:3 wt %, v) 91:9 wt %, vi) 90:10 wt %. 
 
2.7.4 Stability of nanodispersions of branched p(HPMA50-co-EGDMA0.9) into 
solutions of water soluble A-B block copolymer in the presence of NaCl 
 
In order to compare the stability between a co-nanoprecipitation and the nanoprecipitation 
of p(HPMA50-co-EGDMA0.9) into solutions of water soluble A-B block copolymer, NaCl 
studies were conducted. The experimental conditions were as described previously, (20 
µL, 0.5M NaCl to 1 mL of nanodispersion), in order to directly compare both methods. 
Interestingly, the addition of NaCl resulted in instant precipitation during inclusion of both 
p(PEG45-b-HPMA40) and p(PEG114-b-HPMA40) 50 wt %, which was not observed 
previously for simultaneous addition (Table 2.8). This suggests that for these particular 
A-B block copolymers, the HPMA chain was loosely bound onto the nanoparticle surface 
and not entrapped within the core, as destabilisation of the nanoparticles was observed. 
There is a clear improvement in NaCl stability when p(HPMA50-co-EGDMA0.9) is 
nanoprecipitated into both water soluble p(PEG114-b-HPMA80) and p(PEG114-b-
HPMA120) 50 wt %, as sufficient stabilisation was observed during the 7 day test period. 
The presence of a longer hydrophobic chain on the A-B block copolymer appears to affect 
the stability during nanoprecipitation of p(HPMA50-co-EGDMA0.9) into the water soluble 
A-B block copolymers, as this behaviour was not observed when the polymers were added 
simultaneously during a co-nanoprecipitation. 
 
 
 
 
i) ii) iii) iv) v) vi)ia) iia) iiia) iva) va) via)
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Table 2.8 DLS results for the nanoparticles prepared via the nanoprecipitation of p(HPMA50-co-
EGDMA0.9) into solutions of H2O soluble A-B block copolymers and simultaneous co-
nanoprecipitation experiments and their stability to NaCl addition during a 7 day period. 
 
 
2.8 Mechanistic rationale for the role of the A-B block copolymer 
 
The stability of colloidal materials in various media has been widely studied38, 39 and many 
approaches utilise the initial principle, proposed by Derjaguin and Landau40 and Verway 
and Overbeek41 (DLVO), that suggests the total interaction energy (Wtotal) is the simple 
balance of van der Waals attractive interactions (WvdW) and electrostatic repulsions 
(Welect.). This DLVO theory has been questioned by several groups on the role of the so-
called ‘non-DLVO interactions’ such as steric and hydrophobic interactions which are not 
included within classical DLVO approaches;38, 42 the validity of the separate consideration 
of electrostatic and van der Waals interactions has also been questioned.42 Classical 
DLVO theory has been used recently to study the factors governing the growth of 
nanoparticles during nanoprecipitation into aqueous electrolytes of different concentration 
and to understand the stability of the resulting particles.43 Complicating factors for the 
estimation of Wtotal via DLVO theory include the calculation of the Hamaker constant for 
the study materials and the estimation of the surface potential of the nanoparticles for 
which, in experimental terms, the determination of ζ is more readily available. This is 
additionally complicated by the presence of stabilising ligands, but correlations do exist 
for ligand-coated inorganic nanoparticles.44 The direct substitution of ζ values for surface 
potential,45 and the selection of Hamaker constants43 from previously published 
calculations of analogous materials, has been adopted by several groups to allow 
meaningful mechanistic insight into nanoparticle behaviour. The attractive van der Waals 
Sample (50:50 wt %)
Blank Instant 1 day 7 days
Z-ave
(d.nm)
PdI
Z-ave
(d.nm)
PdI
Z-ave
(d.nm)
PdI
Z-ave
(d.nm)
PdI
Nanoprecipitation
Addition of p(HPMA50-co-EGDMA0.9) into an aqueous solution of p(PEG45-b-HPMA40) 80 0.062 514 X X X X X
Addition of p(HPMA50-co-EGDMA0.9) into an aqueous solution of p(PEG114-b-HPMA40) 86 0.048 1679 X X X X X
Addition of p(HPMA50-co-EGDMA0.9) into an aqueous solution of p(PEG114-b-HPMA80) 97 0.067 98 0.015 97 0.050 98 0.051
Addition of p(HPMA50-co-EGDMA0.9) into an aqueous solution of p(PEG114-b-HPMA120) 94 0.118 98 0.123 95 0.107 93 0.090
Co-nanoprecipitation
Simultaneous addition of p(HPMA50-co-EGDMA0.9) and p(PEG45-b-HPMA40) 109 0.048 172 0.038 173 0.020 212 0.020
Simultaneous addition of p(HPMA50-co-EGDMA0.9) and p(PEG114-b-HPMA40)
117 0.048 113 0.079 120 0.029 150 0.031
Simultaneous addition of p(HPMA50-co-EGDMA0.9) and p(PEG114-b-HPMA80)
111 0.081 109 0.089 107 0.062 112 0.083
Simultaneous addition of p(HPMA50-co-EGDMA0.9) and p(PEG114-b-HPMA120) 103 0.045 101 0.050 103 0.060 104 0.043
X = Polymer precipitation
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interaction, repulsive electrostatic interaction, and the total interaction energies of two 
identical nanoparticles, substituting experimentally measured ζ values for surface 
potentials, are given by equations 1−3, respectively: where A is the Hamaker constant, r 
is the radius of the nanoparticles, D is the separation distance, ε0 is the permittivity of free 
space, ε is the relative permittivity of the electrolyte medium, and κ is the reciprocal Debye 
length.  
 
                                            
      
 
  
                                                                                                             
The reciprocal Debye length κ may be calculated from eq. 4, where k is the Boltzmann 
constant, T is the absolute temperature, NA is Avogadro’s number, e is the elementary 
charge, and I is the ionic strength of the medium (mol m-3). 
 
 
2.8.1 DLVO calculations for the A-B block copolymer p(PEG45-b-HPMA120) 
 
The nanoparticles co-nanoprecipitated with the p(PEG45-b-HPMAx) materials showed a 
range of stability/instability rather than consistent stability seen for the p(PEG114-b-
HPMAx) materials. Therefore, the study of p(PEG45-b-HPMAx) materials was more 
meaningful, as we could see a trend in some cases and determine at what wt % values the 
inclusion of the A-B material was not beneficial.  
 
The Dn (DLS) values were used to calculate r, experimental ζ values were determined for 
the nanoparticles after addition of 0.5 M NaCl (20 μL to 1 mL of sample), κ was calculated 
as 3.32 × 108 m−1 at an ionic strength of 10 mol m-3 (0.01 M NaCl), and a Hamaker 
constant of 6.35 × 10−21 J was used due to the previous experimental determination of this 
value for methacrylate-based copolymer latex particles.45 Figure 2.36A shows the 
κ -1 = 
ε0εkT
2NAe
2I
WvdW =
−Ar
12D 
Welect. = 2πεε0rζ 
2exp(−κD)
Wtotal = WvdW + Welect.
(4)
(1)
(2)
(3)
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calculated Wtotal profile for the chosen co-nanoprecipitated particles immediately after salt 
addition.  
The measured ζ value of −4.41 mV suggests considerable screening of nanoparticle 
charge, and this is reflected in a predicted attractive energy profile and would lead to an 
expectation of aggregation and instability in the presence of salt. The addition of the 
poorly water-soluble A−B block copolymer into the initial polymer solution (good 
solvent) does provide for the presence of a stabilising layer of PEG45 chains, assuming co-
nanoprecipitation occurs. 
 
The presence of water-soluble surfactants containing PEG chains of this length were also 
considered in recent classical DLVO analyses of latex particles.45 PEG45 chains are 
reported to have a Flory radius of 3−3.5 nm,45, 46 therefore acting as a steric barrier with a 
distance of approximately 6 nm from the overlapping stabilising layers, as the co-
nanoprecipitates approach each other. A minimum value of Wtotal can be assumed to be 
attained from this overlap distance and has been mathematically determined as −0.74kT, 
considerably higher than the minimum −5kT value that is reported to be indicative of an 
unstable dispersion.45, 47 Although theoretical, calculations were also conducted to contrast 
the energy profile of the co-nanoprecipitate where its pre-salt addition ζ = −21.5 mV value 
was maintained. As can be seen, the increased ζ value would lead to a repulsive Wtotal until 
very small distances. The lack of stability of the co-nanoprecipitates from mixtures 
containing low wt % A−B block copolymer content was also mathematically investigated, 
as the presence of the PEG45 chains would have been expected to offer some stability. 
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Figure 2.36 Mechanistic evaluation of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120) co-
nanoprecipitates. (A) DLVO calculation of total interaction energies for a co-nanoprecipitate 
comprising a 60:40 wt % ratio: calculated balance of attractive and repulsive interactions for the co-
nanoprecipitate in 0.01 M NaCl and measured ζ = −4.41 mV (black solid and blue dashed line), 
aggregation barrier at 2 × PEG45 chain length (red line), theoretical energy profile calculated for initial 
ζ value (green dashed line). B) Analysis of possible surface coverage of the co-nanoprecipitates with 
available PEG45 chains within each nanoprecipitation experiment (>100 % indicates too few PEG45 
chains). 
Previous reports of close-packed PEG45 brushes on the surface of inorganic particles
46 
have estimated that chains can pack within approximately 3.5 nm, therefore occupying a 
surface area of 12.25 nm2 per chain. By taking the Dn (DLS) values, and assuming a 
density of 1 g cm-3 for the polymer nanoparticles (appropriate for polymethacrylates),48 
the mass and surface area of a single particle from each co-nanoprecipitate mass ratio was 
determined and a maximum theoretical number of PEG45 chains required to cover each 
co-nanoprecipitate was therefore derived. Assuming a close-packed brush conformation, 
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the ability of each ratio to completely cover the nanoparticles formed was calculated by 
simply dividing this theoretical maximum number with the number of PEG45 chains 
available during each co-nanoprecipitation. Although this analysis is somewhat 
qualitative, it is interesting to see that the 90:10 wt % ratio of polymers requires >100 % 
of the available PEG45 chains (i.e., too few PEG45 chains were present) within the 
nanoprecipitation solution to generate complete coverage of the nanoparticle surfaces 
(Figure 2.36 B); this ratio was the only nanoprecipitate containing the A−B block 
copolymer that aggregated instantly on addition of NaCl. In addition, when the number of 
PEG45 chains required to cover the surfaces of the nanoparticles fell below 20 % of the 
available PEG45 chains within the polymer mixture, i.e. a large excess of A−B block 
copolymer is present, a loss of polymer size control and an indication of salt instability 
were seen. This may be another limit to successful co-nanoprecipitation as competitive 
nanoprecipitation of the poorly soluble A−B block copolymer may lead to in-homogeneity 
within the composition of the nanoparticles or the potential for vesicle and micelle 
formation. 
 
2.9 Dialysis Studies of co-nanoprecipitated nanoparticles 
 
During inclusion of the A-B block copolymer, p(PEG114-b-HPMA120) with p(HPMA50-
co-EGDMA0.9), stable nanoparticles and the highest tolerance to NaCl addition was 
observed, therefore this particular material was selected for the study. If the A-B block 
copolymer was only loosely associated with nanoprecipitates of branched p(HPMA50-co-
EGDMA0.9) after nanoprecipitation, i.e. adsorbed onto the nanoparticle surface (Figure 
2.10i), then it would be expected that during dialysis of the nanodispersion against water, 
the A-B block copolymer would easily desorb and no longer sterically stabilise 
p(HPMA50-co-EGDMA0.9). In order to investigate this, dialysis tubing with a molecular 
weight cut off (MWCO) of 100 kg/mol was used to conduct a dialysis experiment of a co-
nanoprecipitated dispersion. This particular pore size was selected to ensure the highly 
branched p(HPMA50-co-EGDMA0.9) polymer and any assembled nanoparticles remained 
within the tubing and the A-B block copolymer with a molecular weight <100 kg/mol was 
able to move freely across the membrane and equilibrate, if loose surface adsorption was 
the mechanism (Figure 2.10i).  
 
This study was carried out using p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) co-
nanoprecipitates at a ratio of 50:50 wt % and was prepared as previously discussed. The 
nanoprecipitation experiment was scaled up accordingly so the total polymer 
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concentration was 20 mg/mL. After DLS analysis of the nanodispersion, the particles were 
added to the dialysis tubing and left to stir at ambient temperature over a period of 128 
hours, during which, samples were taken for analysis (Table 2.8 & Figure 2.37). As 
highlighted, the starting nanoparticle dispersion and 128 hour DLS Dz sizes are almost 
identical, suggesting the dialysis experiment has had very little effect on the 
nanodispersion. A DLS overlay of the nanoparticles before and after 128 hour dialysis 
emphasises how the Dz for both samples overlay almost exactly and almost identical sizes 
are obtained (Figure 2.37 B). 
 
Table 2.8 DLS results for dialysis experiment of p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 
50:50 wt % at increasing time intervals. 
 
 
 
 
 
 
 
 
 
 
As previously discussed, the nanoprecipitation of p(HPMA50-co-EGDMA0.9) yields stable 
nanoparticles, but during addition of a small aliquot of NaCl they quickly precipitate. 
However, the inclusion of the A-B block copolymer, p(PEG114-b-HPMA120) introduces 
steric stabilisation and the addition of NaCl has minimal or no effects on the nanoparticles. 
In order to determine if the dialysed nanoparticles had maintained their steric stability, a 
1 mL sample was taken from the dialysis solution inside the bag and NaCl (20 µL of 0.5M 
solution) was added. The process is outlined in Figure 2.38 and the final DLS 
measurement after 7 day NaCl addition, Figure 2.38iii, is almost identical to the initial 
nanodispersion measured before the dialysis experiment. The DLS sizes are reported in 
Table 2.9 and as highlighted, there are very small differences in comparison to the blank 
nanoparticle sample and it is worth noting that all PdI’s remained narrow (<0.057) 
throughout the experiment. These results suggest that the HPMA from the A-B block 
copolymer is becoming fully incorporated with the branched p(HPMA50-co-EGDMA0.9) 
core and the PEG chain of the A-B block copolymer is remaining on the surface (Figure 
2.10ii). 
Time 
(hours)
Dz (nm) PdI Dn (nm) Derived count rate (kcps)
0 123 0.057 96 397200
56 121 0.054 96 391750
80 120 0.045 95 463730
104 124 0.053 99 452240
128 122 0.056 98 487180
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Figure 2.37 DLS overlay for dialysis experiment of p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120), 
before dialysis (black trace) and after 128 hours dialysis (red trace). 
 
Figure 2.38 NaCl addition to dialysed nanoparticles, i) p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) 50:50 wt % blank nanoparticles added to a dialysis bag ii) After 128 hours a 1 mL sample 
of this nanodispersion added to a vial and 20 µL NaCl is added iii) DLS trace after 7 day, NaCl addition 
result.  
 
Table 2.9 DLS results comparing nanoparticle sizes before and after NaCl addition. 
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Before Dialysis 123 0.057 96 397200
Instant 121 0.042 98 479406
1 day 115 0.033 93 346155
7 day 120 0.036 98 273643
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In order to analyse the remaining polymeric material within and outside of the dialysis 
bag, the solutions were concentrated in vacuo and weighed for accurate triple detection 
GPC analysis. Unfortunately, after rotary evaporation of the solution outside of the 
dialysis bag, a brown material as well as polymer was present, which may be residual 
material from the pre-wetted dialysis membrane. The unknown material was not soluble 
in THF, therefore GPC analysis was not possible. However, the material present within 
the dialysis bag was readily solubilised in THF and analysed by GPC (Figure 2.39). 
Although similar retention volumes were obtained for p(HPMA50-co-EGDMA0.9) and the 
solution of polymers dialysed, both the RI and RALS GPC traces suggest there has been 
a change in molecular weight of the initial polymers, and further work would be required 
to determine the differences in the polymer mixture after dialysis. Although the GPC 
analysis was inconclusive, the DLS results discussed earlier do demonstrate that the co-
nanoprecipitates are not affected when dialysed against a large excess of water for ~5 days 
and remain stable during NaCl addition during a 7 day period. 
 
Figure 2.39 A) GPC RI trace overlay of p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt % 
dialysis solution inside the bag (black), p(HPMA50-co-EGDMA0.9) (red dash) and p(PEG114-b-
HPMA120) (blue dash) B) GPC RALS trace overlay of p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) 50:50 wt % dialysis solution inside the bag (black), p(HPMA50-co-EGDMA0.9) (red dash) 
and p(PEG114-b-HPMA120) (blue dash). 
 
2.10 Probing the internal nanoparticle environment and co-
nanoprecipitation mechanism using fluorescent guest molecule  
 
The following experiments aim to investigate the encapsulation of a guest fluorescent 
molecule within nanoparticles to probe the physical properties of the internal environment. 
The results obtained from fluorimetry measurements can provide further indication as to 
8 10 12 14 16 18 20
Y
 A
xi
s
 2
80
100
120
140
Y
 A
xi
s
 3
70
80
90
100
110
RALS branched HPMA vs Col 6 
RI PEG5KHPMA120 vs Col 8 
RALS vs Col 12 
10 12 14 16 18 20
Y
 A
xi
s
 2
-30
-25
-20
-15
-10
-5
0
Y
 A
xi
s
 3
20
40
60
80
100
120
140
Col 1 vs RI dialysis inside bag 
RI kate bHPMA vs Col 6 
RI PEG5KHPMA120 vs Col 10 
10 12 14 16 18 20
Y
 
A
x
i
s
 
2
-30
-25
-20
-15
-10
-5
0
Y
 
A
x
i
s
 
3
20
40
60
80
100
120
140
Col 1 vs RI dialysis inside bag 
RI kate bHPMA vs Col 6 
RI PEG5KHPMA120 vs Col 10 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt% - dialysis solution inside bag 
p(HPMA50-co-EGDMA0.9)
p(PEG114-b-HPMA120) 
10 12 14 16 18 20
Y
 
A
x
i
s
 
2
-30
-25
-20
-15
-10
-5
0
Y
 
A
x
i
s
 
3
20
40
60
80
100
120
140
Col 1 vs RI dialysis inside bag 
RI kate bHPMA vs Col 6 
RI PEG5KHPMA120 vs Col 10 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt% - dialysis solution inside bag 
p(HPMA50-co-EGDMA0.9)
p(PEG114-b-HPMA120) 
Retention Volume (mL) Retention Volume (mL)
A) B)
  
105 
 
whether the PEG chains from the A-B block copolymer are incorporated internally or 
reside on the nanoparticle surface. A similar study has been previously conducted for hyp-
polydendron nanoparticles, which are composed of varying amounts of PEG.3 
 
Encapsulation can be achieved by dissolving the guest molecule within the polymer 
mixture in the good solvent (acetone) before addition to water. For the following studies 
the selected guest molecule was pyrene (Figure 2.40). Pyrene is a small hydrophobic 
molecule composed of four fused benzene rings and is soluble in a range of solvents, 
including acetone. 
The fluorescence emission spectrum of pyrene is sensitive to solvent polarity, therefore 
can be used to probe the internal environment of nanoparticles. The emission spectrum of 
pyrene (π*  π) has five vibronic bands I-V. Peak I (0  0 band) is strongly enhanced in 
polar solvents compared to peak III (0  2 band). Thus, the ratio of the intensities of the 
first and third vibrational bands (the I1/I3 ratio) serves as a quantitative measure of solvent 
polarity. The I1/I3 ratio is one of the most widely used indicators of solvent polarity.
49 The 
reported value for pyrene in non-polar solvents such as hexane is ~0.61 whilst in polar 
solvents this value significantly increases; for example the I1/I3 value for water is reported 
within the range of 1.75 – 2.50, 51 
 
 
 
 
 
 
Figure 2.40 Chemical structure of pyrene. 
 
The reported literature values for pyrene fluorescence were compared with experimental 
values obtained in different solvents (Figure 2.41). The results show that there are minor 
differences between reported and experimental values.  
 
The encapsulation of pyrene into the polymer nanoparticles was conducted by dissolving 
pyrene in acetone to give a stock solution (0.1 mg/mL). The stock solution (300 µL) was 
added to an empty vial, and the acetone was allowed to evaporate to leave 30 μg of dye. 
During a typical 50:50 wt % co-nanoprecipitation, p(HPMA50-co-EGDMA0.9), p(PEGy-b-
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HPMA120) and acetone were added to the vial to give a final concentration of polymer 5 
mg/mL and pyrene 5 μg/mL. The nanoparticles were prepared as previously described, by 
rapid addition of 1 mL of the solution into vigorously stirring distilled water (5 mL). The 
mixture was left for 24 hours at ambient temperature to ensure complete acetone 
evaporation, leading to a final polymer concentration in water of 1 mg/mL and 1 μg/mL 
pyrene in water.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.41 Comparison of literature and experimental values of pyrene dissolved in various solvents, 
literature (black cross) and experimental (red cross). 
2.10.1 p(PEG45-b-HPMA120) pyrene studies 
The size comparison of blank and pyrene encapsulated nanoprecipitates of branched 
p(HPMA50-co-EGDMA0.9) and p(PEG45-b-HPMA120) at various ratios is presented below 
(Figure 2.42) and shows there are only slight deviations from the size of the blank 
nanoparticles which appears to be within the normal error of nanoprecipitation. The Dz 
and PdI values are shown in the Appendix (Table A7). 
 
The fluorescence emission spectra for blank and pyrene encapsulated nanoparticles is 
shown below in Figure 2.43 for p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120). For all 
results presented, the excitation wavelength was set to λex = 335 nm. The emission 
spectrum in the absence of pyrene (Figure 2.43A) shows the absence of emission peaks 
for the blank nanoparticles when excited at 335 nm; this is expected as there are no 
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fluorophores present. For pyrene encapsulated nanoparticles (Figure 2.43B), the five 
vibronic bands are visible and I1 and I3 are highlighted.  
 
 
Figure 2.42 Nanoparticle sizes from DLS of blank nanoparticles (black crosses) and with 0.1 w/w % 
pyrene encapsulated (red crosses) for the p(PEG45-b-HPMA120) series. 
 
Figure 2.43 Fluorescence data for pyrene in water, p(HPMA50-co-EGDMA0.9) and p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA120) co-nanoprecipitated nanoparticles at various ratios. A) fluorescence 
emission spectrum for blank polymeric nanoparticles, B) fluorescence emission spectrum for polymeric 
nanoparticles with encapsulation of 0.1 w/w % pyrene.  
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Figure 2.44 Fluorescence I1/I3 results for the p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120) series. 
I1/I3 ratio for series of nanoparticles with pyrene encapsulated (red crosses) and common solvents as a 
reference (black circles). 
The pyrene encapsulated nanoparticles were prepared from p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA120) between the varying ratios of 100:0 – 50:50 wt % and 
their I1/I3 values are presented in Figure 2.44A, as well as the literature solvent values. 
When pyrene was encapsulated within p(HPMA50-co-EGDMA0.9) nanoparticles, the I1/I3 
value obtained was 1.58. Interestingly, the I1/I3 values across the co-nanoprecipitate ratios 
do not vary significantly (1.58-1.60), suggesting the core is composed mainly of 
hydrophobic p(HPMA50-co-EGDMA0.9) rather than containing additional (hydrophilic) 
PEGy chains (Table 2.10). Previous research within the Rannard research group has 
reported the pyrene nanoprecipitation studies of hyp-polydendrons composed of 
p(HPMA50-co-EGDMA0.9) with covalently bound PEG chains. The I1/I3 values obtained 
were higher for increasing PEG content which suggests that nanoprecipitation of the hyp-
polydendron materials may result in a higher PEG content within the nanoparticle core.3 
For the co-nanoprecipitation system consisting of both branched p(HPMA50-co-
EGDMA0.9) and an A-B block copolymer, the PEG chains are not covalently bound to the 
branched p(HPMA50-co-EGDMA0.9), therefore, the chance of PEG residing within the 
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nanoparticle core is minimised. The I1/I3 value obtained for highest ratio of A-B block 
copolymer (50 wt %) is 1.60, again, suggesting the core is composed mainly of branched 
p(HPMA50-co-EGDMA0.9) rather than PEG from the A-B block copolymer. Figure 2.45 
shows a graphical representation of a branched copolymer with covalently bound PEG 
chains vs a branched/A-B block copolymer assembly along with each proposed internal 
environment.  
Table 2.10 Summary of I1/I3 ratios across the varying ratios of the co-nanoprecipitated particles with 
encapsulated pyrene. 
 
 
 
 
 
 
 
 
Sample Ratio I1/I3 
Pyrene in H2O - 1.81
p(HPMA50-co-EGDMA0.9) 100:0 1.58
p(HPMA50-co-EGDMA0.9): p(PEG45-b-HPMA120) 90:10 1.56
p(HPMA50-co-EGDMA0.9): p(PEG45-b-HPMA120) 80:20 1.60
p(HPMA50-co-EGDMA0.9): p(PEG45-b-HPMA120) 70:30 1.58
p(HPMA50-co-EGDMA0.9): p(PEG45-b-HPMA120) 60:40 1.58
p(HPMA50-co-EGDMA0.9): p(PEG45-b-HPMA120) 50:50 1.60
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Figure 2.45 Graphical representation of pyrene encapsulation and comparison with previously prepared 
nanoparticles within the Rannard research group. A) hyp-polydendron nanoparticles, B) co-
nanoprecipitated nanoparticles. 
 
2.10.2  p(PEG114-b-HPMA120) pyrene studies 
 
The excellent stability properties demonstrated by the p(PEG114-b-HPMA120) series were 
encouraging to study this system further. Also, it was of interest to determine how a water 
soluble A-B block copolymer could affect the core polarity. The blank vs pyrene 
encapsulated nanoparticles (Figure 2.46) demonstrated that there are again negligible 
differences between the nanoparticles sizes, which were discussed previously for the 
p(PEG45-b-HPMA120) series (Appendix, Table A8). The fluorescence data for blank and 
pyrene encapsulated nanoparticles are presented in the Appendix (Fig. A19). 
The fluorimetry results for the p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 
nanoparticles at various ratios are generally higher than the I1/I3 values obtained for the 
p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120) series. The I1/I3 value for 100 % 
branched p(HPMA50-co-EGDMA0.9) was 1.64, so all following results were relative to 
this value, due to the absence of PEG chains (Figure 2.47). Overall, the reported I1/I3 
values did not deviate much from 1.64, and for the 90 wt % p(PEG114-b-HPMA120) A-B 
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block copolymer, a minor decrease to 1.57 was observed. This fluorimetry data suggests 
that the hydrophobic core is composed mainly of HPMA and minimal or no PEG chains. 
This study further suggests that the A-B block copolymer HPMA chain becomes 
incorporated into the branched p(HPMA50-co-EGDMA0.9) core and PEG chains reside on 
the nanoparticle surface (Figure 2.10ii) .  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.46 DLS results of blank nanoparticles (black crosses) and with 0.1 w/wt % pyrene 
encapsulated (red crosses) for the p(PEG114-b-HPMA120) series.  
 
Considering both the I1/I3 ratios and low ζ values obtained previously, the results suggest 
that the PEG chains for both p(PEG45-b-HPMA120) and p(PEG114-b-HPMA120) A-B block 
copolymers are mainly located at the surface of the nanoprecipitates. The encapsulation 
of a hydrophobic organic molecule has highlighted the potential application of such 
materials as carriers of poorly soluble compounds and this study has utilised A−B block 
copolymers whilst varying their compositions. In addition, the process will be investigated 
to extend beyond the chemical compositions presented to enhance the properties of 
materials which have previously been overlooked as potential nanocarriers. 
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Figure 2.47 Fluorimetry results for the p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) series. I1/I3 
ratio for series of nanoparticles with pyrene encapsulated (red crosses) and common solvents as a 
reference (black circles). 
 
Table 2.11  I1/I3 ratios across the varying ratios of the co-nanoprecipitated particles with encapsulated 
pyrene. 
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2.11 Conclusion 
 
The synthesis of both linear p(HPMA50), branched p(HPMA50-co-EGDMA0.9) and 
p(PEGy-b-HPMAx) linear A-B block copolymers via ATRP was successfully achieved. 
The model nanoprecipitation studies of p(HPMA50) and p(HPMA50-co-EGDMA0.9) were 
conducted to support the previous views that there is a clear advantage of using branched 
p(HPMA50-co-EGDMA0.9) copolymers rather than linear homopolymers when seeking to 
achieve narrow, monomodal polymer nanoparticle size distributions. It is evident that 
branched chains effectively collapse to form relatively large nuclei that assemble to form 
the larger, colloidally stable nanoparticles. Further to this, multiple nanoprecipitation 
experiments were conducted without modification of the original nanoparticle size and it 
is worth emphasising that this procedure provides an option to create samples of 
increasing concentration via a relatively simple strategy after initial removal of good 
solvent. The co-nanoprecipitation studies of p(HPMA50-co-EGDMA0.9) with A−B block 
copolymers at varying ratios from 100:0-0:100 wt %, leads to nanoparticle behaviour that 
is different to the individually nanoprecipitated copolymers (branched or A-B block 
copolymer). The size and PdI values did not show any major trend and generally narrow, 
monomodal distributions were obtained across each series. As discussed, this method was 
studied to see if it was possible to improve the properties of charge stabilised nanoparticles 
of p(HPMA50-co-EGDMA0.9) and introduce steric stabilisation via an A-B block 
copolymer. To evaluate the differences in stability, aliquots of NaCl were added to the 
nanoparticle dispersions and generated different results depending on the chemical 
composition of the A-B block copolymer and ratio studied. An apparent maximum of salt 
stability was observed during inclusion of p(PEG114-b-HPMA120) A-B block copolymer. 
This may be indicative of an optimum ratio and A-B block composition necessary for 
efficient polymer interaction during the co-nanoprecipitation process, and at what point 
the increased hydrophilic PEG chains provide sufficient stabilisation. A simplified DLVO 
approach was applied to the co-nanoprecipitated nanoparticles of p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA120) and suggested that the low ζ values present after 
charge screening in salt solutions should lead to aggregation, and indeed, aggregation is 
seen if the number of PEG45 chains is insufficient to provide a barrier to approaching 
nanoparticles. Although no evidence was provided by DLS analysis, it is possible that 
non-uniform decoration of the A−B block copolymer, including the formation of 
structures predominantly resembling micelles or vesicles, occurs at low concentrations of 
branched copolymer. The encapsulation of the hydrophobic organic molecule pyrene and 
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polarity studies has provided further evidence that during addition of increasing levels of 
A-B block copolymer, the hydrophobicity of the internal core is maintained and only a 
slight increase is observed when compared with 100 % p(HPMA50-co-EGDMA0.9). From 
these detailed studies, it appears it is most likely that the HPMA from the A-B block 
copolymer becomes incorporated into the polymer core and the PEG chain resides on the 
nanoparticle surface. Ongoing studies with the A-B block copolymers and varying 
branched copolymer core is of interest to establish a more detailed insight into this facile 
nanoparticle production strategy.  
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Chapter 3 
 
 
 
The Synthesis and Nanoprecipitation Studies of 
Branched and Block Copolymers with Hydrophobic 
Block Segments for Co-nanoprecipitated Particle 
Dispersions and their Pharmacological Studies in vitro. 
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3.1 Introduction  
As discussed in Chapter 2, the detailed co-nanoprecipitation studies of branched 
p(HPMA50-co-EGDMA0.9) copolymers with varying p(PEGx-b-HPMAy) A-B block 
copolymers resulted in the formation of sterically stabilised nanoparticles. To further 
investigate the co-nanoprecipitation process, this research chapter will focus upon the 
synthesis of hydrophobic branched copolymers other than p(HPMA50-co-EGDMA0.9) and 
subsequent aqueous nanoparticle studies in combination with a selection of A-B block 
copolymers including those previously described. It is of interest to investigate the 
behaviour of polymers with varying chemical compositions to evaluate the versatility of 
the co-nanoprecipitation approach.  
 
3.2 Synthesis of hydrophobic branched co/terpolymers via ATRP 
 
The research studies presented in Chapter 2 focused on branched p(HPMA50-co-
EGDMA0.9) copolymers and varying p(PEGx-b-HPMAy) block copolymers. In order to 
investigate the versatility of the co-nanoprecipitation process with A-B block copolymers 
and branched copolymers other than p(HPMA50-co-EGDMA0.9), alternative branched 
copolymers have been synthesised. As discussed, p(HPMA50-co-EGDMA0.9) forms stable 
nanoparticles when nanoprecipitated alone and during co-nanoprecipitation with an A-B 
block copolymer. Stabilised nanoparticles with varying polymer compositions may offer 
the potential to tune nanoparticle behaviour. Herein, the hydrophobic monomers n-butyl 
methacrylate (n-BMA) and t-butyl methacrylate (t-BMA) were evaluated for the 
preparation of branched copolymers. 
The ATRP reaction schemes for the various target branched copolymers; p(n-BMA50-co-
EGDMA0.8) (6), p(t-BMA50-co-EGDMA0.9) (7), p(HPMA25-co-n-BMA25-co-EGDMA0.9) 
(8) and p(HPMA25-co-t-BMA25-co-EGDMA0.9) (9) are shown in Scheme 3.1. In all cases, 
to allow behavioural comparison, the targeted DPn for each primary polymer chain was 
50 monomer units; this also allowed comparison to the branched p(HPMA50-co-
EGDMA0.9) copolymers synthesised in Chapter 2, Section 2.3. The monomer 
concentration within each polymerisation was of 50 wt % with respect to the solvent 
unless otherwise stated. All polymers previously synthesised and studied in Chapter 2 
were analysed using a DMF triple detection GPC instrument at 60°C with 0.01M LiBr, 
due to the solubility of the PEG chains within the A-B block copolymers. However, the 
branched copolymers presented below were analysed using a triple detection GPC 
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instrument employing a THF eluent containing TEA (2 v/v %), as the branched polymers 
were initiated with EBiB and were easily solubilised in this solvent. 
When using EBiB (1) as the initiator, a molar ratio of brancher:initiator of 0.9:1 was 
employed. These conditions were used previously for p(HPMA50-co-EGDMA0.9) in 
Chapter 2, Section 2.3 in order to obtain a high molecular weight polymer. Generally, this 
ratio of brancher:initiator was suitable and a high molecular weight, soluble polymer was 
recovered. However, during the ATRP polymerisation of p(n-BMA50-co-EGDMA0.8), a 
0.9:1 brancher:initiator ratio resulted in the formation of a material which could not be 
fully solubilised in a good solvent, therefore the EGDMA content was decreased to 0.8 
and the resulting polymer was readily soluble.  
The selected solvent for the ATRP synthesis of p(n-BMA50-co-EGDMA0.8) was 
anhydrous methanol at an elevated temperature of 60°C, which has been previously 
reported within our research group.1, 2 Methanol is often used as a precipitant for p(n-
BMAx), yet the Cu-catalysed ATRP in methanol has been shown to yield polymers with 
desired molecular weights and low dispersities. The reports of p(n-BMAx) also 
demonstrated the ability for the temperature of the polymerisation to be lowered to 25°C, 
but upon sampling, precipitation of the polymer was observed. Therefore, monitoring 
conversion became increasingly difficult. 
The solvent system selected for the preparation of p(t-BMA50-co-EGDMA0.9) was a 
mixture of isopropanol (IPA) and H2O (92.5:7.5) (33.3 wt % based on t-BMA), as these 
ATRP polymerisation conditions were previously reported by Rannard and co-workers 
as the first room temperature water-borne ATRP of a hydrophobic monomer in 
homogenous alcoholic media in 2001.3 A ratio of 92.5:7.5% IPA:H2O exhibited the 
ideal ratio in terms of reactivity time without compromising the control of the 
polymerisation.  
For the synthesis of both branched statistical terpolymers (p(HPMA25-co-t-BMA25-co-
EGDMA0.9) and p(HPMA25-co-n-BMA25-co-EGDMA0.9)), the equal ratio of both 
monomers were completely soluble in anhydrous methanol, therefore the same reaction 
conditions previously stated for p(HPMA50-co-EGDMA0.9) (Chapter 2, Section 2.3) were 
employed for the ATRP polymerisations. 
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Scheme 3.1 ATRP synthesis of branched hydrophobic polymers. A) p(n-BMA50-co-EGDMA0.8), B) 
p(t-BMA50-co-EGDMA0.9), C) p(HPMA25-co-n-BMA25-co-EGDMA0.9), D) p(HPMA25-co-t-BMA25-
co-EGDMA0.9). 
A)
B)
D)
C)
(1)
(2)
(6)
(9)
(8)
(7)
(1)
(1)
(1)
(2)
(2)
(2)
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Triple detection GPC was used to determine the molecular weights of the branched 
copolymers (Table 3.1) and the inclusion of EGDMA yielded high molecular weight 
polymeric species with broader dispersities than would be obtained for linear polymers 
(See Appendix, Fig. A20-A22 for GPC example overlays of linear and branched polymers 
comprised of n-BMA, HPMA-co-n-BMA and HPMA-co-t-BMA). It is well documented 
that high Mw branched structures do not form until high conversions are reached, through 
intermolecular reactions when the linear polymer chains join together via a pseudo step-
growth mechanism.4 The high Mw values (Table 3.1) are indicative of the formation of 
high molecular weight branched copolymers; in all cases the polymerisations reached high 
conversions > 97%, as monitored by 1H NMR.  
 
Table 3.1 GPC and 1H NMR analysis of branched copolymers synthesised via ATRP. 
 
The conversion was calculated by integration of the vinyl protons to an internal NMR 
reference (anisole); an example overlay of 1H NMR spectra for branched p(HPMA25-co-
n-BMA25-co-EGDMA0.9) is shown in the Appendix, Fig. A23. Due to the statistical nature 
of branching in ATRP, there is a broad distribution of materials present, which range from 
linear chains to highly branched macromolecules.5 The RI chromatogram overlay (Figure 
3.1A) illustrates the formation of high molecular weight branched copolymers which is 
evident from elution of polymers at low retention volumes. The analysed 1H NMR spectra 
of final branched copolymers are presented in the Appendix, Fig. A24-A27.  
Although a small RI response is detected at lower retention volumes, a more detailed 
representation of the large polymeric species is presented by the RALS chromatogram 
overlay (Figure 3.1B), as this detector is dependent on the size of the polymeric species 
present. The RI detector indicates the overall concentration of each fraction within the 
distribution and although the linear primary chains appear as the most common species, 
Targeted Polymer Composition
Conversion 
(%)a
Mn (g/mol) Mw (g/mol) Đ
p(HPMA50-co-EGDMA0.9) 98 39 100 293 100 7.49
p(n-BMA50-co-EGDMA0.8) 98 36 000 206 100 5.73
p(tBMA50-co-EGDMA0.9) 99 95 100 184 700 1.94
p(HPMA25-co-n-BMA25-co-EGDMA0.9) 97 220 000 3 050 000 13.9
p(HPMA25-co-tBMA25-co-EGDMA0.9) 97 16 000 157 000 9.81
a 
Determined by 1H NMR analysis in DMSO-d6 or MeOD-d4
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the presence of multiple branched species is also obvious within the analysis. It is worth 
noting that the height of each peak has been normalised to aid comparison and does not 
reflect the absolute detector response. 
 
Figure 3.1 GPC analyses for branched copolymers A) RI chromatogram overlays, B) RALS 
chromatogram overlays. 
3.3 Aqueous nanoprecipitation studies  
 
3.3.1 Nanoprecipitation studies of branched co/terpolymers 
 
As previously reported, the formation of aqueous nanoparticles via the nanoprecipitation 
approach is efficient and reproducible.6, 7 To ensure consistency and aid comparison, the 
conditions for all branched copolymer nanoprecipitation experiments were as described 
previously. Therefore, all nanoparticles from this point onwards (unless otherwise stated) 
will be prepared from 1 mL of a 5 mg/ml polymer solution (acetone) into 5 mL of water. 
The initial and final concentration of samples prepared by aqueous nanoprecipitation will 
be described as ix-fy, where x represents the initial concentration and y the final 
concentration in mg/mL, therefore unless otherwise stated, the conditions will be i5-f1. 
Acetone solutions of the branched copolymers and terpolymers; p(n-BMA50-co-
EGDMA0.8), p(t-BMA50-co-EGDMA0.9), p(HPMA25-co-n-BMA25-co-EGDMA0.9) and 
p(HPMA25-co-t-BMA25-co-EGDMA0.9) were nanoprecipitated into water. It was possible 
that nanoprecipitation of the hydrophobic copolymers p(n-BMA50-co-EGDMA0.8) and 
p(t-BMA50-co-EGDMA0.9) may precipitate upon nanoprecipitation and the statistical 
terpolymers would be somewhat stabilised due to the presence of HPMA which has some 
hydrophilic nature although being insoluble in water. Nanoprecipitations were conducted 
and, as expected, p(n-BMA50-co-EGDMA0.8) and p(t-BMA50-co-EGDMA0.9) instantly 
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precipitated upon addition to water. Although the branched terpolymer p(HPMA25-co-t-
BMA25-co-EGDMA0.9) was stable upon initially, after 24 hours the polymer precipitated; 
however, p(HPMA25-co-n-BMA25-co-EGDMA0.9) remained stable (Figure 3.3). Although 
nanoprecipitation of p(n-BMA50-co-EGDMA0.8) resulted in instant precipitation, the 
presence of HPMA monomer units in the statistical terpolymer of p(HPMA25-co-n-
BMA25-co-EGDMA0.9) appeared to provide stabilisation and enabled the formation of 
nanoparticles. This may be due to the presence of the adsorbed hydroxide ions on the 
nanoparticle surface of the nanoparticles, facilitated by the HPMA monomer residues, 
which provide additional stabilisation. This has been reported in the literature for a range 
of material types including films of polystyrene and poly(2-hydroxyethyl methacrylate).8-
10 
 
 
 
Figure 3.2 Schematic representation of the nanoprecipitation approach of co- and terpolymers. 
Fast addition 
into stirring 
water
Evaporation 
of acetone
Association 
of polymer 
molecules  and 
formation of 
nanoparticles
Collapsed branched 
polymer 
nanoparticles in 
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Figure 3.3 Photographs of branched c- and terpolymer nanoprecipitations, final concentration of 
polymer 1 mg/mL, Ai) p(HPMA50-co-EGDMA0.9) ii) p(n-BMA50-co-EGDMA0.8) iii) p(t-BMA50-co-
EGDMA0.9) iv) p(HPMA25-co-n-BMA25-co-EGDMA0.9) v) p(HPMA25-co-t-BMA25-co-EGDMA0.9), 
B) DLS trace for nanoprecipitation of p(HPMA25-co-n-BMA25-co-EGDMA0.9). 
3.3.2 Co-nanoprecipitation studies of branched copolymers and A-B block 
copolymers 
Following the successful preparation of p(n-BMA50-co-EGDMA0.8) and p(t-BMA50-co-
EGDMA0.9) branched copolymers, the highly hydrophobic nature prevented the 
production of stable nanoparticles via nanoprecipitation. As witnessed in Chapter 2, the 
incorporation of an A-B block copolymer within the nanoprecipitation enhanced the 
stability of nanoparticles, particularly in aqueous salt conditions. It was, therefore, 
hypothesised that similar benefits could be introduced by application of the co-
nanoprecipitation method, in order to produce stable nanoprecipitates from these branched 
polymers. It may be expected that the synthesised branched co- and terpolymers will 
interact differently with the A-B block copolymer when co-nanoprecipitated, due to the 
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varying nature of the monomer chemistry within the different hydrophobic polymer 
segments. 
The A-B block copolymer selected for initial study was p(PEG114-b-HPMA120), due to the 
stability of the co-nanoprecipitates generated when this was incorporated, as previously 
discussed in Chapter 2. The DLS results for the co-nanoprecipitation experiments at a 
50:50 wt % ratio of branched co- and terpolymers to A-B block copolymer are shown in 
Table 3.2 and Figure 3.4. This ratio of branched co- and terpolymer to A-B block 
copolymer was selected as previous studies showed successful formation of stabilised 
nanoparticles without the potential complication of competitive nanoprecipitation (i.e. the 
concentration of A-B block copolymer was sufficient to stabilise the nanoparticles without 
also forming nanoprecipitates comprising predominantly of A-B block copolymer).  
Table 3.2 DLS results for the co-nanoprecipitation of varying branched copolymers and p(PEG114-b-
HPMA120). 
 
When p(n-BMA50-co-EGDMA0.8) is nanoprecipitated in the absence of the A-B block 
copolymer, immediate precipitation is observed; however, when the A-B block copolymer 
is co-nanoprecipitated, stable nanoparticles form with a very narrow polydispersity. So 
far, it was believed that the formation of co-nanoprecipitates occurred via incorporation 
of the hydrophobic chain (HPMA120) from the A-B block copolymer into the branched 
polymer core resulting in hydrophilic PEG chains on the surface. The resulting Dz for p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) was 205 nm, which was ~70 nm higher 
than diameters obtained for previous nanoparticles from co-nanoprecipitated branched 
p(HPMA50-co-EGDMA0.9). This suggests that co-nanoprecipitated particles including 
p(n-BMA50-co-EGDMA0.8) reach colloidal stability at a larger size, although it is not clear 
Sample (50:50 wt %) Z-ave (d.nm) PdI Dn (nm)
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 103 0.051 108    
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 205 0.088 170
p(t-BMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 357 0.234 245
p(HPMA25-co-n-BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 161 0.085 125
p(HPMA25-co-t-BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 161 0.066 131
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why this would be the case. For p(HPMA25-co-n-BMA25-co-EGDMA0.9) and p(HPMA25-
co-t-BMA25-co-EGDMA0.9), stable nanoparticles were formed in the presence of the A-B 
block copolymer with virtually identical particle size distributions obtained. However, the 
inclusion of an A-B block copolymer with p(t-BMA50-co-EGDMA0.9) demonstrated 
different behaviour, as the resulting nanoparticles were much larger, with a broader 
polydispersity, and started to precipitate out of solution after 24 hours; this suggests a poor 
compatibility between the branched copolymer and A-B block copolymer. The DLS traces 
(Figure 3.4) illustrate narrow monomodal peaks for all samples with the exception of p(t-
BMA50-co-EGDMA0.9) which has an obviously broader population of nanoparticles and 
a tail that suggests an appreciable concentration of larger particles (Figure 3.4C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 DLS analysis of co-nanoprecipitated nanoparticles with varying branched copolymers. A) 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120), B) p(n-BMA50-co-EGDMA0.8):p(PEG114-b-
HPMA120), C) p(t-BMA50-co-EGDMA0.9):p(PEG114-b-HPMA120), D) p(HPMA25-co-n-BMA25-co-
EGDMA0.9):p(PEG114-b-HPMA120), E) p(HPMA25-co-t-BMA25-co-EGDMA0.9):p(PEG114-b-
HPMA120). All 50:50 wt %. 
This initial study has highlighted the versatility of the co-nanoprecipitation process. 
Overall, the co-nanoprecipitation experiments of p(PEG114-b-HPMA120) with either p(n-
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BMA50-co-EGDMA0.8), p(HPMA25-co-n-BMA25-co-EGDMA0.9) or p(HPMA25-co-t-
BMA-co-EGDMA0.9) (50:50 wt %) appears to provide a quick and relatively simple route 
to stabilising the hydrophobic branched copolymers. 
3.4 Synthesis of a p(PEG114-n-BMA120) A-B block copolymer and 
subsequent aqueous nanoparticle studies 
It has been established that the chemical composition of the branched co- and terpolymer 
can be varied and successfully co-nanoprecipitated with p(PEG114-b-HPMA120) A-B block 
copolymer to produce stable nanoparticles; however, the choice of A-B block copolymer 
stabiliser was purely based on studies in Chapter 2. It was of interest to determine if the 
co-nanoprecipitation approach was possible with varying A-B block copolymers and 
whether these materials could also be used to introduce stability into subsequent 
nanoprecipitates. Utilising the PEG114-Br macroinitiator, p(PEG114-b-n-BMA120) was 
synthesised and the corresponding GPC data is shown in Table 3.3 and Figure 3.5.  
Table 3.3 Table of DMF GPC and 1H NMR molecular weight results. 
 
The conditions for the ATRP synthesis of the A-B block copolymer were as previously 
described for p(PEGx-b-HPMAy) (Chapter 2, Section 2.5.3); however due to the 
hydrophobic nature of the monomer, an elevated temperature of 60°C was selected to 
ensure complete solubilisation in the reaction solvent, MeOH.2 The GPC chromatogram 
was monomodal and a narrow dispersity value was obtained. The resulting molecular 
weights from GPC analysis were slightly higher than expected, which was probably due 
to the initiator efficiency being less than 100 % for the PEG114-Br macroinitiator, as often 
seen in ATRP reactions. 
Targeted Polymer
Composition
Target Mn
(g/mol)
Mn
GPC (g/mol)
Mw
GPC (g/mol)
Đ GPC
DPn
Conversion  % 
(1H NMR )
1H NMR
DPn
PEG114-Br ~5000 4 300 4 380 1.01 - - -
p(PEG114-b-nBMA120) 22100 28 000 30 300 1.08 162 97 112
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Figure 3.5 GPC refractive index (RI) overlay of PEG114-Br macroinitiator and p(PEG114-b-n-BMA120). 
Analysis of p(PEG114-b-n-BMA120) by 
1H NMR (See Appendix, Fig. A28) provided a DPn 
of 112 monomer units, which was less than obtained from GPC analysis but closer to the 
value expected. The DPn calculations by 1H NMR possibly include a small percentage of 
unreacted initiator as well as those within the copolymer, consequently leading to the 
calculation of polymer chains that are shorter than the GPC analysis.11, 12 It is also possible 
that the reported DPn for the PEG macroinitiator precursor is not highly accurate and 
synthesis of the macroinitiator has modified the molecular weight distribution as observed 
by the lower than expected Mn figure measured for the macroinitiator. The A-B block 
copolymer was analysed by DMF GPC due to the presence of the high molecular weight 
PEG segment within the copolymer. 
3.4.1 Nanoprecipitation studies during inclusion of p(PEG114-b-n-BMA120) A-B 
block copolymer 
3.4.1.1 Aqueous co-nanoprecipitation studies of p(PEG114-b-n-BMA120) 
As previously discussed, the co-nanoprecipitation of a branched copolymer and A-B block 
copolymer which both comprise HPMA monomer residues, generates stable nanoparticles 
with narrow polydispersity values. Interestingly, when identical nanoprecipitation 
experiments are conducted with the simple substitution of the HPMA-containing A-B 
block copolymer for one containing a p(n-BMA120) block segment, Dz values of ~100nm 
are still obtained when using the branched copolymer p(HPMA50-co-EGDMA0.9), yet a 
loss of nanoprecipitation control is observed and the polydispersity increases to >0.2, 
Table 3.4. 
17 18 19 20 21
PEG5KnBMA120 vs Col 2 
PEG5K initator vs Col 4 
Retention Volume (mL)
1718192021
PEG5KnBMA120 vs Col 2 
PEG5K initator vs Col 4 
PEG114-Br
p(PEG114-b-n-BMA120)
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As shown previously, the co-nanoprecipitation of p(n-BMA50-co-EGDMA0.8):p(PEG114-
b-HPMA120) (50:50 wt %), gave nanoparticles of a larger size (~200 nm) and a narrow 
polydispersity. However, if both the branched copolymer and A-B block copolymer are 
composed of n-BMA, the size remains ~100 nm and an increase in polydispersity is 
observed. The DLS traces are shown in Figure 3.6 and although the nanoparticle results 
for p(n-BMA50-co-EGDMA0.8):p(PEG114-b-n-BMA120) (50:50 wt %) show a 
monodisperse sample, the polymers started to precipitate after 24 hours. In these limited 
experiments, when the A-B block copolymer comprises a p(HPMA) block segment within 
the co-nanoprecipitation, a narrow dispersity is obtained which increases upon switching 
to an A-B block copolymer containing p(n-BMA) block segments. This gave an insight to 
the possible limitations of the co-nanoprecipitation process, despite variation of the A-B 
block copolymer allowing nanoprecipitates to be formed. This suggests that an overall 
increase in hydrophobicity does have an effect on the mechanism of polymer interaction 
during the co-nanoprecipitation process, but stable nanoparticles are still possible. 
 
Table 3.4 DLS results for the nanoprecipitation or co-nanoprecipitation varying both the branched 
copolymer and A-B block copolymer. 
 
 
 
Sample Name Ratio (wt%) Z-ave (d.nm) PdI
p(HPMA50-co-EGDMA0.9) 100:0 148 0.080
p(n-BMA50-co-EGDMA0.8) 100:0 * *
p(PEG114-b-n-BMA120)
a
100:0 84 0.662
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 108 0.109
p(HPMA50-co-EGDMA0.9):p(PEG114-b-n-BMA120) 50:50 109 0.232
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 205 0.088
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-n-BMA120) 50:50 110 0.199
•* Instant precipitation upon addition to water.
•a Inadequate scattering data.
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Figure 3.6 DLS results for A) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120), B) p(HPMA50-co-
EGDMA0.9):p(PEG114-b-n-BMA120), C) p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120), D) p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-n-BMA120). 
3.5 Probing the internal nanoparticle environment and co-
nanoprecipitation mechanism using fluorescent guest molecules  
 
As discussed in Chapter 2, Section 2.10, the guest molecule pyrene can be encapsulated 
within polymer co-nanoprecipitate particles; this is particularly useful, as its fluorescence 
emission spectrum is highly sensitive to the polarity of the surrounding environment. 
Comparison of the fluorescence of pyrene within co-nanoprecipitates of varying 
composition was hypothesised to provide a more clear indication of the role of the A-B 
block copolymer stabiliser within this process and the environment within the 
nanoprecipitates. To compare the I1/I3 values of co-nanoprecipitates derived from 
p(HPMA50-co-EGDMA0.9) and p(n-BMA50-co-EGDMA0.8), pyrene was encapsulated 
within the p(n-BMA50-co-EGDMA0.8):p(PEG114-b-n-BMA120) (50:50 wt %) co-
nanoprecipitates. The nanoparticles were prepared as previously described in Chapter 2, 
Section 2.10 and the DLS traces of the nanoparticles before and after pyrene addition are 
shown in Figure 3.7.  
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Figure 3.7 DLS size overlays for blank vs pyrene encapsulated nanoparticles. A) p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120), B) p(HPMA50-co-EGDMA0.9):p(PEG114-b-n-BMA120), C) p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-n-BMA120) and D) p(HPMA50-co-EGDMA0.9):p(PEG114-b-n-
BMA120) and p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120). 
 
Generally, the co-nanoprecipitates which include polymers comprising n-BMA, only 
exhibit small deviations in size for blank vs pyrene encapsulated nanoparticles. The 
nanoparticle sizes are shown in Table 3.5 and the PdI values do tend to increase during 
the inclusion of pyrene when either the branched copolymer or A-B block copolymer 
consisting of n-BMA is present. After nanoparticle preparation and analysis. The 
fluorescence emission spectra for polymeric nanoparticles with encapsulation of 0.1 wt % 
pyrene for p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120), p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-n-BMA120) and p(HPMA50-co-EGDMA0.9):p(PEG114-b-n-
BMA120) were measured and are shown in the Appendix, Fig. A29. 
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Table 3.5 DLS results for blank vs pyrene encapsulated nanoparticles and I1/I3 values obtained from 
the fluorimetry experiments. 
 
In comparison with nanoparticles composed of p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) 100:0-50:50 wt %, the co-nanoprecipitations including the branched 
copolymer p(n-BMA50-co-EGDMA0.8) and the A-B block copolymers p(PEG114-b-
HPMA120) and p(PEG114-b-n-BMA120), resulted in an appreciable decrease in I1/I3 values 
from ~1.6 to 1.28, suggesting a decrease in polarity of the nanoparticle core (Figure 3.8). 
If the p(n-BMA) block from the A-B block copolymer was present at the nanoparticle 
surface it would be expected that for p(HPMA50-co-EGDMA0.9):p(PEG114-b-n-BMA120), 
the I1/I3 value would remain ~1.6, however this is not the case. The decrease in I1/I3 values 
to <1.29 further implied that the p(n-BMA) segment from the A-B block copolymer was 
present within the nanoparticle core, as hypothesised previously, Section 3.3.2.  
The versatility of the co-nanoprecipitation process has been explored and stable 
nanoparticles were formed when both the branched polymer and A-B block copolymer 
stabiliser were modified. The loading capabilities were yet to be further explored so far 
were considered for pharmacology studies, therefore, a selection of materials were taken 
forward and their suitability was assessed.  
 
 
Sample (50:50 wt %) Blank Pyrene Encapsulated I1/I3
Z-ave (d.nm) PdI Z-ave (d.nm) PdI
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 205 0.088 217 0.132 1.27
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-n-BMA120) 110 0.199 82 0.213 1.28
p(HPMA50-co-EGDMA0.9):p(PEG114-b-n-BMA120) 109 0.232 124 0.271 1.29
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 103 0.068 106 0.051 1.60
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Figure 3.8 Fluorimetry results for co-nanoprecipitation experiments. I1/I3 ratios for, blue circle = pyrene 
in water, black triangle from left to right = p(HPMA50-co-EGDMA0.9), p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120) 90:10 wt %, 80:20 wt %, 70:30 wt %, 60:40 wt %, 50:50 wt %, red 
square from left to right = p(HPMA50-co-EGDMA0.9):p(PEG114-b-n-BMA120) 50:50 wt %, p(n-BMA50-
co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt % and p(n-BMA50-co-EGDMA0.8):p(PEG114-b-n-
BMA120) 50:50 wt %. 
 3.6 Pharmacological studies of co-nanoprecipitated nanoparticles 
During the design of new polymeric drug carriers, the main route of administration usually 
targeted is intravenous (IV). For treatment of infectious diseases such as HIV, where 
patients require a lifetime of treatment it would not be desirable for frequent dosing via 
IV administration and oral dosing is much more appropriate. An injectable antiretroviral 
formulation has been developed which decreases the dosing from monthly to quarterly 
administration,13 however, this is an intramuscular or subcutaneous depot injection and 
until these formulations can be administered worldwide it is still preferable to administer 
drugs orally as the administration process is fast, easy and patient adherence is improved. 
A nanocarrier approach that focuses on HIV, therefore, requires oral delivery of polymeric 
nanocarriers to generate circulating nanoparticles via permeation through the gut 
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epithelium into the systemic circulation. This has several advantages, including drug 
accumulation through uptake into macrophages which act as a sanctuary site for HIV, 
through the poor accumulation of current anti-retroviral drugs in these cells. 
To assess whether the co-nanoprecipitated particles could be loaded with a model drug 
molecule and act as a drug delivery vehicle, a range of pharmacological experiments were 
performed, mimicking oral dosing. All pharmacological experiments were carried out by 
researchers in the Molecular and Clinical Pharmacology Department at the University of 
Liverpool, through collaboration between the Owen and Rannard research groups and will 
be described in detail in Section 3.6.2. 
3.6.1 Preparation of fluoresceinamine encapsulated nanoparticles 
Following the success of co-nanoprecipitation studies within this research chapter and 
those performed in Chapter 2, a selection of the nanoparticles were progressed forward to 
evaluate their loading capabilities and further suitability for pharmacological studies. The 
dye molecule fluoresceinamine (FA) (Figure 3.9) was selected as a ‘mimic’ drug molecule 
due to its small size and hydrophobic nature which is ideal for encapsulation into various 
hydrophobic cores. 
 
 
 
 
 
Figure 3.9 Chemical structure for FA (Isomer I). 
Nanoprecipitation offers a quick and versatile approach to predict and observe 
nanoparticle encapsulation interactions before undertaking further more complicated 
encapsulation studies; loading was achieved by the facile dissolution of polymer and FA 
(model drug) together in a solvent. A schematic representation of the co-nanoprecipitation 
process used to encapsulate FA is shown in Figure 3.10 and as highlighted, the FA is 
dissolved within the good solvent with a branched copolymer and A-B block copolymer, 
before addition to water. To assess the amount of FA which could be encapsulated into 
the nanoparticles, a series of loading experiments were carried out at various weight 
percentages (wt %), with respect to the mass of polymers used. Nanoparticles were 
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prepared at various weight ratios of branched copolymer:A-B block copolymer and 
increasing amounts of FA were added (up to 17 wt %, see Appendix, Table A9). Above 
this amount, the mixtures were observed to instantly precipitate upon addition into water. 
After a review of previous research and evaluation of future pharmacological experiments, 
the amount of FA encapsulated within the nanoparticles was 10 wt %. This amount was 
well above the concentration required for pharmacological assays (10 µM FA) and <17 
wt % FA is ideal, in order to avoid any stability issues during future experiments. A 
comparison of blank (unloaded) vs. encapsulated (loaded) nanoparticle diameters are 
shown in Figure 3.11 and the loaded nanoparticles show only slight deviations in size from 
the blank nanoparticles. 
 
Figure 3.10 Schematic representation of aqueous nanoparticle formation with addition of the 
hydrophobic dye molecule FA (10 wt %) via the co-nanoprecipitation approach, A) branched 
co/terpolymers, B) amphiphilic A-B block copolymer, C) FA. 
Previous nanoprecipitation studies within the Rannard group, which investigated hyp-
polydendron materials and encapsulation of FA, were limited to 1 wt % loading and 
precipitation was observed for encapsulation amounts of  >1 wt %. However, the co-
nanoprecipitation system appears to offer an increased (>10 times) encapsulation capacity 
when compared with the FA encapsulated hyp-polydendron nanoparticles and again, the 
increased loading further suggests that the PEG moiety is located on the outer surface of 
the nanoparticles as opposed to becoming entrapped within, potentially generating a more 
hydrophilic environment. 
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Figure 3.11 Nanoparticle sizes of blank (Black triangles) and after addition of 10 wt % FA (Red 
squares). 
Due to the limited amount of samples which could be assessed in pharmacology, only 
eight of the branched copolymer:A-B block copolymer nanodispersions were 
encapsulated with FA for the study. The DLS analysis of FA encapsulated nanoparticles 
is presented in Table 3.6 and, as noted previously, there are only minor differences 
between blank and FA encapsulated samples and all PdI values obtained were <0.124. In 
comparison to the blank (no FA) nanoparticles, the overall ζ values obtained were closer 
to neutral for the FA encapsulated nanoparticles which may be due to presence of the FA 
primary amine. 
 
The FA encapsulated nanoparticles were also analysed by SEM, see Figure 3.12 A-H. A 
similar morphology was observed between the blank and loaded nanoparticle dispersions 
(See Chapter 2, Figure 2.19 & 2.20). Generally, the FA loaded nanoparticles appear as 
individual spherical particles, with no crystallised FA observable, indicating that the FA 
is encapsulated within the polymeric nanoparticles. Although there was clear evidence of 
nanoparticle formation, SEM imaging of some samples was not simple to achieve and a 
different morphology was observed, which may be due to PEG film formation or drying 
out of the particles during sample preparation (Figure 3.12 C&F). 
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Table 3.6 DLS analysis for blank and FA encapsulated nanoparticles (10 wt %).  
 
 
Fresh samples of co-nanoprecipitated particles were prepared (formulated from i5-f1, see 
Section 3.3.1)  for pharmacological assessment and their stability was determined by 
addition of both 0.5M NaCl and transport buffer solution (TBS) to mimic physiologically 
relevant conditions; stability in delivery media is crucial, particularly when future 
pharmacological studies are carried out. The in vitro studies are typically performed in 
TBS which is, less complex than complete media (Dulbeccos modified eagle medium 
+15% fetal bovine serum), which means the samples are cleaner when HPLC analysis is 
carried out, but it still contains all the components that cells need to survive. It is adjusted 
to physiological pH, and is not meant to model blood, but is more simply a means of 
delivering the formulations to the cells. The repeat formation of blank nanoparticles 
showed slight, but not significant, variation of Dz and PdI, see Chapter 2, Section  2.6.3. 
Entry p(HPMA50-co-EGDMA0.9) or
p(nBMA50-co-EGDMA0.8):p(PEGx-b-HPMAy)
Ratio 
(wt %) Size
(d.nm)
PdI Dn
(nm)
ζ
(mV)
Size 
(d.nm)
PdI Dn
(nm)
ζ
(mV)
1
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120)
90:10 132 0.059 104 -13 152 0.029 129 -18
2 70:30 113 0.069 88 -23 128 0.080 93 -15
3 50:50 135 0.051 108 -15 126 0.079 101 -13
4
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80)
90:10 112 0.045 90 -27 138 0.038 117 -13
5 70:30 106 0.124 74 -29 137 0.084 107 -12
6 50:50 111 0.081 84 -21 135 0.039 112 -9
7 p(nBMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 158 0.086 122 -24 161 0.092 122 -13
8 p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA80) 50:50 124 0.055 99 -27 139 0.011 119 -13
Blank
FA encapsulated 
nanoparticles (10 wt %)
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Figure 3.12 SEM imaging of FA encapsulated nanoparticles (10 wt %) via co-nanoprecipitation A) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 90:10 B) 70:30 C) 50:50  
D) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80) 90:10 E) 70:30 F) 50:50 G) p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 H) p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA80) 50:50 wt %. 
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To assess their stability, each FA encapsulated nanodispersion was diluted with both 0.5 
M NaCl (final conc 0.01M) (Table 3.7) and TBS (Table 3.8) to mimic physiologically 
relevant conditions. The NaCl and TBS stability results were promising, as all 
nanoparticles demonstrated sustained stability over an extended period of 21 days. These 
stability results highlight how the nanoparticles produced during the co-nanoprecipitation 
studies are robust to both NaCl and TBS solutions, which is one of the initial steps before 
in vitro studies of nanomaterials. Generally, during the 21 day period, a negligible change 
in nanoparticle size was observed and PdI values remained <0.1 during NaCl addition. 
TBS is much more complex than NaCl due to the presence of proteins and buffered saline 
solution, so this may explain the slight increase in size and PdI. Although stable, the 
largest increase of 63nm was observed for p(HPMA50-co-EGDMA0.9):p(PEG45-b-
HPMA80) (50:50 wt %), whilst comparing the blank vs 21 day measurement during TBS 
addition. Interestingly, for p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMAx) and p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-HPMAx)  (50:50 wt %), only slight deviations in size 
were observed in the presence of TBS and the only difference between this dispersion is 
the length of the PEG114 chain present on the A-B block copolymer, which appears to 
provide additional stabilisation. A photograph to highlight the stability of FA encapsulated 
nanoparticles is shown in Figure 3.13, and due to the instability of p(n-BMA50-co-
EGDMA0.8) when nanoprecipitated only, p(HPMA50-co-EGDMA0.9) was used as the 
comparison. Charge stabilised nanoparticles that are formed from p(HPMA50-co-
EGDMA0.9), precipitate immediately upon addition of both TBS and NaCl (Figure 3.13Aii 
& iii); however, as confirmed by DLS, the addition of the A-B block copolymer p(PEG114-
b-HPMA120) provides sufficient stabilisation and no precipitation was observed after both 
addition of TBS and NaCl solution for the p(n-BMA50-co-EGDMA0.8):p(PEG114-b-
HPMA120) (50:50 wt %) co-nanoprecipitated nanoparticles (Figure 3.13 i, ii & iii). 
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 Table 3.7 Stability studies of FA loaded nanoparticles (dilution of nanoparticle dispersion to 0.98 mg/mL) in 0.5M NaCl. 
 
 
Entry
p(HPMA50-co-EGDMA0.9) or
p(n-BMA50-co-EGDMA0.8):p(PEGx-b-HPMAy)
Ratio 
(wt%)
Blank Instant 1 day 7 day 21 day
Size
(d. nm)
PdI Size
(d. nm)
PdI Size
(d. nm)
PdI Size
(d. nm)
PdI Size
(d. nm)
PdI
1
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120)
90:10 152 0.029 137 0.060 135 0.033 137 0.043 136 0.025
2 70:30 126 0.079 133 0.047 132 0.045 133 0.029 131
0.032
3 50:50 128 0.080 164 0.022 165 0.063 161 0.039 163
0.098
4
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80)
90:10 138 0.038 132 0.043 146 0.027 147 0.049 138 0.051
5 70:30 135 0.039 145 0.100 141 0.089 141 0.086 131 0.114
6 50:50 137 0.038 160 0.016 159 0.027 159 0.010 146 0.030
7 p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 139 0.123 140 0.153 137 0.099 134 0.091 142 0.086
8 p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA80) 50:50 139 0.011 159 0.019 158 0.041 157 0.034 143
0.051
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Table 3.8 Stability studies of FA loaded nanoparticles (dilution of nanoparticle dispersions to 0.5 mg/mL) in TBS. 
 
 
Entry
p(HPMA50-co-EGDMA0.9) or
p(n-BMA50-co-EGDMA0.8):p(PEGx-b-HPMAy)
Ratio 
(wt%)
Blank Instant 1 day 7 day 21 day
Size 
(d.nm)
PdI
Size 
(d.nm)
PdI
Size 
(d.nm)
PdI
Size 
(d.nm)
PdI
Size 
(d.nm)
PdI
1
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120)
90:10 152 0.029 137 0.060 136 0.052 136 0.027 140 0.095
2 70:30 126 0.079 133 0.047 132 0.066 136 0.063 136 0.103
3 50:50 128 0.080 123 0.045 128 0.131 120 0.090 119 0.103
4
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80)
90:10 138 0.038 155 0.075 151 0.043 155 0.070 147 0.053
5 70:30 135 0.039 149 0.116 145 0.109 150 0.166 144 0.181
6 50:50 137 0.038 156 0.060 153 0.030 141 0.099 143 0.132
7 p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 139 0.123 144 0.131 123 0.057 147 0.154 148 0.130
8 p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA80) 50:50 139 0.011 135 0.035 158 0.060 179 0.106 202 0.156
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Figure 3.13 A) Photograph of 10 wt % FA nanoparticles p(HPMA50-co-EGDMA0.9)* i) blank 
nanoparticle dispersion, ii) TBS addition, iii) NaCl addition,  B) p(n-BMA50-co-EGDMA0.8):p(PEG114-
b-HPMA120) 50:50 wt %, i) blank nanoparticle dispersion, ii) TBS addition, iii) NaCl addition. (1 mL 
to 1 mL of the nanodispersion) and NaCl addition (20 µL 0.5M to 1 mL of the nanodispersion) (*p(n-
BMA50-co-EGDMA0.8) does not form stable nanoparticles, therefore, p(HPMA50-co-EGDMA0.9)was 
used here as a comparison). 
3.6.2 In vitro pharmacological studies  
The FA encapsulated nanoparticles (Entries 1-8, Table 3.6) were subject to in vitro 
pharmacological testing following the stability  observed in biologically-relevant 
conditions, as well as the encouraging high loading capabilities. To ensure the 
nanomaterials were non-toxic to intestinal epithelial cells and could act as drug carrier 
options, 14C-mannitol permeability and standard cytotoxicity assays were performed. A 
transwell plate Caco-2 assay was selected to evaluate the permeability of materials across 
a model intestinal epithelium and mimic permeation into the systemic circulation. Cellular 
permeability is a characteristic of nanocarriers which is now being considered much 
earlier in the drug discovery process; hence it is relevant to conduct such Caco-2 transwell 
assays. It was also important to consider the cellular accumulation of the nanomaterials to 
ensure drug molecules could accumulate in various types of cells; this will be investigated 
for both Caco-2 and ATHP-1 cells, which will be discussed in more detail below.  
3.6.3 14C-mannitol permeability and cytotoxicity assays 
 
The transcellular permeability studies of the nanomaterials were carried out using the well 
characterised, high-throughput Caco-2 cell monolayer assay. The Caco-2 cell line is a 
continuous line of heterogeneous human epithelial colorectal adenocarcinoma cells. 
Although derived from the colon, when they are cultured under various conditions they 
A) B)
i) ii) iii) i) ii) iii)
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differentiate to form a confluent epithelial cell monolayer resembling enterocytes, which 
line the small intestine.14 These cells express microvilli, tight junctions, enzymes and 
transporters, which are all characteristic of enterocytes. The tight junctions between cells 
prevent movement of material along cell boundaries, encouraging drug molecules to 
passively permeate through the cell or be actively transported. The transport of drug 
molecules via paracellular (between cells) permeation, has been shown for several 
nanoparticle systems15 and cellular accumulation studies can be used to distinguish 
various mechanisms. 
To assess which materials could be taken forward to more complex studies, the 
transcellular permeability was first ascertained. During the preliminary experiment, 10 
μM of FA loaded into co-nanoprecipitated materials or 10 μM aqueous FA (spiked with 
DMSO) were added to the apical or basolateral chamber of the wells, to quantify transport 
in both Apical>Basolateral (A>B) and Basolateral>Apical (B>A) directions, and the 
plates were sampled 4 hours after incubation.  
The integrity of the Caco-2 monolayer after exposure of the FA loaded nanoparticles is 
also an important consideration, therefore, 250 μL of TBS containing 2 μL/mL 
14C-mannitol was added to the apical compartment and incubated for 1 hour. Scintillation 
fluid (4 mL) was added to the apical side (100 μL) and 14C-mannitol concentrations were 
quantified using a scintillation counter. The Caco-2 monolayer was considered 
compromised if the apparent permeability observed for the 14C-mannitol was >0.953 x 10-
6 cm s-1.16 Therefore, p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80)  90:10, 70:30, 
50:50 wt % and p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA80)  50:50 wt % were 
removed from further pharmacological studies, as they all appeared to compromise the 
integrity of the Caco-2 cell monolayer (Figure 3.14). The major difference between these 
materials is the composition of the A-B block copolymer. Interestingly, if either the PEG 
chain length is below 2000 g/mol or the DPn of the HPMA chain is <120, the materials 
appear to compromise the cell monolayer and, until further investigation, it is not clear 
why. One hypothesis is that a significant, but low, concentration of free A-B block 
copolymer is present and this is able to disrupt the monolayer. Therefore, the four 
materials taken forward for cytotoxicity assessment were p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120)  90:10, 70:30 and 50:50 wt % and p(n-BMA50-co-
EGDMA0.8):p(PEG45-b-HPMA120)  50:50 wt %. 
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Figure 3.14 The apparent permeability (Papp) of 14C-mannitol through a Caco-2 cell monolayer during 
exposure to FA encapsulated nanoparticles. 
 
3.6.3.1 Cytotoxicity Assays  
 
During the development of new nanomaterials, it is important to determine their 
cytotoxicity to various cells, particularly Caco-2 cells which are used during the epithelial 
transwell plate experiment. The two cytotoxicity assays which were conducted for the FA 
encapsulated materials were the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium 
bromide (MTT) assay and the adenosine triphosphate (ATP) assay with an incubation 
period of 5 days across a range of concentrations of FA (0.1 – 15 µM). 
 
3.6.3.2 MTT assay 
The MTT assay is a colorimetric assay based on the conversion of MTT (a yellow 
tetrazole) into formazan (purple crystals) by living cells which determines mitochondrial 
activity and, therefore, can be used to assess a drug or material’s cytotoxic effects.17 When 
cells die, they lose the ability to convert MTT to formazan, thus, the colour change is a 
useful indication of only viable cells. A solubilisation solution, usually DMSO, an 
acidified ethanol solution, or a solution of the surfactant sodium dodecyl sulfate in 
diluted hydrochloric acid is added to dissolve the purple formazan crystals and form a 
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homogeneous coloured solution. The absorbance of this solution is then measured using 
a plate reader at a wavelength between 500–600 nm. 
 
The co-nanoprecipitated nanoparticles which did not compromise the integrity of the 
monolayer were taken forward for both cytotoxicity assays. The results of the MTT 
cytotoxicity assay are shown in Figure 3.15 and, after incubation of Caco-2 cells with each 
co-nanoprecipitated nanomaterial for 5 days, it was evident that for p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120) 90:10 wt %, there was a negligible effect on the cell 
viability when compared with the aqueous control (FA in water, spiked with DMSO). The 
co-nanoprecipitated particles composed of p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) 70:30, 50:50 wt % and p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 
50:50 wt %, showed a slight toxicity at 15 µM of FA, however, they were not toxic at the 
concentration used for the Caco-2 transcellular permeation experiments, which were 
performed at 10 μM FA. 
3.6.3.3 ATP assay 
As well as the MTT assay, an ATP based cytotoxicity assay was carried out which utilises 
the bioluminescent measurement of ATP present in metabolically active cells in order to 
assess cell viability.18 The concentration of ATP in cells correlates with cell viability, as 
only living cells produce ATP. A decrease in cell viability is an indicator of cell death. 
The results of the ATP cytotoxicity assay are shown in Figure 3.16 and after incubation 
of each co-nanoprecipitated FA nanomaterial with Caco-2 cells for 5 days the cell viability 
remained between 90-100 % for each sample. The low in vitro cytotoxicity values 
obtained during incubation with Caco-2 cells were important if the nanoparticles were to 
be considered as an oral therapy, as the initial concentration of the drug molecule, in this 
case FA, will be expected to be within the µM concentration range. Therefore, the 
following transcellular permeability experiments were conducted at 10µM. 
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Figure 3.15 In vitro cytotoxicity assessment. Caco-2 cell MTT assay, 5 day incubation: A) Aqueous FA solution B) FA in DMSO C) p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) 90:10 wt %, D) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120)  70:30 wt %, E)  p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %,  F) p(n-BMA50-
co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %. Error = Standard deviation.  
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Figure 3.16 In vitro cytotoxicity assessment. Caco-2 cell ATP assay, 5 day incubation: A) Aqueous FA solution, B) FA in DMSO C) p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) 90:10 wt %, D) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120)  70:30 wt %, E) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %,  F) p(n-BMA50-
co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %. Error = Standard deviation.  
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3.6.4 Transcellular permeability 
 
A schematic representation of the transwell plate experiment is shown in Figure 3.17 and 
the apical and basolateral chambers are represented as (A) and (B) respectively. The apical 
chamber is representative of the gut side of the epithelium whilst the basolateral chamber 
represents the blood side of the epithelium.  
 
During a typical experiment, the sample is deposited onto the monolayer in the apical 
compartment and then incubated for four hours, during which the movement of drug 
molecules from the apical to the basolateral side is measured (A>B) (Figure 3.17 B). The 
same experiment is conducted to measure the movement across the monolayer from the 
basolateral compartment to the apical compartment (B>A).  
 
 
 
 
Figure 3.17 A) Caco-2 monolayer transwell experiment setup, B) schematic representation of the Caco-
2 monolayer representing the apical (model of the gut side) and basolateral (modelling of the blood 
side). From ref19 
The transport of molecules across the membrane is usually reported as an apparent 
permeability (Papp). The estimated value of Papp is determined using equation (1), where 
Papp is the apparent permeability (x 10
-6 cm s-1); dQ/dt is the rate of transport (nM min-1); 
A is the surface area of the membrane (cm2); and C0 is the initial donor concentration 
(nM). The resulting Papp values obtained from both transport directions (apical to 
basolateral side and basolateral to apical side) are used for calculation of efflux ratio.  
 
                                                  (1) 
     
        
Several assumptions need to be made for an accurate estimate of permeability. These 
include, the amount of drug accumulated within the receiver compartment must be 
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proportional to time, the system must comply with ‘sink’ conditions, and, finally cellular 
accumulation, metabolism and nonspecific binding to plastic-ware are absent.14 ‘Sink’ 
conditions imply that once the material has passed through the monolayer, it does not pass 
back across; however, this is not always the case for highly permeable materials. 
 
The Papp results for the FA encapsulated nanoparticles are shown in Figure 3.18; the 
movement from the apical to basolateral (A>B) are shown in blue and the basolateral to 
apical (B>A) are shown in red. The materials which show an increased A>B movement 
when compared with the aqueous control are p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) 70:30 wt % and p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt 
% and an increased B>A for entries p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 
50:50 wt % and p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt % was 
observed. Overall, p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt % shows 
a statistically significant increase in both A>B or B>A movement when compared with 
the aqueous control sample. 
 
Figure 3.18 Apparent permeability (Papp) of FA across the Caco-2 cell monolayer following a 4 hour 
incubation period with aqueous and FA encapsulated co-nanoprecipitated materials. (*, P <0.05 and 
***, P <0.001 (ANOVA) (n=3). Error = Standard deviation.  
The Papp ratio A>B/B>A gives an indication of the permeability of the materials from the 
apical to the basolateral side of the monolayer and the results are shown in Figure 3.19. 
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Both p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 70:30 wt % and p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt % showed an improved A>B/B>A ratio (1.8 
and 3.5 fold increases respectively). Although it of interest to determine the efflux of the 
materials, it is less important here, as this model experiments is conducted under static 
conditions and does not mimic physiological conditions with blood flow. The lead 
material taken forward for further testing was composed of the branched copolymer p(n-
BMA50-co-EGDMA0.8) and the A-B block copolymer, p(PEG114-b-HPMA120) at a ratio of 
50:50 wt %. This was selected due to the statistical significance of the results, highest Papp 
ratio and improved A>B/B>A ratios when compared with the aqueous control. Obviously, 
this is a proof of concept experiment and further studies including stability in the gastric 
environment and penetration of the mucus barrier would require further investigation. 
 
 
Figure 3.19 A) Papp ratio A>B/B>A and B) efflux ratio B>A/A>B for FA encapsulated materials 
compared to the aqueous preparation of FA. Error = Standard deviation. 
 
Additional toxicity testing was carried out for p(n-BMA50-co-EGDMA0.8):p(PEG114-b-
HPMA120) 50:50 wt % using ATHP-1 cells. ATHP-1 cells are monocyte-derived 
macrophage cells so it was important to ascertain the toxicity of the FA nanomaterials 
with these cells. The concentrations of FA presented here are much higher than what 
would be expected to be present in the systemic circulation, therefore, the results within 
the nM range should be considered. The results obtained for the ATP assay for the FA 
nanomaterial show a cell viability >80% between 0.1-1 µM (Figure 3.20 Ai,ii). A slight 
increase in toxicity was observed for the MTT assay and between 0.1-1 µM and the cell 
viability of the FA nanomaterial remained above ~60%. It is unclear why the FA 
encapsulated nanoparticles had an increased toxicity when incubated with ATHP-1 
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derived cells, however, the FA nanomaterial, p(n-BMA50-co-EGDMA0.8):p(PEG114-b-
HPMA120) 50:50 wt % was considered suitable for accumulation studies. 
 
  
Figure 3.20 In vitro cytotoxicity assessment. A) ATHP -1 5 day ATP i) aqueous FA solution ii) p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %,  B) ATHP-1 5 day, MTT i) aqueous FA 
solution, ii) p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %. Error = Standard deviation. 
 
 
3.6.5 Accumulation in Caco-2 and ATHP-1 cells 
 
The lead candidate, consisting of p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 
50:50 wt % was further studied and the cellular accumulation ratio (CAR) for both ATHP-
1 and Caco-2 cells was ascertained. CAR is a measure of the ratio of intracellular 
concentration and extracellular concentration and used to determine the uptake of 
molecules into cells. As discussed, ATHP-1 cells are monocyte derived macrophage cells 
which are used to determine the accumulation of materials in macrophages and can be 
indicative of phagocytic uptake mechanisms. Therefore, the measurement of the CAR in 
macrophages is useful in the study of the treatment of infectious diseases such as HIV as 
this is one of the cellular viral sanctuary sites. Although not statistically significant, the 
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FA encapsulated material did show a small increase in CAR in the ATHP-1 cells when 
compared to the aqueous FA control (Figure 3.20A).  
As well as ATHP-1, Caco-2 cells were also selected to determine whether the FA 
encapsulated nanoparticles were permeating the Caco-2 monolayer via a transcellular or 
paracellular pathway. If the FA loaded materials were present within the Caco-2 cells, this 
would suggest that permeation occurs through the cell i.e. transcellular. The CAR of p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %, shown in Figure 3.21B has 
been plotted against the aqueous control sample. The decreased value for the CAR for this 
sample, suggests a lower accumulation of FA within Caco-2 cells when compared to the 
aqueous control for this particular material. This suggests that the movement of the FA 
from the apical to the basolateral chamber is not transcellular and occurs via another 
mechanism, most likely paracellular, which is the transport between the cells, although it 
is also possible that the nanoparticles are actively and rapidly transported through the cells 
and do not leave the endosome to accumulate appreciably within the interior of the Caco-
2 cells. 
 
Figure 3.21 Cellular accumulation ratios of aqueous FA and FA encapsulated p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120) (50:50 wt%) nanoparticles. A) ATHP-1 cells and B) Caco-2 cells. 
Error = Standard deviation. 
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3.6.6 Cellular accumulation ratio (CAR) and apparent permeability (Papp) of FA 
and FA encapsulated p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) (50:50 
wt %) in the presence of inhibitors 
To confirm if the uptake of the FA encapsulated nanomaterials was energy dependant, and 
therefore an active process, the inhibition of active transport (influx and efflux) was 
conducted by incubating Caco-2 cells with 2-deoxyglucose and rotenone, which are 
commonly used to inhibit ATP.20 To determine an appropriate concentration of 
2-deoxyglucose and rotenone, a control experiment was conducted, and 2 mg/ml 
2-deoxyglucose and 100 nM rotenone were selected over the 3 mg/ml 2-deoxyglucose and 
150 nM rotenone, because within error, there was no real overall difference in ATP 
depletion between the two samples (Figure 3.22A).  
 
Figure 3.22 A) Control experiment for ATP inhibition, determination of an appropriate concentration 
of 2-Deoxyglucose and rotenone, B) CAR for FA nanoparticles = p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %, before and after ATP depletion (the presence of 2-
Deoxyglucose (2mg/mL) and rotenone (100 nM). Error = Standard deviation. 
Caco-2 cells were pre-incubated with 2 mg/ml 2-deoxyglucose and 100 nM rotenone for 
20 min to deplete ATP. Following depletion, cells were washed three times with Hank’s 
Balanced Salt Solution, and replaced with media containing DMSO solubilised 
(<0.1% v/v) fluoresceinamine or p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 
(50:50 wt %) (10 µM final fluoresceinamine concentration) and incubated at 37°C under 
and atmosphere of 5% CO2 for 24 hours. Extra- and intra-cellular samples were extracted 
and analysed using HPLC as previously described. The measured CAR during ATP 
depletion for p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) (50:50 wt%), shows a 
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decrease in accumulation and although not statistically significant, this suggests the 
process could be energy dependant and proceeds via an active mechanism (Figure 3.22B).  
The apparent permeability (Papp) of the FA encapsulated nanomaterial, p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt % through Caco-2 cells has already been 
investigated in Section 3.6.4, therefore, it was of interest to assess Papp in the presence of 
various endocytic inhibitors. It is worth noting that both the CAR and Papp experiments 
are quite different, as Papp is conducted on a monolayer of polarised cells, whereas CAR 
is carried out on Caco-2 cells that have not been polarised, so the results are not directly 
comparable. The movement involving the endocytosis pathway is an active process and 
when the processes were inhibited, a drop in Papp for FA was observed (Figure 3.23). This 
suggests that the movement is not simply passive. This would not be expected due to the 
low accumulation within Caco-2 cells witnessed earlier (Figure 3.21) and for addition of 
each inhibitor, a significant decrease in Papp is observed. Rather than accumulating into 
the cells, it can be hypothesised that FA has moved across the monolayer quite rapidly in 
the transwell experiments, hence a low accumulation.  
  
 
 
 
 
 
 
 
 
 
Figure 3.23 Mechanistic evaluation of transcellular permeation through Caco-2 cells, AQ = aqueous 
FA control, FA nanoparticles = p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) (50:50 wt%), chl = 
chlorpromazine (clathrin-mediated endocytosis), dan = dansylcadaverine (receptor-mediated 
endocytosis), gen = genistein (caveolae-mediated endocytosis), dyn = dynasore (dynamin-dependent 
endocytosis), ind = indomethacin (caveolae-mediated endocytosis). (***, P <0.001 (ANOVA) (n=3). 
(FA nanoparticles = p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %). Error = Standard 
deviation. 
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To ascertain if the monolayer was compromised after the addition of the inhibitors to the 
control samples and FA loaded p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 
wt % sample, during the transwell experiment, the Caco-2 monolayer was exposed for 4 
hours and incubated with 14C-mannitol as described previously in Section 3.6.3. It is 
evident that for both the control and FA loaded sample, the monolayer integrity is 
maintained in the presence of all inhibitors (Figure 3.24 A&B). This control experiment 
was conducted to ensure the results obtained during inhibition experiments could be 
interpreted with confidence. 
 
Figure 3.24 Caco-2 monolayer integrity after exposure to endocytic inhibitors; chl = chlorpromazine 
(clathrin-mediated endocytosis), dan = dansylcadaverine (receptor-mediated endocytosis), gen = 
genistein (caveolae-mediated endocytosis), dyn = dynasore (dynamin-dependent endocytosis), ind = 
indomethacin (caveolae-mediated endocytosis). A) FA = fluoresceinamine control (all samples spiked 
with DMSO), B) FA loaded nanoparticles = p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) (50:50 
wt%). Error = Standard deviation.  
3.7 Conclusion  
 
Throughout this research chapter, the chemical compositions of both the branched 
co/terpolymers and A-B block copolymer have been varied to include the hydrophobic 
monomers, n-BMA and t-BMA. A versatile co-nanoprecipitation system has been 
presented and the addition of an A-B block copolymer resulted in the formation of 
stabilised nanoparticles which was not witnessed when the branched co/terpolymers were 
nanoprecipitated alone. The encapsulation of the hydrophobic guest molecule pyrene and 
subsequent fluorescence measurements of polymers consisting of p(n-BMA), provided 
further information that the A-B block copolymer is becoming entrapped within the 
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nanoparticle core during the co-nanoprecipitation process. The co-nanoprecipitation of the 
branched co/terpolymers, A-B block copolymer and addition of 10 wt % FA generated 
nanoparticles which were stable under physiologically relevant conditions and therefore, 
progressed forward for pharmacological studies. 
 
A series of pharmacological studies were also conducted; an initial 14C-mannitol 
permeability assay showed four FA loaded nanomaterials were shown not to compromise 
Caco-2 monolayers and were the subject of further testing. Subsequent cytotoxicity assays 
of the FA nanomaterials demonstrated a low toxicity when Caco-2 cells were incubated 
with the FA loaded nanomaterials, and 90-100% viability was maintained for each 
material. To determine if the permeation of FA across the Caco-2 monolayer was 
enhanced when encapsulated within the co-nanoprecipitated materials vs non-
encapsulated FA, a transcellular permeability assay was carried out. A statistically 
significant improved A>B/B>A ratio was observed for p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120) (50:50 wt %), which was taken forward for cellular 
accumulation studies. The cellular accumulation experiment highlighted that for the FA 
encapsulated nanomaterial, although not statistically significant, an increased 
accumulation in the ATHP-1 cells was observed. This would be a desirable property in 
the oral dosing therapy treatment of infectious diseases such as HIV, where macrophage 
cells are a sanctuary site for the HIV virus. However, the decreased accumulation in Caco-
2 cells suggested that the FA was being transported across the membrane via another 
mechanism, possibly paracellular permeation. The lead FA nanomaterial, p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120) (50:50 wt %) was further investigated by inhibition of 
the active transport processes and during ATP depletion, a decrease in cellular 
accumulation of FA was observed suggesting uptake occurs via an active process. The 
assessment of the Caco-2 transcellular permeability was also carried out in the presence 
of endocytic inhibitors and a statistically significant decrease in cellular permeability was 
observed, which suggests the movement of FA is not simply passive and does proceed via 
an active mechanism. 
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Chapter 4 
 
 
 
 
 
Co-nanoprecipitation: 
Encapsulation Studies of HIV Anti-retrovirals 
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4.1 Introduction 
 
The preparation of sterically stabilised nanoparticles from polymers with varying 
chemical compositions, was explored in Chapter 3 and highlighted the versatility of the 
co-nanoprecipitation approach. The ability to tune the chemistry of both polymers 
(branched copolymer and A-B stabilising block copolymer) is very appealing for the 
preparation of drug delivery nanoparticles, as both the hydrophobic branched polymer 
core and A-B block copolymers can be tailored for the encapsulation of a particular 
hydrophobic drug molecule.  
 
This research chapter aims to assess the encapsulation capabilities of the 
co-nanoprecipitated materials using clinically relevant antiretroviral drugs used to treat 
human immunodeficiency virus (HIV). Drug encapsulation studies were conducted for 
the hydrophobic drug molecules, efavirenz (EFV), lopinavir (LPV) and ritonavir (RTV) 
(Figure 4.1). Encapsulation into polymeric nanoparticles could potentially increase the 
concentration and aqueous solubility of these drugs, which is advantageous if they were 
to be administered as an oral or intravenous solution of drug loaded nanoparticles. 
 
Figure 4.1 Chemical structures of HIV anti-retrovirals A) efavirenz B) ritonavir C) lopinavir. 
 
When a patient is diagnosed with HIV, they are most likely to be treated via the 
administration of multiple drug molecules, known as highly active anti-retroviral therapy 
(HAART). HAART improves the patient’s quality of life by maintaining function of the 
immune system, and prevents opportunistic infections that are often fatal.1 EFV is a non-
nucleoside reverse transcriptase inhibitor which prevents the replication of HIV type 1,2 
and is the first choice anti-retroviral in an adult and paediatric pharmacotherapy. LPV and 
RTV are both protease inhibitors3 and researchers at the University of Liverpool were first 
to recognise that the co-administration of RTV as a combination therapy with other HIV 
drugs increases their bioavailability and efficiency, therefore, allowing lower dosages to 
A) B) C)
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be administered.4 Although RTV is no longer used as a therapeutic drug, it has found 
considerable use as a ‘booster’; enabling longer circulation times of other antiretrovirals 
by inhibiting their metabolism. RTV and LPV are commonly administered as a dual 
therapy, with a 400/100 mg dosage ratio (LPV/RTV), known as Kaletra©.5 These three 
drugs have made a significant impact on the treatment of HIV patients, however, they all 
show relatively poor solubility in water. 
Examples of biologically relevant polymers, including poly(lactic-co-glycolic acid) 
(PLGA), have been used for the preparation of nanoparticles containing HIV drugs via 
various emulsification methods. For example, Shibata et al have reported the individual 
encapsulation of EFV, RTV and LPV at ~10 wt % via emulsion evaporation.6 To mimic 
the use of drug combinations, encapsulation of HIV molecules in PLGA nanoparticles has 
been reported via water/oil/water homogenisation and anti-retroviral drug loading 
averaged at 4.9 wt %, 5.2 wt %, and 1.9 wt % for RTV, LPV, and EFV, respectively.7 As 
well as PLGA, poly(caprolactone) (PCL) nanoparticles have also been prepared for 
encapsulation of LPV (~10 wt %) utilising the oil in water emulsion-solvent evaporation 
technique.8 Although drug-loading has been achieved for the examples discussed, their 
preparation requires homogenisation, ultracentrifugation and lyophilisation steps which 
can be time consuming and expensive. 
 
HIV drug loaded nanoparticles have also been prepared via nanoprecipitation, however, 
for the examples listed below, nanoparticle dispersion preparation involved combinations 
of ultracentrifugation, washing with water, lyophilisation and, in some cases, filtration. 
Das Neves et al have described the preparation of daprivine (HIV anti-retroviral) 
encapsulated PCL nanoparticles with an estimated drug loading of ~12 wt %.9 Other 
reports include the encapsulation of the HIV anti-retroviral saquinavir (5 wt %)10 and EFV 
(10 wt %)11 into PCL nanoparticles. It is worth noting that all examples described require 
additional polymers to be present within the precipitation water (e.g. poly(vinyl alcohol) 
(PVA) or poly(ethylene glycol) (PEG)), in order to stabilise the nanoparticles. These 
additional materials and purification steps were not required when preparing encapsulated 
nanoparticles via the co-nanoprecipitation approach, as described in Chapters 2 and 3, 
providing an efficient, one-step route to stabilised nanoparticles which do not require 
filtration, centrifugation or surfactants in the water in order to encapsulate a guest 
molecule effectively (10 wt % fluoresceinamine, Chapter 3, Section 3.6.1). 
 
 
 
163 
 
4.2 Encapsulation of anti-retrovirals utilising the co-
nanoprecipitation approach  
The selected HIV anti-retrovirals were co-nanoprecipitated with varying branched 
co/terpolymers and an A-B block copolymer to assess the loading capabilities within the 
nanoparticles. During a typical co-nanoprecipitation, a HIV drug was dissolved within the 
good solvent with one of a selection of branched co/terpolymers; p(n-BMA50-co-
EGDMA0.8), p(t-BMA50-co-EGDMA0.9), p(HPMA25-co-n-BMA25-EGDMA0.9) or 
p(HPMA25-co-t-BMA25-co-EGDMA0.9), and an A-B block copolymer. The nanoparticles 
were prepared under the same conditions as described previously, i5-f1 (from acetone into 
water). It was hypothesised that the branched co/terpolymers with an increased 
hydrophobic nature would solubilise an increased amount of hydrophobic drug within the 
nanoparticle core. Therefore it would be expected that during incorporation of 
p(n-BMA50-co-EGDMA0.8) with an A-B block copolymer, an increased loading of 
hydrophobic drug molecule would be observed. 
To assess the drug encapsulation ability within nanoprecipitated particles, a series of 
loading experiments were carried out at various weight percentages (wt %) of drug, with 
respect to the mass of the total polymer. The p(PEG114-b-HPMA120) A-B block copolymer 
was selected for this study, due to previously demonstrated stability in physiological 
environments, and the encouraging in vitro pharmacological results discussed in Chapter 
3, Section 3.6.2.  
4.2.1 Encapsulation of EFV via co-nanoprecipitation 
 
Initially, co-nanoprecipitation studies were conducted to investigate the encapsulation 
ability with EFV. EFV is a relatively small, hydrophobic molecule (Figure 4.1) and has 
limited aqueous solubility (4 µg/mL);12 however, when co-nanoprecipitated with a 
branched co/terpolymer and A-B block copolymer, the drug became encapsulated within 
the nanoparticles. The DLS analyses for all anti-retroviral co-nanodispersions is shown in 
Table 4.1. The experiments were carried out using a low starting wt % of EFV with 
stepwise increases to ascertain the amount (wt %) of EFV which could be tolerated prior 
to polymer/drug macro-phase separation. The optimum loading of drug molecules into 
nanoparticles is highlighted in blue in each table from this point onwards.  
An example of EFV encapsulation is presented in Figure 4.2i-iv, which shows a 
comparison of EFV in water vs EFV nanoprecipitated with a branched copolymer and A-
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B block copolymer. The optimum encapsulation of 9 wt % EFV was achieved when co-
nanoprecipitated within p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) (50:50 wt %) 
and the presence of EFV appears to have a negligible effect on resulting nanoparticle sizes 
when compared with the blank nanoparticle dispersion. The DLS results obtained for 
nanoparticles with 9 wt % encapsulation is shown in Figure 4.3A, and illustrates a narrow 
monomodal peak. The presence of spherical nanoparticles after encapsulation of 9 wt % 
of EFV into p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) (50:50 wt %), was further 
confirmed by scanning electron microscopy (SEM) of the nanoparticles and after 1 month 
of storage (Figure 4.3 Bi&ii). During addition of 10 wt % EFV, a fine precipitate was 
observed within the sample after 24 hours giving a broad PdI of 0.435 after DLS analysis.  
 
Table 4.1 DLS analysis of EFV encapsulated nanoparticles prepared via co-nanoprecipitation.  
 
 
Branched co/terpolymer:p(PEG114-b-HPMA120) 50:50 wt %
Efavirenz
(wt%)
Size
(d.nm)
PdI
Dn
(nm)
Z-ave (d.nm) / PdI
After 3 days
p(HPMA50-co-EGDMA0.9)
Blank 103 0.051 112 -
1 101 0.050 79 -
2 119 0.048 96 -
5 100 0.073 75 -
9 107 0.058 82 -
10 180 0.435 85 -
p(n-BMA50-co-EGDMA0.8)
Blank 205 0.088 170 -
5 240 0.147 189 239 (0.134)
9 194 0.099 153 193 (0.101)
15 177 0.175 120 166 (0.092)
20 139 0.073 105 155 (0.074)
25 172 0.113 122 187 (0.213)
p(t-BMA50-co-EGDMA0.9)
Blank 357 0.234 245 -
5 389 0.489 182 -
p(HPMA25-co-n-BMA25-EGDMA0.9) 
Blank 161 0.085 125 -
5 136 0.086 101 135 (0.078)
9 133 0.075 103 132 (0.098)
15 117 0.131 76 116 (0.131)
20 171 0.089 104 143 (0.111)
p(HPMA25-co-t-BMA25-co-EGDMA0.9)
Blank 161 0.066 131 -
5 150 0.047 125 149 (0.089)
9 156 0.058 130 154 (0.083)
15 131 0.037 106 131 (0.096)
20 113 0.059 89 121 (0.104)
25 164 0.056 138 169 (0.155)
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Figure 4.2 Photograph of EFV in water and examples of EFV encapsulated nanoparticles (p(HPMA50-
co-EGDMA0.9):p(PEG114-b-HPMA120) (50:50 wt %)), i) EFV in H2O, ii) 1 wt %, iii) 2 wt %, iv) 5 wt 
% EFV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 A) DLS trace for 9 wt % EFV encapsulated p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) 50:50 wt %. B) SEM imagining for 9 wt % encapsulated EFV p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, i) nanoparticles after 24 hours, ii) nanoparticles >1 
month. 
iii) iv)ii)i)
10 100 1000
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The branched copolymers p(n-BMA50-co-EGDMA0.8), p(t-BMA50-co-EGDMA0.9), and 
terpolymers p(HPMA25-co-n-BMA25-EGDMA0.9), p(HPMA25-co-tBMA25-co-
EGDMA0.9), were also subject to encapsulation experiments. Interestingly, the co-
nanoprecipitation of p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %, 
resulted in a 25 wt % loading of EFV, and although there was an increase in the size and 
PdI values during DLS re-analysis after 3 days, there were no visible signs of 
polymer/drug macro-phase separation and precipitation. 
As previously discussed in Chapter 3, the co-nanoprecipitation studies of p(t-BMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, resulted in polymer nanoparticles with 
large size and broad PdI values. To determine if the co-nanoprecipitation of branched p(t-
BMA50-co-EGDMA0.9) could yield stable EFV loaded nanoparticles, an encapsulation 
experiment of 5 wt % was carried out. As shown in Table 4.1 compared to the blank 
nanodispersion, the size and PdI values increased and after a few hours fine precipitate 
was observed. Due to these poor encapsulation results, branched p(t-BMA50-co-
EGDMA0.9) was not studied further. 
The co-nanoprecipitation studies of blank and EFV encapsulated p(HPMA25-co-n-
BMA25-EGDMA0.9):p(PEG114-b-HPMA120) (50:50 wt %), yielded nanoparticles with 
sizes <180 nm and narrow PdI values from each loading experiment. The highest 
encapsulation of EFV was 20 wt % and a small decrease in size and a narrow PdI was 
observed after 3 days. Interestingly, p(HPMA25-co-t-BMA25-co-EGDMA0.9):p(PEG114-b-
HPMA120) 50:50 wt % had a loading capability of 25 wt % and were also stable after the 
3 day re-analysis. 
The DLS analyses of the co-nanoprecipitation studies for the highest loading of EFV are 
presented in Figure 4.4 and narrow monomodal peaks are observed for all three loaded 
co-nanodispersions. Overall, the branched co/terpolymers which encapsulated the highest 
wt % of EFV were p(n-BMA50-co-EGDMA0.8) and p(HPMA25-co-tBMA25-co-
EGDMA0.9) with 25 wt % relative to total polymer content.  
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Figure 4.4 DLS analysis of co-nanoprecipitated nanoparticles for highest wt % encapsulation of EFV 
(25wt %), A) p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %, B) p(HPMA25-co-n-
BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, C) p(HPMA25-co-t-BMA25-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %. 
 
4.2.2 Encapsulation of RTV via co-nanoprecipitation  
The same experiments as described above for EFV, were carried out for the HIV anti-
retroviral RTV. Although clinically administered as a dual therapy, it was important to 
determine if the encapsulation of RTV in the absence of another drug molecule was 
feasible. The encapsulation studies for varying branched co/terpolymers are shown in 
Table 4.2 and the optimum wt % loading is highlighted. Interestingly, p(HPMA50-co-
EGDMA0.9) demonstrated a higher loading capability with RTV when compared to the 
encapsulation of EFV. The highest loading capability observed was through encapsulation 
using the branched copolymer, p(n-BMA50-co-EGDMA0.8). 20 wt % loading was 
achieved with p(HPMA25-co-n-BMA25-co-EGDMA0.9) and p(HPMA25-co-t-BMA25-co-
EGDMA0.9), without polymer and/or drug precipitation observed after ~24 hours, 
therefore, an optimum loading for both branched terpolymers was 20 wt % RTV. 
 
10 100 1000 10000
Col 1 vs nBMA HPMA120 50:50 25 wt% 
10 100 1000 10000
Col 1 vs nBMA HPMA: HPMA120 25 wt % efavirenz 
10 100 1000 10000
Col 1 vs tBMA HPMA:HPMA120 
R
el
at
iv
e 
In
te
n
si
ty
R
el
at
iv
e 
In
te
n
si
ty
R
el
at
iv
e 
In
te
n
si
ty
Size (d.nm) Size (d.nm)
Size (d.nm)
A) B)
C)
 
 
168 
 
Table 4.2 DLS analysis of RTV encapsulated nanoparticles prepared via co-nanoprecipitation.  
 
 
 
Overall, the formulation of co-nanoprecipitated nanoparticles composed of p(n-BMA50-
co-EGDMA0.8) and p(PEG114-b-HPMA120) 50:50 wt %, demonstrated the highest loading 
capability with RTV when compared with nanoparticles formed from the alternative 
branched co/terpolymers. The DLS results for highest encapsulation (wt %) are presented 
in Figure 4.5, again highlighting one monomodal population for each nanodispersion. 
 
 
 
 
 
Branched co/terpolymer:p(PEG114-b-HPMA120) 50:50 wt %
Ritonavir
(wt%)
Z-ave
(d.nm)
PdI Dn
(nm)
Z-ave (d.nm) / PdI
After 3 days
p(HPMA50-co-EGDMA0.9)
Blank 111 0.081 112 -
1 94 0.067 71 -
4 108 0.057 83 -
8 123 0.074 95 122 (0.055)
10 128 0.073 100 128 (0.084)
15 124 0.085 101 116 (0.051)
17 121 0.132 90 118 (0.179)
20 131 0.228 85 X
Blank 205 0.088 170 -
10 242 0.236 158 -
p(n-BMA50-co-EGDMA0.8) 17 244 0.218 137 -
20 329 0.250 216 338 (0.333)
25 143 0.170 100 142 (0.102)
Blank 161 0.085 125 -
10 150 0.084 120 148 (0.092)
p(HPMA25-co-n-BMA25-EGDMA0.9) 17 185 0.083 147 -
20 141 0.072 109 140 (0.079)
25 127 0.132 87 133 (0.106)
p(HPMA25-co-t-BMA25-EGDMA0.9)
Blank 161 0.066 131 -
10 152 0.077 117 149 (0.079)
17 130 0.087 97 -
20 123 0.062 99 123 (0.111)
25 87 0.047 67 92 (0.116)
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Figure 4.5 DLS analysis of co-nanoprecipitated particles for highest wt % encapsulation of RTV, A) 
17wt % RTV + p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, B) 25 wt % RTV + p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %, C) 20 wt % RTV + p(HPMA25-co-n-
BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, D) 20 wt % RTV + p(HPMA25-co-t-
BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %. 
 
4.2.3 Encapsulation of LPV via co-nanoprecipitation  
The final HIV anti-retroviral drug molecule encapsulated within varying branched 
co/terpolymer and A-B block copolymers was LPV. The DLS analysis of the co-
nanoprecipitated encapsulated particles is presented in Table 4.3. During the co-
nanoprecipitation of LPV and p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 
50:50 wt %, an optimum loading of 10 wt % was observed. The behaviour during LPV 
encapsulation would be expected to be similar to RTV (17 wt % loading), due to the 
structural similarities between the drug molecules. However, the wt % loading of LPV 
was similar to that of EFV, which is surprising considering the dissimilarity between the 
drug molecules. The optimum loading appears to lie between 10-15 wt %, as precipitation 
of polymer/drug was observed (as also seen for EFV encapsulation). For the branched 
copolymer, p(n-BMA50-co-EGDMA0.8), and terpolymers, p(HPMA25-co-n-BMA25-co-
EGDMA0.9) and p(HPMA25-co-t-BMA25-co-EGDMA0.9), 20 wt % encapsulation was 
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achieved. Although there was a slight increase observed in PdI for both p(n-BMA50-co-
EGDMA0.8) and p(HPMA25-co-n-BMA25-co-EGDMA0.9), the polymer and drug 
molecules did not appear to precipitate. The lowest PdI value was obtained for the co-
nanoprecipitation of p(HPMA25-co-t-BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 
50:50 wt %, LPV (20 wt %), and a size decrease from 161 to 108 nm was observed when 
compared with the blank sample, suggesting the presence of LPV resulted in the formation 
of smaller nanoparticles. The narrow monomodal size distributions for the nanoparticles 
which achieved the highest encapsulation capabilities are shown in Figure 4.6. 
Table 4.3 DLS analysis of LPV encapsulated nanoparticles prepared via co-nanoprecipitation.  
 
Branched co/terpolymer:p(PEG114-b-HPMA120) 50:50 wt %
Lopinavir
(wt%)
Z-ave
(d.nm)
PdI Dn
(nm)
Z-ave (d.nm) / PdI
After 3 days
p(HPMA50-co-EGDMA0.9)
Blank 111 0.081 112 -
1 112 0.075 84 -
2 104 0.068 78 -
4 102 0.064 80 -
8 135 0.139 91 128 (0.108)
10 130 0.124 96 131 (0.100)
15 155 0.493 79 155 (0.493)
p(n-BMA50-co-EGDMA0.8)
Blank 205 0.088 170 -
15 227 0.108 179 224 (0.114)
20 191 0.154 134 200 (0.154)
p(HPMA25-co-n-BMA25-EGDMA0.9)
Blank 161 0.085 125 -
15 137 0.063 109 137 (0.088)
20 125 0.114 84 140 (0.200)
p(HPMA25-co-t-BMA25-EGDMA0.9)
Blank 161 0.066 131 -
15 166 0.060 134 165 (0.071)
20 108 0.062 87 112 (0.062)
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Figure 4.6 DLS analysis for highest loaded LPV nanoparticles, A) 10wt % LPV + p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, B) 20 wt % LPV + p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %, C) 20 wt % LPV + p(HPMA25-co-n-BMA25-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, D) 20 wt % LPV + p(HPMA25-co-t-BMA25-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %. 
 
Overall, the co-nanoprecipitation method incorporating the branched co/terpolymers p(n-
BMA50-co-EGDMA0.8), p(HPMA25-co-n-BMA25-co-EGDMA0.9) and p(HPMA25-co-t-
BMA25-co-EGDMA0.9) gave a high loading of 20 wt % LPV. A summary of the results 
for the highest encapsulation (wt %) for the co-nanoprecipitated particles within this 
chapter are presented in Table 4.4. Interestingly, the branched copolymer p(n-BMA50-co-
EGDMA0.8) demonstrated the highest wt % encapsulation for each hydrophobic drug 
molecule. As discussed, this may be due to the increased hydrophobicity of this particular 
polymer, as although the other co/terpolymers are insoluble in water, they contain HPMA 
monomer units, which have a hydrophilic nature. The blank co-nanoprecipitates 
containing p(n-BMA50-co-EGDMA0.8), p(HPMA25-co-n-BMA25-co-EGDMA0.9) and 
p(HPMA25-co-t-BMA25-co-EGDMA0.9) and the A-B block copolymer p(PEG114-b-
HPMA120) 50:50 wt %, were generally larger than those comprising of the branched 
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copolymer p(HPMA50-co-EGDMA0.9), which could suggest there is a relationship 
between size and encapsulation wt % and further investigation into varying chemical 
compositions would be required to confirm this. 
Table 4.4 Summary of loading capabilities for anti-retroviral encapsulated co-nanoprecipitated 
particles consisting of a branched co/terpolymer and p(PEG114-b-HPMA120) 50:50 wt %. 
 
For encapsulation of drug molecules within polymer nanoparticles, it is useful to consider 
the hydrophobicity (lipophilicity) of both the drug molecule and polymer. The logP 
(partition coefficient) is a measure of a drug’s hydrophobicity and reflects the relative 
solubility of a drug in octanol (representing the lipid bilayer of a cell membrane) and 
water. LogP values may be measured experimentally or, more commonly calculated. The 
logP values reported within the literature varied between 3.8-4.6 for EFV,13, 14 5.98-6.6315, 
16 for RTV and 4.5617 for LPV. Due to the variation of experimentally determined logP 
values for drugs investigated, a prediction-based approach was used to obtain the logP 
values. The Molinspiration property engine18 was used to calculate the logP values (clogP) 
for EFV, RTV and LPV and oligomers consisting of 3 monomer repeat units for 
p(HPMA), p(n-BMA) and p(t-BMA), see Table 4.5.  
Although the clogP values used to assess the environment within the branched polymers 
are not a true representation of each DP50 polymer, they can provide a measure of the 
differences in hydrophobicity. In terms of the anti-retroviral drugs, the clogP values 
suggest that RTV has the highest lipophilicity and EFV the least, yet the highest loading 
of 25 wt % was observed for both RTV and EFV. This suggests that although there are 
differences between the calculated clogP values for the anti-retroviral drugs, it may be 
HIV Antiretroviral Wt % Polymer Composition (50:50 wt%)
Efavirenz
25
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120)
p(HPMA25-co-t-BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120)
Ritonavir 25 p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120)
Lopinavir 20
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120)
p(HPMA25-co-n-BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120)
p(HPMA25-co-t-BMA25-co-EGDMA0.9):p(PEG114-b-HPMA120)
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that the chemical differences between the polymers has a greater effect on the loading 
capacity. As expected, p(n-BMA) has a higher clogP than p(HPMA), due to the chemical 
differences between the monomers. This difference is reflected in the loading capacities, 
as a consistently higher loading is observed when p(n-BMA50-co-EGDMA0.8) is included 
within the co-nanoprecipitation for each anti-retroviral. Although sufficient encapsulation 
was achieved, addition of p(HPMA50-co-EGDMA0.9) resulted in a lower wt % of EFV and 
LPV when compared with the other branched polymers. However, for RTV, a 17 wt % 
loading was observed, and in terms of differences in clogP values this may not be expected 
as RTV has the highest clogP (7.51) and HPMA is calculated to have a much lower 
lipophilicity (clogP = 2.56). For the co-nanoprecipitation experiments which included the 
terpolymers, high levels of loading were achieved, which may be due to the presence of 
an increasingly hydrophobic monomer; either n-BMA or t-BMA. It is worth nothing that 
the evaluation of the branched co/terpolymers and anti-retrovirals presented here is based 
on calculated clogP values and structural differences between the polymers to rationalise 
the wt % capabilities. 
Table 4.5 Calculation of logP values for HIV drug molecules and polymers. 
 
 
 
 
 
 
 
4.3 Conclusion 
To conclude, the formation of anti-retroviral encapsulated nanoparticles via the co-
nanoprecipitation approach has been successfully achieved and the loading capabilities 
have been investigated. The variation of the branched co/terpolymers throughout this co-
nanoprecipitation study, gave rise to different loading capabilities for each anti-retroviral. 
Therefore, the hydrophobicity and structural differences of the branched co/terpolymers 
were taken into consideration and logP values were calculated to rationalise the 
nanoparticle behaviour in the presence of the anti-retrovirals. During inclusion of the 
logP*
EFV 4.53
RTV 7.51
LPV 5.69
p(HPMA3) 2.56
p(n-BMA3) 7.69
p(t-BMA3) 6.93
*Molinspiration property engine determination of logP.
 
 
174 
 
branched copolymer p(n-BMA50-co-EGDMA0.8), a consistent high loading was achieved 
and up to 25 wt % was observed for both EFV and RTV. Generally the higher loading 
capabilities were achieved when the monomeric unit of the branched co/terpolymers were 
composed of solely n-BMA or partly n-BMA and t-BMA monomeric units. The co-
nanoprecipitation process has provided a fast and efficient route to produce stable anti-
retroviral encapsulated nanoparticles, without the need for filtration or the presence of 
surfactants in the anti-solvent. Further studies are required to investigate stability and drug 
release from the nanoparticles, as well as pharmacology testing to assess their suitability 
in vitro. 
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Chapter 5 
 
 
 
Co-nanoprecipitation: 
Encapsulation of the Anti-Cancer Drug 
SN-38  
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5.1 Introduction 
Cancer is a leading cause of death worldwide and the number of new cases is expected to 
rise by ~70 % during the next two decades, according to the World Health Organisation.1 
One of the most common treatments for cancer is systemic chemotherapy, however, a high 
drug concentration in target tissues is required to achieve a therapeutic effect, which 
frequently results in broad toxicity. During the last few decades, the preparation of drug 
loaded nanocarriers, including polymeric nanoparticles, liposomes, dendrimers and 
micelles, have provided promising options to overcome systemic toxicity, stability issues 
and poor aqueous solubility of anti-cancer drugs.2 The encapsulation of chemotherapeutic 
drug molecules into nanocarriers offers many advantages when compared with current 
delivery methods of chemotherapeutic molecules. Firstly, many anti-cancer drug 
molecules are hydrophobic and only solubilise when added to solvents such as ethanol or 
DMSO, which at high concentrations are highly toxic to cells. Therefore, the incorporation 
of drug molecules into polymeric nanocarriers could potentially enhance the apparent 
aqueous solubility and would not require additional solvents. Secondly, as described in 
Chapter 1 Section 1.5.1, nanocarriers are passively targeted to tumours via the EPR effect, 
resulting in a higher concentration at the tumour site and decreased toxicity in healthy 
tissues.3 The use of nanocarriers or polymer-drug conjugates for the loading of 
chemotherapeutic molecules, can also provide an increased bioavailability when 
compared with administration of free drug molecules which are rapidly eliminated by the 
liver and/or kidneys.4, 5  
 
Camptothecin-11, commonly known as irinotecan (IR), is an anti-cancer chemotherapy 
drug used for the treatment of metastatic colon or rectal cancer, and was approved by the 
FDA in 1998. IR inhibits the enzyme topoisomerase I, which is an enzyme involved in 
DNA replication and RNA transcription. 7-ethyl-10-hydroxyl camptothecin (SN-38) is 
the active metabolite of IR (Figure 5.1) and is 100-1000 more active than IR. After 
intravenous administration, unfortunately, only 1–9% of an injected dose of IR is 
converted to SN-38 in humans.6 However, the clinical applications of SN-38 have been 
limited due to its very poor solubility in aqueous solutions and in most pharmaceutically 
accepted solvents.7 
 
The preparation of SN-38 drug delivery nanocarriers is fairly limited due to the 
hydrophobic nature of SN-38. Recent research which has aimed to increase the aqueous 
solubility of SN-38 has described the preparation of PEGx-SN-38 polymer drug 
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conjugates. Zhang et al reported the attachment of a low molecular weight PEG chain 
(480 g/mol) to SN-38 in a four step synthesis to form an oligoethylene glycol-SN-38 
prodrug (OEG-SN-38), and subsequent preparation of polymeric micelles (~29 nm) with 
a loading of up to 36 wt % of SN-38.8 A PEG-SN-38 polymer drug conjugate which has 
progressed to Phase I clinical trial is EZN-2208 which has a reported loading of 3.7% SN-
38. The studies of EZN-2208 have been taken forward due to potent in vitro cytotoxicity 
against human cell lines and excellent anti-tumour activity in xenograft models of human 
breast, colorectal and pancreatic cancers.9, 10 
 
Figure 5.1 Chemical structures of irinotecan and SN-38. 
There are also alterative reports to the PEGx-SN38 pro-drug approach, which describe the 
loading of free SN-38 into nanocarriers. For example, Gu et al described the preparation 
of micelles, via a modified thin film hydration method, which were composed of Pluronic 
F-108 and PEGx-b-PCL (~125 nm), with an estimated drug loading of 20 wt % of SN-
38.11 Also, recently published reports have described the formation of SN-38 encapsulated 
polymeric nanoparticles via the emulsification solvent evaporation technique. The 
nanoparticles were prepared from PLGA (using a PVA stabiliser), with an average 
diameter of ~ 170 nm and a drug loading of ~5 wt % SN-38.6 Although current research 
towards SN-38 drug delivery has progressed during recent years, it was of interest to 
utilise the co-nanoprecipitation approach described throughout this thesis to investigate 
the encapsulation of SN-38 into nanoparticles consisting of a branched co/terpolymer and 
an A-B block copolymer. 
 
 
Irinotecan SN-38
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5.2 Preparation of aqueous nanoparticles and encapsulation of SN-38 
As discussed, SN-38 has very limited solubility in water and most biologically acceptable 
solvents. In order to conduct a nanoprecipitation experiment, both the polymer and drug 
molecule must completely solubilise in the ‘good’ solvent. During the initial stages of the 
research, the solubility of SN-38 was limited to dimethyl sulfoxide (DMSO) (Table 5.1) 
as this was the only single solvent found to generate useable concentrations. The 1H NMR 
analysis of SN-38 is presented in the Appendix, Fig. A30, and the integration values 
obtained for all proton environments were as expected. 
Table 5.1 Solubility of SN-38 in commercially available solvents (~1 mg/mL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.1 Preparation of SN-38 encapsulated particles via dialysis 
 
For solvents with high boiling points, such as DMSO (189°C), solvent removal after 
nanoparticle formation can be difficult if the dropping-evaporation technique is employed. 
Therefore, co-nanoprecipitation via dialysis was considered, as discussed in Chapter 1, 
Section 1.3.3. The branched copolymer p(HPMA50-co-EGDMA0.9), A-B block copolymer 
p(PEG114-b-HPMA120) and SN-38 were all readily soluble in DMSO at the concentrations 
Solvent Solubility
H2O X
Dichloromethane X
Methanol X
Chloroform X
Ethanol X
Ethyl acetate X
Diethyl ether X
Acetonitrile X
Tetrahydrofuran X
Acetone:Dichloromethane:Methanol 1:1:1 X
Acetone:H2O 1:1 X
DMSO
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required for the nanoprecipitation. During the dialysis experiment, SN-38 (5 wt % to total 
polymer mass), p(HPMA50-co-EGDMA0.9) and p(PEG114-b-HPMA120) were dissolved in 
DMSO at 5 mg/mL for 12-24 hours to ensure complete solubilisation. The stock solution 
of polymers and SN-38 (1 mL) was added to the dialysis bag with a molecular weight cut 
off (MWCO) of 2000 g/mol, containing 5 mL of water. After four days and regular water 
changes, the aqueous solution within the dialysis membrane was isolated and analysed by 
DLS. The size by intensity trace shows a multimodal size distribution for the SN-38 
encapsulated nanoparticles (Figure 5.3Ai). The presence of large particles (though few) 
in the nanodispersion can distort the size intensity distribution to produce an inaccurate 
representation of the particle sizes present. It is, therefore, important to take into 
consideration the number distribution and number average diameter Dn (Figure  5.3Bi), 
which provides a description of relative concentration of particles of each size. 
Unfortunately, after 24 hours, the sample was no longer colloidally stable and 
polymer/SN-38 precipitate was visible. 
 
Figure 5.3 DLS traces of polymer nanoparticles prepared via the dialysis method, 5 wt % SN-38, 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, A) size by intensity, B) size by number. 
 
5.2.2 Preparation of SN-38 encapsulated nanoparticles via co-nanoprecipitation  
 
Fortunately, after exploring additional mixed solvent systems, a 1:1 ratio of 
tetrahydrofuran and acetonitrile (THF:ACN) completely solubilised SN-38 (1 mg/mL), 
after 4-6 hours. The branched co/terpolymers and A-B block copolymers were also soluble 
in the mixed solvent (THF:ACN 1:1), and the relatively low boiling points were ideal for 
fast and easy removal during the co-nanoprecipitation/evaporation experiments. 
Therefore, the dropping technique was reconsidered, and experiments were conducted as 
described for the encapsulation of fluoresceinamine in Chapter 3, and HIV anti-retrovirals 
in Chapter 4.  
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Nanoparticle dispersions were prepared from a 5 mg/mL polymer solution with SN-38 
(0.105 mg/mL, 2 wt %) or (0.265 mg/mL, 5 wt %) and added to 5 mL of water to give a 
final aqueous concentration of 1 mg/mL polymer and either 0.021 or 0.053 mg/mL of SN-
38. For the initial nanoprecipitation experiments, the following SN-38 encapsulated co-
nanoprecipitated particles were targeted; p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120), p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120), p(HPMA25-co-t-BMA25-
co-EGDMA0.9):p(PEG114-b-HPMA120) (all 50:50 wt %) and 2 wt % SN-38 and p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt % and 5 wt % SN-38 wt %. The 
polymers and SN-38 were dissolved in THF:ACN 1:1 for 48 hours, before addition to 
water. After nanoprecipitation and complete evaporation of good solvent, non-
homogeneous nanodispersions and a very fine precipitate was observed during inclusion 
of p(HPMA50-co-EGDMA0.9) (2 wt % SN-38) and p(n-BMA50-co-EGDMA0.8) (5 wt % 
SN-38). The DLS analysis reflected this and for p(HPMA50-co-EGDMA0.9), inadequate 
scattering data and broad PdI values were obtained (Appendix, Table A10). Although 
precipitate was visible for two of the samples, the dropping technique was not ruled out 
for the preparation of SN-38 encapsulated nanoparticles, as further investigation of 
experimental conditions was required. 
To further investigate the nanoprecipitation conditions, stock solutions of branched 
co/terpolymers polymers p(HPMA50-co-EGDMA0.9), p(n-BMA50-co-EGDMA0.8), 
p(HPMA25-co-t-BMA25-co-EGDMA0.9) with p(PEG114-b-HPMA120) (50:50 wt %) and 
SN-38 (5 wt %) were left to solubilise for 5 weeks (roller) to evaluate if a longer 
solubilisation time could yield stable nanoparticles. The results for these experiments are 
shown in Table 5.2 and Figure 5.4.  
Table 5.2 DLS results for 5 wt % encapsulated co-nanoprecipitated particles. 
Sample (50:50 wt %) Size  (d.nm) PdI
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 145 0.112
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 94 0.076
p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 118 0.085
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Interestingly, the nanoparticles formed were within a reasonable size range with narrow 
PdI values, and no precipitate was visible within the samples. The longer solubilisation 
time for the stock solution had clearly affected the co-nanoprecipitation process as stable 
nanoparticles were produced. It is also worth considering other factors such as 
temperature, which could have also effected the nanoprecipitation process although this 
was not studied. The nanoprecipitates showed slight deviations in size when compared 
with the blank (no SN-38) nanoparticles, see Figure 5.5; the corresponding PdI values are 
shown in the Appendix, Table A11. The DLS results for the various batches of SN-38 
nanoparticles prepared throughout this study are presented in the Appendix, Table A12 
and generally for p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120), the nanoparticles 
formed are within the size range of ~110-170 nm, p(HPMA50-co-EGDMA0.9):p(PEG114-
b-HPMA120) ~80-110 nm and p(tBMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-
HPMA120) ~100-140 nm. This range of sizes correlates well with literature values, as the 
optimum size for polymer nanocarriers for drug delivery applications is reported to be 
within the range of 70-200 nm,12 to ensure they can easily permeate through targeted 
biological barriers. 
 
Figure 5.4 DLS results for 5 wt % SN-38 co-nanoprecipitated nanoparticles. A) p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120), B) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120), C) 
p(tBMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120). All 50:50 wt %. 
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The same experimental procedure was utilised for the preparation of 10 wt % of SN-38 
nanoparticles with the three branched co/terpolymers and p(PEG114-b-HPMA120) (50:50 
wt %) but, unfortunately, colloidal stability was not achieved and precipitate was visible 
after complete solvent evaporation. Therefore, all SN-38 nanoparticles prepared via co-
nanoprecipitation from this point onwards had a targeted loading of 5 wt % SN-38. 
 
Figure 5.5 DLS results for blank vs 5 wt % SN-38 encapsulated co-nanoprecipitated particles. 
 
A range of co-nanoprecipitates were studied using SEM, and images for nanoparticles 
loaded with 5 wt % SN-38  and comprised of  p(n-BMA50-co-EGDMA0.8):p(PEG114-b-
HPMA120), p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) and p(tBMA25-co-
HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt % are presented in Figure 5.6, 
providing evidence for spherical nanoparticle formation.  
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Figure 5.6 SEM images for 5 wt % SN-38 encapsulated nanoparticles, i) p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120), ii) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120),  iii) p(t-
BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) (All 50:50 wt %) (Nanoparticle 
dispersions were diluted to 0.1 mg/mL for imaging). 
5.3 Stability of SN-38 encapsulated nanoparticles 
The colloidal stability of the nanoparticles was studied by measuring the Dz, (d.nm) and 
PdI after both 18 days and 5 months. New nanoparticle samples were prepared throughout 
this research and the sizes (instant vs 18 day) for the various samples are shown in Figure 
5.7. It is worth noting that the blank samples were re-measured after 5 months and the size 
and PdI values were almost identical to the original dispersion (Appendix, Table A13). 
The results presented for the three different batches of SN-38 encapsulated nanoparticles, 
confirms the reproducibility in stability across multiple samples. The particles remained 
colloidally stable and there showed only very minor variations in size for SN-38 
encapsulated nanoparticles when comparing instant vs 18 day measurements. 
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Figure 5.7 DLS analysis of samples during an 18 day time period for 5 wt % encapsulated SN-38 co-
nanoprecipitated particles. A) p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120), B) p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120), C) p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-
HPMA120), all 50:50 wt %. The blank samples were re-analysed after 5 months.  
After 5 months of storage at ambient temperature and out of direct light, the Dz and PdI 
values remained similar to those originally measured, see Table 5.3.  
Table 5.3 Stability of 5 wt % nanoparticles during a 5 month period.  
 
Evidently, the polymers and SN-38 remained completely dispersed as no precipitate was 
visible (Figure 5.8 Ai-iii). Therefore, it can be confirmed that these particles remain 
colloidally stable over extended periods of time, as the variation in size and PdI were not 
significant (< 12 nm) (Table 5.3 & Figure 5.8 Bi-iii). This level of stability is not often 
Sample (50:50 wt%)
Instant Size 
(d.nm)
PdI
Size after 5 months
(d.nm)
PdI
p(n-BMA50-co-EGDMA0.8) :p(PEG114-b-HPMA120) 167 0.051 155 0.065
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 84 0.081 78 0.130
p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 129 0.054 133 0.097
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witnessed in the literature for polymer nanocarriers, and when stability is discussed, 
changes in size are usually measured during a much shorter time period (< 7 days).13 The 
stability under more physiologically-relevant conditions is yet to be investigated. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5.8 Stability of SN-38 encapsulated nanoparticles (5 wt %) during a 5 month period. A) 
Photograph to show SN-38 nanoparticles after 5 months in storage, i) p(n-BMA50-co-
EGDMA0.8):p(PEG114-b-HPMA120), ii) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120), iii) p(t-
BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120), B) DLS overlays of size distribution by 
intensity traces for nanoprecipitations, instant vs 5 months, i) p(n-BMA50-co-EGDMA0.8):p(PEG114-b-
HPMA120) ii) p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) iii) p(t-BMA25-co-HPMA25-co-
EGDMA0.9):p(PEG114-b-HPMA120). All 50:50 wt %. 
5.4 Pharmacological studies of co-nanoprecipitated nanoparticles 
The SN-38 encapsulated nanoparticles with varying chemical compositions were taken 
forward for in vitro testing, due to loading capabilities and enhanced aqueous 
concentrations of SN-38. The nanoparticles which were selected for study were; p(n-
BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120), p(HPMA50-co-EGDMA0.9):p(PEG114-b-
HPMA120) and p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) (50:50 wt 
%). The pharmacological cytotoxicity assays were conducted by researchers in the 
Molecular and Clinical Pharmacology department, specialising in cancer research at the 
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University of Liverpool, through collaboration between the Kitteringham and Rannard 
research groups. 
5.4.1 In vitro pharmacological studies 
As cancer cells are being targeted for this study, it is expected that the SN-38 encapsulated 
nanoparticles would decrease the cell viability i.e. increase cell death, when compared 
with blank nanoparticle dispersions (no SN-38). Initial experiments were conducted using 
the CT26 murine cell line. CT26 is an N-nitroso-N-methylurethane induced 
undifferentiated colon carcinoma cell line, which is commonly used for early stages of in 
vitro testing. CT26 were selected as they are readily available and derived from BALB/c 
mice and can be implanted back into these mice to allow use in an immunocompetent 
syngeneic murine model. Depending on the results obtained from this study, the materials 
would be further tested on a human colon carcinoma cell line HCT116. HCT116 cells are 
known to be tumorigenic in nude nice and therefore suitable for translation into murine 
work if experiments were to be conducted in vivo. When using two different cells lines it 
is expected that different drug toxicities will be observed, as the cells are derived from 
different species. 
To compare the cytotoxicity of both IR and SN-38 in the absence of any nanomaterials, 
MTS assays were conducted on both CT26 and HCT116 cell lines (Figure 5.9). The 
concentration range for SN-38 was between 0–9 µM and 0–300 µM for IR, and cells were 
incubated for 48 hours prior to MTS addition. Evidently, SN-38 exhibited a high toxicity 
at much lower concentrations than IR, when tested on both cell lines. During incubation 
with CT26 cells (Figure 5.9A), SN-38 significantly reduces cell viability, whereas IR did 
not cause a significant cell toxicity until a much higher concentration (300 µM), where 
~10 % cell viability was observed. During incubation of SN-38 and IR with HCT116 cells, 
as expected, a low cell viability at low concentrations was observed for SN-38 (~40% at 
9 µM), whilst for IR there was no change in cell viability between 100-300 µM, and a 
maximum of ~55% cell viability was obtained at 300 µM (Figure 5.9B).  
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Figure 5.9 In vitro cytotoxicity for increasing concentrations of IR (blue open squares) and SN-38 (dark 
red open circles) A) CT26 cell line, B) HCT116 cell line. Cell viability was calculated as the absorbance 
ratio of treated to control groups. (IR and SN-38 were both spiked with DMSO). 
5.4.2 MTS assays for SN-38 encapsulated nanoparticles – CT26 cell line  
An MTS assay was conducted to compare the in vitro cytotoxicity of SN-38, 5 wt % SN-38 
encapsulated nanoparticles and blank nanoparticles (no SN-38) using CT26 carcinoma 
cells at concentrations 1, 2 and 4 µM. For all three concentrations, a significant decrease 
in cell viability was observed for the SN-38 nanodispersions (< 10% for both 4 and 2 µM 
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and 19% for 1 µM), when compared with the blank nanoparticles (generally > 80% cell 
viability), see Figure 5.10A-C.  
 
Figure 5.10 In vitro viability of CT26 cancer cells treated with free SN-38, SN-38 encapsulated 
nanoparticles and blank nanoparticles after 48 hour incubation. A) 4 µM, B) 2µM, C) 1 µM. SN-38 
nanomaterial 1 = p(n-BMA50-co-EGDMA0.8) :p(PEG114-b-HPMA120) 50:50 wt %, 5 wt % SN-38, SN-
38 nanomaterial 2 = p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, 5 wt % SN-38, SN-
38 nanomaterial 3 = p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, 5 wt 
% SN-38. Same chemical compositions for blanks in the absence of SN-38. (Each experiment was 
conducted in triplicate). 
When compared to free SN-38, an additional decrease in cell viability was observed for 
nanomaterial 3 (5 wt % SN-38 p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-
HPMA120) (50:50 wt %), at concentrations 4, 2 and 1 µM, which may suggest the release 
of SN-38 from nanoparticles into the cells and further studies would be required to confirm 
this. As an initial toxicity experiment, the low cell viability for SN-38 nanodispersions 
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were promising, in particularly for p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-
HPMA120) 50:50 wt %, which were comparable with free SN-38. 
Due to the increased cytotoxicity observed during incubation with CT26 cancer cells, p(t-
BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, this 
nanomaterial was further assessed within a range of concentrations (0-8 µM) and 
compared with both free SN-38 and IR. The results are shown in Figure 5.11, and 
interestingly free SN-38 and 5 wt % SN-38 p(t-BMA25-co-HPMA25-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt % show an almost identical decrease in cell 
viability (<40%) when compared with free IR, which remains > 80% at 8 µM. It is worth 
noting that the SN-38 encapsulated nanomaterials appear to show an enhanced 
reproducibility, as the standard deviation values across the range of concentrations for free 
SN-38 are much smaller than those obtained for free SN-38. 
 
Figure 5.11 In vitro viability of CT26 cancer cell line treated with free SN-38, SN-38 encapsulated 
nanoparticles and irinotecan after 48 hour incubation. Circle = free SN-38, square = 5 wt % SN-38 
encapsulated within p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %,  
triangle = IR. (Both IR and SN-38 were spiked with DMSO and each experiment was conducted in 
triplicate). 
 
5.4.3 MTS assays for SN-38 encapsulated nanoparticles – HCT116 cell line  
Following the results obtained for the SN-38 encapsulated nanoparticles incubated with 
CT26 cells, MTS assays were performed on HCT116 human carcinoma cells. The 
determination of cytotoxicity was conducted with the same materials as described for 
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above for CT26 cells; SN-38 control, 5 wt % SN-38 encapsulated nanoparticles and blank 
nanoparticles (no SN-38) at concentrations 1, 2 and 4 µM (Figure 5.12A-C). 
 
 Figure 5.12 In vitro viability of HCT116 cancer cells treated with free SN-38, SN-38 encapsulated 
nanoparticles and blank nanoparticles after 48 hour incubation. A) 4 µM, B) 2µM, C) 1 µM. SN-38 
nanomaterial 1 = p(n-BMA50-co-EGDMA0.8) :p(PEG114-b-HPMA120) 50:50 wt %, 5 wt % SN-38, SN-
38 nanomaterial 2 = p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, 5 wt % SN-38, SN-
38 nanomaterial 3 = p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, 5 wt 
% SN-38. Same chemical compositions for blanks in the absence of SN-38. (Each experiment was 
conducted in triplicate). 
The cell viability observed for free SN-38 was ~40% for 4, 2 and 1µM SN-38 and an 
increase in cytotoxicity with increasing concentration was observed. Therefore, the largest 
difference in cell viability for the SN-38 encapsulated and blank nanomaterials, was 
during incubation at 4µM of drug. The material which demonstrated the lowest cell 
viability (47%) was 5 wt % SN-38 p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-
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HPMA120) 50:50 wt % and was, therefore, further assessed within a wider range of 
concentrations (0-8 µM). 
The results obtained for the incubation of HCT116 cells with free SN-38, free IR and 5 wt 
% SN-38 p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt % 
nanomaterial are shown in Figure 5.13. Interestingly, for both free SN-38 and the SN-38 
encapsulated nanomaterial, an almost identical decrease in cell viability across the range 
of concentrations was observed. This was very promising, as this particular nanomaterial 
has demonstrated a comparable toxicity with free SN-38 as an aqueous nanodispersion 
during incubation with human cancer cells. As expected, IR did not show a great level of 
toxicity until reaching higher concentrations ( > 4µM drug).  
 
Figure 5.13 In vitro viability of HCT116 cancer cell line treated with free SN-38, SN-38 encapsulated 
nanoparticles and irinotecan after 48 hour incubation. Circle = free SN-38, square = 5 wt % SN-38 
encapsulated within p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %,  
triangle = IR. (Both IR and SN-38 were spiked with DMSO and each experiment was conducted in 
triplicate). 
 
5.5 Multiple co-nanoprecipitation experiments and encapsulation of 
SN-38 
As discussed in Chapter 2 Section 2.4.2, the formation of colloidally stable p(HPMA50-
co-EGDMA0.9) nanoparticles via nanoprecipitation allowed additional subsequent 
nanoprecipitations into the same anti-solvent mixture. Interestingly, during repeated 
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did not act as nuclei for further growth, and a new nanoparticle distribution of identical 
size was obtained. This multiple addition technique has not yet been utilised with a 
branched terpolymer, A-B block copolymer and a hydrophobic drug molecule. The ability 
to instantly increase the concentration of polymer nanoparticles via low volume additions 
is very appealing for increasing the concentration of a therapeutic drug molecule whilst 
maintaining a constant volume of water, especially if these materials were to be taken 
forward in vivo. 
 
The in vitro cytotoxicity results were most promising for the 5 wt % SN-38 nanomaterial 
consisting of p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, 
therefore, this material was selected for the multiple nanoprecipitation study. A fresh stock 
solution of 5 wt % SN-38, p(t-BMA25-co-HPMA25-co-EGDMA0.9) and p(PEG114-b-
HPMA120) dissolved in THF:ACN (1:1) was prepared and left to solubilise for 6 weeks 
(total polymer concentration 5 mg/mL, SN-38, 0.265 mg/mL). The conditions were kept 
consistent with previous co-nanoprecipitation experiments, and for the first addition, 1 
mL (5 mg/mL polymers, 0.265 mg/mL SN-38) was added quickly into 5 mL of water (i5-
f1) and analysed by DLS after THF:ACN evaporation. The subsequent additions were 
carried out into the same nanoparticle mixture and the DLS results are presented in Table 
5.4.  
 
Table 5.4 DLS multiple nanoprecipitation results for 5 wt % SN-38 and p(t-BMA25-co-HPMA25-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt % for 3 subsequent additions. 
 
As shown in Table 5.4, for repeated additions of the stock solution containing SN-38, 
branched terpolymer and A-B block copolymer (up to 3 mL), the recorded Dz values of 
the nanoprecipitated particles were similar, with an observed increase of just 23 nm after 
the second addition and a minor difference of 4 nm during the third addition. Although 
there are small changes in PdI, the results suggest that new nanoparticles of identical size 
are being formed. The DLS traces for each addition (Figure 5.14 A-C) show monomodal 
size populations, even during the third addition, with an increased final concentration of 
SN-38 (0.159 mg/mL) and branched terpolymer plus A-B block copolymer (3 mg/mL). 
Volume of Polymers
+ SN-38 Added (mL)
Addition no. Dz
(nm)
PdI Dn
(nm)
Derived count rate
(kcps)
Concentration 
of polymers 
(mg/mL)
Concentration 
of SN-38
(mg/mL)
1 1 114 0.156 85 309236 1 0.053 
1 2 137 0.168 96 346456 2 0.106
1 3 133 0.121 94 390176 3 0.159
 
 
194 
 
Although the solution became slightly more turbid after removal of solvent during each 
addition, there was no evidence of polymer precipitation (Figure 5.14 Di-iii). This study 
has highlighted a fast and efficient method to increasing the concentration of SN-38 within 
a constant volume of water, and may not be limited to the chemical compositions and drug 
molecule presented here. 
 
Figure 5.14 Multiple nanoprecipitation study of 5 wt % SN-38 and p(t-BMA25-co-HPMA25-co-
EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt %, A) DLS trace for first addition of polymer and SN-38 
dissolved in good solvent, B) second addition of polymers and SN-38 dissolved in good solvent, C) 
third addition of polymers and SN-38 into good solvent. The conditions were (i5-f1, from THF:ACN 
into water), D) Photograph to show each subsequent addition of 5 wt % SN-38 and p(t-BMA25-co-
HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 50:50 wt % dissolved in THF:ACN 1:1 into the 
original 5 mL H2O, i) 1 mL ii) 2 mL, iii) 3 mL. 
 
5.6 Conclusion  
 
To conclude, the encapsulation of the anti-cancer drug molecule SN-38 has been explored, 
and after initial solubility issues, nanoparticles were successfully prepared at 5 wt % SN-
38 encapsulation via the co-nanoprecipitation approach. The SN-38 nanoparticles were 
10 100 1000
0
5
10
15
Multiple nanoprecipitation vs Col 2 
2D Graph 2
10 100 1000
0
5
10
15
20
2nd addition vs Col 4 
10 100 1000
0
5
10
15
3rd addition vs Col 6 
R
el
at
iv
e 
in
te
n
si
ty
 (
%
)
R
el
at
iv
e 
in
te
n
si
ty
 (
%
)
R
el
at
iv
e 
in
te
n
si
ty
 (
%
)
A) B)
i) ii) iii)
C)
Size (d.nm)
Size (d.nm)Size (d.nm)
D)
 
 
195 
 
colloidally stable for up to 5 months (longest period tested), demonstrated reproducibility 
(size and PdI) across a range of samples and were within the size range required for cancer 
nanotherapies. Three nanomaterials were taken forward for initial in vitro cytotoxicity 
testing and the cell viability was determined for both, CT26 (mouse) and HCT116 
(human) cancer cells. The same general trends were observed throughout and generally 
the SN-38 nanomaterials exhibited a cytotoxicity which was comparable to that of free 
SN-38. The SN-38 encapsulated nanomaterial which demonstrated an almost identical cell 
toxicity to free SN-38 was p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-
HPMA120) 50:50 wt %. Due to the promising in vitro results, the SN-38 encapsulated 
nanomaterials were of interest to an external large pharmaceutical company and release 
studies of SN-38 are currently being conducted prior to a planned more extensive 
collaboration. 
The multiple nanoprecipitation process, first introduced in Chapter 2 Section 2.4.2, 
was further explored with SN-38 and the two polymers required for a co-
nanoprecipitation. Interestingly, the multiple addition was successful and an increased 
concentration of SN-38 was achieved, whilst maintaining the same volume of anti-
solvent. 
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Chapter 6 
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6.1 Conclusions   
The nanoprecipitation conditions for both linear p(HPMA50) and branched p(HPMA50-co-
EGDMA0.9) were initially investigated and there was a clear advantage of using branched 
p(HPMA50-co-EGDMA0.9), rather than linear homopolymers when seeking to achieve 
monomodal polymer nanoparticles. The stability of charge stabilised p(HPMA50-co-
EGDMA0.9) nanoparticles was improved through the introduction of an A-B block 
copolymer when simultaneously added to the anti-solvent during nanoprecipitation. A-B 
block copolymer stabilisers consisting of varying PEG and HPMA (hydrophilic vs 
hydrophobic) blocks were successfully synthesised via ATRP and subsequent co-
nanoprecipitation experiments were conducted at varying ratios from 100:0 through to 
0:100 wt % (branched copolymer:A-B block copolymer respectively) and, generally, the 
nanoparticles produced were within the range considered ideal for drug delivery 
applications with exceptionally narrow monomodal distributions  obtained. The NaCl 
stability was determined across the varying ratios and different levels of success were 
observed, which was useful to determine the region in which stabilised nanoparticles are 
formed. An apparent optimum of electrolyte stability was observed during inclusion of 
the p(PEG114-b-HPMA120) A-B block copolymer, which was taken forward for further 
studies. This particular stabiliser was not limited to co-nanoprecipitation experiments with 
p(HPMA50-co-EGDMA0.9), and a variety of branched polymers were also stabilised, 
including; p(n-BMA50-co-EGDMA0.8), p(t-BMA50-co-EGDMA0.9), p(HPMA25-co-n-
BMA25-EGDMA0.9) or p(HPMA25-co-t-BMA25-co-EGDMA0.9). To further investigate 
how both the branched polymer and A-B block copolymer associate during a co-
nanoprecipitation, the fluorescent dye molecule pyrene was encapsulated within the 
nanoparticles, to probe the internal environment. The polarity studies provided further 
evidence that during addition of increasing levels of A-B block copolymer, the 
hydrophobicity of the internal core was maintained and only slight deviations were 
observed when compared with 100 % p(HPMA50-co-EGDMA0.9). From these detailed 
studies, it is most likely that the HPMA block from the A-B block copolymer becomes 
incorporated into the polymer core and the PEG chain resides on the nanoparticle surface. 
The co-nanoprecipitation approach provided a fast and efficient route to stabilised 
nanoparticles, without the need for polymeric surfactants as additives within the aqueous 
anti-solvent solution. The ability to tune both the chemistry of the branched polymer and 
A-B block co-polymer is very appealing when considering a new drug delivery 
nanocarrier. 
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To assess the potential of the nanoparticles as drug delivery vehicles, co-nanoprecipitation 
experiments were conducted with a guest dye molecule fluoresceinamine (FA) and an 
encapsulation of up to 17 wt % (relative to total polymer mass) was observed. In vitro 
cytotoxicity and 14C-mannitol permeability assays were performed using the Caco-2 cell 
line which represents the first barrier to orally dosed materials, the intestinal epithelium. 
The studies were conducted on a selection of the FA encapsulated nanomaterials, which 
were stable to both NaCl and transport buffer solution, to ensure the nanoparticles 
remained dispersed during the pharmacological assays. The materials which appeared to 
compromise the integrity of the Caco-2 monolayer, and were not further studied, consisted 
of A-B block copolymers with a PEG chain length of 2000 g/mol and a HPMA block with 
a DPn < 120 monomer units. The materials taken forward did not cause toxicity to Caco-
2 cells across a range of concentrations and 90-100% cell viability was maintained up to 
relatively high concentrations. The lead material which showed positive potential 
pharmacological benefits was FA encapsulated p(n-BMA50-co-EGDMA0.8):p(PEG114-b-
HPMA120) (50:50 wt %), as an enhanced transcellular permeability was observed when 
compared with the control (free FA in water/DMSO). The subsequent cellular 
accumulation experiments highlighted that for the FA nanomaterial, although not 
statistically significant, an increased accumulation in ATHP-1 cells (macrophages) was 
observed. This would be a desirable property for an oral dosing therapy of infectious 
diseases such as HIV, where macrophage cells are a sanctuary site for the HIV virus. 
However, for Caco-2 cells, a decreased accumulation was observed which suggested that 
FA was traversing the membrane via mechanisms such as paracellular permeation. To 
gain a greater insight, further experiments were conducted and active transport processes 
were inhibited. Surprisingly, during ATP depletion, a decrease in cellular accumulation 
of the FA nanomaterial was observed, suggesting uptake does in fact occur via an active 
process. The assessment of the Caco-2 transcellular permeability was also carried out in 
the presence of endocytic inhibitors, and a statistically significant decrease in cellular 
permeability during the presence of each inhibitor was observed, which suggests the 
movement of the mimic drug molecule was not simply passive and does proceed via an 
active mechanism. 
 
There was huge variability in loading capabilities of the drug molecules studied and 
interestingly, p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 50:50 wt %, (lead 
material during early pharmacological studies) also demonstrated an excellent loading 
potential when co-nanoprecipitated with HIV anti-retrovirals; up to 25 wt % of efavirenz 
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and ritonavir and 20 wt % lopinavir were encapsulated. To rationalise the behaviour, the 
calculated logP of the varying branched co/terpolymers was considered and during 
inclusion of an increasingly hydrophobic polymer, higher loading capabilities were 
observed. 
Further encapsulation studies were conducted for the hydrophobic anti-cancer drug 
molecule SN-38. After various solubilisation difficulties, co-nanoprecipitation 
experiments were successfully conducted and stabilised nanoparticles were produced. The 
nanoparticles were within the preferred size range for drug delivery, remained stable 
during a minimum of 5 months (study period) and samples were very reproducible. The 
SN-38 nanoparticles were progressed forward for various in vitro cytotoxicity studies and, 
as cancer cells were being targeted, a decrease in cell viability was expected. Two cancer 
cell lines were used for the experiments; CT26 (mouse cell line) and HCT116 cells (human 
cancer cell line). The SN-38 encapsulated nanoparticles showed an almost identical 
toxicity with free SN-38, yet, the nanoparticles existed as an aqueous nanodispersion, 
which would be preferred if administered as an intravenous solution. As a comparison, 
blank nanoparticles (no SN-38) were also subject to toxicity assays and demonstrated a 
negligible toxicity, therefore, the SN-38 was resulting in toxicity observed for the SN-38 
nanoparticles. The nanomaterials which showed an increasing toxicity when compared to 
other samples was p(HPMA25-co-t-BMA25-co-EGDMA0.9), which is currently being 
studied further. It is worth noting that the encapsulation of SN-38 may not be limited to 5 
wt % loading, which is presented here, as the chemistry is yet to be optimised for drug 
loading.  
The multiple nanoprecipitation studies conducted during early stages of the research gave 
promising results for p(HPMA50-co-EGDMA0.9), showing that a single precipitation anti-
solvent could be used several times leading to an increase in the  concentration of polymer 
nanoparticles rather than growth of larger particles. This effect was utilised in the co-
nanoprecipitation of SN-38 with branched copolymers and linear A-B stabilising block 
copolymers. Interestingly, the multiple addition experiments were successful and an 
increased concentration of SN-38-loaded nanoparticles was achieved, whilst maintaining 
the same volume of anti-solvent. The original nanoparticle size was maintained during 
each addition suggesting a new nanoparticle dispersion of similar size was generated. It is 
worth emphasising that this procedure provides an option to create samples of increasing 
concentration via a relatively simple strategy after initial removal of good solvent. 
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Overall, the properties of the original studied p(HPMA50-co-EGDMA0.9) charge stabilised 
nanoparticles have been greatly improved via the addition of an A-B block copolymer 
stabiliser. Not only is the technique a fast and reproducible route to sterically stabilised 
nanoparticles, it does not require additional surfactants dissolved in the anti-solvent or 
subsequent filtration which is regularly reported in the literature. The stability is 
maintained during encapsulation of hydrophobic drug molecules and generally the size 
change during encapsulation is negligible. The selection of chemical compositions studied 
within this research are not limited to those presented and could be further expanded for 
nanomedicine applications. 
6.2 Future Work  
The co-nanoprecipitation approach has provided a fast and efficient route to sterically 
stabilised nanoparticles with high loading (wt %) capabilities. The research presented 
within this thesis is not limited to the chemical compositions discussed and future research 
directions will focus a series of avenues listed below: 
 Further investigation of the versatility of hydrophobic branched co/terpolymers 
and A-B block copolymers for increasing loading capabilities of SN-38. 
 The use of targeting A-B block copolymers and their inclusion within a branched 
hydrophobic core e.g. sugars, proteins and the formation of biologically relevant 
nanoparticles.  
 Multiple nanoprecipitation experiments for HIV encapsulated nanoparticles to 
yield nanoparticles with an increased concentration of anti-retrovirals within the 
same volume of water. 
 Alternative architectures to A-B block copolymers such as A-B-A functional 
polymers (See 6.3). 
 Formation of polymer-drug conjugates and subsequent co-nanoprecipitation 
experiments (See 6.4). 
 
Additional pharmacological studies: 
 Pharmacological studies of efavirenz encapsulated nanoparticles: 
o Cytotoxicity  
o Drug release 
 In vivo work for 5 wt% SN-38 encapsulated co-nanoprecipitated nanoparticles. 
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6.3 Preliminary aqueous encapsulation co-nanoprecipitation studies 
utilising an A-B-A triblock polymer  
As well as an A-B block copolymer, it was also of interest to investigate nanoparticle 
formation during incorporation of an A-B-A triblock polymer, therefore p(HPMA120-b-
PEG~105-b-HPMA120) was synthesised from a di-functional PEG macroinitiator (
1H NMR, 
see Appendix A31) and polymerised with HPMA via ATRP. The analysis for the di-
functional initiator and A-B-A triblock polymer are presented in the Appendix, Fig A32 
& A33. To investigate the nanoparticle behaviour, co-nanoprecipitation experiments of 
both p(HPMA120-b-PEG~105-b-HPMA120) and p(HPMA50-co-EGDMA0.9) (50:50 wt%) 
were conducted. The PEG chain length and particular DPn of HPMA were selected based 
upon the success of the co-nanoprecipitation experiments which included the A-B block 
copolymer p(PEG114-b-HPMA120). Due to time constraints, the preliminary experiments 
were conducted for branched p(HPMA50-co-EGDMA0.9) only. When switching from an 
A-B block copolymer to an A-B-A triblock polymer, it was expected that during the co-
nanoprecipitation bridging between the nanoparticles would be observed, and HPMA 
blocks from the A-B-A triblock could become incorporated into two different branched 
polymer cores. However, it appears that this did not occur and the nanoparticles formed 
during addition of the A-B-A to p(HPMA50-co-EGDMA0.9) were ~100 nm with a  
monomodal size distribution (Figure 6.1A).  
 
Figure 6.1 A) DLS size by intensity, p(HPMA50-co-EGDMA0.9):p(HPMA120-b-PEG~105-b-HPMA120) 
50:50 wt %, B) Scanning electron microscopy image of p(HPMA50-co-EGDMA0.9):p(HPMA120-b-
PEG~105-b-HPMA120) 50:50 wt % (Nanoparticles were diluted to 0.1 mg/mL for imaging). 
When compared to the incorporation of the A-B block copolymer p(PEG114-b-HPMA120), 
the sizes obtained were very similar (103 nm), which further suggests bridging between 
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particles is not occurring. The nanoparticles were also analysed via SEM imaging and 
evidence of spherical nanoparticle formation was observed (Figure 6.1B). 
To ascertain if anti-retroviral drug loaded nanoparticles could be prepared via co-
nanoprecipitation, experiments including the A-B-A triblock polymer, p(HPMA120-b-
PEG~105-b-HPMA120) were conducted. The polymers and antiretrovirals were dissolved in 
a good solvent and completely solubilised before addition to water. The good solvent 
which has been used for all co-nanoprecipitation experiments previously was acetone, but 
due to the poor solubility of the A-B-A triblock in this solvent, methanol was preferred. 
The DLS results for all encapsulation experiments are outlined in Table 6.1 and the 
corresponding DLS traces are presented in the Appendix, Fig A34. Interestingly, the co-
nanoprecipitation of p(HPMA50-co-EGDMA0.9), A-B-A triblock polymer and an anti-
retroviral gave promising results, as narrow size distributions were obtained for each 
sample and the nanoparticle sizes were within the range of 86-144nm. To explore the co-
encapsulation of both ritonavir and lopinavir, encapsulation experiments at a 1:1 ratio, 
with a total wt % of 1, 5 and 10 were conducted. The ability to co-encapsulate drug 
molecules within a nanoparticle is very appealing and for this system 5 wt % of both 
ritonavir and lopinavir (total 10 wt %) have been co-encapsulated to generate stabilised 
nanoparticles.  
Table 6.1 DLS analysis for p(HPMA50-co-EGDMA0.9):p(HPMA120-b-PEG~105-b-HPMA120) 50:50 wt 
% of encapsulated HIV antiretrovirals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV Antiretroviral Wt % Size (d.nm) PdI
Blank nanoparticles 0 112 0.068
Efavirenz
1 144 0.044
5 106 0.049
10 86 0.070
Ritonavir
1 92 0.043
5 91 0.048
10 134 0.043
Lopinavir
1 107 0.052
5 113 0.058
10 103 0.101
Ritonavir + Lopinavir (1:1)
1 103 0.050
5 93 0.046
10 95 0.058
 
 
204 
 
The resulting nanoparticles formed after encapsulation and co-encapsulation are presented 
in Figure 6.2, and highlight the insolubility of the anti-retrovirals vs the dispersions 
obtained when co-nanoprecipitated with p(HPMA50-co-EGDMA0.9):p(HPMA120-b-
PEG~105-b-HPMA120) 50:50 wt %. Although ritonavir and lopinavir are administered as a 
4:1 ratio, this initial experiment has highlighted the possibility of encapsulating two drug 
molecules within a co-nanoprecipitated particle. The spherical shape of the nanoparticles 
was confirmed by SEM imaging (Figure 6.3). The maximum wt % of the antiretrovirals 
which could be encapsulated within co-nanoprecipitated particles which contain an A-B-
A triblock polymer is yet to be investigated. The initial results from this study suggest that 
the co-nanoprecipitation process is not limited to incorporation of A-B block copolymers, 
and A-B-A triblock polymers also form stabilised nanoparticles with drug loading 
capabilities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Photographs to show the solubility of 1) efavirenz, 2), lopinavir 3), ritonavir and 4) ritonavir 
and lopinavir (1:1) in water and the corresponding encapsulated co-nanoprecipitated particles of 
p(HPMA50-co-EGDMA0.9):p(HPMA120-b-PEG~105-b-HPMA120) (50:50 wt%) and each anti-retroviral, 
from left to right – 1 wt %, 5 wt % and 10 wt %. 
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Figure 6.3 Scanning electron microscopy images of HIV encapsulated particles prepared from 
p(HPMA50-co-EGDMA0.9):p(HPMA120-b-PEG~105-b-HPMA120) 50:50 wt %, A) efavirenz 10 wt %, B) 
ritonavir 10 wt %, C) lopinavir 10 wt %, D) ritonavir and lopinavir (1:1) 10 wt %. 
 
6.4 The preparation of ibuprofen polymer-drug conjugates and their 
incorporation into aqueous nanoparticles  
6.4.1 Synthesis of ibuprofen modified polymers via ATRP 
 
Polymer-drug conjugation is a widely exploited technique which is often utilised to 
improve the therapeutic properties of small therapeutic molecules, as discussed in Chapter 
1, Section 1.2.4. Drug molecules which contain reactive functional groups such as 
carboxyl or hydroxyl moieties can be converted to a wide variety of polymerisable 
derivatives. The monomeric unit 2-hydroxypropyl methacrylate (HPMA) (1), has a 
pendant alcohol group, which can be further reacted with a small hydrophobic drug 
molecule. The drug molecule selected for the preliminary experiments was Ibuprofen 
(IBU) (2), due to the presence of a reactive carboxylic acid functional group. 1 and 2 were 
reacted via an activated Steglich esterification and IbuPMA (3) was successfully 
synthesised1 (Scheme 6.1). For analysis of IbuPMA, see Appendix, Figure A35 & A36.  
  
 
 
 
200 nm 200 nm
100 nm 200 nm
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Scheme 6.1 Synthesis of IbuPMA. 
Following the successful synthesis of IbuPMA, the preparation of the statistical 
copolymer, p(PEG114-co-IbuPMA20-co-HPMA60) was conducted via ATRP (Scheme 6.2). 
For detailed GPC and 1H NMR analysis, see Appendix, Table A14 & Fig. A37. The 
number of IbuPMA units determined by 1H NMR was ~15 units per chain, and a higher 
Mn and Mw were achieved (Mn = 25600 & Mw = 31400 g/mol) when compared with 
p(PEG114-b-HPMA80) A-B block copolymer (Mn = 20600 & Mw = 25000 g/mol), which 
would be expected due to the increasing molecular weight of the IbuPMA monomeric 
unit. 
 
Scheme 6.2 Synthesis of p(PEG114-co-IbuPMA20-co-HPMA60) via ATRP. 
As well as incorporation of the monomeric unit IbuPMA, the post modification of 
p(PEG114-b-HPMA120) was also considered and IBU was directly reacted with the A-B 
block copolymer via an esterification reaction. The targeted polymer was p(PEG114-co-
HPMA80-co-IbuPMA40), as 40 HPMA monomer units were targeted with IBU. For 
detailed GPC and 1H NMR analysis see Appendix, Table A15 & Fig. A38. The predicted 
number of IbuPMA units present by 1H NMR was ~17 per chain, and an increase in 
DCM
24hr
N,N'-Dicyclohexylcarbodiimide
4-Dimethylaminopyridine
(1)
(2)
(3)
MeOH
Bpy, Cu(I)Cl
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molecular weight was observed during GPC analysis (Mn = 37400, Mw = 47800 g/mol) 
when compared with the initial A-B block copolymer (Mn = 29500, Mw 37500 g/mol). 
 
 
 
 
 
 
 
Scheme 6.3 Post modification of p(PEG114-b-HPMA120). 
IbuPMA was successfully incorporated into two A-B polymers via two different methods, 
a statistical copolymerisation and post modification of an A-B block copolymer, therefore, 
the next step was to prepare an IBU modified branched polymer. IbuPMA, HPMA and 
EGDMA were polymerised via ATRP and the branched polymer targeted was p(HPMA60-
co-IbuPMA20-co-EGDMA0.85) (Scheme 6.4). A high monomer conversion was achieved 
(98%) and the GPC results (Mn = 60000 and Mw = 986000 g/mol) suggested the formation 
of a high molecular weight branched architecture. For GPC analysis, see Appendix, A39.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6.4 Synthesis of p(HPMA60-co-IbuPMA20-co-EGDMA0.85). 
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6.4.2 Aqueous nanoprecipitation studies of an IBU polymer-drug conjugate 
After successful synthesis of the IBU incorporated materials, co-nanoprecipitation 
experiments were conducted to determine if it was A) possible to co-nanoprecipitate an 
IBU modified A-B block copolymer and p(HPMA50-co-EGDMA0.9), B) co-
nanoprecipitate IBU modified p(HPMA60-co-IbuPMA20-co-EGDMA0.85) with an A-B 
block copolymer, C) co-nanoprecipitate IBU modified p(HPMA60-co-IbuPMA20-co-
EGDMA0.85) and an IBU modified A-B block copolymer and finally, D) co-
nanoprecipitate IBU modified branched p(HPMA50-co-EGDMA0.9), IBU modified A-B 
block with free IBU (Figure 6.4).  
 
Figure 6.4 Schematic representation of the co-nanoprecipitation of the IBU incorporated materials. 
 
During a typical co-nanoprecipitation experiment, 25 mg of an A-B polymer and 25 mg 
of a branched polymer were added to 10 mL of MeOH and solubilised for 6-8 hours. 1 mL 
of the 5 mg/mL solution of polymers was quickly added to 5 mL of stirring water and left 
for 24 hours for complete solvent evaporation.  
+
+
+
+
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C)
D)
Co-nanoprecipitation?
= Ibuprofen 
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During the co-nanoprecipitation of p(HPMA50-co-EGDMA0.9):p(PEG114-co-HPMA60-
IbuPMA20) (50:50 wt %), the nanoparticles formed had a broad PdI of 0.230 when 
compared with the co-nanoprecipitation conducted in the absence of IBU (Table 6.2). This 
suggests that the presence of the IbuPMA on the A-B polymer does affect the co-
nanoprecipitation process, as a broader distribution of nanoparticles are formed.      
Interestingly, for the co-nanoprecipitation experiment including post modified p(PEG114-
co-HPMA80-co-IbuPMA40) and p(HPMA50-co-EGDMA0.9), stable nanoparticles with a 
size of 99 nm, PdI 0.156 were produced and were not too dissimilar from the comparison, 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) (50:50 wt %). During inclusion of the 
IBU modified polymeric core, p(HPMA80-co-IbuPMA20-co-EGDMA0.85) and the A-B 
block copolymer p(PEG114-b-HPMA80), there were minor differences in the absence of 
IBU suggesting the nanoprecipitation including p(HPMA80-co-IbuPMA20-co-
EGDMA0.85) generates stable nanoparticles with a narrow size distribution. 
Table 6.2 DLS results for IBU co-nanoprecipitation experiments. 
 
To determine if stable nanoparticles could be prepared when both polymers included IBU, 
both p(HPMA80-co-IbuPMA20-co-EGDMA0.85) and p(PEG114-co-HPMA60-co-IbuPMA20) 
were co-nanoprecipitated. Although a broad PdI value was obtained, the nanoparticles 
appeared to be stabilised and macrophase separation was not observed. Interestingly, 
during the co-nanoprecipitation of p(HPMA80-co-IbuPMA20-co-EGDMA0.85) and the post 
modified A-B polymer p(PEG114-co-HPMA80-co-IbuPMA40), reasonably narrow 
nanoparticles were formed with a size of 63 nm. As a final experiment, all three 
components were co-nanoprecipitated, including p(HPMA80-co-IbuPMA20-co-
Figure 6.4 Ref. Sample 50:50 wt % Size (d.nm) PdI
No IBU p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80) 111 0.081
A) Incorporation of IbuPMA p(HPMA50-co-EGDMA0.9):p(PEG114-co-HPMA60-co-IbuPMA20) 108 0.230
No IBU p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 135 0.051
A) Post modification of HPMA p(HPMA50-co-EGDMA0.9):p(PEG114-co-HPMA80-co-IbuPMA40) 99 0.156
No IBU p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80) 111 0.081
B) Incorporation of IbuPMA to the branched core p(HPMA80-co-IbuPMA20-co-EGDMA0.85):p(PEG114-b-HPMA80) 114 0.116
C)
Combined IBU modified core and 
IBU A-B block (Statistical)
p(HPMA80-co-IbuPMA20-co-EGDMA0.85):p(PEG114-co-HPMA60-co-IbuPMA20) 72 0.266
C)
Combined IBU modified core and 
IBU A-B block 
(Post modified)
p(HPMA80-co-IbuPMA20-co-EGDMA0.85):p(PEG114-co-HPMA80-co-IbuPMA40) 63 0.122
D)
Combined Ibu core and Ibu A-B block
+ Free ibuprofen
p(HPMA80-co-IbuPMA20-co-EGDMA0.85):p(PEG114-co-HPMA80-co-IbuPMA40)
+ Free Ibuprofen (3 wt %) 
92 0.217
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EGDMA0.85):p(PEG114-co-HPMA80-co-IbuPMA40) 50:50 wt % + free Ibuprofen (3 wt %) 
and although a broad PdI was observed the formation of stable nanoparticles was 
achieved.  
The ability to attach a hydrophobic drug molecule to both an A-B block copolymer and a 
branched copolymer has been successfully achieved and early co-nanoprecipitation 
experiments have shown that the formation of stabilised nanoparticles is possible. It is 
worth noting that the polymer-drug conjugate experiments were purely proof of concept 
in order to explore the versatility of the co-nanoprecipitation method. Further work would 
include cleavage of the hydrolysable ester bonds present and determination of the amount 
of IBU which is released, as the main purpose of polymeric prodrugs is the achievement 
of controlled drug release. 
6.5 References  
1. M. Babazadeh, M. Sheidaei, S. Abbaspour and L. Edjlali, Scientia Pharmaceutica, 
2013, 81, 281. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
211 
 
 
 
Chapter 7 
 
 
 
Experimental 
 
  
 
 
 
 
 
 
 
212 
 
7.1 Experimental techniques 
Both gel permeation chromatography (GPC) and dynamic light scattering (DLS) were 
used frequently throughout this PhD research and will be discussed in more detail below. 
7.1.1 Gel permeation chromatography 
Gel permeation chromatography (GPC) is a type of size exclusion chromatography (SEC) 
that separates molecules on the basis of size in an appropriate eluent. The separation of 
the different chain lengths within a polymer molecular weight distribution is performed 
by utilising columns containing porous beads with various pore sizes. The smaller 
polymeric materials can enter the pores more easily and therefore have a longer path 
length, increasing their retention time. Conversely, larger molecules spend little if any 
time in the pores and are eluted quickly. All columns have a range of molecular weights 
that can be separated. 
Triple detection systems use refractive index (RI), differential viscometry and light 
scattering detectors to calculate the absolute molecular weight of the polymer. Each 
detector can be used to calculate different parameters which collectively determine the 
molecular weights of the different fractions within the polymer sample. The calculations 
conducted with the data collected by each detector are shown in equations (1) - (3) below, 
where, KRI, KV and KLS are instrument calibration constants, conc is the concentration, and 
dn/dc is the change in RI (the RI increment) with the change in concentration. The RI 
detector is a concentration sensitive detector that simply measures the difference in 
refractive index between the eluent in the reference side, and the sample plus eluent in the 
sample side. The dn/dc is an important parameter and is calculated from the concentration 
entered when injecting the sample, whilst the viscometer also calculates the intrinsic 
viscosity of the sample based on this entered concentration. The differential refractometer 
calculates the dn/dc from the concentration entered when injecting the sample, whilst the 
viscometer also calculates the intrinsic viscosity of the sample based on the entered 
concentration. The absolute molecular weight calculated by light scattering is also 
dependant on the concentration and the square of the dn/dc. Therefore, it is crucial when 
using a triple detection GPC system, to calculate the concentration of the sample 
accurately as any errors can result in inaccurate calculation of molecular weights. 
Alternatively, if the dn/dc for the polymer is known, then it is possible to calculate the 
concentration of the sample and therefore the molecular weights and dispersity.  
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𝑅𝑒𝑓𝑟𝑎𝑐𝑡𝑜𝑚𝑒𝑡𝑒𝑟 =  𝐾𝑅𝐼 𝑥 
𝑑𝑛
𝑑𝑐
 𝑥 𝑐𝑜𝑛𝑐          (1) 
 
𝑉𝑖𝑠𝑐𝑜𝑚𝑒𝑡𝑒𝑟 = 𝐾𝑣 𝑥 𝑖𝑛𝑡𝑟𝑖𝑛𝑠𝑖𝑐 𝑣𝑖𝑠𝑐𝑜𝑠𝑖𝑡𝑦 𝑥 𝑐𝑜𝑛𝑐      (2) 
𝐿𝑖𝑔ℎ𝑡 𝑠𝑐𝑎𝑡𝑡𝑒𝑟𝑖𝑛𝑔 = 𝐾𝐿𝑆 𝑥 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑥 (
𝑑𝑛
𝑑𝑐
)
2
 𝑥 𝑐𝑜𝑛𝑐    (3) 
 
7.1.2 Dynamic light scattering 
 
Dynamic Light Scattering (DLS) works by measuring the intensity of light scattered by 
the molecules in the sample as a function of time. DLS is a well-established technique 
which relies on the calculation of particle size using Brownian motion. Brownian motion 
is the random movement of particles due to the bombardment by solvent molecules 
surrounding them. The smaller the particle is, the more rapid the Brownian motion and 
the larger the particle is, the slower the Brownian motion becomes. The velocity of the 
Brownian motion is defined by a property known as the translational diffusion coefficient 
(usually given the symbol, D).  The size of the particle is calculated from the translational 
diffusion coefficient using the Stokes-Einstein equation; 
 
𝑑(𝐻) =  
𝑘𝑇
3𝜋𝜂𝐷
 
Where:- 
d(H) = hydrodynamic diameter 
k = Boltzmann’s constant 
T = absolute temperature 
η = viscosity 
D = translational diffusion coefficient   
 
As well as Dz, the number average and volume average may also be calculated and can 
provide information about the particle population present in a sample. For the size 
distribution by intensity calculations, the intensity in light scattered is proportional to the 
diameter to the power of 6, therefore larger particles have a greater effect on the 
population. Therefore if an equal mixture of 10 and 100 nm particles was measured, the 
number average would be equal for both populations as they are present in a ratio of 1:1. 
The size distribution by volume would be 103 higher for the 100 nm compared to the 10 
nm particle (the volume of a sphere is described as 4/3π(d/2)3). Whilst the size distribution 
by intensity will be even more weighted towards the 100 nm population as the 100 nm 
particles will scatter 106 as much light as the 10 nm particle. If a multimodal distribution 
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is observed, the number of particles present should be taken into consideration as although 
the larger nanoparticle population may appear, it is possible that the smaller particles 
present dominate. 
7.2 Materials 
Poly(ethylene glycol) monomethyl ether (Mn ~2,000 g/mol),  poly(ethylene glycol) 
monomethyl ether (Mn ~5,000 g/mol), poly(ethylene) glycol (Mn ~4600 g/mol), 
triethylamine (TEA, 99%), 4-dimethylaminopyridine (DMAP, 99%), N,N'-
dicyclohexylcarbodiimide, α-bromoisobutyryl bromide (BIBB, 98%), 2-hydroxypropyl 
methacrylate (HPMA, 97% mixture of isomers, contains 180-220 ppm monomethyl ether 
hydroquinone as inhibitor), ethyl α-bromoisobutyrate (EBiB, 98%), Cu(I)Cl (99%), 
2,2’-bipyridyl (bpy, 99%), ethylene glycol dimethacrylate (EGDMA, 98%), tert-butyl 
methacrylate (t-BMA, 98%, contains 200 ppm monomethyl ether hydroquinone as 
inhibitor), n-butyl methacrylate (n-BMA, 99%, contains 10 ppm monomethyl ether 
hydroquinone as inhibitor), anisole (99%), fluoresceinamine, isomer I, pyrene (98 %), 
basic aluminium oxide and Dowex marathon exchange beads were purchased from Sigma 
Aldrich and used without any further purification. 2-(4-Isobutylphenyl)propionic Acid 
(98%) was purchased from TCI Europe. Efavirenz, lopinavir and ritonavir were purchased 
from LGM pharma.  Biotech CE dialysis tubing, pre-wetted and hydrophilic (MWCO – 
2000 g/mol, 100 kg/mol) was purchased from spectrum labs and used as received. All 
solvents were analytical grade and purchased from Fisher scientific and used as received.   
7.3 Instrumentation 
 
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded in chloroform-
d, methanol-d4, acetone-d6, DMSO-d6 or D2O using a 400 MHz Bruker Avance 
spectrometer. Chemical shifts are reported in parts per million (ppm) with respect to 
an internal reference of tetramethylsilane (0 ppm). 
 
Average molecular weights (Mn & Mw g/mol) and dispersities (Ð) were estimated 
using; i) A triple detection gel permeation chromatography instrument (GPC; 
Malvern/Viscotek) equipped with a GPC max VE2001 auto-sampler, two Viscotek 
D6000 columns (and a guard column) and a triple detector array TDA305 (refractive 
index, light scattering and viscometer) with a mobile phase of DMF containing 0.01 M 
lithium bromide at 60°C and a flow-rate of 1 mL/min or ii) Malvern Viscotek 
instrument equipped with a GPCmax VE2001 auto-sampler, two Viscotek T6000 
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columns (and a guard column), a refractive index (RI) detector VE3580 and a 270 
Dual Detector (light scattering and viscometer) with a mobile phase of THF (2 v/v % 
TEA) and a flow rate of 1.0 mL/min. 
 
Dynamic light scattering (DLS) measurements were performed using a Malvern 
Zetasizer Nano ZS (4 mW He–Ne 633 nm laser) on nanoparticle dispersions at 1 
mg/mL (unless otherwise stated) at 25 °C. Size measurements were obtained as an 
average of 3 individual measurements. Nanoparticle dispersions were measured 
directly without additional filtration or centrifugation. Zeta potentials were determined 
using the same apparatus described above. The measurements were obtained for 
aqueous dispersions at 1 mg/mL (unless otherwise stated) and 25°C using disposable 
capillary zeta cells.  
 
Scanning electron microscopy (SEM) images were obtained using a Hitachi S-4800 
FE-SEM. Aqueous nanoparticle samples (0.1 mg/mL in water) were dropped onto a 
silicon wafer mounted on an aluminum stub with a carbon tab, dried overnight at 
ambient temperature and then gold sputter-coated (EMITECH K550X) at 20 mA for 
30 seconds. 
 
Fluorescence spectra were obtained using a Shimadzu RF-5301PC 
spectrofluorophotometer.  Emission spectra for pyrene were recorded between 300 and 
500 nm.  An excitation wavelength of λex = 335 nm was used for all studies, as well as an 
excitational slit width of 1.5 nm and an emission slit width of 1.5 nm with a scan rate of 
100 nm/min. 
 
7.4 Chapter 2 
 
7.4.1 Synthesis  
 
7.4.1.1 Synthesis of linear p(HPMA50) via ATRP 
 
In a typical ATRP synthesis, EBiB (0.14 g, 0.69 mmol, 1 eq.), HPMA (DPn = 
50 monomer units, 5 g, 34.68 mmol, 50 eq.) and anisole (0.2 mL) were added to a 
round-bottomed flask equipped with a nitrogen inlet/outlet and a stirrer bar. 
Anhydrous methanol was added (50 wt %, based on HPMA) and the solution was 
degassed via nitrogen sparge for 10-15 minutes. The copper salt Cu(I)Cl (0.069 g, 0.69 
mmol, 1 eq.) and bpy ligand (0.22 g, 1.39 mmol, 2 eq.) were added to the flask and 
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the reaction medium was further degassed for 5 mins. The reaction was carried out at 
30°C and the monomer conversion was monitored by 1H NMR spectroscopy. The 
polymerisation was terminated by exposure to air and addition of THF when the 
HPMA monomer had reached > 98 % conversion, judged by 1H NMR. The polymer 
was purified using Dowex Marathon exchange beads (~10 g) in order to remove 
excess copper catalyst followed by passing the sample through a basic alumina 
column. Excess THF was removed under vacuum to concentrate the sample before 
precipitation into cold hexane. The resulting polymer was characterised by 1H NMR 
in DMSO-d6 and triple detection GPC with a mobile phase of DMF. 
1H NMR (400 
MHz, DMSO-d6) δ ppm = 4.85-4.5 (br, OH), 4.12-3.150 (br, 3H, CH2 and CH from 
pendant group), 2.11-1.52 (br, 2H, CH2 from polymer backbone), 1.32-0.50 (br, 6H, 
CH3 from polymer backbone and CH3 from pendant group).  
 
7.4.1.2 Synthesis of p(HPMA50-co-EGDMA0.9) branched copolymer via ATRP 
 
The branched copolymer, p(HPMA50-co-EGDMA0.9) was synthesised and purified 
using the procedure described above for linear p(HPMA50) with the addition of the 
branching agent/co-monomer EGDMA (0.12 g, 0.62 mmol, 0.9 eq. to EBiB initiator). 
The resulting branched material was characterised by 1H NMR in DMSO-d6 and triple 
detection GPC with a mobile phase of DMF. 1H NMR (400 MHz, DMSO-d6) δ ppm 
= 4.85-4.50 (br, OH), 4.12-3.15 (br, 3H, CH2 and CH from pendant group), 2.11-1.52 
(br, 2H, CH2 from polymer backbone), 1.32-0.50 (br, 6H, CH3 from the polymer 
backbone and CH3 from pendant group).  
 
7.4.1.3 Synthesis of poly(ethylene glycol) mono-functional ATRP macro-initiator 
(PEG45-Br) 
For a typical synthesis, PEG45-OH (30 g, 15 mmol, 1 eq.) was dissolved in toluene 
(100 mL) in the presence of triethylamine (2.275 g, 22.5 mmol, 1.5 eq.) and 
4-dimethyl-aminopyridine (0.092 g, 0.75mmol 0.05 eq.) in a two necked round-
bottomed flask fitted with an addition funnel, a nitrogen inlet/outlet and a stirrer bar. 
α-bromoisobutyryl bromide (5.175 g, 22.5 mmol, 1.5 eq.), diluted with toluene 
(15 mL), was placed into an addition funnel. The reactor was put under stirring at 
ambient temperature and the α-bromoisobutyryl bromide solution was added slowly 
over a period of 20-30 min and the reaction was left to stir for 24 hours. The rapid 
formation of a white precipitate (triethylamine salt Et3NH
+Br-) indicated the progress 
 
 
217 
 
of the reaction. The reaction medium was filtered and concentrated on the rotary 
evaporator. The resulting product was diluted in acetone and purified by precipitation 
into cold petroleum ether (40-60). This last step was repeated and the product was 
finally dried under vacuum at 40 °C for 24 hours. The resulting macro-initiator was 
confirmed by 1H NMR in D2O, triple detection GPC with a mobile phase of DMF and 
MALDI-TOF mass spectrometry. Yield = 75 %. 1H NMR (400 MHz, D2O) δ ppm = 
4.31 (m, 2H), 3.76 (m, 2H), 3.56-3.4 (m, 181H), 3.55 (m, 2H), 3.31 (s, 3H) and 1.89 
(s, 6H).  MALDI-TOF: MNa+ = distribution ~ 2054 Da.  
 
7.4.1.4 Synthesis of poly(ethylene glycol) mono-functional ATRP macro-initiator 
(PEG114-Br) 
During a typical synthesis, MeO-PEG114-OH (20 g, 4 mmol, 1 eq.) was dissolved in 
toluene (160 mL) in the presence of triethylamine (0.61 g, 6 mmol, 1.5 eq.) and 
4-dimethyl-aminopyridine (0.024 g, 0.2 mmol, 0.05 eq.) in a two necked round-bottomed 
flask fitted with an addition funnel, a nitrogen inlet/outlet and a stirrer bar. α-
bromoisobutyryl bromide (1.38 g, 6 mmol, 1.5 eq.), diluted with toluene (15 mL), was 
placed into an addition funnel. The reactor was put under stirring at ambient temperature 
and the α-bromoisobutyryl bromide solution was added slowly over a period of 20-
30 minutes and the reaction was left to stir for 24 hours. The rapid formation of a white 
precipitate (triethylamine salt Et3NH
+Br-) indicated the progress of the reaction. The 
reaction medium was filtered and concentrated on the rotary evaporator. The resulting 
product was diluted in acetone and purified by precipitation into cold petroleum ether (40-
60). This last step was repeated and the product was finally dried under vacuum at 40 °C 
for 24 hours. Yield = 71 %. 1H NMR (400 MHz, D2O) δ ppm = 4.31 (m, 2H), 3.76 (m, 
2H), 3.56-3.4 (m, 456H), 3.55 (m, 2H), 3.31 (s, 3H) and 1.89 (s, 6H).  
7.4.1.5 Synthesis of linear p(PEG45-b-HPMAx) via ATRP 
In a typical reaction, targeting a number average degree of polymerisation (DPn) of 120 
monomer units, PEG45-Br macroinitiator (0.62 g, 0.29 mmol, 1 eq.) and HPMA (5 g, 34.68 
mmol, 120 eq.) and anisole (0.2 mL) were added to a round-bottomed flask equipped with 
a nitrogen inlet/outlet and a stirrer bar. Anhydrous methanol was added (50 wt %, based 
on HPMA) and the solution was degassed via nitrogen sparge for 10-15 minutes. The 
copper salt Cu(I)Cl (0.029 g, 0.29 mmol, 1 eq.) and bpy ligand (0.09 g, 0.58 mmol, 2 eq.) 
were added to the flask and the reaction medium was further degassed for 5 mins. The 
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reaction was carried out at 30°C and the monomer conversion was monitored by 1H NMR 
spectroscopy. The polymerisation was terminated by exposure to air and addition of THF 
when the HPMA monomer had reached >97% conversion. The copper catalytic system 
was removed by passing the polymer solution through an alumina column. The solution 
was concentrated by rotary evaporation and the sample was purified by precipitation into 
40-60 petroleum ether. The resulting polymer was characterised by 1H NMR in DMSO-
d6 and triple detection GPC with a mobile phase of DMF. 
1H NMR (400 MHz DMSO-d6) 
δ ppm = 4.94-4.50 (br, OH), 3.94-3.56 (br, 3H, CH2 and CH from pendant group), 3.56-
3.40 (br, 184H), 3.24 (s, 3H), 2.10-1.50 (br, 2H, CH2 from polymer backbone), 1.30-0.50 
(br, 6H, CH3 from polymer backbone and CH3 from pendant group). The resulting 
polymer was characterised by 1H NMR in DMSO-d6 and triple detection GPC with a 
mobile phase of DMF. The procedure described above was used for all other degree of 
polymerisations for HPMA 40 and 80. 
7.4.1.6 Typical ATRP synthesis of a linear p(PEG114-b-HPMAx)  
The same experimental applies as above for the synthesis of p(PEG114-b-HPMAx) with 
MeO-PEG114-Br as opposed to the MeO-PEG45-Br macroinitiator. The DPn of HPMA 
targeted was 40, 80 and 120. The ATRP of p(PEG114-b-n-BMA120) was also carried out 
utilising the MeO-PEG114-Br macroinitiator in MeOH at an increased temperature of 60°C 
and 50 wt % MeOH (relative to the HPMA monomer). 
7.4.2 Aqueous nanoparticle formation  
 
7.4.2.1 Typical nanoprecipitation 
During a typical nanoprecipitation experiment, 50 mg of polymeric material was 
dissolved in 10 mL of analytical grade acetone for 12-24 hours for complete 
solubilisation. 1 mL of the resulting 5 mg/mL solution of polymers was added rapidly 
to 5 mL of deionised water (under vigorous stirring). The mixture was left for 24 hours 
at ambient temperature to ensure complete acetone evaporation leading to a final 
polymer concentration in water of 1 mg/mL. 
 
7.4.2.2 Typical co-nanoprecipitation  
 
During a typical co-nanoprecipitation, targeting a weight fraction of 50 wt % A-B block 
copolymer and 50 wt % branched copolymer, a total mass of 50 mg of material was 
weighed out (25 mg of p(HPMA50-co-EGDMA0.9) and 25 mg of p(PEG45-b-HPMA120)) 
into a vial. The polymers were dissolved in 10 mL of analytical grade acetone over a 
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period of 12-24 hours to ensure complete solubilisation. 1 mL of the resulting 5 mg/mL 
solution of polymers was added rapidly to 5 mL of deionised water (under vigorous 
stirring). The mixture was left for 24 hours at ambient temperature to ensure complete 
acetone evaporation leading to a final polymer concentration in water of 1 mg/mL. 
 
7.4.2.3 Co-nanoprecipitation of p(HPMA50-co-EGDMA0.9) into aqueous solution of 
A-B block copolymer 
 
A stock solution of p(HPMA50-co-EGDMA0.9) (2.5 mg/mL) was prepared in acetone and 
1 mL of this solution was added to an A-B block copolymers solubilised in H2O (0.1 
mg/mL in 5 mL H2O). The mixture was left for 24 hours at ambient temperature to ensure 
complete acetone evaporation leading to a final polymer concentration in water of 1 
mg/mL. 
 
7.4.2.4 Encapsulation of the hydrophobic guest molecule pyrene 
 
Pyrene was dissolved in acetone to give a stock solution (0.1 mg/mL). The stock solution 
(300 μL, 0.1 mg/mL) was added to an empty vial and the acetone was allowed to evaporate 
to leave 30 μg of dye. For a typical 50:50 wt % co-nanoprecipitation, p(HPMA50-co-
EGDMA0.9) (15 mg), p(PEG45-b-HPMA120) (15 mg) and 6 mL of acetone were added to 
the vial to give a final concentration of polymer 5 mg/mL and pyrene 5 µg/mL. The 
solution was left to stir for period of 12-24 hours for complete solubilisation. The 
nanoparticles were prepared by rapid addition of 1 mL of the solution into vigorously 
stirring deionised water (5 mL). The mixture was left for 24 hours at ambient temperature 
to ensure complete acetone evaporation leading to a final polymer concentration in water 
of 1 mg/mL and 1 μg/mL pyrene in water. 
 
7.4.2.5 Solubility evaluation of p(PEG45-b-HPMA120) 
 
The solubility of p(PEG45-b-HPMA120) in H2O was determined by rolling a 0.5 mg/mL 
solution of p(PEG45-b-HPMA120) in deionised H2O for 24 hour. The sample was then 
allowed to settle and 3 mL of the supernatant was added to a pre-weighed dish. After water 
evaporation (vacuum oven) the weight was recorded and the amount of p(PEG45-b-
HPMA120) was calculated. This procedure was repeated 3 times to generate an average 
value. 
 
 
 
 
 
220 
 
7.4.2.6 NaCl stability studies 
Prior to study, 1 mL of the 1 mg/mL nanodispersion was added to a vial and 20 µL of an 
aqueous NaCl (0.5M) solution was added. For the instant addition measurement, the 
solution was agitated before addition to a disposable sizing cuvette for DLS analysis 
(average of 3 measurements). The sample was returned to the vial for the 1, 7 and 21 day 
measurements and studies were carried out as described above. 
7.2.4.7 Repeated aqueous NaCl addition 
 
Prior to study, 1 mL of the 1 mg/mL nanodispersion was added to a disposable sizing 
cuvette and multiple additions of aqueous NaCl (0.5M, 2 µL- 2000 µL) were added, 
agitated quickly and instantly measured using DLS (average of 2 measurements). 
 
7.2.4.8 Dialysis experiments 
 
During a typical dialysis experiment, p(HPMA50-co-EGDMA0.9) (10 mg) and p(PEG45-b-
HPMA120) (10 mg) were dissolved in acetone (5 mg/mL) and nanoprecipitated into H2O 
(4 mL of polymer solution into 20 mL H2O). After complete acetone evaporation, the 
nanoparticle dispersion was transferred into a 100 kg/mol MWCO dialysis membrane and 
placed into 1L of H2O and left to stir for ~5 days (The solution within the dialysis 
membrane was sampled and measured by DLS at various time points), after which both 
solutions outside and within the dialysis membrane were concentrated in vacuo and further 
analysed by GPC. 
 
7.5 Chapter 3 
7.5.1 Synthesis of branched copolymers via ATRP 
7.5.1.1 Synthesis of p(n-BMA50-co-EGDMA0.8) branched copolymer (Synthesised by 
Pierre Chambon – Rannard research group) 
For the synthesis of p(n-BMA50-co-EGDMA0.8), targeting a number average degree of 
polymerisation (DPn) = 50 monomer units, EBiB initiator (137.2 mg, 0.70 mmol, 1 eq.), 
n-BMA (5 g, 35.16 mmol, 50 eq.), EGDMA (111.5 mg, 0.56 mmol, 0.8 eq.) and anisole 
(0.2 mL) were added to a round-bottomed flask equipped with a nitrogen inlet/outlet and 
a stirrer bar.  To this, anhydrous MeOH (50 wt % based on n-BMA) was added and the 
solution was stirred and deoxygenated using a nitrogen (N2) purge for 15 minutes. Cu(I)Cl 
(69.61 mg, 0.70 mmol, 1 eq.) and bpy (219.65 mg, 1.4 mmol, 2 eq.) were added to the 
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flask and left to purge for a further 5 minutes under a positive flow of N2. The 
polymerisation mixture was left to polymerise at 60⁰C and samples were taken 
periodically from the reaction mixture for 1H NMR analysis. Reactions were terminated 
when > 98 % conversion was reached, as judged by 1H NMR, by exposure to oxygen and 
addition of THF. The catalyst residues were removed by passing the mixture through a 
basic alumina column. THF was removed under vacuum to concentrate the sample before 
precipitation into cold methanol and drying in the vacuum oven overnight. 
7.5.1.2 Synthesis of p(t-BMA50-co-EGDMA0.9) branched copolymer (Synthesised by 
Hannah Rogers – Rannard research group) 
For the synthesis of p(t-BMA50-co-EGDMA0.9), targeting a number average degree of 
polymerisation (DPn) = 50 monomer units, EBiB initiator (109.7 mg, 0.56 mmol, 1 eq.), 
t-BMA (4 g, 28.13 mmol, 50 eq.) and EGDMA (100.36 mg, 0.50 mmol) and anisole (0.2 
mL) were added to a round-bottomed flask equipped with a nitrogen inlet/outlet and a 
stirrer bar.  To this, degassed aqueous isopropanol (IPA/H2O) (92.5/7.5 %) (38.4 % v/v 
based on t-BMA) was added and the solution was stirred and deoxygenated using a 
nitrogen (N2) purge for 15 minutes. Cu(I)Cl (55.7 mg, 0.56 mmol, 1 eq.) and bpy (175.7 
mg, 1.125 mmol, 2 eq.) were added to the flask and left to purge for a further 5 minutes 
under a positive flow of N2. The polymerisation mixture was left to polymerise at 30°C 
and samples were taken periodically from the reaction mixture for 1H NMR analysis. 
Reactions were terminated when > 98 % conversion was reached, as judged by 1H NMR, 
by exposure to oxygen and addition of THF. The catalyst residues were removed by 
passing the mixture through a basic alumina column. THF was removed under vacuum to 
concentrate the sample before precipitation into hexane and drying in the vacuum oven 
overnight. 
7.5.1.3 Synthesis of p(HPMA25-co-n-BMA25-co-EGDMA0.9) branched statistical 
copolymer 
For the synthesis of p(HPMA25-co-n-BMA25-co-EGDMA0.9), targeting a total number 
average degree of polymerisation (DPn) = 50 monomer units, EBiB initiator (150 mg, 
0.769 mmol, 1 eq.), HPMA (2.772g, 19.23 mmol, 25 eq.) n-BMA (2.735g, 19.23 mmol, 
25 eq.), EGDMA (137.2 mg, 0.69 mmol, 0.9 eq.) and anisole (0.2 mL) were added to a 
round-bottomed flask equipped with a nitrogen inlet/outlet and a stirrer bar. To this, 
anhydrous MeOH (50 wt % based on n-BMA and HPMA) was added and the solution 
was stirred and deoxygenated using a nitrogen (N2) purge for 15 minutes. Cu(I)Cl (76.1 
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mg, 0.769 mmol, 1 eq.) and bpy (240.2 mg, 1.54 mmol, 2 eq.) were added to the flask and 
left to purge for a further 5 minutes under a positive flow of N2. The polymerisation 
mixture was left to polymerise at 30°C and samples were taken periodically from the 
reaction mixture for 1H NMR analysis. Reactions were terminated when > 98 % 
conversion was reached, as judged by 1H NMR, by exposure to oxygen and addition of 
THF. The catalyst residues were removed by passing the mixture through a basic alumina 
column. THF was removed under vacuum to concentrate the sample before precipitation 
into cold hexane and drying in the vacuum oven overnight. 
7.5.1.4 Synthesis of p(HPMA25-co-t-BMA25-co-EGDMA0.9) branched statistical 
copolymer 
For the synthesis of p(HPMA25-co-t-BMA25-co-EGDMA0.9), targeting a total number 
average degree of polymerisation (DPn) = 50 monomer units, EBiB initiator (150 mg, 
0.769 mmol, 1 eq.), HPMA (2.772g, 19.23 mmol, 25 eq.) n-BMA (2.735g, 19.23 mmol, 
25 eq.), EGDMA (137.2 mg, 0.693 mmol, 0.9 eq.) and anisole (0.2 mL) were added to a 
round-bottomed flask equipped with a nitrogen inlet/outlet and a stirrer bar.  To this, 
anhydrous MeOH (50 wt % based on t-BMA and HPMA) was added and the solution was 
stirred and deoxygenated using a nitrogen (N2) purge for 15 minutes. Cu(I)Cl (76.1 mg, 
0.769 mmol, 1 eq.) and bpy (240.2 mg, 1.538 mmol, 2 eq.) were added to the flask and 
left to purge for a further 5 minutes under a positive flow of N2. The polymerisation 
mixture was left to polymerise at 30⁰C and samples were taken periodically from the 
reaction mixture for 1H NMR analysis. Reactions were terminated when >98 % 
conversion was reached, as judged by 1H NMR, by exposure to oxygen and addition of 
THF. The catalyst residues were removed by passing the mixture through a basic alumina 
column. THF was removed under vacuum to concentrate the sample before precipitation 
into cold hexane and drying in the vacuum oven overnight. 
7.1.1.5 ATRP synthesis of a linear p(PEG114-b-n-BMA120) 
Same synthesis as described for p(PEG114-b-HPMAx) at an elevated temperature of 60°C 
(Section 7.4.1.6). 
7.5.1.6 Encapsulation of fluoresceinamine (FA) 
During a typical nanoparticle preparation, targeting 10 wt % FA, 5.56 mL of a 1 mg/mL 
acetone solution of FA was added to a vial and left to evaporate overnight.  To this vial, 
25 mg of the branched co/terpolymer and 25 mg of the A-B block copolymer were added 
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and dissolved in 10 mL of acetone during 6-8 hours to ensure complete solubilisation.  1 
mL of the 5 mg/mL solution of polymers and FA was added to 5 mL of vigorously stirring 
deionised water and left for 24 hours for complete acetone evaporation (final 
concentration of polymer 1 mg/mL, FA 0.11 mg/mL). 
7.5.1.7 Stability of FA encapsulated co-nanoprecipitated particles 
For NaCl addition, as described in Section 7.4.2.6 
For transport buffer solution (TBS) addition - prior to study, 1 mL of the 1 mg/mL 
nanodispersion was added to a vial and 1 mL of TBS solution was added. For the 
instant addition measurement, the solution was agitated before addition to a disposable 
sizing cuvette for DLS analysis (average of 3 measurements). The sample was returned 
to the vial for the 1, 7 and 21 day measurements and studies were carried out as 
described above. 
 
7.6 Pharmacological Studies (Chapter 3) 
As discussed throughout, pharmacology assessment of various co-nanoprecipitated 
materials was conducted. The fluoresceinamine encapsulated materials were studied to 
assess their cytotoxicity to Caco-2 cells, permeation through Caco-2 cell monolayers, 
cellular accumulation and permeation and accumulation in the presence of inhibitors.  
7.6.1 Materials  
 
Dulbecco’s Modified Eagles Medium (DMEM), Hanks buffered saline solution (HBSS), 
Trypsin-EDTA, bovine serum albumin (BSA), FA, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT reagent), acetonitrile (ACN) and all general 
laboratory reagents were purchased from Sigma (Poole, UK). Foetal bovine serum (FBS) 
was purchased from Gibco (Paisley, UK). The CellTiter-Glo® Luminescent Cell Viability 
Assay kit was from Promega (UK). The 24-well HTS transwell plates were obtained from 
Corning (New York, USA). The 96-well black walled, flat bottomed plates were from 
Sterilin (Newport, UK). Rotenone, 2-deoxyglucose, chlorpromazine hydrochloride, 
dansylcadaverine, indomethacin, genistein, dynasore hydrate were all purchased from 
Sigma Aldrich. 
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7.6.2 Characterisation  
 
Cell count and viability was determined using a Countess automated cell counter 
(Invitrogen). Absorbance was read using a Tecan Genosis plate reader at 560 nm (Tecan 
Magellan, Austria). 
 
Luminescence was then measured using a Tecan Genios plate reader (Tecan Magellan, 
Austria).  
 
Fluoresceinamine encapsulated samples were run on a Dionex HPLC using a Fortis C18 
column (100 mm x 4.6 mm i.d., 3 μm). The mobile phase consisted of: (A) 95% H2O; 5% 
ACN; 5 mM NH4FA (B) 95% ACN; 5% H2O; 5 mM NH4FA. Elution peaks were 
monitored with a fluorescence detector at; 490 (λex), 530 (λem) (Thermo Spectrasystem 
FL3000) and subsequently analysed using Chromeleon v.6.8. software. 
7.6.3 Routine cell culture/cell maintenance  
 
Caco-2 cells were purchased from American Type Culture Collection (ATCC, USA) and 
maintained in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 15 % 
filtered sterile foetal bovine serum. Cells were incubated at 37°C and 5 % CO2 and were 
routinely sub-cultured every 4 days when 90 % confluent. Cell count and viability was 
determined using a Countess automated cell counter (Invitrogen). 
7.6.4 Cytotoxicity studies (FA)  
 
Caco-2 cells were seeded at a density of 1.0 x 104 cells / 100 μL in DMEM supplemented 
with 15 % FBS into each well of a 96 well plate (Nunclon, Denmark) and incubated at 37 
°C and 5 % CO2. Cells from 4 separate flasks of biological replicates of each cell type 
were used (N1-4) to improve statistical power. Media was then aspirated from column 1 
and replaced with media containing each co-nanoprecipitated material or aqueous FA 
solution at an equivalent 1 μM FA concentration then diluted 1:1 in media across the plate 
up to column 11. For the aqueous preparation of fluoresceinamine the total DMSO added 
is <0.1% of the total volume of media. Column 12 served as a negative control and 
consisted of media and untreated cells. Following co-nanoprecipitated material addition, 
the plates were incubated for 24 hours or 5 days at 37 °C, 5 % CO2 prior to assessment of 
cytotoxicity.  
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7.6.4.1 MTT cytotoxicity assay 
  
Following incubation of treated plates for 24 hours or 120 h, 20 μL of 5 mg/mL MTT 
reagent was added to each well and incubated for 2 hours. Subsequently, 100 μL MTT 
lysis buffer (50 % N-N-Dimethylformamide in water containing 20 % SDS, 2.5 % glacial 
acetic acid and 2.5 % hydrochloric acid, pH 4.7) was added to each well to lyse overnight 
at 37 °C, 5 % CO2. Following incubation the absorbance of each well was read using a 
Tecan Genosis plate reader at 560 nm (Tecan Magellan, Austria).  
 
7.6.4.2 ATP cytotoxicity assay  
 
Following incubation of treated plates for 24 hours or 5 days, cells were equilibrated to 
room temperature for approximately 30 minutes. All but 20 μL of media was removed 
from each well and 20 μL CellTiter-Glo® (Promega, UK) reagent was added. All reagents 
were made fresh and in accordance with the manufacturer’s instructions. Plates were put 
on an orbital shaker for 10 minutes to mix contents and allow for stabilisation of 
luminescence signal. Luminescence was then measured using a Tecan Genios plate reader 
(Tecan Magellan, Austria). 
 
7.6.5 Caco-2 permeation studies (FA)  
 
Transwells were set up and propagated to a monolayer over a 21 day period as previously 
described. Only wells with TEER values >800 Ω were used. 10 μM of fluoresceinamine 
co-nanoprecipitated material or 10 μM aqueous fluoresceinamine (transport buffer spiked 
with DMSO dissolved fluoresceinamine, DMSO final volume <1 % of total volume), was 
added to the apical or basolateral compartment of the wells to quantify transport in both 
Apical>Basolateral (A>B) and Basolateral>Apical (B>A) directions (n=3). Plates were 
sampled following 4 hours incubation at 37°C, 5 % CO2, apical and basolateral contents 
were stored at -30°C prior to analysis. To assess monolayer integrity following incubation, 
250 μL of transport buffer containing 2 μL/mL 14C mannitol was added to the apical 
compartment and incubated for 1 hour. 4 mL of scintillation fluid was added to 100 μL of 
the sampled contents and quantified on the scintillation counter (Packard 3100 TR).  
 
7.6.6 Aqueous fluoresceinamine solution for cellular studies  
 
An aqueous FA solution was prepared in DMSO at 1 mg/mL final concentration and used 
to spike either complete growth media or transport buffer. The resulting 1 μM final 
concentration FA solution was subsequently used in cytotoxicity assays or for 
transcellular permeability assessment respectively. Transport buffer consisted of; Hanks 
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buffered Saline Solution (HBSS), 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), and 1 mg/mL Bovine Serum Albumin (BSA), adjusted to pH 7.4.  
 
7.6.7 Extraction and quantification of fluoresceinamine  
 
150 μL of sample and prepared calibration for each co-nanoprecipitated material, were 
extracted using 9 volumes of acetone, sonicated for 6 min and centrifuged for 3 min prior 
to drying at 30 C on a vacuum centrifuge. Each sample was reconstituted using 150 μL 
of 25 % DMSO. Samples were run on a Dionex HPLC using a Fortis C18 column (100 
mm x 4.6 mm i.d., 3 μm). The mobile phase consisted of: (A) 95% H2O; 5% ACN; 5 mM 
NH4FA (B) 95% ACN; 5% H2O; 5 mM NH4FA. Elution peaks were monitored with a 
fluorescence detector at; 490 (λex), 530 (λem) (Thermo Spectrasystem FL3000) and 
subsequently analysed using Chromeleon v.6.8. software.  
 
7.6.8 Cellular accumulation of fluoresceinamine in Caco-2 and ATHP-1 cells  
 
Caco-2 cells were seeded into 6 well plates (NunclonTM) at a density of 4 x 106 per well 
and incubated at 37°C 5 % CO2 for 24 hours. THP-1 cells were seeded at a density of 4 x 
106 cells per well in a 6 well plate and allowed to differentiate to ATHP-1 cells for 7 days 
in 10 nM PMA supplemented RPMI-1640 10% FBS prior to use. Following incubation, 
the media was aspirated and cells washed twice with HBSS (37°C) and subsequently 
replaced with pre-warmed (37 C) transport buffer solution containing either 10 μM (final 
concentration) aqueous fluoresceinamine or 10 μM (final concentration) co-
nanoprecipitated fluoresceinamine material. Following 24 hours incubation at 37°C, 5 % 
CO2, 150 μL of the extracellular media was sampled. The remaining media was aspirated 
and cells were washed twice with ice cold 290 HBSS. The ice cold HBSS was aspirated 
and replaced with 500 μL of a 50% acetone 50% water solution and incubated for 24 hours 
at -20°C, 150 μL of the lysate was subsequently sampled. Finally, 9 volumes of acetone 
was added to each intracellular and extracellular sample to extract fluoresceinamine for 
quantification on the HPLC as previously described, see Section 7.6.7. Average cell 
volumes were previously determined using a Scepter 2.0 Automated Cell Counter 
(Millipore) and used to calculate Cellular Accumulation Ratios (CAR); (Intracellular 
concentration/Volume)/(Extracellular concentration/Volume). 
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7.6.9 ATP depletion of Caco-2 cells using varying concentrations of 2-deoxyglucose 
and rotenone 
Caco-2 cells were incubated with varying concentrations of 2-deoxyglucose and rotenone 
as outlined for 20 min at 37oC 5% CO2. Following incubation, ATP assays were carried 
out using CellTiter-GLO® kit to determine relative depletion of ATP compared to an 
untreated control.  
7.6.10 Cellular accumulation ratio (CAR) of fluoresceinamine 
Caco-2 cells were pre-incubated with 2 mg/ml 2-deoxyglucose and 100 nM rotenone for 
20 min to deplete ATP. Following depletion, cells were washed three times using pre-
warmed HBSS and replaced with media containing DMSO (<0.1% v/v) solubilised 
fluoresceinamine or co-nanoprecipitated fluoresceinamine material (10 µM final 
fluoresceinamine concentration) and incubated at 37oC 5% CO2 for 24 hours. Extra- and 
intracellular samples were extracted and analysed using HPLC as previously described. *, 
P < 0.05 (ANOVA) (n=4). 
7.6.11 Apparent permeability (Papp) for fluoresceinamine encapsulated materials 
Caco-2 cell monolayers were pre-incubated for 30 min in transport buffer containing 
either: 30 µM chlorpromazine (Chl); 200 µM dansylcadaverine (Dan); 10 µM genistein 
(Gen); 150 µM dynasore (Dyn); or 150 µM Indomethacin (Ind) prior to washing three 
times with pre-warmed (37oC) HBSS. Following washing, the Caco-2 monolayers were 
co-incubated with the various endocytosis inhibitors as outlined, and either aqueous 
(DMSO spiked ; <0.1% v/v) or nanocarrier formulated fluoresceinamine for 4 h at 37°C 
5% CO2. ***, P <0.001 (ANOVA) (n=4).  
7.6.12 Caco-2 permeation studies (FA) after presence of inhibitors and polymer 
nanocarrier materials  
 
As described in section 7.6.5. 
7.7 Chapter 4 
7.7.1 Preparation of aqueous HIV anti-retroviral encapsulated nanoparticles (typical 10 
wt % loading)  
During a typical nanoparticle preparation, targeting 10 wt % anti-retroviral, 5.56 mL of a 
1 mg/mL acetone solution of anti-retroviral was added to a vial and left to evaporate 
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overnight.  To this vial, 25 mg of the branched co/terpolymer and 25 mg of the A-B block 
copolymer were added and dissolved in 10 mL of acetone during 6-8 hours to ensure 
complete solubilisation.  1 mL of the 5 mg/mL solution of polymers and anti-retroviral 
was added to 5 mL of quickly stirring deionised water and left for 24 hours for complete 
acetone evaporation (final concentration of polymer 1 mg/mL, anti-retroviral 0.11 
mg/mL). 
7.8 Chapter 5 
7.8.1 Preparation of aqueous SN-38 encapsulated nanoparticles (typical 5 wt % loading) 
Before conducting the co-nanoprecipitation experiments, a stock solution of SN-38 was 
prepared in THF:Acetonitrile 1:1 (1 mg/mL). During a typical co-nanoprecipitation, 2.635 
mL of the SN-38 stock solution was added to a vial and to this, 25 mg of a branched 
copolymer and 25 mg of A-B block copolymer were added and dissolved in 7.365 mL of 
THF:Acetonitrile (1:1). The solution was tightly sealed and left rolling for 5 weeks to 
ensure complete solubilisation. 1 mL of the resulting 5 mg/mL solution of polymers and 
SN-38 was added rapidly to 5 mL of deionised water (under vigorous stirring). The 
mixture was left for 24 hours at ambient temperature to ensure complete THF and 
acetonitrile evaporation leading to a final polymer concentration in water of 1 mg/mL, 
0.053 mg/mL SN-38). 
7.8.2 Preparation of SN-38 nanoparticles via dialysis 
During a typical dialysis experiment, 2.65 mL of SN-38 dissolved in DMSO solution (1 
mg/mL), 25 mg of the branched copolymer and 25 mg of the A-B block copolymer were 
dissolved in 7.35 mL of DMSO during 6-8 hours to ensure complete solubilisation. 1 mL 
of the 5 mg/mL solution of polymers was added to a dialysis membrane with a molecular 
weight cut off (MWCO) of 2000 g/mol and left to dialyse in deionised water during 4 days 
(regular water changes). 
7.9 Pharmacology Studies (Chapter 5) 
7.9.1 Materials  
Irinotecan and SN-38 were purchased from J&HChem chemical company. [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt;MTS] CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) from 
promega. All general laboratory reagents were purchased from Sigma Aldrich. CT26 cells 
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were purchased from American Type Culture Collection (ATCC) and HCT116 from 
European Collection of Cell Cultures (ECACC). Dulbecco’s Modified Eagles Medium 
(DMEM) and Roswell Park Memorial Institute (RPMI) 1640 medium were purchased 
from Sigma Aldrich. Trypsin-EDTA and fetal bovine serum (FBS) were purchased from 
life technologies. Greiner CELLSTAR® 96 well plates and Varioskan™ Flash Multimode 
reader at 490 nm was used for all assays. 
 
7.9.2 Determination of cell viability - MTS assay 
During a typical experiment, CT26 or HCT116 cells were seeded at a density of 0.5 x 104 
cells / 100 μL in DMEM supplemented with 10 % FBS into each well of a 96 well plate 
and left overnight to adhere. Media was then aspirated from each well and replaced with 
media containing each co-nanoprecipitated material or control solution at the desired 
concentrations. Following co-nanoprecipitated material addition, the plates were 
incubated for 48 hours at 37 °C, 5 % CO2 prior to assessment of cytotoxicity. MTS/ 
phenazine methosulfate was added (20µL per well) and the plates were incubated for 2.5 
hours, after which the absorbance was recorded at 490 nm.  
 
7.9.3 In vitro cytotoxic effect of different concentrations of irinotecan and SN-38 (free 
drug molecules) 
7.9.3.1 Irinotecan 
During a typical experiment, CT26 or HCT116 cells were seeded at 96 well plate with  
5000-10000 cells / well  (0.5-1 x 106 per ml) in DMEM supplemented with 10 % FBS into 
each well and incubated at 37 °C and 5 % CO2. The cells were left overnight to adhere. 
After 24 hours, the media was aspirated and 100uL each concentration after vortexing 
were dosed with irinotecan at 300, 100, 33.3, 11.1, 3.7, 1.23 and 0 µM and the control of 
DMSO in media. Wells were 0.375% DMSO by volume. The plates were incubated for 
48 hours at 37 °C, 5 % CO2 prior to assessment of cytotoxicity. MTS/ phenazine 
methosulfate was added (20µL per well) and the plates were incubated for 2.5 hours, after 
which the absorbance was recorded at 490 nm using the plate reader.  
7.9.3.2 SN-38  
Same as for irinotecan above (Section, 7.9.3.1) but within the concentration range, 9, 3, 1, 
0.33, 0.11 and 0.037 µM.  
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7.9.3.3 In vitro cycotxicity for co-nanoprecipitated materials, irinotecan and SN-38 for 
both CT26 and HCT116 cells 
96 well plate with 10000 cells / well (10 x 105 per ml) 100µL. 5mg/ml MTT dissolved in 
Hanks – as before MTS. Plate out cells at 5000 per well per plate which were left overnight 
to adhere. For SN-38 co-nanoprecipitated materials - 100µL consisting of either SN-38 
co-nanoprecipitated materials, blank co-nanodispersions, media and water final 
concentrations 4µM 2µM and 1µM. For 100% SN-38 in DMSO - 4µM, 2µM and 1µM. 
For controls - 1.6µL DMSO was added to 968.4µL media followed by 30µL sterile water. 
Add 30uL sterile water to 970µL media. For blank co-nanoprecipitated materials - 
Concentrations 4µM, 2µM and 1µM. Media was aspirated on a 96 well plate and dosed 
with 100µL of each solution in triplicate. This was left for 48 followed by MTS addition. 
20µL MTS was added per well and left for 2.5 hours and the absorbance was measured at 
490 nm using the plate reader. 
7.9.4 In vitro cycotxicity dose response for irinotecan SN-38 and co-nanoprecipitated 
nanomaterials for both CT26 and HCT116  
7.9.4.1 Irinotecan   
The MTS assay was conducted as discussed above. A 40mM irinotecan stock solution 
(2.346mg in 100µL DMSO). 5µl of this stock solution was added to 2147.2µL of water + 
77.8µL DMSO (ensuring complete solubilisation) giving a 89.77µM stock solution 
(Irinotecan in DMSO/water – 0.32% DMSO. A serial dilution of this stock was then 
carried out to give the following concentrations: 8µM, 4µM, 2µM, 1µM, 0.5µM and 
0.25µM. 100µL added of each. 
7.9.4.2 SN-38   
This MTS assay was conducted as discussed above. A 2.5mM stock SN-38 solution (2mg 
in 2000uL DMSO) (SN-38 in DMSO/water – 0.32% DMSO). 10µL of this solution was 
added to 269µL of water (ensure all dissolved) giving a 89.77µM stock solution. A serial 
dilution of this stock was then carried out to give the following concentrations: 8µM, 4µM, 
2µM, 1µM, 0.5µM and 0.25µM. The two control experiments were media and water and 
media, water and DMSO. 
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7.9.4.3 Blank co-nanoprecipitated materials  
The MTS assay was conducted as discussed above. A serial dilution of this stock was then 
carried out to give the following concentrations of co-nanoprecipitated materials: 8µM, 
4µM, 2µM, 1µM, 0.5µM and 0.25µM. 100µL added of each. 
7.9.4.4 SN38 co-nanoprecipitated materials  
The MTS assay was conducted as discussed above. A serial dilution of this stock was then 
carried out to give the following concentrations of co-nanoprecipitated materials: 8µM, 
4µM, 2µM, 1µM, 0.5µM and 0.25µM. 100µL added of each. 
7.10 Chapter 6 
7.10.1 Preparation of an A-B-A triblock and subsequent nanoparticles studies  
7.10.1.1 Synthesis of Br-PEG~105-Br bifunctional macro-initiator 
During a typical synthesis, OH-PEG~105-OH (Mn ~4600g, 20 g, 4.35 mmol, 1 eq.), TEA 
(13.05 mmol, 1.819 mL, 3 eq.) and DMAP (0.053 g, 0.435 mmol, 0.1 eq.) were added to 
toluene (80 mL) in a two necked round bottom flask fitted with a nitrogen inlet/outlet and 
stirrer bar. α-bromo isobutyryl bromide (13.05 mmol, 1.613 mL, 3 eq.) diluted in toluene 
(20mL) was added drop-wise over 15 minutes through an additional funnel and left to stir 
at ambient temperature for 24 hours. Excess amine was removed using DOWEX marathon 
exchange beads. This was then filtered and the solvent removed by rotary evaporation. 
The product was dissolved in acetone, concentrated and purified by precipitation into cold 
petroleum ether 40-60°C and dried under vacuum. The difunctional macro-initiator was 
analysed by 1H NMR and GPC. Yield = 72%. 1H NMR (400 MHz, D2O) δ ppm= 1.8 (s, 
CH3), 3.7-3.4 (m, CH2 polymer backbone), 4.6 (m, polymer backbone signals).  
7.10.1.2 Synthesis of p(HPMA120-b-PEG~105-b-HPMA120) via ATRP 
In a typical reaction, targeting a number average degree of polymerisation (DPn) of a total 
of 240 monomer units, Br-PEG~105-Br macroinitiator (1.063 g, 0.23 mmol, 1 eq.) and 
HPMA (8.0 g, 55.4 mmol, 240 eq.) and anisole (0.2 mL) and anhydrous methanol (50 wt 
%, based on HPMA) was added to a round bottomed flask fitted with an nitrogen 
inlet/outlet and stirrer bar. The solution was degassed via nitrogen sparge for 10-15 
minutes. The copper salt Cu(I)Cl (0.023 g, 0.23 mmol, 1 eq.) and bpy ligand (0.072 g, 
0.46 mmol, 2 eq.) were added to the flask and the reaction medium was further degassed 
for 5 mins. The reaction was carried out at 30°C and the monomer conversion was 
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monitored by 1H NMR spectroscopy. The polymerisation was terminated by exposure to 
air and addition of methanol when the HPMA monomer had reached > 99% conversion. 
The copper catalytic system was removed by passing the polymer solution through an 
alumina column. The solution was concentrated by rotary evaporation and the sample was 
purified by precipitation into cold hexane. The resulting block copolymer was analysed 
by 1H NMR and GPC. 
7.10.1.3 Preparation of aqueous polymer nanoparticles including an A-B-A triblock 
polymer and anti-retroviral encapsulation 
Methanol was used as the good solvent and the procedure was as previously described in 
Section 7.7.1. 
7.10.2 Ibuprofen modified polymers 
7.10.2.1 Synthesis of the ibuprofen modified HPMA (IbuPMA) 
During a typical synthesis, HPMA (1.5 g, 10.40 mmol 1 eq.), Ibuprofen (2.79 g, 13.52 
mmol 1.3 eq), DMAP (0.64 g, 5.2 mmol, 0.5 eq) and DCC (2.79g, 13.53 mmol, 1.3 eq)  
were dissolved in 30 mL of THF in a round bottom flask and stirred at ambient 
temperature for 24 hours.  The DCU salt was filtered and the product was washed with 
THF followed by rotary evaporation.  DCM (100 mL) was added and the product washed 
with 1M sodium bisulfate solution to remove excess DCU, then dried over NaSO4 and 
concentrated in vacuo.  Residual DCU was removed by storage of the monomer at -20°C 
and a minimal amount of ethyl acetate followed by filtration.  The final product was stored 
at -20°C. Yield = 68%. 1H NMR (400 MHz, CDCl3) δ ppm, 7.10 (m, 4H, CH), 6.02 (m, 
1H, CH), 5.52 (m, 1H, CH), 5.2 (m, 1H CH), 4.15 (m, 2H CH2), 3.69 (m, 1H, CH), 2.43 
(d, 2H, CH2), 2-1.75 (m, 4H), 1.47 (d, 3H, CH3), 1.19 (d, 3H, CH3), 0.88  (d, 6H, CH3). 
7.10.2.2 Synthesis of p(PEG114-b-HPMA60-co-IbuPMA20) via ATRP  
The targeted degree of polymerisation (DPn) was HPMA60-IbuPMA20.  MeO-PEG114-Br 
macroinitiator (0.59 g, 0.116 mmol, 1 eq.) and HPMA (1 g, 6.96 mmol, 60 eq.) and 
IbuPMA (0.77 g 2.32 mmol, 20 eq.) were added to a round-bottomed flask equipped with 
a nitrogen inlet/outlet and a stirrer bar. Methanol was added (43 wt %, based on HPMA + 
IbuPMA) and the solution was stirred vigorously under nitrogen for 10-15 minutes. The 
copper catalyst Cu(I)Cl (11.48 mg, 0.116 mmol, 1 eq.), bpy (0.036 g, 0.232 mmol, 2 eq.) 
and anisole (0.2 mL) were added to the flask and the temperature was fixed at 30°C. The 
reaction was monitored by 1H NMR spectroscopy and terminated with methanol when 
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both monomers had reached >98% conversion. The polymer was purified using a neutral 
alumina column flushed with THF to remove excess copper catalyst. Excess THF was 
removed under vacuum to concentrate the sample before precipitation into cold 40-60 
petroleum ether. The resulting polymer was confirmed by 1H NMR in methanol-d4, triple 
detection GPC with a mobile phase of THF. 
7.10.2.3 Post modification of p(PEG114-b-HPMA120)   
MeO-PEG114-HPMA120 (1 g, 0.033 mmol, 1 eq.), Ibuprofen (0.27 g, 1.33 mmol, 40 eq.), 
DCC (0.274 g, 1.33 mmol, 40 eq.) and DMAP (1x10-3 g) were dissolved in THF (12 mL) 
and left to react for 24 hours. The DCU salt was filtered off and the product was washed 
with THF and concentrated in vacuo. The polymer was dissolved in a minimal amount of 
THF and precipitated into cold hexane. Excess DMAP and DCU were removed by 
dissolving the product in DCM, washing with 1M sodium bisulfate, dried with MgSO4 
and dried under vacuum. The resulting polymer was confirmed by 1H NMR in DMSO-d6, 
triple detection GPC with a mobile phase of THF. 
7.10.2.4 Synthesis of p(HPMA60-co-IbuPMA20-co-EGDMA0.85) via ATRP 
The targeted degree of polymerisation (DPn) monomeric units of HPMA. During a typical 
ATRP synthesis, EBiB initiator (0.012 g, 0.060 mmol 1 eq.) and HPMA (0.52 g, 0.217 
mmol 60 eq.) and IbuPMA (0.4 g, 0.012 mmol, 20 eq.) were added to a round-bottomed 
flask equipped with a nitrogen inlet/outlet and a stirrer bar. Methanol was added (50 wt%, 
based on HPMA + IbuPMA) and the solution was stirred vigorously under nitrogen for 
10-15 minutes. The branching agent EGDMA (0.1015 g, 0.051 mmol 0.85 eq. to EBiB 
initiator), copper catalyst Cu(I)Cl (0.0059, 0.06 mmol, 1 eq.) and bpy (0.0188 g, 0.121 
mmol 2 eq.) and anisole (0.2 mL) were added to the flask and the temperature was fixed 
at 30°C. The reaction was monitored by 1H NMR spectroscopy and terminated with 
methanol when the monomers had reached >98% conversion.  The polymer was purified 
using a neutral alumina column flushed with THF. Excess THF was removed under 
vacuum to concentrate the sample before precipitation. The polymer was precipitated from 
MeOH into cold petroleum ether 40-60. The resulting polymer was confirmed by 1H NMR 
in methanol-d4, triple detection GPC with a mobile phase of THF. 
7.10.3 Aqueous nanoparticle preparation including ibuprofen modified polymers 
During a typical nanoparticle preparation, targeting 50 wt % of each polymer, 25 mg of 
block copolymer and 25 mg of branched polymer were added to 10 mL of MeOH during 
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6-8 hours to ensure complete solubilisation over 6-8 hours. 1 mL of the 5 mg/mL solution 
of polymers was added to 5 mL of vigorously stirring deionised water and left for 24 hours 
for complete methanol evaporation.  
The same procedure was repeated for other variations of the nanoparticles using the same 
experimental as described above. Free ibuprofen was also added at the desired wt % based 
on the total mass of both polymers into the good solvent methanol.  
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Chapter 2 - Synthesis and Characterisation of p(HPMA) for Investigation and 
Optimisation of Nanoprecipitation Conditions and Introduction to Co-
nanoprecipitation. 
 
 
 
 
 
 
 
 
 
 
 
Figure A1 Overlay of branched p(HPMA50-co-EGDMA0.9) 1H NMR conversion during 
polymerisation.(MeOD-d4, 400 MHz). 
 
 
Figure A2 1H NMR analysis of p(HPMA50) (DMSO-d6, 400 MHz). 
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Figure A3 1H NMR analysis of p(HPMA50-co-EGDMA0.9) (DMSO-d6, 400 MHz). 
 
Table A1 DLS analysis for nanoprecipitation studies of p(HPMA50-co-EGDMA0.9) before and after 
solvent addition. 
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Table A2 DLS analysis for increasing multiple nanoprecipitation experiments 
 
 
Figure A4 MALDI-TOF mass spectrum of the mono-functional ATRP macro-initiator, PEG45-Br. 
 
 
 
 
Volume of Polymer in Solution Added (mL) Addition no. Dz (nm) PdI Derived count rate
(kcps)
Acetone
3 1 162 0.054 1443879
2 293 0.156 1369079
4 1 452 0.132 531722
2 831 0.541 49720
THF
3 1 143 0.047 1471637
2 * * *
4 1 538 0.145 527875
2 * * *
* Polymer precipitated visible, sample not suitable for DLS analysis
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Figure A5 1H NMR PEG114-Br (D2O, 400 MHz) of the mono-functional ATRP macro-initiator, 
PEG114-Br. 
 
 
Figure A6 1H NMR p(PEG45-b-HPMA80) (DMSO-d6, 400 MHz). 
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Figure A7 1H NMR p(PEG45-b-HPMA120) (DMSO-d6, 400 MHz). 
 
 
Figure A8 1H NMR p(PEG114-b-HPMA40) (DMSO-d6, 400 MHz). 
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Figure A9 1H NMR p(PEG114-b-HPMA80) (DMSO-d6, 400 MHz). 
 
Figure A10 1H NMR p(PEG114-b-HPMA120) (DMSO-d6, 400 MHz). 
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Figure A11 1H NMR kinetics for p(PEG45-b-HPMA40) (methanol-d4, 400 MHz). 
 
Figure A12 1H NMR kinetics for p(PEG114-b-HPMA40) (methanol-d4, 400 MHz). 
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Table A3 Various batches of branched p(HPMA50-co-EGDMA0.9) nanoparticles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A13 Histograms showing size distributions (diameters; nm) of nanoprecipitates and co-
nanoprecipitates comprising various p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA120) ratios: A) 50:50 
(dark red), B) 60:40 (dark blue), C) 70:30 (dark green), D) 80:20 (yellow), E) 90:10 (pink), and F) 
100:00 (black). 
Various Batches of p(HPMA50-co-EGDMA0.9) 
Nanoparticles  
Z-ave 
(d.nm) 
PdI Dn (nm) 
1 148 0.080 112 
2 115 0.089 84 
3 186 0.030 161 
4 116 0.051 89 
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Figure A14 DLS analyses of co-nanoprecipitates: A)  overlay of p(HPMA50-co-EGDMA0.9):p(PEG45-
b-HPMA40) ratios i) 90:10 (black), 80:20 (dark blue), 70:30 (dark red), 60:40 (green) and 50:50 (dark 
pink), ii) 40:60 (dashed black), 30:70 (dashed blue), 20:80 (dashed dark pink), 10:90 (dashed cyan), B) 
overlay of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA80) ratios C) overlay of p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA120) ratios, all same colours apply to ratios as for A). 
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Figure A15 DLS analyses of co-nanoprecipitates: A) overlay of p(HPMA50-co-EGDMA0.9):p(PEG114-
b-HPMA40) ratios i) 90:10 (black), 80:20 (dark blue), 70:30 (dark red), 60:40 (green) and 50:50 (dark 
pink), ii) 40:60 (dashed black), 30:70 (dashed blue), 20:80 (dashed dark pink), 10:90 (dashed cyan), B) 
overlay of p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80) ratios C) overlay of p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120) ratios, all same colours apply to ratios as for A). 
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Figure A16 Histograms showing size distributions (diameters; nm) of nanoprecipitates and co-
nanoprecipitates comprising various p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) ratios: A) 
50:50 (dark red), B) 60:40 (dark blue), C) 70:30 (dark green), D) 80:20 (yellow), E) 90:10 (pink), and 
F) 100:00 (black). 
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Figure A17 DLS results during solubilisation of A-B block copolymers in water at 1 mg/mL. A) 
p(PEG45-b-HPMA40), B) p(PEG114-b-HPMA40), C) p(PEG114-b-HPMA80), D) p(PEG114-b-HPMA120). 
Table A4 DLS results during solubilisation of A-B block copolymers in water at 1 mg/mL. 
 
 
 
 
 
 
Figure A18 Number average (nm) for p(PEG114-b-HPMA120), In absence of NaCl (black line), NaCl 
addition 1 day (red line) and NaCl addition 21 day (blue line)
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1 10 100 1000
p(PEG114-b-HPMA120)
p(PEG114-b-HPMA120) 1 day
p(PEG114-b-HPMA120) 21 day
Polymer Dz (nm) PdI Derived count rate 
(kcps)
p(PEG45-b-HPMA40) 31 (37nm 95%, 4045nm 5%) 0.316 520
p(PEG114-b-HPMA40)* 355 0.462 880
p(PEG114-b-HPMA80) 29 0.157 1310
p(PEG114-b-HPMA120) 53 (43nm 64%, 367nm 36%) 0.396 6910
* Inadequate scattering data
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Table A5 Summary of DLS results for NaCl addition to varying ratios of p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMAx), (20 µL addition to 1 mL of nanodispersion).  (X =  
polymer precipitation , * inadequate scattering data 
p(HPMA50-b-EGDMA0.9):p(PEG45-b-HPMA40) p(HPMA50-EGDMA0.9):p(PEG45-b-HPMA80) p(HPMA50-EGDMA0.9):p(PEG45-b-HPMA120) 
Wt% Blank Instant 24hour 7 day 21 day Blank Instant 24hour 7 day 21 day Blank Instant 24hour 7 day 21 day
90:10
Dz (nm) 113 1846* X X X 114 320 255 252 260 120 2660 X X X
PdI 0.067 0.48 0.045 0.278 0.221 0.192 0.185 0.066 0.57
80:20
Dz (nm) 94 771* X X X 127 129 129 128 126 111 193 225 213 221
PdI 0.123 0.581 0.061 0.06 0.056 0.032 0.053 0.033 0.117 0.202 0.083 0.111
70:30
Dz (nm) 106 195 234 322 X 115 117 128 141 149 108 123 150 173 X
PdI 0.029 0.077 0.03 0.047 0.053 0.033 0.018 0.024 0.021 0.037 0.045 0.056 0.032
60:40
Dz (nm) 115 139 203 240 265 111 114 119 128 142 103 107 125 149 174
PdI 0.047 0.024 0.019 0.032 0.083 0.037 0.031 0.027 0.024 0.079 0.069 0.065 0.044 0.027 0.023
50:50
Dz (nm)
109 172 173 212 251 115 117 191 198 220 109 109 167 211 X
PdI 0.0480 0.038 0.020 0.020 0.112 0.071 0.093 0.132 0.052 0.119 0.032 0.069 0.125 0.118
40:60
Dz (nm) 75 75 166 108 107 76 81 268* X X 95 112 260* X X
PdI 0.152 0.066 0.223 0.015 0.067 0.113 0.112 0.035 0.051 0.109 0.082
30:70
Dz (nm) 75 93 140* 106 107 69 90 286* X X 114 122 225 X X
PdI 0.166 0.222 0.2 0.039 0.04 0.122 0.136 0.08 0.061 0.066 0.124
20:80
Dz (nm) 78 78 153 96 99 56 112 239 159 159 159 156 246 X X
PdI 0.111 0.109 0.456 0.034 0.038 0.126 0.149 0.102 0.119 0.108 0.068 0.034 0.538
10:90
Dz (nm) 77 76 185* X X 76 81 195 144 143 215 265 209 253 349*
PdI 0.163 0.123 0.555 0.113 0.112 0.174 0.092 0.08 0.167 0.25 0.048 0.086 0.544
0:100
Dz (nm) 268 152 121 164 230 131 134 124 275 266 372 404 256 363 466
PdI 0.338 0.314 0.688 0.595 0.361 0.227 0.171 0.209 0.203 0.287 0.145 0.179 0.066 0.229 0.212
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Table A6 Summary of DLS results for NaCl addition to varying ratios of p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMAx), (20 µL addition to 1 mL of nanodispersion). (X =  
polymer precipitation , * inadequate scattering data). 
p(HPMA50-EGDMA0.9):p(PEG114-b-HPMA40) p(HPMA50-EGDMA0.9):p(PEG114-b-HPMA80) 
p(HPMA50-EGDMA0.9):p(PEG114-b-
HPMA120) 
Wt% Blank Instant 24hour 7 day 21 day Blank Instant 24hour 7 day 21 day Blank Instant 24hour 7 day 21 day
90:10
Dz (nm) 111 2173* x x x 112 122 142 151 161 132 130 130 131 132
PdI 0.055 0.311 0.045 0.03 0.014 0.039 0.015 0.059 0.060 0.044 0.033 0.036
80:20
Dz (nm) 103 415 291 343 522 106 139 109 114 118 127 126 127 125 126
PdI 0.152 0.432 0.205 0.171 0.33 0.118 0.272 0.055 0.025 0.032 0.043 0.057 0.060 0.046 0.048
70:30
Dz (nm) 121 143 194 236 275 106 121 107 106 110 113 113 112 110 113
PdI 0.061 0.037 0.007 0.027 0.037 0.124 0.22 0.086 0.061 0.195 0.069 0.060 0.068 0.044 0.049
60:40
Dz (nm) 107 116 165 206 235 103 105 105 110 103 117 117 117 114 115
PdI 0.028 0.023 0.014 0.013 0.021 0.065 0.045 0.057 0.148 0.057 0.059 0.060 0.036 0.051 0.045
50:50
Dz (nm) 117 113 120 150 134 111 109 107 112 116 103 101 103 104 104
PdI 0.048 0.079 0.029 0.031 0.018 0.081 0.089 0.062 0.083 0.191 0.045 0.05 0.06 0.043 0.091
40:60
Dz (nm) 76 72 104 91 321* 84 73 96 74 956* 70 71 69 75 276*
PdI 0.178 0.118 0.218 0.04 0.404 0.332 0.165 0.279 0.203 0.857 0.085 0.136 0.056 0.193 0.441
30:70
Dz (nm) 75 71 78 83 104 71 71 70 69 271* 62 61 60 62 154*
PdI 0.224 0.112 0.093 0.115 0.082 0.096 0.076 0.065 0.125 0.497 0.085 0.058 0.013 0.135 0.509
20:80
Dz (nm) 75 68 72 101 318* 67 70 67 117 442* 56 55 55 80 64
PdI 0.212 0.112 0.073 0.246 0.498 0.14 0.182 0.073 0.271 0.58 0.075 0.067 0.065 0.253 0.249
10:90
Dz (nm) 73 81 69 77 1010* 56 60 75 64 1254* 46 47 47 59 186*
PdI 0.254 0.214 0.214 0.192 0.913 0.184 0.175 0.278 0.245 0.89 0.152 0.088 0.106 0.32 0.276
0:100
Dz (nm) 317 289 276 272 268 89 86 86 93 66 49 50 59 44 39
PdI 0.373 0.392 0.301 0.358 0.369 0.738 0.322 0.396 0.249 0.466 0.265 0.292 0.322 0.131 0.121
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Table A7 DLS results for encapsulation of pyrene for varying ratios of p(HPMA50-co-
EGDMA0.9):p(PEG45-b-HPMA120). 
 
Table A8 DLS results for encapsulation of pyrene for varying ratios of p(HPMA50-co-
EGDMA0.9):p(PEG114-b-HPMA120). 
 
 
Figure A19 Fluorescence data for p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120), A) Control 
fluorescence emission spectrum for blank polymeric nanoparticles B) Fluorescence emission spectrum 
for pyrene in H2O and polymeric nanoparticles with encapsulation of 0.1 w/w% pyrene. 
2D Graph 4
340 360 380 400 420 440
0
100
200
300
400
500
600
Pyrene in H2O
100:0
90:10 
80:20 
70:30
60:40
50:50
30:70
10:90
300 320 340 360 380 400 420 440
0
200
400
600
800
1000
1200
100:0
90:10
80:20
70:30
60:40
50:50
Wavelength (nm) Wavelength (nm)
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Ratio  p(HPMA50-co-EGDMA0.9): 
p(PEG45-b-HPMA120) 
Blank size 
(d.nm) 
PdI Pyrene encapsulated  
size (d.nm) 
PdI 
100:0 99 0.058 93 0.047 
90:10 120 0.066 151 0.058 
80:20 121 0.036 123 0.067 
70:30 108 0.038 110 0.061 
60:40 121 0.028 110 0.034 
50:50 124 0.069 107 0.024 
Ratio  p(HPMA50-co-EGDMA0.9): 
p(PEG114-b-HPMA120) 
Size (d.nm) PdI Pyrene encapsulated  
Size (d.nm) 
PdI 
100:0 99 0.058 93 0.047 
90:10 97 0.045 91 0.033 
80:20 99 0.054 94 0.046 
70:30 107 0.080 96 0.038 
60:40 105 0.062 95 0.048 
50:50 103 0.068 106 0.051 
30:70 92 0.110 92 0.075 
10:90 63 0.156 72 0.230 
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Chapter 3 - The Synthesis and Nanoprecipitation Studies of Branched and Block 
Copolymers with Hydrophobic Block Segments for Co-nanoprecipitated Particle 
Dispersions and their Pharmacological Studies in vitro. 
 
 
 
 
 
 
 
 
 
Figure A20 GPC refractive index (RI) chromatogram overlay, black line = branched p(n-BMA50-co-
EGDMA0.9), black dashed line = linear p(n-BMA50). (Synthesised by Dr. Pierre Chambon – Rannard 
research group). 
 
 
 
 
 
 
 
 
 
 
Figure A21 GPC refractive index (RI) chromatogram overlay, black line = branched p(HPMA25-co-n-
BMA25-co-EGDMA0.9), black dashed line = linear p(HPMA25-co-n-BMA25). 
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Figure A22 GPC refractive index (RI) chromatogram overlay, black line = branched p(HPMA25-co-t-
BMA25-co-EGDMA0.9), black dashed line = linear p(HPMA25-co-t-BMA25). 
 
 
 
 
 
 
 
 
 
 
 
Figure A23 Overlay of branched p(HPMA25-co-n-BMA25-co-EGDMA0.9) NMR conversion during 
polymerisation (MeOD-d4, 400 MHz). 
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t=0
2D Graph 3
10 12 14 16 18 20 22 24
linear HPMA tBMA vs Refractive Index (mV) 
HPMA tBMA branched Retention Volume (mL) vs Refractive Index (mV) 
Retention Volume (mL)
 
 
253 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A24 1H NMR analysis of p(n-BMA50-co-EGDMA0.8) (CDCl3, 400 MHz). (Synthesised by 
Pierre Chambon with the Rannard research group). 
 
Figure A25 1H NMR analysis of p(t-BMA50-co-EGDMA0.9) (CDCl3, + MeOD 400 MHz). (Synthesised 
by Hannah Rogers with the Rannard research group). 
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Figure A26 1H NMR analysis of p(HPMA25-co-n-BMA25--co-EGDMA0.9) (DMSO-d6, 400 MHz). 
 
 
 
Figure A27 1H NMR analysis of p(HPMA25-co-t-BMA25-co-EGDMA0.9) (DMSO-d6, 400 MHz). 
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Figure A28 1H NMR analysis of p(PEG114-b-n-BMA120) (CDCl3, 400 MHz). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A29 Fluorescence emission spectrum for polymeric nanoparticles encapsulated with pyrene. 
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Table A9 DLS analysis for 17 wt% fluoresceinamine encapsulated co-nanoprecipitated particles 
 
 
Chapter 5 - Co-nanoprecipitation: Encapsulation of the Anti-Cancer Drug SN-38  
 
 
 
Figure A30 1H NMR (DMSO-d6, 400 MHz) of SN-38. 
 
 
 
 
 
 
Sample (50:50 wt %) Fluoresceinamine (wt %) Z-ave
(d.nm)
PdI
p(HPMA50-co-EGDMA0.9):p(PEG45-b-HPMA40) 17 218 0.108
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA80) 17 160 0.026
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 17 125 0.081
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Table A10 DLS results for nanoparticles prepared via the dropping technique after 48 hour 
solubilisation. 2 wt % and 5 wt % SN-38. 
 
Table A11 Blank vs encapsulated PdI values SN-38 encapsulated nanoparticles 
Sample (50:50 wt%) Blank PdI Encapsulated PdI 
 
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 
0.168 0.112 
 
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 
0.188 0.076 
 
p(tBMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-
HPMA120) 
0.166 0.085 
 
Table A12 DLS results for various batches of SN-38 (5 wt%) co-nanoprecipitated particles 
 
Sample 50:50 wt % + 5 wt % SN-38 Batch Size (d.nm) PdI
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120)
1 145 0.112
2 123 0.079
3 149 0.156
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120)
1 94 0.076
2 82 0.085
3 99 0.079
p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120)
1 118 0.085
2 100 0.120
3 125 0.064
Sample (50:50 wt %) SN-38 (wt %) Size (d.nm) PdI
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 2 105* 0.278
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120)
2 146 0.205
p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120)
2 103 0.275
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120)
5 280 0.368
* Result does not meet DLS quality criteria
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Table A13 DLS results for blank co-nanoprecipitated nanoparticles - 5 month stability 
 
Chapter 6 – Conclusions and Future Work 
 
Figure A31 1H NMR p(Br-PEG~105-Br) (D2O, 400 MHz). 
 
 
 
 
Sample 50:50 wt %
Instant size
(d.nm)
PdI
Size after
5 months (d.nm)
PdI
p(n-BMA50-co-EGDMA0.8):p(PEG114-b-HPMA120) 168 0.168 172 0.073
p(HPMA50-co-EGDMA0.9):p(PEG114-b-HPMA120) 82 0.188 83 0.101
p(t-BMA25-co-HPMA25-co-EGDMA0.9):p(PEG114-b-HPMA120) 101 0.166 105 0.170
a
a a
ab
b'
c
d
a
b, b’
d c
D2O
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Figure A32 1H NMR p(120HPMA-b-PEG~105-b-HPMA120) (Methanol-d4, 400 MHz). 
 
 
 
 
 
 
 
 
 
 
Figure A33 GPC RI overlay for (Br-PEG~105-Br) bifunctional macroinitiator and p(120HPMA-b-
PEG~105-b-HPMA120) polymer. 
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Figure A34 A) p(HPMA50-co-EGDMA0.9):p(HPMA120-b-PEG~105-b-HPMA120) 50:50 wt%, B) 
Efavirenz encapsulated co-nanoprecipitated nanoparticles, C) ritonavir encapsulated nanoparticles, D) 
lopinavir encapsulated nanoparticles, E) Ritonavir + lopinavir encapsulated nanoparticles (1:1). Black 
= 1 wt%, black dashed = 5 wt%, dark red = 10 wt %. 
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A35 Mass spectrum (ES-MS) of IbuPMA. 
 
 
A36 1H NMR analysis of IbuPMA (CDCl3, 400 MHz). 
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Table A14 GPC results for incorporation of IbuPMA. (DMF GPC system) 
 
 
 
Figure A37 1H NMR p(PEG114-co-HPMA60-co-IbuPMA20) (DMSO-d6, 400 MHz). 
 
Table A15 GPC results for post modification of p(PEG114-b-HPMA120). (DMF GPC system) 
 
 
Sample
Targeted Mn
(g/mol)
Mn
(g/mol)
Mw 
(g/mol)
Ð 
DP 
1H NMR
1H NMR 
Conversion
PEG114-Br ~5000 5500 5550 1.01 113 -
p(PEG114-b-HPMA120) 22300 29500 37500 1.27 115 HPMA 99
Post modified p(PEG114-co-HPMA80-co-IbuPMA40) 29800 37400 47800 1.28 ~17 IBU units 
per chain
-
Sample
Targeted Mn
(g/mol)
Mn
(g/mol)
Mw 
(g/mol)
Ð 
DP
1H NMR
1H NMR 
Conversion
PEG114-Br ~5000 5500 5550 1.01 113 -
p(PEG114-b-HPMA80) 16500 20600 25000 1.21 65 HPMA 99
p(PEG114-co-HPMA60-co-IbuPMA20)
(Assuming 1:1 monomer conversion)
20300 25600 31400 1.23 ~15 IBU units per chain 97
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Figure A38 1H NMR p(PEG114-co-HPMA80-co-IbuPMA40) (DMSO-d6, 400 MHz). 
 
Figure A39 GPC analysis for p(HPMA60-co-IbuPMA20-co-EGDMA0.85). 
 
 
8 10 12 14 16 18 20
Retention Volume (mL) vs Refractive Index (mV) 
Mn = 60 000 g/mol
Mw = 986 000 g/mol
Đ = 16.4
Retention Volume (mL)
R
ef
ra
ct
iv
e 
in
d
ex
 d
et
ec
to
r 
o
u
tp
u
t 
si
g
n
al
 
